¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>F-¨È·à±d
­Y2022¦~¤¤±N¨È·à±dªº¥«­È±a¤W10»õ¬üª÷¡A±z´N¬O¨ô¶VªºCEO     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©t¨àÃÄ10140658  µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(­Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475

2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19

2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2

2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c

2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8

·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/26 ¤U¤È 05:25:17²Ä 6608 ½g¦^À³
®Ú¾ÚSEC¸ê®Æ¡A¥Ø«e¤jªÑªF¤S¦h¥Ó³ø¤FINTRACOSTAL LLC(4.4%)¸òLIND GLOBAL FUND(5.7%)¡A³£¬O³o¤@¦¸ªº¨p¶Ò¹ï¶H¡AªÑ¥»¿±µÈ«á¥Ø«e¤w¸g¨S¦³«ùªÑ¶W¹L10%ªºªÑªF¤F¡A¥hª¦ª¦Â¤å¡A±q2023¦~7¤ë¸Ñª¼ªÑ»ù±Y¶^¡A¦³¨Ç¤@ª½¥D±i¥D¤O¦b¦Y³f¡A±q4.X±Y¨ì0.4¨ì²{¦b0.6X¡A®É¶¡¤w¸g¹L¤F§Ö9­Ó¤ë¡A¦³½Ö§ä¨ì¦Y³fªº¥D¤O¤F¶Ü¡A¤p§Ì¸ê½è¾q¶w§ä¤£¤Ó¥X¨Ó³â¡AµM«á¹L¤F9­Ó¤ëÁÙ¨S§ä¨ì¤H¤@°_±À¶i¤T´Á¡A§Ú¬Ý¤]¬O¤¿¦h¦N¤Ö.....

**°¸º¸À°¦Ñ·à¤Í§ó·s¤@¤USECªº¸ê®Æ¡A¤£µMSEC³o»ò¤Î®É¸ò·Ç½T³£¨S¤H­n¬Ý¡A³£¶]¥h¬Ý¤@¨Çºô¯¸µM«á¸£¸É¤@°ï¤p¼@³õXD

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/3/18 ¤U¤È 10:43:25²Ä 6607 ½g¦^À³
§CÀɼɺ¦¼É¶^

³o¬O¤£¬O¥s¾_­Ü¥ÏÃâªü......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/18 ¤U¤È 10:42:40²Ä 6606 ½g¦^À³
§ó¥¿»P¸É¥R

Duplimab ¨â­Ó¤T´ÁÁ{§É¡A¹êÅç²Õ»P¹ï·Ó²Õ¤H¼Æ¬ù²¤¬Û¦P¡A

TRED-DX¹êÅç²Õ»P¹ï·Ó²Õ¤H¼Æ¤ñ昰50¤H/25¤H¡A¦¬®×¹ï¶HEASI ¦Ü¤Ö18¤À¥H¤W¡A¥ÎÃÄ16¶g¡A³o22¤Hblinded data ·íµM¥ÎÃIJթâ¨ì¤H¼Æ·|¤ñ¹ï·Ó²Õ¦h¡C

¥t¥~¤½¥q°T®§¤¤¦³´£¨ì£¸¤p¬q­@¤H´M¨ýªº¸Ü¡A­È±oª`·N

³o9¤H·|¤£·|´N¬O¹êÅç²Õ

9¦W±wªÌ¤¤¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90¡A5 ¦W±wªÌ (56%) ¹F¨ì vIGA µû¤À¬° 0 ©Î 1¡C¨´¤µ¬°¤î¡AªvÀøªº­@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹,¨S¦³µo²{µ²½¤ª¢¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/18 ¤U¤È 09:01:46²Ä 6605 ½g¦^À³
eblasakimab

¥¼¨Ó¦³¾÷·|»PDupilumab¶i¤JÄvª§¡A¹ï¤âªº¼Æ¾ÚÅܦ¨«Ü­«­nªº«ü¼Ð¡AÃĪ«ªº¬ãµo¨S¦³§¹¬üªº³Ì¦n¡A¥u¦³¤£Â_³Ð·sªº§ó¦n

Dupilumab SOLO1¬ã¨s

¹F¨ì IGA score 0 or 1 ¹ï·Ó²Õ¤H¼Æ224¤H¤¤¦³23¤H(10%)¹F¼Ð

¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@85¤H( 38¢H)¹F¼Ð

¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@83¤H( 37¢H)¹F¼Ð

¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-75 ¦@115¤H( 51¢H)¹F¼Ð

¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìI

EASI-75 ¦@117¤H( 52¢H)¹F¼Ð

EASI-90

¹ï·Ó²Õ224¤H¤¤¦³17¤H 8¢H¹F¼Ð

¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-90 ¦@80¤H( 36¢H)¹F¼Ð

¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìEASI-90 ¦@74¤H( 33¢H)¹F¼Ð

Dupilumab SOLO2¬ã¨s

¹F¨ì IGA score 0 or 1

¹ï·Ó²Õ¤H¼Æ236¤H¤¤¦³20¤H(8%)¹F¼Ð

¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@84¤H( 36¢H)

¹F¼Ð¡C

¹êÅç²Õ223¤H¨C¶g¤@°w¹F¨ìIGA score or 1 ¦@87¤H( 36¢H)¹F¼Ð

¹êÅç²Õ236¤H¨â¶g¤@°w¹F¨ìEASI-75 ¦@103¤H( 44¢H)

¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìEASI-75 ¦@115¤H( 48¢H)¹F¼Ð

EASI-90

¹ï·Ó²Õ236¤H¤¤¦³17¤H 8¢H¹F¼Ð

¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-90 ¦@70¤H( 30¢H)¹F¼Ð

¹êÅç²Õ223¤H¨C¶g¤@°w¹F¨ìEASI-90 ¦@73¤H( 31¢H)¹F¼Ð

¥H¤U昰Dupilumabµoªí¦b·s­^®æÄõÂå¾Ç´Á¥Z¨â­Ó¤T´ÁÁ{§Éªº¹Ïªí¼Æ¾Ú

½Æ»s«á·j´M

phase 3 trials of dupilumab versus placebo in atopic dermatitis nejm

©¹¤U§ä¨ì Results

«ö¤U¥h¥i¥H§ä¨ì¹Ïªí1»P¹Ïªí2

¬ÛÃö°ò¥»¸ê®Æ»PÁ{§É¼Æ¾Ú¡AÀ³¦³ºÉ¦³¡C

¥»¦¸22¤H¥¼¸Ñª¼ªì¨B¤ÀªR¡A45%¹F¨ìEASI-90

10/22¡A¦Ê¤À¤§50¹F¨ìIGA score o/1 11/22¡A¨ä¤¤·|¦³¦h¤Ö¤H¨Ó¦Û¹ï·Ó²Õ¡A¥i¥H参¦ÒDupilumab SOLO1,SOLO2 ¨â­Ó¤T´ÁÁ{§É¤¤

¹ï·Ó²Õ¦bEASI-90,IGA score o/1¦û¤ñ¡A¥i¬Ý¥Xªì¨BºÝ­Ù¡A

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¼Æ¾Ú¥H·s­^®æÄõÂå¾Ç´Á¥Z¬°¥D

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/17 ¤U¤È 11:07:31²Ä 6604 ½g¦^À³
SOLO1¹F¨ì vIGA 0 or 1 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§10¡A¹êÅç²Õ¹F¨ìvIGA 0 or 1 ¬ù¦b¦Ê¤À¤§37~38

SOLO2¹F¨ìvIGA 0 or 1 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§8¡A¹êÅç²Õ¹F¨ìvIGA 0 or 1 ¬ù¦b¦Ê¤À¤§36

¥»¦¸¤½§iªº22¤Hªì¨B¥¼¸Ñª¼¼Æ¾Ú昰

¦³¦Ê¤À¤§50ªº¤H¹F¨ìvIGA 0 or 1

±q¹L¥hdupilumab¨â­Ó¤T´ÁÁ{§É¼Æ¾Ú¨Ó¬Ý¡A³o11­Ó¤H¹F¼Ð¤¤¦³¦h¤Ö¤H昰¹ï·Ó²Õ¦P¼ËÃø«×¬Û·í°ª

50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/17 ¤U¤È 10:37:20²Ä 6603 ½g¦^À³
1ªoºj¤j«e«h¤À¨É¬O¥¿½Tªº¡A§Ú¿ù§â±µ¨üªvÀø22¤H¥þ³¡·í¬°¹êÅç²Õ¡A³o­Ó昰blinded data,¦~©³¤½§iªº¤~¬Ounblind data ¡A¤]´N¬O¸Ñª¼ªº¼Æ¾Ú¡C

2¤½¥q¤½¥qªº­^¤å¥þ¤å

In a preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their EASI score (EASI-90) and 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline unblinded data from the full dataset is expected at the end of 2024

3´N§Ú¦L¶H©Ò¤Î¡Adupilumab¨â­Ó¤T´ÁÁ{§É

SOLO1¹F¨ìEASI90 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§8¡A¹êÅç²Õ¹F¨ìEASI90 ¬ù¦b¦Ê¤À¤§33~36

SOLO2¹F¨ìEASI90 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§7¡A¹êÅç²Õ¹F¨ìEASI90 ¬ù¦b¦Ê¤À¤§30~31

³o¦¸¤½¥q¤½§iªº22¤H¥¼¸Ñª¼ªºªì¨B¼Æ¾Ú¡A¹ï·Ó²Õ­n¦³¦Ê¤À¤§45ªº¨ü¸Õ¹F¨ìEASI90Ãø«×¬Û·í°ª¡A

¤j®a´N­@¤ßµ¥«Ý¡Aµ¥«Ý¼Æ¾Ú»¡¸Ü¡C

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/17 ¤U¤È 07:43:36²Ä 6602 ½g¦^À³
¥xÁÞ¤j³£»¡¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü¤F¡A§Ú´N¸É¥R¥H¤U´XÂI´N¦n¡G

1.¥»¦¸¨p¶Ò500¸UªÑ+»{ªÑÅvÃÒ500¸UªÑ¡A¨Ã¨S¦³³¬Âê´Á5¦~ªº°ÝÃD¡A»{ªÑÅvÃÒ5¦~¨ì´Á¬O«üµo¦æ«áÀH®É¥i¥H¥Î1¤¸ÁʶR¡A»{ªÑÅv5¦~«á¨ì´Á´N¥¢®Ä¤F¡A¨p¶Ò§¹ªÑ¥»¿±µÈ3¦¨¡A»{ªÑÅvÃÒ³£¦³¦æ¨Ï¡AªÑ¥»¿±µÈ6¦¨¡A¦pªG¨ÖÁÊ»ù®æ¤£ÅÜ¡AªÑ¥»¿±µÈ3~6¦¨µ¥©ó¨CªÑ»ù®æ¤Ö¤F25%~40%¡A§Ú¬O¤£»{¬°³o¥sªÑ¥»¼W¥[¤£¦h°Õ¡A°²³]10»õ¬ü¦¬ÁÊ¡A­ìªÑ¥»¤@ªÑ60¤¸¡A¿±µÈ«á·|¥u³Ñ24~45¤¸¡A³o¥u¬O²{¦³ªº¼Æ¾Ú³á¡AÁÙ¤£ºâ¤W¤§«á¦³¥i¯àÄ~Äò¼W¸ê...

2.³o¦¸TREK-DX¤½¥¬ªºªì´Á¼Æ¾Ú¬O¥¼¸Ñª¼¼Æ¾Ú¡A«üªº¬O³o22­Ó§¹¥þ¤£ª¾¹D¹êÅç²Õ¸ò¹ï·Ó²Õªº¤À°t¡A©Ò¥H¥xÁÞ¤j§â³o22­Ó³£ºâ¨ì¹êÅç²Õ¨ä¹ê¬O¿ù»~ªº¡A³o22­ÓÀ³¸Ó¬O¹êÅç²Õ¹ï·Ó²Õ³£¦³¡A­n¸Ñª¼¤~·|ª¾¹D¦p¦ó¤À°t¡A©Ò¥HTREK-AD¤G´Á¸Ñª¼·|±Y·´¸òCNTB¤@¼Ë¡A¬Ý¨ìªì´Á¼Æ¾Ú³£Ä±±oÀø®Ä¶W¦n¡]¦]¬°³£¤ñ·Ó§ù¥²ª¢ªº¹ï·Ó²Õ¼Æ¾Ú¡^¡A«á¨Ó¸Ñª¼«á¤~µo²{­ì¨Ó¹ï·Ó²Õ¦³§ïµ½ªº¤ñ¨Ò·¥°ª¡A¾É­P¹êÅç²Õ¸ò¹ï·Ó²Õ®t¶Z¨S¦³©Ô¶}¡A©Î³\¦¬®×¼Ð·Ç­×§ï¥i¥H§ïµ½¡A¦ý§âªì´Á¼Æ¾Ú³£·í¦¨¹êÅç²Õ³o¼Ë·|¾É­P»~§P¡A§O§Ñ¤FTREK-DX¤G´ÁªººGªp¡A¹ê»Úµ²ªGÁÙ¬O¥H¸Ñª¼¥X¨Ó¦A»¡§a...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/17 ¤U¤È 03:43:33²Ä 6601 ½g¦^À³
¥t¥~½Í¨ì¤Ñ©R¤jªº±ÂÅvª÷±À¦ô¡A§Ú»{¬°¬O¦X²zªº±À¦ô¡A´«¦¨£¸¯ë§ë¸ê¤H¤]·|¥Î¤½¥q±ÂÅvµ¹¤é¥»ªºª÷ÃB°£¥H¤é¥»ÃÄ«~¥«³õ¥«¦û²v¡A·íµM³o¬O·§²¤¦ôºâ¡A¤½¥q¥Ø«eµ¦²¤¦A昰±À¥X´³¨rÃĪ«¡A³o­Ó¤G´Á¬ã¨sFAST-AA ¤T­Ó¤ë¥ª¥k´N­n¤½§i¼Æ¾Ú¡A¥H´£°ª¤½¥q»ù­È¡A³o¤äªÑ²¼¤W¤W¤U¤U¡AÅý§ë¸ê¤H¤ß¦Ç·N§N¡A¥Ø«eªÑ»ù§¹¥þ¨S¦³¤ÏÀ³À³¦³ªº»ù­È¡A¯u¥¿·N¹Ï¤£©ú¡H¥u¦³®É¶¡¤~¯àµ¹¥Xµª®×¡A昰­n§â´²¤áÄw½X¥þ§l¨«À£§C¶i³f¡A¦A¤j´T©Ô¤É¡A¦A«Å§G¨Ö©Î±ÂÅvª÷¡A¦Y¹¡³Ü¨¬¡A¥u¦³¤½¥q¬£¡A¤jªÑªF¡A¤jªº§ë¸ê¾÷ºc¤~ª¾¹D¡H¡H¡H

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/17 ¤U¤È 01:45:57²Ä 6600 ½g¦^À³
¤p©ú¤j

¹L«×¼ÖÆ[»P¹L«×´dÆ[³£¬O«D²z©Ê·Qªk¡A¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü¡A¤j®a·Q£¸·QTREK-DX »PTREK-AD

昰¤£¬O¬Û¤¬½÷¬M¡A¬Û¤¬±Ï´©¡ATREK-AD¤C¤ëªìªº¼Æ¾Ú¹ï·Ó²Õ¤ñ¹w´ÁÁÙ¦n¡A¸g¹L¦¸²Õ¸s¤ÀªR²×©ó§ä¨ì¦¬®×ÄY®æ¤~¯à¯u¥¿¤ÏÀ³¨â²Õªº®t¶Z¡ATREK-DX

©Û¶Ò75¦W¡A¥ß§Y§ó§ï¦¬®×¼Ð·Ç¡Aªì¨B22¤H¼Æ¾ÚÃÒ

©ú¨ä¥O¤HÅåÆvªºÀø®Ä¡A22¤H¥ÎÃIJÕ昰¤°»ò·N«ä¡A

³o¦¸¦¬®×75¤H¡A¹êÅç²Õ50¤H¡A¹ï·Ó²Õ25¤H

22¤H\50¤H¡A¤½§i¼Æ¾Ú±µªñ¦Ê¤À¤§45¡A§Ö£¸¥b¤F¡A³o¨Ç¨Ï¥ÎDuplicub ¨S®Ä©Î¬O°Æ§@¥Î©Î¬O¨ä¥L¦]¯ÀÂ÷¶}ªº¯f±w¡A³o¸sÃøªvªº¯f±w¨Ï¥ÎASLAN004 16¶g ¨C¶g400mg¾¯¶q²£¥Í¥O¤H

¦L¶H²`¨èªºÀø®Ä»P¦w¥þ©Ê¡ATRED-DX ÃÒ©úTRED

AD¥ý«eªº°²³]¦¬®×ÁÍÄY®æªº¥¿½T©Ê¡A³o¬O£¸­Ó±µ¤OÁÉ¡A«e­±Áö±¼´Î¡A«á­±°¨¤W°l»°¤W¨Ó¡AÀHµÛ¼Ú¬ü§ó§ï¦¬®×¤è¦¡¡A¦~©³¼Æ¾Ú¤£·|®t¤Ó¦h¡AÁÙ®t¦Ê¤À¤§55¥ÎÃIJռƾڡAÀR«Ý¦~¤¤»P¦~©³¼Æ¾Ú¡A

²{¦bÁ`¥«­È¤~£¸¤d¦h¸U¬ü¤¸¡A¤£©ÈªÑ¥»¼W¥[£¸¨Ç¡A¤]¤£ª¾¹D¦³¦h¤ÖªÑ­n³¬Â꤭¦~¡H¯u¥¿¼W¥[¤]¬O¦³­­¡AÀø®Ä»P¨ÖÁʩαÂÅv¤µÃB¤~¬O³Ì­«­nªº

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/16 ¤U¤È 05:43:27²Ä 6599 ½g¦^À³
¥xÁÞ¤j¡A

§A«Ü¥Î¥\¨Ã«O«ù¼ÖÆ[¡A

¦ý§ÚÁÙ¬O¤£¬Ý¦n¡AÁöµM§Ú¤]¤£½æªÑ¤F¡A´N·í½ä³Õ¿é嘞¡A

¸Ó¤½¥qªº¸Û«H¤£¨Î¡A¦h¦¸©ó¸Ñª¼µo¥¬¼ÖÆ[°T®§¡A

¸Ñª¼«á´N«æ³t¼É¶^¡A¹ï¤½¥qªº®ø®§§Ú¬O¤£·|¬Û«H¤F¡A

¦A»¡¦pªG¦³¤½¥q©Ò»¡¡ATREK-DX¸ÕÅ禳¦¨®Ä¡A

¡A

¦ÛµM·|¦³±M®a¬ã¨s¨ä¦¨®Ä¡A

¤½¥q¬°¦ó¥uº¦¤@¤Ñ´N«æµÛ½â½æªÑ²¼¨p¶Ò¡A

³o¤£²Å¦XÅÞ¿è¡A

¦Ó¥B¤Ñ©R¤j¤wÂ÷¶}¥»ª©¤@¦~¡A¤]³\¦­¤w¥X²MªÑ²¼¡A

¥Lªº½×­z¤]¤w¨Æ¹L¹Ò¾E¡A¦A¤Þ­z¥i¯à¤£©y¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/15 ¤U¤È 09:08:12²Ä 6598 ½g¦^À³
§ó¥¿

¤Ñ©R¤j¥h¦~¤»¤ë¤G¤Q¤T¤é¹ïASLAN 004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¹w¦ô­È¡A¥D­n昰®Ú¾Ú¤é¥»ÃÄ«~¥«³õ

¦û¤ñ±À¦ô¥þ²y¥«³õ±ÂÅvª÷(¤£¥]¬AASLAN003¯Z¨r) ­È±o¤j®a参¦Ò¡A¨º®É­Ô©|¥¼¤½§GTREK-DX

¥O¤HÅåÆvªºªì¨B¼Æ¾Ú

¸É¥R

1 TREK-DX Àu²§ªºªì¨B¼Æ¾Ú¨Ó¦Û©óTREK-AD ªº¦¸±Ú¸s¤ÀªR, ¨Ã§Ö³t½Õ¾ã¦¬®×ÁͦVÄY®æ¼Ð·Ç

ªºµ¦²¤(¼Ú¬ü¦P¨BÁͦVÄY®æ)TREK-DX »P EblasaKimab in Atopic Dermatitis TREK-AD

¦P¨BÁͦVÄY®æ¦¬®×

2 FAST-AA ¬ã¨s¡A¹w­p¸Ó¬ã¨sªº¤¤´Áµ²ªG±N©ó 2024 ¦~¤¤¤½§G, ªÎ¤ô¤£¸¨¥~¤H¥Ð»°§Ö¥Ó½Ð±M§Q«OÅ@ (ªø¹F20¦~)

3 ASLAN Pharmaceuticals °õ¦æªø Carl Firth ³Õ¤h»¡¡C

¡u§Ú­Ì«Ü°ª¿³¦¬¨ì¼Ú¬w±M§Q§½Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¥¿­±ªì¨B·N¨£¡A¨Ã»{¥i§Ú­Ì©Ò¦³

ªºÅv§Q­n¨D§¡¨ã¦³·s¿o©Ê©M³Ð³y©Ê¡C¦pªG¦b°ê®a¶¥¬qÀò±o±ÂÅv¡A·s±M§Q±N§âfarudodstatªº±M§Q«OÅ@

©µªø¦Ü¦Ü¤Ö2043¦~¡C³o±NÅãµÛ¼W±jfarudodstatªº°Ó·~¿W¦û©Ê¡A¬O§Ú­Ì¦b©Ò¦³ÃöÁä°Ó·~»â°ìfarudodstat

¥[±j ¥Ñ©ó´³¨r±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü«Ü¤Ö¡A§Ú­Ìªº¥Ø¼Ð¬O¬°±wªÌ´£¨Ñ¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/15 ¤U¤È 08:30:14²Ä 6597 ½g¦^À³
¤Ñ©R¤j¥h¦~¤»¤ë¤G¤Q¤T¤é¹ïASLAN 004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¹w¦ô­È¡A¥u­n昰®Ú¾Ú¤é¥»Ãħ½¥«³õ¦û¤ñ±À¦ô¥þ²y¥«³õ±ÂÅvª÷¡A(¤£¥]¬AASLAN003¯Z¨r)

­È±o¤j®a参¦Ò¡A¨º®É­Ô©|¥¼¤½§GTREK-DX¥O¤HÅåÆvªº¼Æ¾Ú

¥H¤U¬O¤Ñ©R¤j¹w¦ô

ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô

¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸.

¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸----B

C=B-A=27.7»õ¬ü¤¸-7.8»õ¬ü¤¸(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»«á¤§§Q¯q)

¤@¤@¤@¤@¤@ASLN004 ¤§»ù­È:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í¤@¤@¤@¤@

⋯¡]¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q)

¥H¤W¥¼§tASLAN003ªº»ù­È¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/14 ¤U¤È 07:53:27²Ä 6596 ½g¦^À³
³o¤@¦¸¬O¨p¶Ò500¸UªÑADS¡]¨p¶Ò»ù1¤¸¡^¦A¥[¤W500¸UªÑªº»{ªÑÅvÃÒ¡]»{ÁÊ»ù1¤¸¡^¡A»{ªÑÅvÃÒ5¦~«á¨ì´Á¡A»{ªÑÅvÃÒ´N¥b¶R¥b¬Û°e¤£¥t¦¬Åv§Qª÷ª½±µµ¹¨p¶Òªº¤H¤F¡AÁ`¦¬¤J¬°467.5¸U¬ü¤¸¡A­n¬O»{ªÑÅvÃÒ¥þ³¡¦æ¨Ï¡AªÑ¥»ª½±µ¿±µÈ6¦¨¥H¤W¡AÁ`¦¬¯qºâ967.5¸U¬ü¤¸¦n¤F¡A¦U¦ì»{¬°³o°Ï°Ï967.5¸U¬ü¤¸±Ï±o¤Faslan?¬JµM³oµ§¿ú¤w¸gµLÃö¥G¤j§½¡A¤S¬°¦ó­nÅýªÑ¥»¿±µÈ6¦¨¡H¡H¡H³o´N¬O©Ò¿×ªº¨ÖÁʤj®v¡H¡H¡H¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/13 ¤U¤È 09:27:06²Ä 6595 ½g¦^À³
«Ó°¶¤j»¡ªº¨S¿ù¡AªGµM¤Þ°_§ë¸ê¾÷ºc

zacks investment research ªºª`·N

¥Zµn¤½¥q¤½§i¸ê°T¥þ¤å¡A¥i·j´M

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

March 12, 2024 ¡X 09:58 am EDT

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/13 ¤U¤È 08:53:29²Ä 6594 ½g¦^À³
¦U¦ì·à¤Í¯u¬O¨üºÉ§é¿i¤F¡A

§Ú­Ó¤H»{¬°¡A

¤½¥q¨p¶Ò5¦Ê¸UªÑ¡A­q»ù1¬üª÷¡A

¥æ©ö¤é3¤ë14¤é¡A¤­¦~«á¤~¨ì´Á¡A

¥Ø«eªÑ»ù§C©ó1¤¸¡A¦pªG©ú¤Ñ¤´¯à¨Ì¬ù§¹¦¨¥æ©ö¡A

§Ú·Q¤½¥q¤§¥Øªº¡A¬OÅýªÑ»ù¦b6¤ë©³«eºû«ù¦b1¬üª÷¤§¤W¡A

ºû«ùÄ~Äò¦bNASDAQªº¥æ©ö¤è¦¡¡A

¨Ã¥Bª§¨ú¤@¨ÇÎA©µ´Ý³Ýªº®É¶¡¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/13 ¤U¤È 07:51:12²Ä 6593 ½g¦^À³
¼ÖÆ[¥J¯uªº«Ü¼F®`¡A¥u­n·h¥X¥«³õ¼ç¤O«Ü¤j¡Aµe­Ó¤j»æ´N¥i¥H¹L¤é¤lªº·Pı¡A§Y¨ÏCOPD¡BAA¤G´Á®Ú¥»¤°»ò¨M©w©Êªºµ²ªG³£ÁÙ¨S¥X¨Ó´N¥i¥H±·¦¨³o¼Ë¡A¥t¥~ÁÙ¦³µêµLÄÆ´ùªº¥D¤OÀ£§CªÑ»ù¦Y³f»¡ªk¤]¬O¤@µ´¡A°ò¥»¤W«ùªÑ¶W¹L5%´N­n¥Ó³ø¤F¡A¨ì²{¦b³Ìªñ¥Ó³øªº¤]´NBVF,K2¸òUBS¡A³o¤G¤Ñ¶gÂà²v¤j·§¬ù180%¸ò90%¡A¦pªG³o´X¤Ñ¨S¦³¥Ó³ø«ùªÑ¶W¹L5%ªº·s¤jªÑªF¡A´Nª¾¹D¼ÖÆ[¥J­Ìªº¥D¤O´N¬O¯º¸Ü¤@«h¡A¨ì©³­þ¸Ì¨Óªº¼oª«¥D¤O³sÄò¤G¤Ñ¶gÂà²v³o»ò°ªÁÙ¦¬¤£¨ì¶W¹L5%Äw½X¡A¦Ó¥B¥HAslan¥«­È1»õ¬ü¤¸¡]ªÑ»ù¬ù6¬ü¤¸¡^¨Ó»¡¡A5%¥«­È¤]¤~500¸U¬ü¡A§ó¦óªp±q2024¦~1¤ë¥H¨Ó¡AªÑ»ùªø´Á¦b0.5¬ü¤¸¥ª¥k¡A5%«ùªÑ¤]¤~¤£¨ì50¸U¬ü¤¸¡A¨ì©³¬O­þ­Ó¼oª«¥D¤O³s50¸U¬ü³£¶R¤£°_°Õ¡AÃø¤£¦¨³o°¶¤jªº¥D¤O­nÀ£§C¨ì0.05Ä~Äò¦Y³f¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§_¨ì©³°Õ10148994  µoªí®É¶¡:2024/3/13 ¤U¤È 07:06:00²Ä 6592 ½g¦^À³
m.investing.com/news/stock-market-news/aslan-pharmaceuticals-announces-5-million-offering-93CH-3334785

¥i¥ß§Y¦æ¨Ï¡A¤­¦~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2024/3/13 ¤U¤È 02:32:58²Ä 6591 ½g¦^À³
¥ý¤£ºÞªÑ»ù¤S¦^¨ì­ìÂI

¦Ü¤Ö¶q¦³ª£¥X¨Ó¡AÅý¤j®aÃöª`¨ì´N¬O¦n¨Æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/3/13 ¤U¤È 01:47:47²Ä 6590 ½g¦^À³
½Ð°Ý¦U¦ì¤j¤j

¬üªÑ¨p¶ÒªÑ²¼

¦³³¬Âê´Á¶Ü¡H

¦³ªº¸Ü ¦h¤[¡H

½Ðª¾¹Dªº¤j¤j ½ç±Ð

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/13 ¤U¤È 01:09:30²Ä 6589 ½g¦^À³
ªº½T´²¤áªº®zÂI´N¬O¬Ý¨£ªÑ»ù¶^ªº®É­Ô·|¶°Å鮣·W½æ¥X«ùªÑ , ¤W¨R¤U¬~®É¤£°í©wªºÄw½X

³vº¥¸¨¤J¤jªÑªF¤â¤W, ¨ä¹ê´N¬O¥H¤j´Û¤p ( ¤jªÑªF¤â¤W¦³ªÑ²¼ ¤S¦³²{ª÷ )

µ¥¬y³qÄw§l¦¬¹L¥b®ÉªÑ»ù©Ô©ï°_¨Óªý¤OÅܤp ( ¯d¤Uªº´²¤á³£¬O°í©wªºÄw½X) ªÑ»ù¤~¦³¯u¥¿ªº¤W¤É

¤jªÑªFÁöµM¾Ô³NÆF¬¡¿W¥ß©Î¦X¤O©Ô©ïªÑ»ù µL©¹¤£§Q , ´²¤á¯u¥¿­nÃö¤ßªº°£¤FªÑ»ù ¨ÖÁÊ»ù¥~¬O¾Ô²¤ªº¥¿½T

¤]´N¬O¤½¥q¶}µo²£«~¬O§_¨ã¦³Àø®Ä»P¦w¥þ©Ê ¶}µo²£«~ªººØÃþ»P¥«³õ¤j¤p , ¥»¦¸¶Ò¸ê500¸U¬ü¤¸¥D­n¥Î©ó

¸ê§U·sªº©M¨ä¥L¥¿¦b¶i¦æªº¬ãµo¬¡°Ê¡BÀç¹B¸êª÷©M¨ä¥L¤@¯ë¤½¥q¥Î³~, ¯à¶Ò¨ì¸êª÷³Ì­«­n ,¦³¸êª÷¤~¦³

«áºüªº¬ãµo, ·í²£«~½u¦h¤¸¤S¦³Ävª§¼ç¤O¥¼¨Ó³Q¨ÖÁÊ»ù¤~·|°ª, ´²¤á»P¨äÃö¤ßªÑ»ù¤£¦pÃö¤ß¨ÖÁÊ»ù

ÁÉ¿Õµá¡B¦A¥Í¤¸

ÀHµÛºC©Êªý¶ë©ÊªÍ¯fªºÂX±i¡A¾P°âÃB¥¼¨Ó¥i¯à¹F¨ì 20B ¬ü¤¸°ª®p , 2023¦~ ¬ù115.9 »õ¬ü¤¸

( Dupixent global net sales soared by 33% to $11.59 billion in 2023)

¨Ì¾Ú¤½¥q¤½§i¼Æ¾Ú 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§

¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î

±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À¹F¨ì0©Î1¡A

¦Ê¤À¤§81.5ªº¯f±w¨Ï¥ÎÀø®ÕµLªkªø´Á¹F¨ìIGAµû¤À¹F¨ì0©Î1,³o¬O£¸­Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡A

¤]¬Oeblasakimab ¤d¸üÃø³{ªº¾÷·|

( Eblasakimab °£¤FTREK-AD »Pdupilumab¥¿­±¹ï¨M¥~ ,¨Ï¥Î¹Ldupilumab Àø®Ä¤í¨ÎªÌªº¥«³õ¤]«ÜÃe¤j,

¥i¥H¤j¤O·m§ð ¥t¥~ÁÙ¦³¦Ê»õ¬ü¤¸¥«³õªº fast-AA COPD )

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©t¨àÃÄ10140658  µoªí®É¶¡:2024/3/13 ¤W¤È 11:52:30²Ä 6588 ½g¦^À³
±±½L©ó§_¹ï§b·à¦Ó¨¥¡A¬Oµu½u½Ä®ö«ÈªºÃöª`¡FµM³o¤½¥q­Y¨S¦³¨ÖÁʪº°Ê¦V¬O¨S¦³ªø»·¤U¤@¨Bªº¡A¤j®a­n²`«×«ä¼{¦p¤T´Á­nªá¦h¤Ö¿ú?´Nª¾¹Dªü·à¥¼¨Ó­n«ç»ò¿ì¤F?

¤j®a°Ñ¦Ò¡A¬ÕÁ«¦Û­t~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2024/3/13 ¤W¤È 09:35:39²Ä 6587 ½g¦^À³
5M ªÑADS¨p¶Ò¡A¬ù¦ûÁ`ªÑ¥»16.7M ¤§3¦¨¡A¤ñ¨Ò«Ü°ª

---------------------------------------------------------------

ÉÜ®a¤£±±盘

ÉÜ®a¤£±±盘¤@¥uªÑ²¼·N¨ýþÓÉÜ®a§C¤_这²¼ªº10%ªº¬y³q筹码¡AÉÜ®a¤â¤¤¤£¨¬10%ªº¬y³q筹码谈¤£¤W±±盘状态¡A¥u¯à说¬O¤@个¤¤¤j户¦Ó¤w!

轻«×±±盘

ÉÜ®a¯à轻«×±±盘¤@¥u个ªÑªº话¤â¤¤个ªÑ³Ì°_码¦³20%¦Ü30%¥ª¥kªº¬y³q筹码¡A这30%ªº¬y³q筹码³£¬O随Éó·t¤¤§C§lªº;³£¬O¾a´²户卖¥XªÑ²¼¡AÉÜ®a¬Ý¦n这²¼¡A³v渐§C§l¦Ó来ªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/13 ¤W¤È 08:57:25²Ä 6586 ½g¦^À³
5M ªÑADS¨p¶Ò¡A¬ù¦ûÁ`ªÑ¥»16.7M ¤§3¦¨¡A¤ñ¨Ò«Ü°ª

¦Ó¥B­q»ù1¬üª÷¡AÁ`¶Ò¸ê¤~500¸U¬üª÷¡AÁÙ­nµ¹¥N²z°Ó¶Äª÷¡A

¹ê®³¤£¨ì500¸U¬üª÷¡A¦p¦¹¾Þ§@¥i¯à¤w¤s½a¤ôºÉ¡A«æ»Ý¥Î¿ú¤S§ä¤£¨ì¿ú¡A

³oªü¤TCEO±q¦b¥xÆW´N­J§@«D¬°¡A±q¤£¦Ò¼{ªÑªF§Q¯q¡A

¦pªG®Ä¥Î¤ñ§ù¥²ª¢¦n¡A¦ÛµM·|¦³¤H¶R³æ¡A¨º¤S¬°¦ó¤~º¦¤@ÂI´N«æµÛ½æ¿ú¡A

¦A¥Í¤¸ªÑ»ù²{¤w9¦Ê¦h¬üª÷¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2024/3/13 ¤W¤È 08:47:36²Ä 6585 ½g¦^À³
§ë¸ê·sÃĥͧÞÁÙ¬OÃöª`¦b¨ä¦¨¥\²v»PÃÄ«~¥«³õ.

¤pªÑªF¦h¤£³ßÅw§CªÑ»ù¡A¤£¹L§CªÑ»ù¦³§Q©ó²ø®a!

1.¤@ª÷¿Ä¤k³Õ¤h说¯}ªÑ¥«¡G为¤°¤\ÉÜ®a´±¥´压ªÑɲ¡AúÒ¤£©È别¤H抢·Gɲ筹码¡H

xueqiu.com/6895810792/146076771

2.¨p¶Ò¾Þ½L¤â³zÅS¡G²ø®a«Ø­Ü¤âªk¥þ§ð²¤

news.cnyes.com/news/id/1154883

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/3/13 ¤W¤È 08:06:04²Ä 6584 ½g¦^À³
·í®É004 ¦b¤@´Áªì

³o¦¸¤G´Á¤w°µ§¹ ·Ç³Æ¤T´Á

ÁÙ¦h°µ¤F¦³«Ø³]©Êªº¸ÕÅç

·íªì4 ¤¸¨p¶Ò ªÑ»ù«æ©Ô¨ì8 ¤¸

»¤¾É¾÷ºc°Ñ¥[¨p¶Ò

³o¦¸ªÑ»ù¼Æ­Ó¤ë¤@ª½¦b 1 ¤¸¥H¤U

°Ñ¥[ªÌÄ@·N¥H 1 ¤¸ÁʤJ

¨p¶ÒÀ³¸Ó¬O«æ©Ô¨ì2 ¤¸ ¤§«e´N½Í¦n¤F

¤½¥¬¨p¶Ò®ø®§«á «æ®À¦^°_ötÂI¡]0.62¡^¤W¤@ÂIÂI

À£¦^¤~¬O¹ïªº

¤£µM ª½öt¤W¥h °Z¤£¬O¦³¤º½u¥æ©ö¤§¶û

500 ¸U¬ü¤¸ªº¨p¶Ò¤£ºâ¤jµ§

¬°¦ó¦³¾÷ºc­n¥Î1 ¤¸°Ñ¥[³o¨p¶Ò

«áÄò

ªÑ»ù¦p¨S¦A¤U¦æ

ÅuµP®É­Ô¨ì¤F

­@¤H´M¨ý

­@¤H´M¨ý

­@¤H´M¨ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/13 ¤W¤È 04:34:51²Ä 6583 ½g¦^À³
ªGµM³Q§Ú§¹¥þ©R¤¤¡A¸òaslan004¤@´Áµo¥¬ªì´Á¼Æ¾Úªº®É­Ô§¹¥þ¤@¼Ë¡A´N¥u¬O¬°¤F¨p¶Ò½Ä°ª»ù®æ¦Ó¤w¡]¤§«eµo¥¬«á½L«e½Ä°ª¨ìUSD8¤¸¡AµM«á¤]¬Oª½±µUSD4¤¸¥ª¥k¨p¶Ò¡AªÑ»ùª½±µ±YÄê¡^¡A³o¦¸¤]¬Oµo­Óªì´Á¥¼¸Ñª¼¼Æ¾Ú¡A½Ä°ª»ù®æ«á¥ß¨è§C»ù¨p¶Ò¡AµM«áªÑ»ùª½±µ±YÄê¡A¾ú¥vÁ`¬OÅå¤Hªº¬Û¦ü¡A¤w¸g¤Wºt³o»ò¦h¦¸¤F¡AÁÙ¬O¦³¤H¿ï¾ÜµLµø¡A¦³¤HÁ`¬O¤@ª½¦b»¡carl firth¬O¨ÖÁÊ°ª¤â¡A½Ð°Ý¥i¥H§ä¥X¤@­Ó¨Ò¤lµ¹¤j®aÁ@Á@¡A¨Ó¬Ý¬Ý¨ì©³¦h·|¨ÖÁÊ¡H§Ú¥uª¾¹D¬O­Ó°é¿ú°ª¤â¦Ó¤w¡A«ö·Ó¤W¦¸¸gÅç¡A±µ¤U¨ÓªÑ²¼·|«ùÄò½w¶^«Üªø¤@¬q®É¶¡¡A¦Ó¥BªÑ¥»¤]¶}©lºCºC¿±µÈ¤¤¤F¡A¦Ñ·à¤Í­Ì½Ð«O­«¡A§O¦A¬Û«H¨º¨Ç¼ÖÆ[¥J¤F¡A¤j®a¥i¥H¥h½½Â¤å¡A´N¥i¥Hª¾¹D¼ÖÆ[¥Jªº¤ÀªR°ò¥»¤W¨S¦³·Ç¹LRRR¡A­Ë¬O§Úµo¤å´£¿ô¤j®aª`·N¡A¼ÖÆ[¥JÁÙ¤£¼Ö¨£¡A¨ì©³¬O½Ö©~¤ß¥r´ú©O¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/12 ¤U¤È 11:41:05²Ä 6582 ½g¦^À³
ªGµM¤@¦p¬J©¹¡A¬Q¤Ñ¤£ºÞ¬O½Ö©Ô°ªªº¡A¤W2¤¸«áª½±µ¤@®Ú¤j¶ÂK¥X³f¡A¥u³Ñ°l°ªªº®M¦b¤s³»¡A¬Ý¬Ý±q2¤¸¨º¤@®Ú±þ¤U¨Ó¤§«á¡A¦¨¥æ¶q¾ã­ÓµäÁY¡A´Nª¾¹D¬Q¤Ñ©Ô°ªªº¥D¤O¦­¶]¤F¡A¥u³Ñ´²¤á­ú·w¦b´Z©Ò¡AµM«á´N¥u¯àÄ~Äò½w¶^¤F¡A¨C¦¸Aslan¦³´Á¤¤¼Æ¾Ú¤½¥¬³£·|¨Ó³o¤@©Û¡A¯uªº¼Æ¾ÚÀu¨q¡A«ç»ò·|¬Q¤Ñ½L«e´X¥G¨S¤ÏÀ³¡Aª½¨ì½L¤¤¤~¶}©l©Ô¡A´N¬O·íµu½uª£¤@ªi¡A¶¶«KÅý¼ÖÆ[¥J¦í®M©Ð¡A¦Ñ·à¤ÍÀ³¸Ó³£«Ü¼ô±x³o®M¸ô¤F.....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/3/12 ¤U¤È 10:00:55²Ä 6581 ½g¦^À³

³¥°¨²æÅ·

¶Õ¤£¥i¾×

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/12 ¤U¤È 09:28:06²Ä 6580 ½g¦^À³
ASLAN Pharmaceuticals ¸g¾ú³sÄòÁ{§É¥¢§Q¦p¤µ­WºÉ¥Ì¨Ó¡A°t¦Xªñ´ÁÁ{§É¼Æ¾Úªºµo§G¡A

ªÑ»ù§Þ³N½u«¬§Î¦¨¦hÀY±Æ¦Cªº±j¯P¶R¶i°T¸¹¡A

ªÑ»ù·|»¡¸Ü¡Aªñ´X­Ó¤ë¥kÃä¤j¶q¦Y±¼¥ªÃä¶q¡A

³oºØ¼Qµo¤Wº¦¤è¦¡¨M«D´²¤á©Ò¬°¡AÁÙ¨S¤W¨®

ªº¤j¤jµ¥®É¾÷¤W¨®¡A¤£¥Î¦Ç¤ß¡C

²Ö¿n¨ÖÁʽͧP¹ê¤O :

TREK-DX :(ªñ¤é¤wµo§G22¤H´¿¨Ï¥Î¹L dupilumab ªº±wªÌ¤¤Âà¨Ï¥ÎeblasakimabªºÀø®Ä¼Æ¾Ú)

63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À¹F¨ì0©Î1¡A³o¬O£¸­Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡A¤]¬Oeblasakimab ¤d¸üÃø³{ªº¾÷·|¡C

TREK-AD : TREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab ¦³¼ç¤O¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅT

Àø®Ä¡A¨Ã¦¨¬° AD ªº»â¥ýÀøªk

FAST-AA : (´Á«Ý¦~¤¤µo§G´³¨r¬ã¨sªº´Á¤¤¼Æ¾Ú)

¨ä¥L¦³¼ç¤Oªº»â°ì

COPD : (ºC©Êªý¶ë©ÊªÍ¯f ´Á«Ýªñ´Á°ê»Ú´Á¥Z¬ã¨sªº¶i¤@¨B¼Æ¾Ú )

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/3/12 ¤U¤È 06:13:49²Ä 6579 ½g¦^À³
¨Ì·ÓAslanªººD¨Ò¡A³£·|¥ý¤½¥¬³¡¤ÀÀø®Ä¬Ý°_¨Ó«ÜÀu¨qªº¼Æ¾Ú¡AµM«á§Q¦h¶}©l¥XÅ¢¡AÀHµÛªÑ»ù¦bµ²ªG¤½¥¬«e¤i¹F¨ì°ªÂI¡AµM«áµ²ªG¥X¨Ó¤£¦p¹w´Á¡Aª½±µ¥´¦^­ì§Î¡A¬Ý¬ÝAslan001¡A»¡ªºÃĮĦh¦n¦h¦³«H¤ß¡Aª¼¼Æ¾Ú¤]¬O»¡¦h¦n¦h¦n¡Aµ²ªG¸Ñª¼«á¤£ºÞ¬O¸~½F¤ÏÀ³²vÁÙ¬O¦s¬¡´Á¡A³£¸ò¦w¼¢¾¯²Õ®t¤£¦h¡A¨ì©³­þ¸Ì¨Óªº«H¤ß¡HAslan004¤]¬O¤@´Á³¡¤À¼Æ¾Ú«ÜÀu¨q¡Aµ²ªG§¹¾ãµ²ªG¥X¨Ó¤]¬O¾ãÅéÀø®Ä¤£¦p¤@°_ªì´Á¼Æ¾Ú¡A¤G´Á¤]¬Oµ²ªG¥X¨Ó¤~¦A»¡¦w¼¢¾¯²Õ¤ÏÀ³²v¤]«Ü°ª¡A¤§«áªÑ»ù´N±Y½L¤F¡A«e¦¸¶gÂà²v¯}¦Ê´N¬O¤@´Áªì´Á¼Æ¾Ú¥X¨Ó¡AµM«áªÑ»ù¶}°ª«á¤½¥q¥ß¨èµo¥¬¨p¶Ò¡AµM«á¤@¸ô±YÄê¡A·íªì¨p¶Ò¶i¨Óªº¥þ³¡®M¦º¡AAslan¤£¯Êµe¤j»æªº¯à¤O¡A»æµeªº¦A¤j¡A¤´Â¤ñ¤£¤W³Ì«áªº¹êÅçµ²ªG¡A³oºØ´Á¤¤¼Æ¾Ú°Ñ¦Ò´N¦n¡A¦Ñ·à¤Í­ÌÀ³¸Ó¤w¸g§K¬Ì¤F.....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2024/3/12 ¤U¤È 05:27:43²Ä 6578 ½g¦^À³
©~µM¤@¤U´N¨S§CÂI¥i¶R...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/12 ¤W¤È 08:15:08²Ä 6577 ½g¦^À³
¬Q±ß¦¨¥æ¶q¬O¾ú¥v¤W³Ì¤j¶q¡A

§CÀÉ¥X¤j¶qÀ³¬O¦n¨Æ¡A

¦ý³o¶q¤]¤ÓÅå¤H¤F¡A

¸Ó¦p¦ó¸ÑŪ¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/12 ¤W¤È 08:01:12²Ä 6576 ½g¦^À³
¦U¦ì¤j¤j

¨È·à±dªÑ²¼Á`¶q¦³16.7MªÑ¡A

¥i¬O¬Q¤Ñªº¦¨¥æ¶q25.2MªÑ¡A

µ¥©ó¬O©Ò¦³ªÑ²¼³£³Q½æ¹L1¦¸¥H¤W¡A

³o¶q¬O§_¥¿½T©O¡A

´X¥G©Ò¦³ªÑ²¼³£´«¤H©Î¬O¦h¦¸¶R½æ¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/12 ¤W¤È 12:08:57²Ä 6575 ½g¦^À³
§ó¥¿¸É¥R

TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦ó­ì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬AAD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Îµo¥Í¤£¨}¨Æ¥ó¡A¨Ã¥H 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¨C¶g¤@¦¸¡A«ùÄò 16 ¶g¡C ¦b¹ï 22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬dªº¼Æ¾ÚºI¤î®É

®Ú¾Ú³Ìªìªº¯Ç¤J¼Ð·Ç¤J²Õ¡A¥H 2:1 ªº¤ñ¨ÒÀH¾÷¤À°t¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A17 ¦W±wªÌ§¹¦¨¤F 16¶gªvÀø´Á¡A5 ¦W±wªÌ¦b 16 ¶gªvÀø´Á§¹¦¨«e°±ÃÄ¡C 10 ¦W±wªÌ¡]§Y 45%¡^ªº EASI ¤À¼Æ¤U­°¦Ü¤Ö 90¡]EASI-90¡^¡A11 ¦W±wªÌ¡]§Y 50%¡^

Àò±o¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô (vIGA) ¤À¼Æ 0 ©Î 1¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^¡C

9¦W±wªÌ¤¤¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90¡A5 ¦W±wªÌ (56%) ¹F¨ì vIGA µû¤À¬° 0 ©Î 1¡C¨´¤µ¬°¤î¡AªvÀøªº­@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C ¨S¦³µ²½¤ª¢ªº³ø§i¡A¤]¨S¦³µù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C ¨Ó¦Û§¹¾ã¼Æ¾Ú¶°ªº³Ì­«­nªº«Dª¼¼Æ¾Ú

¹w­p2024¦~©³¡C

¡u63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^2

¡A ©M¤j¬ù¤@¥bªº±wªÌ½T¹ê¹F¨ì¤F³oºØ¤ÏÀ³¡A¦ý¦b±µ¤U¨Óªº 36 ¶g«á¨Ã¨S¦³ºû«ù³oºØ¤ÏÀ³

¡A©Ò¥H¦³­¢¤Á»Ý­nÃB¥~ªº¥Íª«Àøªk¨Ó´£¨Ñ¦w¥þ¦³®Äªºªø´ÁªvÀø¥¼¹F¨ì¨¬°÷¤ÏÀ³ªº±wªÌªº¿ï¾Ü¡C

­Ó¤Hµû½×

63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À

¹F¨ì0©Î1¡A³o¬O£¸­Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/11 ¤U¤È 11:13:41²Ä 6574 ½g¦^À³
Dupilumab experienced 22¤Hªì¨B¼Æ¾Ú ¶W¥G¹w´Áªº¦n ( Dupilumab Àø®Õ ¤í¨Î¤¤¤S±Ï¤F45%-50 % ªº¤H )

(10¤H/22¤H 45% ¹F¨ì EASI 90 11¤H/22¤H 50% ¹F¨ì vIGA¤À¼Æ 0 ©Î 1 (EASI 75 ¼Æ¾Ú·|¤ñEASI 90 §ó¦n)

(¨ÖÁÊ»ù®æ´£¤É 1 AD ¤G B¼Æ¾Ú 2 ¦~¤¤AA ¼Æ¾Ú 3 TREK-DX¼Æ¾Ú ( ´£¦­¤½§i75¤H¤¤ªº22¤H )

¤µ¤é°T®§«Üªø ­«ÂI¦p¤U

TREK-DX ¯Ç¤J¼Ð·Ç¤w¦¬ºò¼Ð·Ç¡A©Û¶Ò°ò½uÀã¯l­±¿n©MÄY­«µ{«×«ü¼Æ (EASI) µû¤À¦Ü¤Ö¬° 18 ¤À

¡]¦Ó¤£¬O 16 ¤À¡^ªº±wªÌ¡C¦P®É¡A¤]¹ê¬I¤F¿W¥ßµû¼f­û¹ï°ò½u EASI ¤À¼Æªº½T»{¡C ¬ü°êºô¯¸¥Ø«e¥¿¦b®Ú¾Ú§ó·sªº¼Ð·Ç©Û¶Ò±wªÌ¡A¼Ú¬wªº¨ä¥L¯¸ÂI¤]¹w­p¦b¼Ú¬w¶}©ñ2024 ¦~¤W¥b¦~¡C

TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦ó­ì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬AAD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Îµo¥Í¤£¨}¨Æ¥ó¡A¨Ã¥H 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¨C¶g¤@¦¸¡A«ùÄò 16 ¶g¡C ¦b¹ï 22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬dªº¼Æ¾ÚºI¤î®É®Ú¾Ú³Ìªìªº¯Ç¤J¼Ð·Ç¤J²Õ¡A¥H 2:1 ªº¤ñ¨ÒÀH¾÷¤À°t¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A17 ¦W±wªÌ§¹¦¨¤F 16¶gªvÀø´Á¡A5 ¦W±wªÌ¦b 16 ¶gªvÀø´Á§¹¦¨«e°±ÃÄ

10 ¦W±wªÌ¡]§Y 45%¡^ªº EASI µû¤À¤U­°¦Ü¤Ö 90%¡]EASI-90¡^

11 ¦W±wªÌ¡]§Y 50%¡^Àò±o¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô (vIGA) ¤À¼Æ 0 ©Î 1

¨´¤µ¬°¤î¡AªvÀøªº­@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C

Dupilumab experienced(½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w)

¤j®a·Q¤@·Q TREX-DX ¹êÅç¼Æ¾Ú¬OÀø®Ä¤ñ¸û­«­n ÁÙ¬O¦­¤@ÂI¤½§i¼Æ¾Ú¤ñ¸û­«­n ? ¤½¥q½Õ¾ã¦¬®×µ¦²¤

¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡¬O¥¿½Tªº¿ï¾Ü

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/11 ¤U¤È 08:23:31²Ä 6573 ½g¦^À³
TREK-DX ¬O²Ä¤@­Ó¦b¸g¾ú dupilumab ªº²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¸sÅ餤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¬ã¨s¡A¤w¶}©l®Ú¾Ú§ó·sªº¤è®×¦b¬ü°ê©Û¶Ò±wªÌ¡F ·sªº¼Ú¬w¯¸ÂI¹w­p©ó 2024 ¦~¤W¥b¦~¶}·~

¦b¹ï¨´¤µ¬°¤î±µ¨üªvÀøªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªºªì¨B¼f¬d¤¤¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö­°§C¤F90%¡A50% (11/22)ªº±wªÌ¹F¨ì¤F16 ¶g«á vIGA µû¤À¬° 0 ©Î 1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡C ¹w­p§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬

Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦VIL-13R »PIL-4R ªº®ÄªG¦s¦b®t²§¡Aªí©úeblasakimab ¦³¥i¯à¹ïDupilumab ¥¼¹F¨ì¨¬°÷¤ÏÀ³ªºAD ±wªÌ¦³®Ä¡A³o¬O¤@­Ó­«­n¥BªA°È¤£¨¬ªº±wªÌ¸sÅé¡A«Ü¤Ö¦³¦w¥þ©Mªø´ÁªºªvÀø¿ï¶µ¡A

¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2024 ¦~3 ¤ë11 ¤é¡]Àô²y³q°TªÀ¡^¡XASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§J¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¡G¸Ó¤½¥q¤w¶}©l¦b¬ü°ê®Ú¾Ú¥¿¦b¶i¦æªºTREK-DX ¸ÕÅ窺§ó·s¤è®×©Û¶Ò±wªÌ¡A¦b¨Ï¥Î¹Ldupilumab ªº¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢(AD) ±wªÌ¤¤¬ã¨seblasakimab¡C

TREK-DX ¬O²Ä¤@­Ó¦b¬J©¹±µ¨ü¹L dupilumab ªvÀøªº AD ±wªÌ¤¤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¸Ó¥«³õ¹w­p¨ì 20291 ¦~±N¹F¨ì 100 »õ¬ü¤¸¡C±j½Õ¤F¬ü°êAD ±wªÌ¸sÅ骺ÅܤơA TREK-DX ¯Ç¤J¼Ð·Ç¤w¦¬ºò¡A¥H©Û¶Ò°ò½uÀã¯l­±¿n©MÄY­«µ{«×«ü¼Æ(EASI) µû¤À¦Ü¤Ö¬°18¡]¦Ó¤£¬O16¡^ªº±wªÌ¡C»P¦¹¬Ûµ²¦X¡A¿W¥ßµû¼f­û°ò½u EASI ¤À¼Æªº½T»{¤]¤w¹ê¬I¡C ¬ü°êªº¯¸ÂI¥Ø«e¥¿¦b®Ú¾Ú§ó·sªº¼Ð·Ç©Û¶Ò±wªÌ¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹w­p±N©ó 2024 ¦~¤W¥b¦~¶}©ñ¡C

TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦ó­ì¦]¡]¥]¬A AD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Î¤£¨}¨Æ¥ó¡^°±¤î dupilumab ªvÀøªº±wªÌ¡A¨Ã¨C¶g¨Ï¥Î 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¥L­Ì¡A«ùÄò 16 ¶g¡C ¦b¹ï®Ú¾Ú­ì©l¯Ç¤J¼Ð·Ç¤J²Õªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬d®É¡A³o¨Ç±wªÌ«ö2:1 ªº¤ñ¨ÒÀH¾÷¤À¬°¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A¦b¼Æ¾ÚºI¤î®É¡A17 ¦W±wªÌ§¹¦¨¤F16 ¶gªºªvÀø´Á¡A5 ¦W±wªÌ¦b§¹¦¨«e°±ÃÄ16¶gªºªvÀø´Á¡C ¦b²Ä16 ¶g©Î³Ì«á¤@¦¸´N¶E®É¡A10 ¦W±wªÌ¡]§Y45%¡^ªºEASI µû¤À¤U­°¤F¦Ü¤Ö90%¡]EASI-90¡^¡A11 ¦W±wªÌ¡]§Y50%¡^¹F¨ì¤F0 ©Î1 ¤Àªº¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô(vIGA) µû¤À¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^¡C ¦b¥ý«e¹ïdupilumab ¤ÏÀ³¤£¨¬ªº9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡C¨´¤µ¬°¤î¡AªvÀø­@¨ü©Ê¨}¦n¡A¨S¦³·sªº¦w¥þ©Ê°T¸¹³QÃѧO¡C ¥Ø«eÁÙ¨S¦³µ²½¤ª¢ªº³ø§i¡A¤]¨S¦³µù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C ¹w­p§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬¡C

¡u63% ±µ¨üdupilumab ªvÀøªº±wªÌ¦b16 ¶g«á¥¼¯à¹F¨ì³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬°0 ©Î1¡^2¡A¨Ã¥B¦b¹F¨ì³oºØ¤ÏÀ³ªº±wªÌ¤¤¡A¤j¬ù¤@¥b¦bÀH«áªº36 ¶g«á¨S¦³ºû«ù³oºØ¤ÏÀ³3¡A¦]¦¹­¢¤Á»Ý­nÃB¥~ªº¥Íª«Àøªk¡A¬°¹ï dupilumab ¨S¦³¨¬°÷¤ÏÀ³ªº±wªÌ´£¨Ñ¦w¥þ¦³®Äªºªø´ÁªvÀø¿ï¾Ü¡C EASI-90 ©M vIGA ¬O AD ¬ã¨s¤¤³ÌÄY®æªº²×ÂI¤§¤@¡C ¾¨ºÞ³o¬O°ò©ó¹ïª¼ªk¼Æ¾Úªºªì¨B¼f¬d¡A¦ý§Ú­Ì¹ªÀyÆ[¹î¨ì TREK-DX ¬ã¨s¤¤¨´¤µ¬°¤î¹F¨ì³o¨Ç²×ÂIªº±wªÌ¤ñ¨Ò«Ü°ª¡C §Ú­Ìªº¥«³õ¬ã¨sµo²{¡A¤j¦h¼Æ AD ±wªÌ¹ï¥Ø«eªºªvÀø¶È·P¨ì¤¤µ¥º¡·N«×¡C ³o»P§Ú­Ì²£¥ÍªºÂà¤Æ¼Æ¾Ú¤@°_¤ä«ù¤F eblasakimab §@¬°³o¨Ç±wªÌªvÀøªº¼ç¦b§@¥Î¡A¨Ã¥B§Ú­Ì¦b TREK-DX ¬ã¨s¤¤²£¥Íªº¼Æ¾Ú¥i¥HÃÒ©ú¡A¹ï©ó³\¦h±wªÌ¨Ó»¡¡Aeblasakimab ¬Æ¦Ü¥i¥H±±¨î¥L­Ìªº¯e¯fdupilumab «o¨S¦³¡A ¡vASLAN »sÃĤ½¥q°õ¦æªøCarl Firth ³Õ¤h»¡¡C

Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦V IL-13R »P IL-4R ªº®ÄªG¦s¦b®t²§¡A³oªí©ú§Y¨Ï¦b dupilumab µL®Äªº±¡ªp¤U¡Aeblasakimab ¤]¦³¥i¯à¦³®Ä¡C

Eblasakimab °w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé (IL-13R) ¨È°ò¡Aªý¤î³z¹L¥Õ¦å²y¤¶¯À 4 (IL-4) ©M¥Õ¦å²y¤¶¯À 13 (IL-13) ªº°T¸¹¶Ç¾É¡C ¨âªÌ³£¬OAD µoª¢ªºÃöÁäÅX°Ê¦]¯À¡AµM¦Ó¡A³ÌªñµoªíªºÂà¤Æ¼Æ¾Ú±j½Õ¤F¦bAD ±wªÌ¥~©P¦å³æ®Ö²Ó­M¤¤¡Aeblasakimab ¹v¦VIL-13R ¬Û¹ï©ódupilumab ¹v¼ÐIL-4 ¨üÅé(IL-4R)ªºÀu¶Õ4¡C »P IL-4R ªýÂ_¬Û¤ñ¡AIL-13R ªýÂ_¥i§ó¦³®Ä¦a´î¤Ö»P 2 «¬ÅX°Ê¡]¹L±Ó©Ê¡^µoª¢¦³Ãöªº²Ó­M¦]¤l¡A¨Ã­°§C 1 «¬«Pª¢²Ó­M¦]¤lªº¤ô¥­¡C ¨Ó¦Û AD ±wªÌ¥Ö½§¬¡Àˤ¤ eblasakimab ©M dupilumab ªºÀY¹ïÀY¬ã¨sªº¨ä¥L¼Æ¾ÚÃÒ¹ê¤F¹v¦V IL-13R »P IL-4R5 ªº®t²§¤Æ®ÄªG¡C ¦b³o¶µ¬ã¨s¤¤¡Aeblasakimab ¤ñ dupilumab §ó¦³®Ä¦a´î¤Ö¤F¥Ö½§²Õ´«Pª¢ 2 «¬²Ó­M¦]¤lªº§½³¡¤Àªc¡A³oªí©ú eblasakimab ¥i¯à¹ï dupilumab ¥¼²£¥Í¨¬°÷¤ÏÀ³ªº AD ±wªÌ¦³®Ä¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/11 ¤U¤È 08:16:04²Ä 6572 ½g¦^À³
TREK-DX ¬O²Ä¤@­Ó¦b¸g¾ú dupilumab ªº²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¸sÅ餤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¬ã¨s¡A¤w¶}©l®Ú¾Ú§ó·sªº¤è®×¦b¬ü°ê©Û¶Ò±wªÌ¡F ·sªº¼Ú¬w¯¸ÂI¹w­p©ó 2024 ¦~¤W¥b¦~¶}·~

¦b¹ï¨´¤µ¬°¤î±µ¨üªvÀøªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªºªì¨B¼f¬d¤¤¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö­°§C¤F90%¡A50% (11/22)ªº±wªÌ¹F¨ì¤F16 ¶g«á vIGA µû¤À¬° 0 ©Î 1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡C ¹w­p§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬

Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦VIL-13R »PIL-4R ªº®ÄªG¦s¦b®t²§¡Aªí©úeblasakimab ¦³¥i¯à¹ïDupilumab ¥¼¹F¨ì¨¬°÷¤ÏÀ³ªºAD ±wªÌ¦³®Ä¡A³o¬O¤@­Ó­«­n¥BªA°È¤£¨¬ªº±wªÌ¸sÅé¡A«Ü¤Ö¦³¦w¥þ©Mªø´ÁªºªvÀø¿ï¶µ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/7 ¤U¤È 11:34:33²Ä 6571 ½g¦^À³
¤½¥q¤T¤ë¤»¤é­«­n°T®§¡A¨â¦ì¬ì¾ÇÅU°Ý¾Ç¸g¾ú

2024 ¦~ 3 ¤ë 6 ¤é

ªü´µÄõ»sÃĤ½¥q (ASLAN Pharmaceuticals) ¤½§G Eblasakimab ªvÀøºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº·sÂà¤Æ¼Æ¾Ú¡A¨Ã¥ô©R»â¥ýªº©I§l¨t²Î±M®a¬°¬ì¾ÇÅU°Ý

¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¹ïeblasakimab©Mdupilumab¶i¦æªºÀY¹ïÀY¬ã¨sªº·sÂà¤Æ¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡Aeblasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è­±Àu©ódupilumab

»â¥ýªº©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h©M Reynold Panettieri Âå¾Ç³Õ¤h³Q¥ô©R¬°¬ì¾ÇÅU°Ý¡A¬°eblasakimabªº®t²§¤Æ¥H¤Î¥¼¨Ó COPDÁ{§É¶}µo´£¨Ñµ¦²¤«Øij

¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A 2024 ¦~ 3 ¤ë 6 ¤é¡V ASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤F¨Ó¦Û¤@®a¤½¥qªº·sªº¿n·¥Âà¤Æ¼Æ¾Ú¡C¦bºC©Êªý¶ë©ÊªÍ³¡¯e¯f (COPD) ¤HÅé²Õ´¼Ò«¬¤¤¹ïdupilumab»PeblasakimabCOPD¥Íª«Àøªkªº¼ç¤O´£¨Ñ¤F¶i¤@¨B¤ä«ù¡C¦¹¥~¡A¸Ó¤½¥qÁÙ«Å¥¬¥ô©R©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h¡B«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡BÂå¾Ç³Õ¤h¡Bù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø Reynold Panettieri Jr ³Õ¤h¬° ASLAN ¬ì¾Ç¹Î¶¤¦¨­û¡C¿Ô¸ß©e­û·|¥¿¦bµû¦ôeblasakimab§@¬°ªvÀøºC©Êªý¶ë©ÊªÍ¯f¥H¤Î²§¦ì©Ê¥Ö½§ª¢(AD) ªº¼ç¦bÀøªk¡C

¡u¦b»P ASLAN ¹Î¶¤¦X§@¡A±qeblasakimab©Mdupilumab¦b COPD ±wªÌ²Õ´¤¤ªºÀY¹ïÀY¬ã¨s¤¤Àò±o¥O¤H¦L¶H²`¨èªºÂà¤Æ¼Æ¾Ú«á¡A§Ú«Ü°ª¿³¥¿¦¡¥[¤J¬ì¾ÇÅU°Ý©e­û·|¡A¶i¤@¨B±´¯Áeblasakimab¦b COPD ¤¤ªº¼ç¤O¡A¡¨³Õ¤h»¡

¡u§Ú«Ü°ª¿³¯à»P ASLAN ¹Î¶¤¦X§@¡A§Q¥Î³o­Ó¥O¤H¿³¾Äªº¾÷·|¨Óµû¦ôeblasakimab¦b COPD¡]¤@ºØ 2 «¬ÅX°Ê¯e¯f¡^¤¤ªº¶}µo¸ô®|¡C§Ú¬Û«H¥Íª«»s¾¯¦³«Ü¤jªº¾÷·|§ïÅܳoºØºC©Ê¯fªºªvÀø®æ§½¡A´N¹³§Ú­Ì¦b¨ä¥L©I§l¨t²Î¯e¯f¦pÄY­«®ð³ÝªºªvÀø¤¤©ÒÆ[¹î¨ìªº¡C³o¨Ç·s¼Æ¾Úªí©úeblasakimab¦³¼ç¤O¦¨¬° COPD ªº¤@¬y¥Íª«ÀøªkÃĪ«¡A§Ú´Á«Ý§Ú­Ìªº¦X§@¹Ù¦ñÃö«Y¡A¡vù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø Reynold Panettieri Jr ³Õ¤h»¡¡C

2023 ¦~ 11 ¤ë¡AASLAN «Å¥¬¤F¨Ó¦Û°·±d®½Ãت̲Õ´ªºÂà¤Æ¼Æ¾Ú¡AÅã¥Üeblasakimab§@¬° COPD ªvÀøÃĪ«§í¨î 2 «¬µoª¢ªº¼ç¤O¡C¨Ï¥Î COPD ±wªÌªºªÍ²Õ´¶i¦æ¤F¶i¤@¨Bªº¬ã¨s¡A¤ñ¸û¤F¬Û¦P¿@«×ªºeblasakimab©Mdupilumab¡C¨CºØªvÀø±ø¥ó§¡¦b¦Ü¤Ö 6 ­Óºë½T¤Á³ÎªºªÍ¤Á¤ù¤¤¶i¦æ´ú¸Õ¡C¦b COPD ±wªÌ²Õ´¤¤¡Aeblasakimab¥i¦³®Ä«ì´_¦¬ÁY¡A¥HÀ³¹ï IL-4 ©M IL-13 ªº¬D¾Ô¡A¨Ã¦b¦¬ÁYªº®ð¹D¤¤ªí²{¥XºÖ²ö¯Sù»¤¾Éªº§Ö³t®ð¹DÂX±i¡CºÖ²ö¯Sù¬O¤@ºØªø®Ä£]¨üÅé¿E°Ê¾¯¡A¬O®ð³Ý©MºC©Êªý¶ë©ÊªÍ¯f±wªÌ±`¥Îªº¤@ÃþÃĪ«¡C­È±oª`·Nªº¬O¡Aªì¨B¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡A eblasakimab¦b¦h­Ó»â°ìªºªí²{Àu©ódupilumab¡A¥]¬A IL-4 ©M IL-13 §ðÀ»«á®ð¹D¥\¯àªº«ì´_

¡C

¡u§Ú­Ì¬Û«Heblasakimab¦³¼ç¤O¦¨¬°»â¥ýªºªvÀø¿ï¾Ü¡A¦]¬°§Ú­Ì¥¿¦b±´¯Á¨ä¦b AD ¥H¥~ªº¨ä¥L¯e¯f¤¤ªº¾A¥Î©Ê¡A¨Ò¦p COPD¡A³o¬O¤@­Ó©|¥¼Àò±o§å­ãªº¥Íª«»s¾¯ªº¤j«¬¥«³õ¡C§Ú­Ì´Á«Ý»P Krishnan ³Õ¤h©M Panettieri ³Õ¤h¥H¤Î¼ç¦b¦X§@¹Ù¦ñ¦X§@¡A¦Ò¼{ COPD ªº¼ç¦b·§©ÀÅçÃÒ²Ä 2 ´Á¬ã¨s³]­p¡A¨Ã±´¯Á³Ìªñ¶i¦æªº¥Íª«¾Ç¬ã¨s¤¤ªº·s²×ÂI¡A¡vASLAN ­º®u°õ¦æ©x Carl Firth ³Õ¤h»¡

¦³ÃöeblasakimabªvÀøºC©Êªý¶ë©ÊªÍ¯fªº§ó¦hÂà¤Æ¼Æ¾Ú±N¦b§Y±N¥l¶}ªº¬ì¾Ç¤j·|¤W´£¥æµoªí¡C

Ãö©ó Ramaswamy Krishnan¡A«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡B­õ¾ÇºÓ¤h¡B³Õ¤h

Ramaswamy Krishnan³Õ¤h¬O«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡C¥Lªº¹êÅç«Ç±Mª`©óªÍ¤O¾Ç©M¾÷±ñ¶Ç¾É¡A±Mª`©ó®ð¹D¦p¦ó¦¬ÁY©M©ñÃP¡C¬°¦¹¡A¥Lµo©ú¤F¤@®M§Þ³N¨Ó´ú¶q®ð¹D²Ó­M©M²Õ´ªº¦¬ÁY¡BÃP¦¢¡B¤O¶Ç»¼©M¤O¶Ç¾É¡C³o¨Ç§Þ³N¤£¶È¨Ï¥L¦Û¤vªº¹êÅç«Ç¯à°÷µo²{ªvÀøºC©Êªý¶ë©ÊªÍ¯f©M®ð³Ýªº·s­Ô¿ïÃĪ«¡A¦Ó¥BÁÙ¦b¥þ²y½d³ò¤º³Q¥Î§@µû¦ô«Ý©w­Ô¿ïÃĪ«ªº¤ä®ðºÞ«OÅ@©M¤ä®ðºÞÂX±i¥\¯àªºÂà¤Æ¤èªk¡CKrishnan ³Õ¤h¦b­ô­Û¤ñ¨È¤j¾ÇÀò±o¾÷±ñ¤uµ{³Õ¤h¾Ç¦ì¡A¨Ã¦b«¢¦ò¤j¾Ç¶i¦æªÍ¥Í²z¾Ç³Õ¤h«á¬ã¨s¡C¥Lµoªí¤F¶W¹L 75 ½g¤å³¹¡Bµû½×¡BªÀ½×©M³¹¸`¡A¨ä¤¤³\¦hµoªí¦b¡m¦ÛµM²Ó­M¥Íª«¾Ç¡n©M¡m¦ÛµM§÷®Æ¡nµ¥µÛ¦W¦P¦æµû¼f´Á¥Z¤W¡C

Ãö©ó Reynold Panettieri Jr ³Õ¤h¡]Âå¾Ç³Õ¤h¡^ ù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø

Reynold A Panettieri Jr Âå¾Ç³Õ¤h¬Où®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç¬ã¨s©Òªº­º¥ô©Òªø©MÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø¡A¦¹«e´¿¾á¥ô»«¦{¤j¾Ç®ð¹D¥Íª«¾Ç­p¹º¥D¥ô¡CPanettieri ³Õ¤hªº¹êÅç«Ç±Mª`©ó®ð¹D¥­·Æ¦Ùªº§K¬Ì¥Íª«¾Ç¡BÀô¹Ò¬r¯À¹ï®ð¹D°ª¤ÏÀ³©Êªº¼vÅT¥H¤Î®ð³Ý©MºC©Êªý¶ë©ÊªÍ¯fªvÀø¤èªkªº·s¼Ð¹v©M¥­¥xªºÃѧO¡C°£¤F¥Lªº¬ã¨s©MÁ{§É¿³½ì¤§¥~¡APanettieri ³Õ¤hÁÙ¾á¥ô NIH ªÍ²Ó­M¡B¤À¤l©M§K¬Ì¥Íª«¾Ç¬ã¨s³¡ªùªº¥D®u¡A¨Ã¥B¬O NIH ³Ç¥X½s¿è¤p²Õªº¦¨­û¡CPanettieri ³Õ¤hµoªí¤F¬ù 450 ½g¥Xª©ª«¡A¨Ã¦b»«¦{¤j¾Ç±µ¨ü¤FÂå¾Ç°ö°V¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/7 ¤U¤È 10:28:28²Ä 6570 ½g¦^À³
A ¤j®a§Ñ¤F¶}µo¤@ºØÃĪ«¥i¥H¦³«Ü¦h¾AÀ³¯g ( eblasakimab ¶}µo²§¦ì©Ê¥Ö½§ª¢AD , ®ð³Ý»PºC©Êªý¶ë©ÊªÍ¯f

COPD , Farudodstat ¶}µo Alopecia areata ¯ë¨r )

B Dupilumab experienced(½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w)

¤j®a·Q¤@·Q TREX-DX ¹êÅç¼Æ¾Ú¬OÀø®Ä¤ñ¸û­«­n ÁÙ¬O¦­¤@ÂI¤½§i¼Æ¾Ú¤ñ¸û­«­n ? ¤½¥q½Õ¾ã¦¬®×µ¦²¤

¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡¬O¥¿½Tªº¿ï¾Ü

C Eblasakimab¬O¤@ºØ·s«¬¥þ¤H·½³æ®è IgG4 §ÜÅé¡A¥i¯S²§©Êµ²¦X¥Õ¦å²y¤¶¯À (IL)-13 ¨üÅé (IL-13R)¡A

ªý¤î³z¹L 2 «¬¨üÅé¶Ç»¼ IL-4 ©M IL-13 °T¸¹¡C 2 «¬¨üÅé¬O¥]§tIL-4¨üÅé(IL-4R)©MIL-13¨üÅé(IL-13R)

ªº²§¤G»EÅé¡C²Ó­M¿E¯À IL-4 ©M IL-13 ³z¹L 2 «¬¨üÅéµo¥X°T¸¹¡A¬Oµoª¢ªºÃöÁäÅX°Ê¦]¯À¡A¬O¤Þµo AD¡B®ð³Ý

©M COPD µ¥ 2 «¬¯e¯fªº¹L±Ó¯gª¬ªºÃöÁä

D 2024 ¦~ 3 ¤ë 6 ¤éªü´µÄõ»sÃĤ½¥q (ASLAN Pharmaceuticals) ¤½§G Eblasakimab ªvÀøºC©Êªý¶ë©ÊªÍ¯f

(COPD) ªº·sÂà¤Æ¼Æ¾Ú¡A¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¹ïeblasakimab©Mdupilumab¶i¦æªºÀY¹ïÀY¬ã¨sªº·sÂà¤Æ

¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡Aeblasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è­±Àu©ódupilumab

E »â¥ýªº©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h©M Reynold Panettieri Âå¾Ç³Õ¤h³Q¥ô©R¬°¬ì¾ÇÅU°Ý¡A¬°eblasakimabªº®t²§¤Æ¥H¤Î¥¼¨Ó COPDÁ{§É¶}µo´£¨Ñµ¦²¤«Øij (¹ï¤S¤@­Ó¦Ê»õ¬ü¤¸ªº¾AÀ³¯g °Ê§@¶W§Ö¬O¥i²z¸Ñªº)

Dupilumab¤]¬O¤@¼Ë¶}µo«Ü¦h¾AÀ³¯g

Dupilumab¾A¥Î©óªvÀø¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢(2017 FDA )¡B¤¤«×¦Ü­««×®ð³Ý(2018 FDA) ¡A

¥H¤ÎªvÀø¦ñÀH»ó®§¦×ªººC©Ê»óÄuª¢

2022 ¦~ 5 ¤ë¡Adupilumab ªº·s¾AÀ³¯gªvÀø12 ·³¤Î¥H¤W¡BÅé­«¦Ü¤Ö 40 ¤½¤ç¡]88 ½S¡^ªº¤Hªº

¶Ý»Ä©Ê²É²Ó­M©Ê­¹¹Dª¢

2022 ¦~ 9 ¤ë¡Adupilumab ªº·s¾AÀ³¯g¬°¥]¬AªvÀø¦¨¤Hµ²¸`©ÊÄo¯l¡]PN¡^

¬ã¨s¤¤ COPD

2023 ¦~ 3 ¤ë¡AÁɿյ᤽§G¤F¤@¶µ 3 ´Á¸ÕÅ窺µ²ªG¡A¸Ó¸ÕÅçÀˬd dupilumab ªvÀø

ºC©Êªý¶ë©ÊªÍ¯f(COPD) ªºÀø®Ä¡C¦b³o¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅ礤¡Adupilumab

ÃÒ©ú COPD ¤¤«×©Î­««×«æ©Ê´c¤Æ´î¤Ö 30%¡A¥B COPD ±wªÌªºªÍ¥\¯à©M¥Í¬¡«~½èÅãµÛ§ïµ½

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/3/7 ¤U¤È 12:28:16²Ä 6569 ½g¦^À³
§Úı±oÀ³¬OTREX-DX¸ÕÅç¼Æ¾Ú¤£¦n¡A

©Ò¥H¤~Åܧ󦬮׹ï¶H¤§¼Ð·Ç¡A

²{ªp¤S¨S¸g¶O°µ004 3´Á¸ÕÅç¡A

¥ý§ä­Ó±µÄò´À¥N­pµeÄ~Äò©¿巄¤j®a¡A

¬Ý¯à¤£¯à¦bÄFÂI¸g¶Oª¯©µ´Ý³Ý¡A

¤£ºÞ¬O¨rÀYÃĩάOCOPDÃÄ¡A

³£¬Oªü¤TÄF¿ú¥Îªº¤â¬q¡A

µL¸Û«Hªº¤½¥q¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©t¨àÃÄ10140658  µoªí®É¶¡:2024/3/7 ¤W¤È 08:56:36²Ä 6568 ½g¦^À³
«æº¦¤Å³ß¡A«æ¶^¤Å¼~¡F±o¤§§Ú©¯¡A¥¢¤§§Ú©R¡F¬Ýºò²ü¥]¡A¬ÕÁ«¦Û­t!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/3/6 ¤U¤È 10:38:33²Ä 6567 ½g¦^À³
3h«eªº·s»D

¤§«e°µ¥Ö½§¹L±Ó

²{¦b§ïÅÜ·s¤è¦V¥h°µ©I§l¹DªÍ¯f?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/3/1 ¤U¤È 10:32:44²Ä 6566 ½g¦^À³
¤½¥qªº¬ãµo²£«~¥D­n¥H¤jÃĬ°¥D ¨âÁû¤jÃÄ©è¹L¤QÁû¤pÃÄ

§Ú­Ìªº²£«~²Õ¦X¥H eblasakimab ¬°¥D¾É¡A³o¬O°w¹ï IL-13 ¨üÅ骺¼ç¦b¤@¬y§ÜÅé¡A¦³¥i¯à

§ï¶i¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C §Ú­Ì¤]¥¿¦b¶}µo Farudodstat¡A¤@ºØ DHODH 酶

ªº¦³®Ä¤fªA§í¨î¾¯¡A§@¬°ªvÀø´³¨rªº¼ç¦b¤@¬yÀøªk¡C

1 Eblasakimab IL-13R£\1 Atopic dermatitis

¬O¤@ºØ¥¿¦b¶}µoªº¥Î©ó¤¤­««× AD ªº·s«¬¥Íª«»s¾¯¡A¦³¥i¯à±q¤@¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¥B¤£¼vÅTÀø®Ä

¨Ì¾Ú¤½¥q2024¦~¤@¤ë²³ø ¨ì2029¦~ ²§¦ì©Ê¥Ö½§ª¢¥þ²y¥«³õ190»õ¬ü¤¸

2 Dupilumab experienced ½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w)

T

3 Type 2-driven disease (¤G«¬ª¢¯g) 81% ²§¦ì©Ê¥Ö½§ª¢¯f±w¦³¤G«¬¬ÛÃöª¢¯g( ¦p¹L±Ó ®ð³Ý)

4 ¨ä¥L¦³¼ç¤O¾AÀ³¯g COPD ºC©Êªý¶ë©ÊªÍ¯f

5 Farudodstat DHODH Alopecia areata Phase 2a interim topline data mid-2024

2022 ¦~¬ü°ê´³¨r¡]²æ¾v¡^ªvÀø¥«³õ¦ô­È¬° 34.44 »õ¬ü¤¸¡A¹w­p 2023 ¦~¦Ü 2030 ¦~½Æ¦X¦~¼W

ªø²v¬° 5.50%¡A¨ì 2030 ¦~¹F¨ì 52.85 »õ¬ü¤¸¡C(¥þ²y¥«³õ2030¦~ 137»õ¬ü¤¸)

¨Ì¾Ú¤½¥q2024¦~¤@¤ë²³ø´³¨r²×¥Íµo¯f²v¦Ê¤À¤§2.1% 2020¦~¬ü°ê¯f±w70¸U¤H

¨ä¤¤¦Ê¤À¤§25 ÄÝ©óÄY­«±¡ªp 62%´³¨r¯f±w·|±µ¨üÃĪ«ªvÀø

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/3/1 ¤W¤È 01:56:33²Ä 6565 ½g¦^À³
µ²ªG¨ÈÀã±d ¾a¨rÃÄ­n½¨­?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/2/29 ¤U¤È 10:23:10²Ä 6564 ½g¦^À³
2024 ¦~ 2 ¤ë 29 ¤é ªü´µÄõ»sÃĤ½¥q Farudodstat ªºª«½è²Õ¦Xª«±M§Q¥Ó½Ð¼Ú¬w±M§Q§½ªº¦nµû

farudodstatªº·sª«½è²Õ¦X±M§Q±N¥[±j´¼¼z°]²£Åv«OÅ@¡A¨Ã¬°farudodstat´£¨Ñ°Ó·~¿W¦ûÅv¡A

¦Ü¤Ö«ùÄò¨ì 2043 ¦~¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2024 ¦~ 2 ¤ë 29 ¤é¡V ASLAN Pharmaceuticals Ltd.

¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¨ä

¤wÀò±o¦³§Qªº±M§QÅv§@¬°°ê»Ú¼f¬d­ûªº¼Ú¬w±M§Q§½ (EPO) ¹ïFarudodstatªº¦h´¹«¬±M§Q¥Ó½Ðµoªí¤F·N¨£¡A

¦pªG¦b°ê®a¶¥¬qÀò±o§å­ã¡A±N§âFarudodstatªº¦³®Ä±M§Q«OÅ@©µªø¦Ü¦Ü¤Ö 2043 ¦~¡C

Farudodstat¬O¤@ºØ¦³®Äªº¤fªA¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í¨î¾¯¡A¦³¥i¯à¦¨¬°´³¨r (AA) ªº¤@¬yªvÀø

¿ï¾Ü¡CASLAN ¥Ø«e¥¿¦b AA ¤¤¶i¦æ 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¡]¡uFAST-AA ¬ã¨s¡v¡^¡A¹w­p¸Ó¬ã¨sªº¤¤´Áµ²ªG

±N©ó 2024 ¦~¤¤´Á¤½§G¡C

ASLAN Pharmaceuticals °õ¦æªø Carl Firth ³Õ¤h»¡¡C

¡u§Ú­Ì«Ü°ª¿³¦¬¨ì¼Ú¬w±M§Q§½Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¥¿­±ªì¨B·N¨£¡A¨Ã»{¥i§Ú­Ì©Ò¦³

ªºÅv§Q­n¨D§¡¨ã¦³·s¿o©Ê©M³Ð³y©Ê¡C¦pªG¦b°ê®a¶¥¬qÀò±o±ÂÅv¡A·s±M§Q±N§âfarudodstatªº±M§Q«OÅ@

©µªø¦Ü¦Ü¤Ö2043¦~¡C³o±NÅãµÛ¼W±jfarudodstatªº°Ó·~¿W¦û©Ê¡A¬O§Ú­Ì¦b©Ò¦³ÃöÁä°Ó·~»â°ìfarudodstat

¥[±j ¥Ñ©ó´³¨r±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü«Ü¤Ö¡A§Ú­Ìªº¥Ø¼Ð¬O¬°±wªÌ´£¨Ñ¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C

Ãö©ó Farudodstat

Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í¨î¾¯¡A¥i³z¹LªýÂ_ DNA ½Æ»s©Ò»ÝªºáGÔr±qÀY ²£¥Í¨Ó

§í¨î§K¬Ì²Ó­M¼W´Þ©M IFN-£^ ¤Àªc¡C»P²Ä¤@¥N DHODH §í¨î¾¯¬Û¤ñ¡A farudodstat ¹ï DHODH ©M

T ²Ó­M¬¡©Êªº§í¨î®ÄªG¬ù¬° 30 ­¿¡A¨Ã¥B¨ã¦³¨}¦nªº­@¨ü©Ê¦w¥þ©Ê¡CASLAN ²£¥Íªº¼Æ¾ÚÅã¥Ü¡A

farudodstat ¥i¥H¼ç¦b¦a¨¾¤î¤òÅn§K¬Ì¯SÅv³à¥¢¡A¤ä«ù¨ä§@¬° AA ¤@¬yªvÀø¿ï¾Üªº¼ç¤O¡C

AA ªº 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¡]FAST-AA ¬ã¨s¡^¥Ø«e¥¿¦b¶i¦æ¤¤¡A¹w­p±N©ó 2024 ¦~¤¤´Á¤½§G¤¤´Áµ²ªG¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/2/27 ¤U¤È 09:20:32²Ä 6563 ½g¦^À³
NVIDIA(½÷¹F) 22¤é¤½¥¬°]³ø¡Aªí²{¶W¥G·Q¹³ªº¦n¡A¬Q¤éªÑ»ù790.92 USD ¡I

¯¸¦bAI®ö¼é¦yºÝªº¥L¡A¶À¤¯¾±ªñ¤é«o¶}¥Ü¥Í©R¬ì¾Ç¤~¬O¥¼¨ÓÅã¾Ç

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/2/27 ¤U¤È 06:36:11²Ä 6562 ½g¦^À³
1.§ÚÁöµM¤£¬Ý¦nASLAN¡A¦ý¤]¤£±Æ°£³Ì«áµ²ªG¥´Áy§Ú¡A¤£¹L¦³¤@説¤@¡A°ò¥»¤W13F¤£¥i¯à´¦ÅS«ù¦³³¡¦ìªº¶R¶i»ù®æ¡A´N¹³¤Úµá¯S¤§«e¶R¶i¥x¿n¹q¡A¤j®a¤]¥u¯àÂÇ¥Ñ13F¥h§PÂ_¶R¶iªº®É¶¡ÂI¬O²Ä´X©u¶i¦Ó¥h¦ôºâ§¡»ù¡Awhalewisdom.com¤W­±ªº»ù®æ¤]¥u¬O°Ñ¦Ò¡Awhalewisdom.com¨Ã¤£·|³qÆF¡A©Ò¥H§Ú¤~»¡ºô¯¸¸ê®Æ¦³À°¦£¾ã²z«ùªÑ¸ê®Æ½T¹ê¤è«K¡A¦ý¦³¨Ç¸ê°T°Ñ¦Ò§Y¥i¡A¤£¥Î¹L«×Ár´ú¡A»{¯u­n¬ÝÁÙ¬O¥h¬ÝSECªº­ì©l¸ê®Æ¤ñ¸û¦n¡C

2.¸Û¦p¸Ø±i¤j©Ò»¡¡AASLAN¨Ã¤£¬O¼öªùªÑ²¼¡A©Ò¥H³o1.2¤¸«ç»ò¦ô¥X¨Óªº§Ú¤£ª¾¹D¡A¦ý«Ü©úÅãwhalewisdomªººô¯¸¸ê®Æ´N¬O2023Q4²Ä¤@¦¸¶R¶iªº«ùªÑ³£¬O1.2¤¸¡A¥h¥J²Ó¬Ý´NÆZ©úÅ㪺¡A¨Ò¦pBVF,Parkman Healthcare,Rhumbline³£¬O2023Q2²Ä¤@¦¸¶R¶i¡A¶R¶i»ù®æ¤]³£¬O3.65¡ASchonfieldÁöµM¬O3.24¡A¦ý¬O¬O¦]¬°«áÄò¦³¼W«ù¼vÅT¨ìwhalewisdomªº¦¨¥»­pºâ¡A©Ô¦^¥hwhalewisdom¸ÌASLANªº2023Q2«ùªÑ¸ê®Æ¡A¥i¥H¬Ý¨ìSchonfied¶R¶i»ù®æ¤]¬O3.65¡A©Ò¥H¨ä¹ê¤£¦s¦b©Ò¿×¤º½uªº°ÝÃD°Õ¡A³»¦h´N¬O¦³7®a§ë¸ê¾÷ºc¶i¨Ó¦Ó¤w¡A¨ä¤¤¦³UBS³o¤j©@¡A´N¥u¬O³o»ò²³æ¡A¦pªG¯uªº¦³¤º½u¡AASLAN¥«­È¤~¦h¤Ö¡Aª½±µ¶R¤U¨Ó³£¥i¥H¤F¡A7®a¦X­p¤~¶R¤J¤£¨ì150¸UªÑ¡A¥H0.5¤¸¨Óºâ¤]¤~75¸U¬ü¡A¸òªk¤Hªº§ë¸ê³¡¦ì¤ñ°_¨Ó¡A´N¬OªáÂI¤p¿ú¶R­Ó¼Ö³z¦Ó¤w.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/2/26 ¤U¤È 05:04:26²Ä 6561 ½g¦^À³

¯u§Æ±æ¸Ø±i¤j©Ò¼gªº

¬O ¯«µo²{

¨È·à³o­Ó»ù ½æ¤F ½ß­Óª¯¦Y«Ë£½

¥u¯à§Ñ¤F¥¦ ¬ß°]¯«·Ý²²ÅU

ÁÂÁ¸رi¤j¡I¡I¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/26 ¤W¤È 08:40:51²Ä 6560 ½g¦^À³
whalewisdom.com/stock/asln

¥h¦~²Ä¤T©uºI¤î¡A¦³22®a§ë¸ê¾÷ºc«ù¦³¨È·à±dªºªÑ²¼

¦Ó¦Ü112/12/31(112¦~²Ä¥|©u)µ²§ô

§ï¥Ñ23®a§ë¸ê¾÷ºc«ù¦³¨È·à±dªºªÑ²¼(6®a¥X²M¡B7®a·s¶i)

(23®aºâ«Ü¤Ö¤F)

¦Ó23®aùØ­±¦³7®a¬O¥h¦~²Ä¥|©u¤~­è·s¶iªº§ë¸ê¾÷ºc

7®a¾÷ºc¦p¤U

1. UBS GROUP AG¶R¶i625,000ªÑ

2. SHAY CAPITAL LLC¶R¶i400,000ªÑ

3. LANDSCAPE CAPITAL MANAGEMENT, L.L.C.¶R¶i83,259ªÑ

4. XTX TOPCO LTD¶R¶i27,666ªÑ

5. JANE STREET GROUP, LLC¶R¶i23,093ªÑ

6. ONYX BRIDGE WEALTH GROUP LLC¶R¶i22,727ªÑ

7. CUTLER GROUP LLC¶R¶i1,000ªÑ

·s¶iªº7®a¥þ³¡³£¬O²Ä¤@¦¸¶R¶i¡A¤]³£¦P¤@»ù¦ì¡A¶R¶iªº»ù¦ì³£¬O1.2¤¸/ªÑ¡A³o»ò¥©

(¦³¤º½u¤~´±¶i¨Ó¶R§a)

¥h¦~²Ä¥|©uªÑ»ù°ªÂI1.92¤¸¡AªÑ»ù§CÂI0.392¤¸

½Ð¤j¤jÀ°¦£ºâ¤@¤U7®a³£¶R¦P¤@»ù¦ìªº¾÷²v¬O¦h¤Ö?

(­Y¤À§å¶R¡A³Ì«á¥­§¡¬O1.2¤¸¤]¤£Â²³æ~~~¦ý½Ð¤£­n³o»ò·Q)

¨È·à±d¤£¬O¼öªùªÑ§a(¼öªùªÑ(¥x¿n¹q-ADR)§Ú´N¬Û«H¬O¥©¦X)(´N¥ý¥H¤º½u¸ÑŪ)

¨ä¤¤112¦~Q4ªº·ç»È§Q¥ÎªÑªF¨­¤À©ó113¦~1¤ë

¶i¦æ¡G

1.¸ò¨È·à±d°ª¼h°Q½×´M§ä¦X§@¹Ù¦ñ¶i«×

2.§ä¨ìªÑ²¼½æ®a(½æ®a¬°¦ó­n½æ?)

3.½Í¦n¥æ©ö»ù¦ì

«á

113/2/6¦A¥[½X¥Ó³ø¶R¶i16,292,600ªÑ

ÁÙ¦³2/1~2/13ªº½L¤¤¨C¤ÀÄÁ¥æ©ö¤Î2/15¨C¤Q¤ÀÄÁ¥æ©ö1000ªÑªº¸ê°T¡A³£­n¨ì5/15¤~ª¾¹D¡C³o­Ó¤~¼F®`¡C

(­Y¨È·à±d5/15«e³Q¨Ö¡A§A´Nª¾¹D­þ¨Ç¤½¥q¦³¤º½u¤F)

¸ò¦U¦ì¤À¨É

¨Ã½Ð«ü¥¿(7®a³£¶R¦P¤@»ù¦ì¡A¦U¦ì¤j¤j¬Û«H¬O¥©¦Xªº½Ð»¡©ú¤@¤U¡A§ÚÅ¥¬Ý¬Ý¦X¤£¦XÅÞ¿è¡AÁÂÁÂ)(§ë¸ê­·ÀI½Ð¦Û¦æµû¦ô)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/2/24 ¤U¤È 10:22:29²Ä 6559 ½g¦^À³
1.Dupilumab¾P°âÃB°ª¡A°£¤FAD¥~¡A³o´X¦~«ùÄò§ð§J¤F¦h¶µ¾AÀ³¯g¸ò¥i¨Ï¥Î±Ú¸s¡ACOPD¤]¬OFDAª½±µµ¹Àu¥ý¼f¬dÅv¥[³t¼f®Ö³q¹L¡A¦³³o¨Ç¤~³y´N¤F¦Ê»õ¤jÃÄ¡AEblasakimab¤G´Á¤w¸g¹L¤F¤j¥b¦~¡A¹ï¤@­Ó«ùÄò¿N¿úªº·sÃĤ½¥q¨Ó»¡¡A³o®ö¶Oªº®É¶¡¦¨¥»¥N»ù«D±`°ª©ù¡A¦pªGEblasakimab¯uªº¥«³õ¼ç¤O¦p¦¹Àu¨q¡A«ç·|©ì¤F³o»ò¤[ÁÙ¥d¦b³o¸Ì¡H¤@°ï¤jÃļt¦£µÛ©ï»ù¦X§@³£¨Ó¤£¤Î¤F¡A²{¦b´Nºâ¦³¦X§@¹ï¶H¥i¥H¿ï¾Ü¡A¤j·§²v³£¬O¦X§@±ø¥ó¤£¬Æ²z·Q¡A¤~·|¥d³o»ò¤[¡A²¦³º³o¤j¥b¦~´X¥G¬ãµo¨SÔ£¶i®i¡A¯uªº¦³¤jÃļt·P¿³½ìªº¸Ü¡AÀ³¸Ó¤G´Á«e´N¶}©l³W¹º¬¢½Í¡A¤G´Áµ²ªG¥X¨Ó´N«æµÛ±ÂÅv©Î¨ÖÁʤF¡Aµo­Ó¤G´Á¸ÕÅ窺¶i¤@¨B¥Íª«¼Ð°O¸ò¦¸±Ú¸s¤ÀªR´N§O»¡¬OÔ£¶i®i¤F¡A´N¬O¨S¿ú°µ¤T´Á¡A¥u¯à²`¤J¤ÀªR¤@¤U¤G´Á¼Æ¾Ú¡A¤£µMÁÙ¯à«ç»ò¿ì¡HCOPD¤]¥u¬O¤Á¤ù¹êÅç¡A³£ÁÙ¦bªì´Á±´¯Á´N¤£­n¦n°ªÄE»·¤F¡A¥ý·Q¿ìªk±À¶iAD¤T´Á§a....

2.whalewisdom.comªº¸ê®Æ§Ú¬O»{¬°°Ñ¦Ò§Y¥i¡A¦pªG­n»{¯u¬ã¨s¬üªÑ¡AÁÙ¬O¥h¬Ý¤½¥qªºSEC¸ê®Æ¤ñ¸û·Ç½T¡A¥u³æ¾aºô¯¸¾ã²zªº¸ê®Æ¨ä¹ê¦³­·ÀI¡A¦]¬°¸Ì­±ªº¸ê®Æ¨ä¹ê¦³¨Ç¸Óµù©ú¨Sµù©úªº¡A¨Ò¦p¦³¨ÇªÑªFªº«ùªÑ³æ¦ì¬O¥ÎADS¡]25ªÑ­ì©lªÑ¡^¡A¦³¨ÇªÑªFªº«ùªÑ³æ¦ì¬O¥Î­ì©lªÑ¡ABVF.K2³æ¦ì³£¬O­ì©lªÑ¡AÀ³¸Ó¬O¦]¬°2023¦~¨p¶Ò¸ò»{ªÑÅvªº³æ¦ì³£¬O­ì©lªÑªº½t¬G¡A©Ò¥HSEC¤å¥ó¤W¥Ó³øªº³æ¦ì¤]³£¬O­ì©lªÑ¡Awhalewisdom.com¶È¶È¥u¬O§â¼Æ¦r¦C¤W¥h¦Ó¤w¡ABVF¹ê»Ú¤W«ùªÑ¼W¥[¡A¨Ã«D¬O±q¥«³õ¤W¶R¶i¡A¬O¥Ñ¤§«e¨p¶Ò»{ªÑÅv»{ªÑ¦Ó¨Ó¡A³o¦bSEC¤å¥ó¤¤³£¦³µù©ú¡A¦Ówhalewisdom.com¤W¨Ã¤£·|´¦ÅS¨ì³o»ò¸Ô²Ó¡C

3.¥H§ë¸ê¨Ó»¡¡AªÑ»ù²×¨s·|¦^Âk°ò¥»­±¡A±q2018¦~ADS¾ú¥v³Ì°ª»ù52.195¨ì2024¦~ªÑ»ù¤£¨ì0.5¡A§O¦Aè¤ß¦k·Q¬O¥«³õ¨Sµo²{ASLANªº»ù­È¤F¡A¦Ó¬OASLAN¹ê»Ú¤W´N¥u­È³o¼Ë¡A´L­«¥«³õok?

4.½Ð¦Ñ·à¤Í­Ì¦ò¨t¬Ý«Ý«ùªÑ¡A¨S½ß´NºâÁȨì¤F¡A§O«ü±æ·|¤jÁÈ¡A²¦³º«ù¦³¦¨¥»À³¸Ó³£¤£§C¡A¤]§O·Q¤p¿ú¤jÅu¥­¡A¨S¥²­n¬°¤F¥W³æ·d¨ì³s¤p¿ú³£½ß¶i¥h¡A¤ñ°_¯{¿ú¦bASLAN¡A®³¥h§ë§Oªº¤ñ¸û¹ê»Ú........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/2/24 ¤U¤È 05:48:12²Ä 6558 ½g¦^À³
µ¥¸ó±i¤jªº

¾÷ºc«ùªÑ

¦³¦ó¥©¦X¤§¨Æ

ÁÂÁ±z¡I¡I¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/2/23 ¤W¤È 09:42:52²Ä 6557 ½g¦^À³
³o³¾Âû¦ØªÑ¡A

©ñ±ó§a¡A

©{¦p¶BÄF¶°¹Î¡A

³s¤@ª½¹ª§jªº¤H¡A

¤]»{©R°h¥X¤£¨£¤F¡A

©ú¤Ñ¹L«á¤j¡A¤~¬O¥ýª¾¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦N10151329  µoªí®É¶¡:2024/2/23 ¤W¤È 09:35:26²Ä 6556 ½g¦^À³
ÁÙ¥H¬°¤µ¦~·|ºCºC¤W¥h, µ²ªG¤S³oºØ¶^ªk

¤Ó§é¿i

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/2/23 ¤W¤È 05:29:52²Ä 6555 ½g¦^À³
¶ã©I«s«v¡I¡I¡I

ªÑ»ù¤£µ¹¤O

³oºØ¶^ªk

¤Ó§é¿i¤H¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/17 ¤U¤È 10:57:15²Ä 6554 ½g¦^À³
¥h¦~²Ä¥|©u,¾÷ºc«ùªÑÁÙ¦³§ó¥©ªº¨Æ,¤U¶g¤À¾å.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/2/17 ¤U¤È 09:51:47²Ä 6553 ½g¦^À³
·ç»È·s¼W«ùªÑ¨Ó¨ì16,917,600ªÑ ( ¸ê°T¦b Page2 ) whalewisdom.com/stock/asln

·ç»È¦X¨Ö·ç«H«áÅD¤É¥þ²y²Ä¤G¤j°]´IºÞ²z¾÷ºc ¼W¥[ ASLN «ùªÑ ¥²¦³¨ä±M·~§PÂ_ªº²z¥Ñ

112/12/31¤î

«ùªÑ²Ä1¦WBVF ­ì«ùªÑ8,488,000 ªÑ ·s¼W«ùªÑ34,856,975ªÑ Á`­p43,344,975ªÑ

«ùªÑ²Ä2¦WK2 ­ì«ùªÑ5,293,226 ªÑ ·s¼W«ùªÑ17,174,449ªÑ Á`­p22,467,675ªÑ

«ùªÑ²Ä3¦W·ç»È ­ì«ùªÑ625,000 ªÑ ·s¼W«ùªÑ16,292,000ªÑ Á`­p16,917,600ªÑ

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

¨ü¸Õ¨Ó¦Û¤£¦P°ê®a ¤£¦P¸~±Ú( ¬ü°ê ¥[®³¤j ¯Ã¦èÄõ ¿D¦{ ¦L«× ·s¥[©Y ªiÄõ) ( ¬ü¦{ ¿D¦{ ¨È¦{ ¼Ú¦{ )

CNTBªºCBP-201 ¤G´ÁÁ{§É ¬d¸ß ClinicalTrials.gov ¨ü¸Õ§½­­¦b¦Û¤v°ê®a ¦P¤@ºØ±Ú

®æ§½¤£¦P ¥ø¹Ï¤ß¤£¦P Àø®Ä»P¦w¥þ©Ê¤£¦P ¥@¬É¯Å¤jªÑªF«ùªÑ¤£¦P ---- »ù­È·íµM¤£¦P

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/17 ¤U¤È 05:04:41²Ä 6552 ½g¦^À³

¦³¾÷ºc½æ¥X¡A·íµM´N¦³¾÷ºc¶R¤J¡C

(¦ý´N¬O³o»ò¥©¦X)

ºI¦Ü112/12/31´N¦³6®a¾÷ºc¶R¦b¦P¤@»ù¦ì

1. UBS GROUP AG¶R¶i625,000ªÑ

2. SHAY CAPITAL LLC¶R¶i400,000ªÑ

3. LANDSCAPE CAPITAL MANAGEMENT, L.L.C.¶R¶i83,259ªÑ

4. XTX TOPCO LTD¶R¶i27,666ªÑ

5. JANE STREET GROUP, LLC¶R¶i23,093ªÑ

6. ONYX BRIDGE WEALTH GROUP LLC¶R¶i22,727ªÑ

¤W­z6®a³£¬O²Ä¤@¦¸¶R¶i¡A¶R¶iªº»ù¦ì³£¬O1.2¤¸/ªÑ¡A³o»ò¥©

(¦U¦ì¥i¥H¥h¬d¥L­Ìªº­t³d¤H)

¨È·à±d¤£¬O¼öªùªÑ§a(¼öªùªÑ§Ú´N¬Û«H¬O¥©¦X)

(´N¥ý¥H¤º½u¸ÑŪ)

¨ä¤¤·ç»È113/2/6¦A¥[½X¶R¶i16,292,600ªÑ

¸ò¦U¦ì¤À¨É³o­Ó´¡¦±

(§ë¸ê­·ÀI½Ð¦Û¦æµû¦ô)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/2/17 ¤U¤È 03:17:52²Ä 6551 ½g¦^À³
1.Dupilumabªº¦¨ÁZ¦³¥Ø¦@¸@¡A§âEblasakimab®³¨Ó¤ñ¸û¡A·íµM¬Ý°_¨Ó«e³~¤@

¤ù¥ú©ú¡A¦pªG¯uªº¯à¸òDupilumab¤À®x§Ü§¡A¨º¦Ñ·à¤Í­Ì´N¦³ºÖ¤F¡A¦ý¤ñ°_

¸òDupilumab¬Û¤ñ¡AASLAN¥Ø«eªºª¬ªp§Ú­Ë¬Oı±o¸òCNTB¤ñ¸û¬Ûªñ¡A¤@¼Ë¬O

¬D¾ÔDupilumab¡A¦ý¤G´Á¸ÕÅçµ²ªG³£¦]¦w¼¢¾¯²Õ¤ÏÀ³²v¤]°ª¡A»P¹êÅç²ÕÀø®Ä

®t²§¨S¦³·Q¹³¤¤¤j¡A¾É­PªÑ»ù§C°g¤£®¶¡AASLAN¸òCNTB¤]³£ÁnºÙ¦¸±Ú¸s¤ÀªR

ªí¥ÜAD¸û¬°ÄY­«ªÌ¡A¦w¼¢¾¯²Õ»P¹êÅç²Õ®t¶Z§¡¦³®Ä´£°ª¡ACNTBªºCBP-201±q

2022¦~¤G´Á¸Ñª¼µ²§ô¨ì²{¦b³£¥¼Äw¨ì¤T´Á¸êª÷¡A2023¦~11¤ëµo¥¬CBP-201©µ

¦ù¨ì52¶gªºªvÀøµ²ªG¡A­ì¦³16¶g¦³®Ä±wªÌ«ùÄòªvÀø¨ì52¶g«á¬ù¦³8.9¦¨¯àºû

«ùÀø®Ä¡AµM«áñ­q±ÂÅv¦X¬ù¡A¦¬¨ú«eª÷¤j¬ùUSD2100¸U¡AÁ`±ÂÅvª÷¬ù

USD1.25»õ¡A²{¦bAD¤T´Á¤]¬OÄw¤£¨ì¸êª÷¿ð¿ðµLªk¶}©l¡A¶ZÂ÷¸Ñª¼¦Ü¤µ¤w

¹L1¦~¥H¤W¡A¥u¯à´Â­ý³Ý¥tÅP³~®|¡A¤£Ä±±o³o¸òASLAN¤ñ¸û±µªñ?¶Z¸Ñª¼¦Ü¤µ

¤]¤w¹L¤F¤j¥b¦~¡ATREK-DX¹w­p¦³µ²ªG¤]¬O2024¦~©³¤F.......

2.³o¤@ªi°h³õªºªÑªF­Ì°£¤FTANG¡A²H°¨¿üµ¥µ¥¸û¦­´ÁªºªÑªF¤]³£¤@°_ºM¤F

¡AÁöµM«ùªÑ³°Äò¦³ªk¤H±µ¤â¡A¦ý©Ò¿×ªº¤º½uÃø¹D¨­¬°³Ì¤jªÑªFªºTANG¤]¤£

ª¾¹D¡A¼ÝµM¨MµM¥X°â¤j¶q«ùªÑ?³o§Ú«ù«O¯dºA«×¡A¤£¹L¦³¤HªÖ±µªº½T¤]¬O¦n

¨Æ¤@¼Î¡C

3.²{¦b°ò¥»¤W´N¬O¤@½¤GÀü²´¡A¼ÖÆ[ªÌı±o¤ñªÓDupilumab¡A´dÆ[ªÌı±o¸ò

CBP-201®t¤£¤F¦h¤Ö¡AÁ`¤§°µ¦n¤ß²z·Ç³Æ§Y¥i¡AŤ§§Ú©¯¡A¿é¤§§Ú©R¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/17 ¤W¤È 10:02:52²Ä 6550 ½g¦^À³
(·s¼W§ùÁת¢2023¦~¾P°âÃB)

¨È·à±d¨ÖÁʪ÷ÃBºâªk¦p¤U¡G

°Ñ¦Ò·|­û¡G¤Ñ©R¤j10141925 µoªí®É¶¡:2023/6/22 ¤U¤È 08:20:52

ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô

¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸.

¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸

27.7-7.8(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»¤§§Q¯q)

ASLN004 ¤§»ù­È:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í

¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q)

¥H¤W¥¼§t003°Ó¥Î«á¤§¨ÖÁÊ»ù¡C

¥[003°Ó¥Î«á¤§¨ÖÁÊ»ù¦ô¬ù¬üª÷25»õ¤¸³Q¨ÖÁÊ(©¹«áªº20¦~¡C¨C¤@¦~ªº10% ¾P°â¤À¼í¥¼ºâ¶i¥h)¡C

¥tÃö©ó¾P°â¤À¼í¨C¦~10%¡G

¥H§ùÁת¢2023¦~Á`¾P°âÃB115.9»õ­pºâ¡A

·sÃĤò§Q¥H8¦¨­pºâ¡G115.9*0.8=92.72»õ¬ü¤¸¬OÁÉ¿Õµá³æ³æ2023¦~½æ§ùÁת¢²bÁÈ­È

115.9*10%=11.59»õ¬ü¤¸´N¬O·í(¥h)¦~¾P°â¤À¼í10%ªº­È

§ùÁת¢¦~«×¾P¦¬ª÷ÃB¦p¤U¡G(·PÁ¤ѩR¤j´£¨Ñ)

2017¦~/2.279»õ¬ü¤¸

2018¦~/9.22»õ¬ü¤¸

2019¦~/23.156»õ¬ü¤¸

2020¦~/40.448»õ¬ü¤¸

2021¦~/61.988»õ¬ü¤¸

2022¦~/86.811»õ¬ü¤¸

2023¦~/115.9»õ¬ü¤¸

§ùÁת¢¦Ü2023¦~¤î¦@¾P°â339.8»õ¬ü¤¸

¾P°â¤À¼í10%=33.98»õ¬ü¤¸(´«ºâ¾P°â¤À¼í15¦~§Y¶W¹L150»õ)( Eblasakimab¦p¥xÁÞ¤j©Ò»¡ªGµM¬O¶W¯Å¤jÃÄ)

ASLN ¦¨¾À¯È¾÷²v¬Û·í§C¡D

¦ý¶W°ªÀø®Ä¤£¥i¯à¡D

¥u­nÀø®Ä¡B¥ÎÃÄÀW²vĹ¹L§ùÁת¢§Y¥i

Eblasakimab¦b©¹«á20¦~ªº¾P°â¹w¦ô­È¤@©w°Ñ¦Ò§ùÁת¢­q©w

³o20¦~ªº¾P°â¤À¼í¥[Á`(¾P°â¤À¼í¨C¦~10%)¤]·|¨Ö¤J¨È·à±d³Q¨Öª÷ÃB¸Ì­±¡C

(¥H¤W³¡¤À¯ÂÄÝÁr´ú¡BÁr´ú¦p¦³¹p¦P¡B¹êÄÝ¥©¦X)

¥H¤W½Ð«ü¥¿

(§ë¸ê¦³­·ÀI¡B½Ð¦Û­t¬ÕÁ«)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/2/16 ¤U¤È 05:09:19²Ä 6549 ½g¦^À³
·PÁ¸ó±i¤j

¦pªG¬O³o¼Ëªº¸Ü

Aslan ÁÙ¦³À¸

§Æ±æ ±µ¤U¨Ó

¦nÀ¸³s¥x

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/16 ¤U¤È 04:38:48²Ä 6548 ½g¦^À³
½Ð¬d¥H¤Uºô¯¸

whalewisdom.com/stock/asln

(½Ð°O¤U¨Ó¡A113/5/15ÁÙ·|¦A¬d¤@¦¸)

112/12/31¤î

«ùªÑ²Ä1¦WBVF ·s¼W«ùªÑ34,856,975ªÑ¨Ó¨ì43,344,975ªÑ

«ùªÑ²Ä2¦WK2 ·s¼W«ùªÑ17,174,449ªÑ¨Ó¨ì22,467,675ªÑ

«ùªÑ²Ä3¦W·ç»È ·s¼W«ùªÑ16,292,600ªÑ¨Ó¨ì16,917,600ªÑ

­ð¤½¥q´î«ù39,020,205ªÑ³Ñ6,134,975ªÑ

­ð¸ê¥»¥X²M1,901,552ªÑ

(ªoºj·Æ±¼¤j¤j¦b2024/1/3 ¤W¤È 10:36¦³µoªí¤F)

(§Ú¬Q¤Ñ¥u·Q½T»{¬y¦V¡A¦]¬°¶q¤j¡A­n¦³¤H¥i¥H±µ¤U¨Ó¡C­ì¨Ó¬OBVF¡BK2±µ¨«)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2024/2/16 ¤U¤È 02:33:39²Ä 6547 ½g¦^À³
¬O¦b»¡¹Ú¸Ü¶Ü¡H

½Ð°Ý¸ó±i¤j

­ðªºÄw½X³Q³o¨â®a±µ¨«ªº¸ê®Æ

­þ¸Ì§ä±o¨ì¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/16 ¤U¤È 12:40:16²Ä 6546 ½g¦^À³
¬Q±ß(2/15)ªº½L§ó©úÅã

¨C¹j¬ù10¤ÀÄÁ¥æ©ö900~1000ªÑ

¥D¤O¦b¸Ì­±

¥t

­ð¤½¥qªºÄw½X¥þ³QBVF¡BK2±µ¨«

BVF¡BK2¬O¥h¦~2¤ëªº¶U´Ú»È¦æ

(ª¾¹D¨È·à±d·|­Ë¡AÁÙ¶U´Úµ¹¥¦¡AÁÙ±µ¥¦ªºªÑ²¼???)

(ÁÙ´ÚÁÙ®i©µ¨ì114¦~1¤ë1¤é)

¥t

¤µ¦~2/1~2/13¤Î2/15ªº½L¤¤¥æ©ö¹ï¶H

¦]Äݤµ¦~Q1¡A­n¤µ¦~5¤ë15¤é¤~·|ª¾¹D

½L¤¤¥æ©ö¹ï¶H¤~¬O­«ÂI

¦]¨È·à±d³Q¨Öªº¤º³¡¸ê°T¤w¸g©ú®Ô

³o´N¬O¤º½u

5¤ë15¤é«e³Q¨Ö¾÷·|¤j

³Q¨Ö«á

µ¥¨ì5/15§Ú­Ì´Nª¾¹D¤µ¦~2/1~2/13¤Î2/15ªº½L¤¤¥æ©ö¹ï¶H¬O½Ö¤F

³o´N¬O¤º½u

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2024/2/14 ¤U¤È 11:06:17²Ä 6545 ½g¦^À³
2/1~2/13(¬Q¤Ñ),¨C¤ÀÄÁ³£¦³¦¨¥æ°O¿ý,¬O¤£¥¿±`ªº¡C¥u¯àÃÒ©ú¦³¥D¤O¦bùØ­±¡C

²{¦b(2/14),

10:30(¶}½L)¦¨¥æ134ªÑ

10:42¦¨¥æ6000ªÑ

10:45¦¨¥æ100ªÑ

10:46~11:00¨S¦¨¥æ¶q¡C

¤µ¤Ñ½L¶Õ«ì´_¥¿±`(¨S¦³¨C¤ÀÄÁ³£¦³¦¨¥æ¶q)¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/2/9 ¤U¤È 10:44:14²Ä 6544 ½g¦^À³
´N½u½×½u

ªñ´Á©³³¡¥X¶q¡A¶}§C¨«°ª¦h¤é¯dªø¤U¼v½u¡A

¤ë½u¦­¤w¬ð¯}©u½u½u§e²{¤¤´Á¦hÀY±Æ¦C¡A¤µ¤é¦A¶}§C¨«°ª

¤Q¤é½u±N¬ð¯}¤ë½u¡Aµu´Á¦hÀY±Æ¦C§Î¦¨¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/2/9 ¤W¤È 10:06:18²Ä 6543 ½g¦^À³
·Pı¦³¤H³s3¤Ñ¦b0.55ªþªñ¦Y³f¡A

ªÑ»ù¤w¸gÄê«Ü¦h¦~¤F¡A

§Æ±æ¯àÀs¦~·s¦~·s®ð¶H¡A

¯¬ºÖ¤j®a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/2/8 ¤W¤È 12:14:35²Ä 6542 ½g¦^À³
¤S½M¤SÄê §j³£¤£·| ªÑ»ù¤]¼µ¤£°_¨Ó=_=
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gblessyiche10143957  µoªí®É¶¡:2024/1/19 ¤U¤È 11:58:58²Ä 6541 ½g¦^À³
½Ð°ÝFirstrade «ç»ò²{¦b¤£¯à¶R¡A¥u¯à½æ°Ú¡H

¥X²{¡¨¡¨Illiquid,Opening Position Trades Not Accepted ¡¨ »Ý­nñ¸p¤°»ò¸ê®Æ¶Ü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2024/1/17 ¤W¤È 11:39:26²Ä 6540 ½g¦^À³
¬Q¤Ñ©M¥h¦~7¤ë6¤éII´Á¸Ñª¼­«®À¤@¼Ë¡A

¤U¶^ªñ4¦¨¡A¤S±N¶}±Òªø´Á¤U¶^ÁͶաA

½Ð°Ý¦U¦ì¤j¤j¡A

¹w­q1¤ë24¤éªÑªF·|±ÂÅv¤½¥q¸ê¥»¼W¥[¡A

¬O¤£¬O¦³¤H¤£·Q°Ñ¥[¥ý¨«¡A©Î¬Oµu´ÁÀò§Q¤Fµ²¡A

·Pı³oªÑ¦h¨a¦hÃø¡A±q¥¼À°ªÑªF¿Ñ¤@ÂIÂIçħQ¡A

¤Ñ©R¤j±zªº¬Ýªk©O

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/1/16 ¤U¤È 09:14:11²Ä 6539 ½g¦^À³
·íAslan pharmaceutical ADR ¹L¤F1¬ü¤¸¡A¤U¥«ºÃ¼{¸Ñ°£¡A´N¬O²¢»e»ùªº¶}©l¡A°²¦p§ë¸ê¾÷ºcµû¦ô¤½¥q¦³16¬ü¤¸¡A¶V±ß¦^¸É²¢»e«×¶V§C,¶V¦­¦^¸É²¢»e«×¶V°ª¡A§C»ù´N¬O³Ì¤jªº»¤¦]¡C

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ²`¤Jµû¦ô ¦A°µ¨Mµ¦

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/1/12 ¤U¤È 11:43:30²Ä 6538 ½g¦^À³
¤w¸g0.86 §CÂI¹L¤F¶R¤£¨ì²¢²¢»ù¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/1/12 ¤U¤È 09:04:41²Ä 6537 ½g¦^À³
³¡¥÷§ë¸ê¾÷ºc°ªÂI½æ¥X«ùªÑ,À£§CÀ~¥XÄw½X,¥Ø«e²{ª÷º¡º¡¥i¥H±q§CÂI¦^¸É,¤]¥i¥H»{ªÑÂX¤j«ùªÑ¤ñ²v

«ç»ò¤U¨Ó«ç»ò¤W¥h, «ùªÑ¦¨¥»°ª¨S¦³½æ¥X©Î¤w½æ¥X¦³»ù®t, ¦pªG¦Û¤vµû¦ô¥Ø«e¤½¥q¬ãµoÃĪ«¦³¼ç¤O¡A

¨S¦³·Q¹³ªº¨º»ò®t,±©¤@ªº«Øij°Ê§@´N¬O¶q¤O¦Ó¬°ºÉ§Ö¦^¸É,¤p¿ú¤jÅu¥­,§Ö³t­°§C¦¨¥»

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2024/1/12 ¤U¤È 08:20:32²Ä 6536 ½g¦^À³
º¦¹L¨Ã¯¸Ã­1¤¸§Ú´N¶R¦^
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/1/11 ¤W¤È 03:13:56²Ä 6535 ½g¦^À³
¯u¤û¹G ©³³¡¤û¥« ¤S¤jº¦20% ¿ð¿ð¤£´±¥[½X¤@ª½¦b¬ÝÀ¸ ­n¦^¥»¤]¦nÃø
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/1/9 ¤U¤È 06:43:30²Ä 6534 ½g¦^À³
Eblasakimab ¦bºC©Êªý¶ë©ÊªÍ¯fCOPD ªº¼ç¤O (¥þ²yCOPD¥«³õ 2022¦~181»õ¬ü¤¸ ¹w´Á¨ì 2032¦~¹F298.8»õ¬ü¤¸)

Eblasakimab¬O¤@ºØ·s«¬¥þ¤H·½³æ®è IgG4 §ÜÅé¡A¥i¯S²§©Êµ²¦X¥Õ¦å²y¤¶¯À (IL)-13 ¨üÅé (IL-13R)¡Aªý¤î³z¹L 2 «¬¨üÅé¶Ç»¼ IL-4 ©M IL-13 °T¸¹¡C 2«¬¨üÅé¬O¥]§tIL-4¨üÅé(IL-4R)©MIL-13¨üÅé(IL-13R)ªº²§¤G»EÅé¡C²Ó­M¿E¯À IL-4 ©M IL-13 ³z¹L 2 «¬¨üÅéµo¥X°T¸¹¡A¬Oµoª¢ªºÃöÁäÅX°Ê¦]¯À¡A¬O¤Þµo AD¡B®ð³Ý©M COPD µ¥ 2 «¬¯e¯fªº¹L±Ó¯gª¬ªºÃöÁä¡C

Dupilumab ¬O¤@ºØ¥þ¤H·½³æ®è§ÜÅé¡A¥iªýÂ_¥Õ²Ó­M¤¶¯À 4 ©M¥Õ²Ó­M¤¶¯À 13 ªº¦@¨É¨üÅ馨¤À¡A¥Õ²Ó­M¤¶¯À 4 ©M¥Õ²Ó­M¤¶¯À 13 ¬O 2 «¬µoª¢ªºÃöÁäÅX°Ê¦]¯À¡C

Dupilumab¥h¦~°ò©ó BOREAS ªº¥¿­±µ²ªG¡AFDA ±Â¤© Dupixent ¬ð¯}©ÊÀøªk»{©w¡A§@¬°¥¼¨ü±±¨îªº COPD ¦¨¦~±wªÌªºªþ¥[ºû«ùªvÀø¡A³o¨Ç±wªÌ¦³¥[­«¥v©M¶Ý»Ä©Ê²É²Ó­Mªí«¬¡CFDA ®Ú¾Ú¸Ó¸ÕÅ窺¼Æ¾Ú±Â¤© Dupixent ªvÀøºC©Êªý¶ë©ÊªÍ¯fªº¬ð¯}©ÊÀøªkºÙ¸¹¡C ¼Ú¬wÃÄ«~ºÞ²z§½¤w¸g¦b¼f¬d Dupixent §@¬°ªvÀø¥¼¨ü±±¨îªº±w¦³ 2 «¬µoª¢ªº COPD ±wªÌªºÃĪ«¡C

Dupixent 3 ´Á¸ÕÅçÁ{§É¼Æ¾Ú

Dupixent ¦b²Ä¤G¶µ¿n·¥ªº 3 ´Á¸ÕÅ礤ÅãµÛ´î¤Ö¤F COPD ´c¤Æ¡A¥[³t¤F FDA ªº´£¥æ¨Ã½T»{¤F¦¨¬°²Ä¤@­Ó§å­ã¥Î©óªvÀø³oºØÄY­«¯e¯fªº¥Íª«»s¾¯ªº¼ç¤O NOTUS ¸ÕÅç¥HÀ£­Ë©ÊªºÀø®Ä¹F¨ì¤F¥D­n²×ÂI¡AÅã¥Ü¦b¦³2 «¬µoª¢ÃÒ¾Ú¡]§Y¦å²G¶Ý»Ä©Ê²É²Ó­M≥300 ­Ó²Ó­M/£gL¡^ªº¤¤­««×COPD ±wªÌ¤¤¡A»P¦w¼¢¾¯¬Û¤ñ¡ADupixent ÅãµÛ­°§C¤F34% ªº¯f±¡¥[­«¡AÃÒ¹ê¤Fµ²ªG¨Ó¦Û¨ã¦³¨½µ{¸O·N¸qªº BOREAS ÃöÁä¸ÕÅç¦b²Ä 12 ¶g®É¡A»P¦w¼¢¾¯¡]FEV 1¬° 57 mL¡^¬Û¤ñ¡ADupixent ¨³³tÅãµÛ§ïµ½¤FªÍ¥\¯à¡] FEV 1¬° 139 mL¡^ ­p¹º©ó 2023 ¦~©³´£¥æ¸É¥R BLA

¥ú¬O¦b¬ü°ê´N¦³¬ù 30 ¸U¤H±w¦³¤£¨ü±±¨îªººC©Êªý¶ë©ÊªÍ¯f¡A¨Ã¦³ 2 «¬µoª¢ªºÃÒ¾Ú¡F¤Q¦h¦~¨Ó¨S¦³·sªºªvÀø¤èªkÀò±o§å­ã

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2024/1/9 ¤W¤È 01:07:44²Ä 6533 ½g¦^À³
³Ìªñ0.4¥ª¥k «Ü®e©ö´N©Ô1¸ò10´X% ´N½u½×½uªº¸Ü 0.58 ÀV½u¹L¥h¤j®a·|¨ÓÉu¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/1/8 ¤U¤È 04:03:08²Ä 6532 ½g¦^À³
¥¼¨Ó®i±æ¦pªG¯uªºÀu¨q¡A³Ì¤jªÑªF¦ó¥H¤j½æ¤â¤¤«ùªÑ?Ãø¤£¦¨TANG CAPITAL¤ñ¦U¦ìÁÙ¤£²M·¡ASLAN?TANG CAPITAL¤]¬O«ù¦³¤F

¤@¬q®É¶¡¡A¬°¦ó¿ï¦b¥¼¨Ó¤j¨Æ¥óµo¥Í«e½æªÑ?¤ñ°_2.3¤ë¥Ó³ø2023/12«ùªÑ¤~µo²{¤jªÑªF¶]¤F¡A²{¦bSEC¤å¥ó¤w¸g´¦ÅS¤F¡A¤£¥Î

µ¥¨ìTANG CAPITAL¥Ó³ø«ùªÑ´Nª¾¹D¤w¸g½æ¥ú­ì¥»«ù¦³ADS¡A¥h½½Â¤å´N¥i¥Hª¾¹D¬Y¨Ç¯S©w¤H¤h¦h·R´£TANG CAPITAL¦h¤j©@

¡A«ùÄò¥[½X«ùªÑ¡A¤S¬O¤jªÑªF¤S¬OSurveyor¡Aµ²ªGTANG CAPITAL¤w¸g¥X²MADS¡A«o¤£·í¤@¦^¤l¨Æ¡AÁ`¤§¤jªÑªF¥X²æ«ùªÑ¬O­Ó

ĵ°T¡A­YÁÙ«ù¦³ªº·à¤Í¤]¤£«Øij½æ¤F¡A¥Ø«e»ù®æ»P¨ä³B¤À¡AÁÙ¤£¦p©ñµÛµ¥«Ý©_ÂÝ¡A¦ý­Y¬O·Q­n¥[½XÅu¥­½Ð¤T«ä¡A²¦³º¯uªº©_

Âݵo¥Í¡A­ì¦³«ùªÑ¥»´N²zÀ³¦³Àò§Q¡A¦ý¦pªG¤£¦p¹w´Áªº¸Ü¡A¬ü³W¾À¯È¤£µL¥i¯à.......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2024/1/3 ¤U¤È 10:23:41²Ä 6531 ½g¦^À³
¤µ¦~·|µo§GCOPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅç¶i¤@¨B¼Æ¾Ú

ºë±K¤Á³ÎªÍ¤Á¤ù (PCLS) ¤¤ÀY¹ïÀY¤ñ¸ûªº·sªº¡B¦³§Æ±æªº¼Æ¾Úªí©úeblasakimab ¤ñ dupilumab ¨ã¦³´£°ªÀø®Äªº¼ç¤O

¤°»ò¬OÀY¹ïÀY¬ã¨s( Head to Head study)

¬O¨Ï¥Î¤w¸g¦b¨Ï¥ÎªºªvÀøÃĪ«§@爲ª½±µ¹ï·Ó²Õ¡A¥iµø爲¨âºØÃĪ«ªºª½²y¹ï¨M, ª½±µPK( ¬ã¨sÃĪ«»P¨Ï¥Î¤¤ªºªvÀøÃÄ) ¡C°w¹ïÃĪ«ªºÀø®Ä»P¦w¥þ©Ê¶i¦æ§óª½±µªºPK ¡A¥HÁקKÂùª¼¸ÕÅç®É¯f±w©â¨ì¦w¼¢¾¯²Õ¦Ó¼vÅT¯f±¡ ¬OÄÝ©ó¤ñ¸û²Å¦X¤H¹DªºÁ{§É¸ÕÅç³]­p, Head to Head study ³]­p¥¼¨Ó·|¶V¨Ó¶V¨ü¨ì­«µø»P±Ä¥Î

Âà¤Æ¤u§@ÃÒ©ú¤F eblasakimab ¦b COPD ¤¤ªº¼ç¤O¡AÀY¹ïÀY¼Æ¾Úªí©ú¨ä¥i¯àÀu©ó dupilumab¡A¤ä«ù eblasakimab ¸Ñ¨M¼sªxªº AD ¦@¨Ö¯gªº¼ç¤O¡C¥O¤H¿³¾Äªº¬O¡A¦b¨Ï¥Î¤HÃþ COPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅ礤¡A§Ú­ÌÆ[¹î¨ì eblasakimab ¤ñ dupilumab ¨ã¦³§ó±jªº®ÄªG¡A§Ú­Ì´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡C

New, promising data of head-to-head comparison in PCLS suggests

eblasakimab has potential for improved efficacy over dupilumab ( 2024 ¦~1¤ë ²³øP18)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2024/1/3 ¤W¤È 10:36:42²Ä 6530 ½g¦^À³
¦³½ìªº¨Æ±¡¨Ó¤F.....

1.2023/7/11ªºSEC¤å¥óÅã¥Ü¡ATANG CAPITAL«ù¦³180.6¸UªÑADS + 5ªÑ­ì©lªÑ(0.2ªÑADS)¡C

2.ºI¦Ü2023/9/30¡ATANG CAPITAL¥Ó³ø«ù¦³aslan190.16¸UªÑads¡A«ùªÑ¬ù11.41%¡C

3.2024/1/2ªºSEC¤å¥óÅã¥Ü¡ATANG CAPITAL¥X²M©Ò¦³ADS¡A¶È³Ñ«ù¦³5ªÑ­ì©lªÑ + °õ¦æ»{ÁÊÅvªº6,134,970ªÑ­ì©lªÑ¡A

¦X­p¬ù245,399ªÑADS¡A«ùªÑ¬ù1.5%¡C(¾ÚSEC¤å¥ó´¦ÅS¡A°õ¦æ»{ªÑÅv«á«ùªÑ¶W¹L9.99%¡A«h»{ªÑÅvµLªk°õ¦æ¡A¤£ª¾¹DTANG CAPITAL¬O§_¬°¤F°õ¦æ»{ªÑÅv½æ¥X«ùªÑ¡A¦ý¥þ³¡¥X²M¤S»{ªÑ¡A§Ú¬Oı±o¦³ÂI¥Ù¬Þ...)¡C

2023/9/30ªÑ»ùÁÙ¦³1.8ªþªñ¡A±q10¤ë¶}©l¤@¸ô±Y¶^¡A¬Ý¨ÓÀ³¸Ó¤j·§²v¬OTANG CAPITAL¥X²M190.16¸UªÑADSªº½t¬G¡AÁ`¤§´N¬O¨Æ¹ê³¯­z¤F¡A«ç»ò¸ÑŪ´N¬Ý¦U¦ì·à¤Í¤F.......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2024/1/2 ¤U¤È 08:38:54²Ä 6529 ½g¦^À³
­è¦¬¨ì·à¤lªºmail

­n¶}§ë¸êªÌ·|ij

¸Ó¤£·|¦³¤°»ò®ø®§

¦³ÂI·Q¶R¦^«ùªÑ½ä¤@¤U¡]Äo¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/29 ¤U¤È 04:41:15²Ä 6528 ½g¦^À³
¤£¥Îµe¥¼¨Ó¤j»æ

©ú¦~TREK-DX ¸ÕÅç¡A¦p¥¼¹F²Î­pÅãµÛ®ÄªG

°¨¤W´N¤@¤M²¦©R

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/12/29 ¤U¤È 03:04:38²Ä 6527 ½g¦^À³
­P±M®a¡B¾ÇªÌ¡B§ë¸êªÌ¡B½ä®{¡B«Ó°¶¡G

¨È·à±d¶}©l¦³360¤Ñ(ªÑ»ù§C©ó1¬ü¤¸)(§t180¤Ñ«á¤½¥q´£¥Xªº²§Ä³)§K©ó¤U¥«¡C

ªÑ»ù¤£¬O­«ÂI¡A­«ÂI¬O¨È·à±d²{ª÷¥u°÷¥Î¨ì113¦~©³(ÄY®æ¨ÓÁ¿¥u°÷¥Î¨ì113¦~9¤ë)¡C

¥B¶i¤JÁ{§É¤T´Á¸ÕÅç¤]¶·¥Î¿ú¡C

¤½¥q¤]»¡©ú¥Ø«e¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡C

¤½¥q113¦~©³«e¤@©w­n§ä¨ì¿ú¡A¤£µM´N­Ë¤F(¤£¬O¤U¥«¡A¬O­Ë³¬)¡C

112¦~12¤ë23¤é¤½¥q¤½§i¼W¥[ªk©wªÑ¥»

«Ü©úÅã¦X§@¹Ù¦ñ©Ò¶}ªº±ø¥ó¤w¸g¥X¨Ó¤F¡A©Ò¥H¤½¥q«ö³W©w­n´£ªÑªF·|¦P·N

(¤½¥qµLªk¾B»\ÂX¼Wªk©wªÑ¥»¡A¦]³o­nªÑªF·|¦P·N)(¦pªG¨S´£½ÐªÑªF·|¦P·Nªº¨Æ¶µ¡A§Ú­Ì¤£·|ª¾¹D¶i«×)

(¦X§@¹Ù¦ñ©M«´¬ù±ø¥óÅSÀ`¤F)

¦X§@¹Ù¦ñ¨­¤À¤w¸g½T»{¤F¡C

¬O¨p¶Ò¡B°Ï°ì±ÂÅv¡B³Q¨ÖÁÊ¡A¤]¤w¸g½T»{¤F¡C

ºî¤W

®¥³ß¦U¦ì¡A³Ñ¤£¨ì¥b¦~®É¶¡´N·|ª¾¹D¨È·à±d¬OÅܦ¨²r·àÁÙ¬O¡K¡K

½Ð¤U¦nÂ÷¤â

112¦~1¤ë1¤é~112¦~6¤ë21¤é¡G¨È·à±d»P¤é¥»Zenyaku Kogyo °Ó°Q¤é¥»±ÂÅv¤º®e¡C

112¦~6¤ë22¤é¡G¨È·à±d¤½§iEblasakimab¦b¤é¥»°Ïªº±ÂÅv¥ÑZenyaku Kogyo¿WÅó¡C

112¦~12¤ë12¤é¡G¨È·à±d»¡©ú¥Ø«e¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡C

112¦~12¤ë23¤é¡G¨È·à±d¼W¥[ªk©wªÑ¥»©ó113¦~1¤ë24¤é´£ªÑªF·|¦P·N¡C

(¥ý§âªk©wªÑ¥»ÂX¨ì¬Û·í¤j(50»õ´¶³qªÑ)¡A¥H½T©w¯à²Å¦X¨C(¦h)®a¦X§@¹Ù¦ñ©Ò¶}ªº±ø¥ó)

(ªk©wªÑ¥»ÂX¨ì¬Û·í¤j¬Oµ¦²¤¡A¤]¬O¥²¶·§@ªº¡AÅý¦X§@¹Ù¦ñµLªkª¾¹D¨È·à±d¥´¤°»òºâ½L)

(¦X§@¹Ù¦ñ¤£²M·¡¨È·à±d¸ò´X®a¡§¹Ù¦ñ¡¨±µ¬¢¡A¤è«KÅý¨È·à±d¯à¿ï¾Ü±ø¥ó¦nªº¹Ù¦ñ)

(½Í§P»Ý­nÂI®É¶¡¡A±Ä¥Î©ì©µ¾Ô³N¡A³q±`¯àÅý·NÄ@°ªªº¹Ù¦ñ¥[»ù)

(¨È·à±d¸³®y¬O¨ÖÁÊ°ª¤â¡A§Ú­Ì­n¬Û«H¥L¡C)

113¦~1¤ë8~10¤é¡G¨È·à±d¦bª÷¤s°Ñ¥[¥Ö½§¯f¾Ç·|¡A·|¨q¥X¥Íª«¼Ð»x¬ÛÃö¼Æ¾Ú¡C

(¼Æ¾ÚºCºCºÝ¥X¨Ó¡A¦A¥[¤W©ì©µ¾Ô³N¡A³q±`¯àÅý·NÄ@°ªªº¹Ù¦ñÄ~Äò¥[»ù)

(¼Æ¾Ú¨ì§Ú­Ì¤â¤W³£¬Oªº¡A¦]«e´X­Ó§«ô¡A¬Æ¦Ü«e´X­Ó¤ë¤½¥q´Nª¾¹D¤F¡AÃø©Çªñ´ÁªÑ»ù¥X¶q)

112¦~10¤ë1¤é~113¦~2¤ë29¤é¡G¨È·à±d¤w±q¦h®a¦X§@¹Ù¦ñ¤¤¿ï¥X³Ì¾A¦Xªº¦³¼ç¤O¦X§@¹Ù¦ñ¡A¬ÛÃö«´¬ù±ø¥ó¤j­P©³©w¡C

113¦~2¤ë1¤é¡G¦¬ADRºÞ²z¶O(2¤ë8¤é²Ä¤@¦¸¶Êú¡B2¤ë15¤é²Ä¤G¦¸¶Êú)¡C

113¦~3¤ë1¤é¡G¨È·à±d¤½§i¥Ñù¤ó¥H¬üª÷¦Ü¤Ö25»õ¤¸¦¬ÁÊ¡C

113¦~5¤ë1¤é¡G¨È·à±dADR°±¤î¥æ©ö¡C

¨ÖÁʪ÷ÃBºâªk¦p¤U¡G

°Ñ¦Ò·|­û¡G¤Ñ©R¤j10141925 µoªí®É¶¡:2023/6/22 ¤U¤È 08:20:52

ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô

¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸.

¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸

27.7-7.8(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»¤§§Q¯q)

ASLN004 ¤§»ù­È:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í

¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q)

¥H¤W¥¼§t003°Ó¥Î«á¤§¨ÖÁÊ»ù¡C

¥[003°Ó¥Î«á¤§¨ÖÁÊ»ù¦ô¬ù¬üª÷25»õ¤¸³Q¨ÖÁÊ(©¹«áªº20¦~¡C¨C¤@¦~ªº10% ¾P°â¤À¼í¥¼ºâ¶i¥h)¡C

¥tÃö©ó¾P°â¤À¼í¨C¦~10%¡G

¥H§ùÁת¢2022¦~Á`¾P°âÃB86.8»õ­pºâ¡A

·sÃĤò§Q¥H8¦¨­pºâ¡G86.8*0.8=69.44»õ¬ü¤¸¬OÁÉ¿Õµá³æ³æ2022¦~½æ§ùÁת¢²bÁÈ­È

86.8*10%=8.68»õ¬ü¤¸´N¬O·í¦~¾P°â¤À¼í10%ªº­È

§ùÁת¢¦~«×¾P¦¬ª÷ÃB¦p¤U¡G(·PÁ¤ѩR¤j´£¨Ñ)

2017¦~/2.279»õ¬ü¤¸

2018¦~/9.22»õ¬ü¤¸

2019¦~/23.156»õ¬ü¤¸

2020¦~/40.448»õ¬ü¤¸

2021¦~/61.988»õ¬ü¤¸

2022¦~/86.811»õ¬ü¤¸

§ùÁת¢2022¦~¤î¦@¾P°â223.902»õ¬ü¤¸

¾P°â¤À¼í10%=22.902»õ¬ü¤¸(¾P°â¤À¼í15¦~§Y¶W¹L¦Ê»õ)( Eblasakimab¬O¶W¯Å¤jÃÄ)

ASLN ¦¨¾À¯È¾÷²v¬Û·í§C¡D

¦ý¶W°ªÀø®Ä¤£¥i¯à¡D

¥u­nÀø®Ä¡B¥ÎÃÄÀW²vĹ¹L§ùÁת¢§Y¥i

Eblasakimab¦b©¹«á20¦~ªº¾P°â¹w¦ô­È¤@©w°Ñ¦Ò§ùÁת¢­q©w

³o20¦~ªº¾P°â¤À¼í¥[Á`(¾P°â¤À¼í¨C¦~10%)¤]·|¨Ö¤J¨È·à±d³Q¨Öª÷ÃB¸Ì­±¡C

(¥H¤W³¡¤À¯ÂÄÝÁr´ú¡BÁr´ú¦p¦³¹p¦P¡B¹êÄÝ¥©¦X)

¥H¤W½Ð«ü¥¿

(§ë¸ê¦³­·ÀI¡B½Ð¦Û­t¬ÕÁ«)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2023/12/28 ¤U¤È 11:37:24²Ä 6526 ½g¦^À³
ÁöµM§Ú¤w¨S¦³¨È·à±d

¦ý§Úı±o¥Ø«e0.4ªºªÑ»ù¨ä¹ê®t¤£¦h¬O©³

¦]¬°§ë¸êªÌ²{¦b½æ¤]½æ¤£¤F¦h¤Ö¿ú,©Ò¥H°ò¥»¤W³£·|©ñµÛµ¥©_ÂÝ

°£«D³Ì²×Ãz±¼¥¢±ÑÂk¹s

¤£µM²{¦b¨ä¹ê¤]¤£¥Î©È·|¶^¨ì­þ¸Ì¥h

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/28 ¤U¤È 09:35:42²Ä 6525 ½g¦^À³
ªÑ¤Í§ë¸êASLAN Pharmaceuticals ¤w¸g·l¥¢ºG­«¤F¡A·Q¤£³q¬°¦ó¦³¤H¤@ª½©¹¤U¹w´úªÑ»ù

¡A¤£Â_©¹¶Ë¤fÅxÆQ¡A¤SµLªk½×­z¤½¥q¬ãµoÃĪ«¨º¸Ì¨S¦³¼ç¤O¡A¯u¤£ª¾¦ó¥H¥Î¤ß¦p¦¹¨}­W¡H

·íµM¤p¥Í§Þ¤½¥q¦bªì´Á¬ãµo¹Lµ{¤¤¥²µM·|¾D¹J®À§é¡A¥þ²yªº¥Í§Þ¤½¥qµo®i³£¬O¦b¦p¦¹ªº¹D¸ô¤¤¤£Â_¦¨ªø­_§§¡A¨«¥X£¸¤ù¤Ñ

ª©¤W¦UºØ½×­z¦³¥¿­±¤]¦³­t­±¡A³£À³µ¹¤©´L­«¡A¥¿­±­n»¡¥X¥¿­±²z¥Ñ¡A­t­±­n»¡¥X­t­±²z¥Ñ¡A¤~¯àÅý¤H«HªA¡A

¥Ø«e¶^¨ì³o­Ó»ù¦ì¦A½æ¤]¨S¦³¤°»ò·N¸q¡A¦pªG¦Û¤vµû¦ô¥Ø«e¤½¥q¬ãµoÃĪ«¦³¼ç¤O¡A¨S¦³ª©¤W©Ò¨¥¨º»ò®t

±©¤@ªº°Ê§@´N¬O¦Ò¼{¦^¸É¡A¤½¥q¸Ó°µªº°Ê§@¤w¸g°µ¥X¨Ó¤F¡A¸Ó¶}ªºÁ{®ÉªÑªF·|¤]¥l¶}¤F¡A³o·|Åý¸êª÷¡A¨ÖÁʽͧP¡A§l¤Þ§ë¸ê¡AÂX¥Rª©¹Ï

¦³§ó¥[ÆF¬¡©P©µ»P°j±ÛªÅ¶¡

¥H¤W¸É¥R¤À¨É»P«Øij¡A¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/12/28 ¤U¤È 04:16:20²Ä 6524 ½g¦^À³
ÞË......§Ú¦b¤§«eªº½×­z¤]¬O¦³»¡­n¨Ì¹ê»Úµo¦æªÑ¼Æ¬°¥D¡A§Ú¬Æ¦Ü³s(¥Hasln¤½¥¬ªº2023Q3°]³øÅã

¥Ü¡AÁöµMªk©wµn°OªÑ¼Æ¦³10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ¡A25ªÑ=1ads¨Óºâ¡A¤j¬ù¬°1720¸UªÑ

ads¡Aµ¥©óÁÙ¦³2280¸UadsªºªÅ¶¡¥i¥H¼W¸ê)¤½¥qÁÙ¦³2280¸UªÑ¥i¥Hµo¦æ¼W¸ê³£ºâ¥X¨Óµ¹¦U¦ì·à¤Í¬Ý

¤F¡A¨ì©³¬O½Ö¨S¦b¬ÝXD¡AµM«á¤@ª½¶K¤@¨Ç½Ķ¹L¨Ó·F¹Àªü¡A§Ú¦Û¤vª¦Â¤å´N¦æ¤Fªü......¡A¦³¤H

¬O«æ¤FÁÙ¬O«ç¼ËXD¡A¥H¤U¬O´XÂI­Ó¤H¬ÝªkÅý¦U¦ì·à¤Íµû¦ô§a!

1.³W©w¸ò¹ê°È¤W¾Þ§@°ò¥»¤W¬O¤G¦^¤l¨Æ¡AªÑ²¼¤U¥«°ò¥»¤W¤£·|®ø¥¢¡AOTC¥i¥H¥æ©ö¨S¿ù¡A¸Õ°Ý¦U¦ì

ªº¨é°Ó­þ­Ó¤ä´©OTC¥æ©öªº!?¬Æ¦Ü¤U¥«¤§«á¬ÛÃöªÑ°È¥N²z®ü¥~¨é°Ó©Î°ê¤º½Æ©e°UÁÙ¥i¥H¤ä´©?

°ê¤º¤U¥«ªÑ²¼¥æ©ö¸òªÑ°ÈÃø«×´N°÷¤j¤F¡AÁÙ·d¨ì®ü¥~ªºADS?

2.¯uªº¹ê»Úµo¦æªÑ²¼¡A³W©w¤W­nªÑªF¦P·N¡A¦ý¹ê°È¤W1/24¸¹ªºªÑªF·|¤@©w·|ªþ±a¨Mij¡A¨Ò¦pµn°O

¸ê¥»ÃB´£°ª«á¡A«áÄòµo¦æ·sªÑ(¥]¬A¦ý¤£­­©ó¨p¶Òµ¥)¥þ©e¥Ñ¸³¨Æ·|¿ì²z¡Aµ¥¦PªÑªF¦P·N«áÄò³£

¥Ñ¸³¨Æ·|¿ì²z¡A¤£µM³Ìªñ´X¦¸¨p¶Ò¤½¥q¦³¼x¨D¹LªÑªFªº·N¨£!?

3.¸Û¦p¤§«e­pºâ¤½¥q¤j·§ÁÙ¦³2280¸UªÑADS¥i¥H¼W¸ê¡A²{¦bµn°O¸ê¥»ÃB´£°ª¨ì¥i¥Hµo¦æ2»õªÑADS

¡A¬O¬°¤F¤°»ò?¡A¤£´N¬O­ì¦³2280¸UªÑ¤£°÷¤F¡A¥ýµn°O¨ì2»õªÑ¬°¤F¤§«á¶Ò¸ê¤§¥Î¡A¤§«á·|¤£·|µo

º¡2»õªÑ¤£½T©w¡A¦ýµ´¹ï¬°¼Æ¤£¤Ö°_½X¤£·|®t¤G»õªÑ¤Ó¦h¡A¤£µM¨S¨Æµn°O¨ì³o»ò¦h·F¹À¡A¦pªG¨S

¦³¸ÕÅçµ²ªG¨Ó´£°ªªÑ»ù¡A¥H¹ê°È¤W¨Ó¬Ý³q±`¨p¶Ò»ù®æ¤£·|¶W¹L²{ªÑ»ù®æ¡A¥H²{¦bªÑ»ùºâ0.45¦n¤F

¡A´Nºâµoº¡2»õªÑ¦n¤F¡A¤]¤~Äw¸ê0.8»õ¡A³s°µ¤T´Á³£¤£°÷¡A©Ò¥H§Ú¹w¦ô¤j·§²v¬O¥H¤U2ºØ±¡ªp

(1)¤Þ¶i¦X§@¹Ù¦ñ¡AµM«á¨«¦X§@¹Ù¦ñ±ÂÅvªº¼Ò¦¡¡Aµ¥¨ì3´Áµ²ªG½T»{«á¥Ñ¦X§@¹Ù¦ñ¦¬ÁÊ¡A¦ý«e´Á

¨p¶Ò¦X§@¹Ù¦ñ¼W¸ê¤JªÑ¼Æ¶qÀ³¸Ó«Ü¥iÆ[¡A²¦³º¤½¥q³£¨S¿ú¥i¥H¿N¤F¡A¨S¦X§@¹Ù¦ñ´£¨Ñ¸êª÷¤]

ª±¤£¤U¥h¡A½Í§P±ø¥ó¤£·|¤Ó¦n¡C

(2)¥i¯à¶Ò¸ê®Éµ{¨S³o»ò§Ö¡Aµ¥¸ÕÅçµ²ªG¥X¨Ó¡A¥B¾Ô¥B¨«¡AªÑ»ù¼Q¥Xªº¸Ü¡A«áÄò¶Ò¸êªÑ¥»¤]¤£¦Ü

©ó¿±µÈªº¤Ó§Ö¡A¦ý­n¬O¸ÕÅçµ²ªG¥X¨Ó¤£²z·Q¡AÀ³¸Ó´Nª½±µ¦º¤`¤F¡A¨«³o¤è¦¡¥i¥H´Á«Ý¤@¤U¡A

¥Nªí¤½¥q¥i¯à«Ü¦³«H¤ß¡A¦ý¾÷²v¤£°ª¡A²¦³º­·ÀI¤Ó¤j¤FXD¡C

¤£ºÞ¬O¨«(1)©Î(2)¡A³£¥i¥H¬Ý¥X·íªÑ»ù§C°g¡AÄw¸ê¯à¤O´N¬OºG¡A³o¤]¬O§Ú³Ì²×©ñ±óASLANªº­ì¦]¡A

¤½¥q°ª¼hµLªkºû«ùªÑ»ù¡A­n¿ú´N¬O­n®³¤j¶qªÑ²¼¨Ó´«¡A¤@³s¦ê¤U¨Ó´N¬O³ø¹S²v¥i¯à¨S·Q¹³¤¤¦n¡A

§Ú¤]ª½±µ¦Y·l¥X³õ¡AÃÄ¥i¯à«Ü¦n¡A¦ý¹ï¤½¥q°ª¼hµLªk­e¦P¡A¦Y·l§Ú»{¤F¡A¤Ï¥¿§ë¸ê¦Y·l¥¿±`¡A¥u

¬O§Ú11/8µo¤å´¿¸g¤ÀªR¹L¡A¦pªG¥«­È1»õ¤¸¬ù²öµ¥©ó¤@ªÑads6¤¸(«e´£¬OªÑ¥»¤£¿±µÈ)¡A±µµÛ¤@­Ó

¤ë«áª½±µ·Ç³Æ´£°ªµn°O¸ê¥»ÃB¡AÁöµMÁÙ¨Sµo¦æ¡A¦ý§ó¥[¦LÃÒ°ª¼h¨S¯à¤O´£°ªªÑ»ù¡A¥u¯à¤j¦LªÑ²¼

Äw¸ê¡A¥H²{¦³®Éµ{¨Ó¬ÝEblasakimab¸òFarudodstat³Ì§Ö³£­n¦~¤¤¤~¦³µ²ªG¡A§Ú¬O¤£Ä±±o¤½¥q°ª¼h

¦³¿ìªk¥i¥H¦b³o¬q®É¶¡´£°ªªÑ»ù³â¡A´Nµ¥µÛ¬Ýµ²ªG¦p¦ó§a¡A¥uı±o¤½¥q¤§«eÄw¸ê¤£¤Ö¡Aµ²ªG¤@¤â

µP¥´¦¨³o¼Ë¡A¿ú³£¿N¥ú¤FÁÙ¨SÔ£¦¨ªG¡A§Ú¤]¬O¥u¯à­W¯º¡C

4.¤p¤Ï»é¤@¤U©Î³\¥Îµoº¡2»õªÑ¨Ó°²³]¥i¯à¬O¦³ÂI¯B¸Ø¤F¡A¦ý§Ú¦¬ÁÊ»ù®æ¥i¤£¬O¥Î3~10»õ¨Óºâ³á¡A

§Ú¥i¬O´£°ª¨ì20»õ¤FXD¡A¦pªG³Ì«á¥uµo1»õªÑ¡A¦ý¦¬ÁÊ»ù5»õ¤¸¡A¥i¬O¤@ªÑ¥u¦³5¤¸³á¡A¦ýµo¦æªÑ

¼Æ¦h¡AÄw±o¸êª÷¸û¦h¡A²b­ÈÂॿ¼Æ¤F¡A¤½¥q¥«­È¤~¦³¤£§C©ó²{ª÷¤ô¦ìªºÄ³ÃD¡A²¦³º²{ª÷³¡¦ì°£¤F

­É¨ÓªºÁÙ¦h¤F¼W¸êªº¸ê¥»¡A¹ï¦¬ÁÊ¥«­È¤]¬O¯à´£°ª³â¡A¥u¬O®Ä¯q·¥«×¤£¹ü´N¬O¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/28 ¤W¤È 09:31:23²Ä 6523 ½g¦^À³
¤µ¤Ñ¦¬½L«á¦³¤@µ§±µªñ63¸UªÑ¦¨¥æ¡AªÑ»ù¥¼¥¨¤jªi°Ê¡A

§Ú»{¬°¬O¯S©w¤H¤¬ºV¥æ©ö¡A

½Ð°Ý¤j¤j­Ì¬Ýªk¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/27 ¤U¤È 10:26:53²Ä 6522 ½g¦^À³
½Ð¤Å§â¼W¥[ªk©wªÑ¥»»Pµo¦æ·sªÑ²V¬°¤@½Í , ªk©wªÑ¥»¬O«ü¤½¥q¨Ìªk¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº³Ì¤j¼Æ¶q¡C

¥i¤À¦¸¼W¥[ªk©wªÑ¥», ¤]¥i´î¤Öªk©wªÑ¥», ¥u¬Oµ¹¤@­ÓÃB«× , ¤½¥q·|¨Ì¾Ú¹ê»Ú±¡ªp¼u©Ê¨Ï¥Î´£¨Ñ¤FÆF¬¡©Ê

©M¥¼¨ÓÄw¶°§ó¦h¸ê¥»ªº¯à¤O¡C¨Ï¤½¥q ¯à°÷§ì¦í¦¨ªø¾÷·|¡A§l¤Þ§ë¸ê,«P¶i¨ÖÁʹê¬I, ¼W¥[ªk©wªÑ¥»¤£·|ª½±µ

¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ù­È¡Cµo¦æ·sªÑ¤~·|µ}ÄÀªÑÅv , ¥H«eªk©wªÑ¥»10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ

,¥»¦¸Á{®ÉªÑªF·| ªk©wªÑ¥»10»õªÑ´¶³qªÑ»P50»õªÑ´¶³qªÑ¶i¦æªí¨M( 50»õ´¶³qªÑ³o¬O¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº

³Ì¤j¼Æ¶q,³Ì­«­nªº¬O¹ê»Úµo¦æªÑ¼Æ, ³Ì­«­nªº¬O¹ê»Úµo¦æªÑ¼Æ, ³Ì­«­nªº¬O¹ê»Úµo¦æªÑ¼Æ, ¹ê»Úµo¦æªÑ¼Æ·|¤ñ

ªk©wªÑ¥»¤Ö )

ªoºj¤j»¡: ¥H³Ì«á¼W¸ê¨ì50»õªÑ=2»õªÑADS¨Óºâ¡A´Nºâ³Ì«á³Q20»õ¤¸¦¬ÁÊ¡A´«ºâ¦^¨Ó¤]¤~¤@ªÑADS10¤¸

½Ð°Ý¤½¥qÁÙ¨S¤½§i­n¹ê»Úµo¦æªÑ¼Æ¤£¯à¥Î°²³]¼W¸ê¨ì50»õªÑ´¶³qªÑ¨Ó¶i¦æ½×­z

¼g³o»ò²M·¡¦n¦n¬Ý

1 ªk©wªÑ¥»¬O«ü¤½¥q¨Ìªk¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº³Ì¤j¼Æ¶q¡C¥¦¥Nªí¤½¥q¥i¥Hµo¦æªºªÑ²¼Á`»ù­È¡C

2 ¤½¥q¿ï¾Ü¼W¥[ªk©wªÑ¥»ªº­ì¦]¦³«Ü¦h¡C¥¦¥i¯à¬O¬°¤F¾AÀ³¥¼¨Óªº¦¨ªø©MÂX±i­p¹º¡A§l¤Þ§ë¸êªÌ©M¸êª÷¡A

«P¶i¨ÖÁÊ¡A©Î¹ê¬I­û¤u«ùªÑ­p¹º¡]ESOP¡^

3 ¼W¥[ªk©wªÑ¥»¬°¤½¥q´£¨Ñ¤FÆF¬¡©Ê©M¥¼¨ÓÄw¶°§ó¦h¸ê¥»ªº¯à¤O¡C¥¦¨Ï¤½¥q¯à°÷§ì¦í¦¨ªø¾÷·|¡A§l¤Þ§ë¸êªÌ¡A

«P¶i¤½¥q¦æ°Ê¡A¨Ã³z¹L­û¤u«ùªÑ­pµe¨ó½Õ­û¤u§Q¯q¡C

4 ¼W¥[ªk©wªÑ¥»ªº¬yµ{¨Ì¥qªkºÞÁÒ°Ï©M¤½¥q³¹µ{ªº¤£¦P¦Ó¦³©Ò¤£¦P¡C¤@¯ë¥]¬AÀò±o¸³¨Æ·|§å­ã¡B³z¹LªÑªF·|

´M¨DªÑªF§å­ã¡B¿í¦uºÊºÞ­n¨D¡B­×§ï¤½¥q³¹µ{

5 ªk©wªÑ¥»¼W¥[«á¥i¥H³z¹LÀò±o¸³¨Æ·|©MªÑªF§å­ãªºÃþ¦ü¬yµ{¨Ó´î¤Öªk©wªÑ¥»¡CµM¦Ó»Ý¿í¦uªk«ß­n¨D¨Ã¿í´`

´î¤Öªk©wªÑ¥»ªº¥²­nµ{§Ç

6 ¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ù­È¡CµM¦Ó¡A¦pªGµo¦æ·sªÑ¡A´N·|µ}ÄÀªÑÅv¡C

²{¦³ªÑªF¦³Åv¥H¨ä²{¦³«ùªÑ¤ñ¨ÒÁʶR·sªÑ¡A¥Hºû«ù¨ä«ùªÑ¤ñ¨Ò¡C

7 ¼W¥[ªk©wªÑ¥»»Pµo¦æ·sªÑ¬O¤£¬Û¦P , ¥[ªk©wªÑ¥»¬O«ü´£°ª¤½¥q¥i¥Hµo¦æªºªÑ²¼¼Æ¶qªº­­¨î¡C¥t¤@¤è­±

µo¦æ·sªÑ¯A¤Î¹ê»Ú³Ð«ØªÑ¥÷¨Ã±N¨ä¤À°tµ¹ªÑªF

8 ¥[ªk©wªÑ¥»®É»Ý­n¤½¥q¦b¼W¿í¦u¨äºÞÁÒ½d³ò¤º¯S©wªºªk«ß©MºÊºÞ­n¨D¡C³o¨Ç­n¨D¥i¯à¥]¬A´£¥æ¥²­nªº¤å¥ó

¡B¤ä¥I¶O¥Î¥H¤ÎÀò±oºÊºÞ¾÷ºc©MªÑªFªº§å­ã

9 ¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT¤½¥qªº°]°È³øªí¡CµM¦Ó¡A·í¦]¼Wµo¦Óµo¦æ·sªÑ®É¡A¥i¯à·|¼vÅT¸ê²£­t¶Åªíªº

Åv¯q³¡¤À©M¨CªÑ¬Õ¾l¡]EPS¡^ªº­pºâ¡C

10 ªk©wªÑ¥»¨Ó¥i¥H®Ú¾Ú¤½¥q­n¨D¦h¦¸¼W¥[¡CµM¦Ó¨C¦¸¼W¸ê³£»Ý­n¿í¦uªk«ßµ{§Ç¨ÃÀò±oªÑªF©MºÊºÞ¾÷ºcªº¥²­n§å­ã¡C

¸ê°T¨Ó·½ : Understanding the Increase in Authorized Share Capital: A Comprehensive Guide

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/27 ¤U¤È 06:06:06²Ä 6521 ½g¦^À³
¨Ì³o®a¤½¥q¸Û«H¡A

¥¼¨Ó¦¨¥\ªº§Æ±æ¡AÀ³¸Ó¬O¤£¤j¡A

¤Ñ©R¤j¡A¤]¥i¯à¦­¤w±ó¨®¤F¡A

ªüÀ±ªû¦ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/12/27 ¤U¤È 12:55:35²Ä 6520 ½g¦^À³
­n¹w´úªÑ»ù¦V¤Uªº²z¥Ñ¤Ó¦h¤Fªü¡A¦Ó¥B§Ú°ò¥»¤W³£¬O®Ú¾Ú¤½¥q´¦ÅSªº°]³ø¸ò

¸ê°T±Ô­z¡A¤£¹³ª©¤W¤j¤j±q¼Æ¾Ú¥¼¤½¥¬´N¶}©l¹w´ú¸ÕÅçµ²ªG¡A³Ì«á¸ÕÅçµ²ªG

¥X¨Ó¤£¦p¹w´Á¤]¥i¥HÄ~Äò§j±·¡AµM«á¦UºØ¹w¦ô¨ÖÁʮɵ{¦ý³Ì«á³£¦UºØdelay¡A

³o¼Ë³£¸Ë¨S¨ÆÄ~Äò½Ð¤j®aÅÞ¿è«ä¦Ò¤F¡A§Ú­Ë¬Oı±o§ÚÆZ¤¤¥ß«ÈÆ[ªº¡A¨ä¥L¬Ý

Ãaªº¤H¤]³£¬O´¿¸gªº·à¤Íªü¡A¬O¯uªºÄê¨ì³s´¿¸g¤j¶q«ù¦³ªº³£¸õ²î¡A¬ÝµÛªÑ

»ùÄ~Äò§C°g¨Ó¦R¼Ñ¡A¥H¤U¬O²³æ´XÂI¤£¬Ý¦nªº­ì¦]¡A¦]¦¹§Ú¤]¥X²Maslan¡A

²{¦bÄ~ÄòÃöª`¥u¬O·Q¬Ý¬Ý³Ì«á·|¤£·|¯uªº¤U¥«¡Aµ¥¯uªº¤U¥«´Nª¾¹DOTC¥æ©ö

¥u¬O»¡»¡¡A°ò¥»¤WµL¥æ©ö¥i¯à...

1.¥Ø«e´X®a§ë¸ê¾÷ºc§¡µ¹¥XUSD16¤¸¤W¤Uªº¥Ø¼Ð»ù¡A¦ý¥h¬Ý¤@¤U¤ÀªR®v(CHEN

YI)ªº¸ê®Æ¡A±Æ¦W¶È¤¤¬q¡A¹w´ú¦¨¥\²v¤£¨ì30%¡A¥­§¡³ø¹S²v-10%¥H¤W¡A¥t

¤@®a¤]®t¤£¦h¡A³o¨Ç¤ÀªR®vµ¹¥Xªº¥Ø¼Ð»ù§Ú¬Oı±o°Ñ¦Ò¥i¥H¡A¦ý­n©^¦p¦c

¯å¤j¥i¤£¥²¡A³oÂI½Ð·à¤Í°Ñ¦Ò§Y¥i¡C

2.ºI¦Ü2023¦~Q3¤½¥q²{ª÷ÁÙ¦³4000¸U¤W¤U¡A¥Ø«e¥«­È¤£¨ì700¸U§C©ó¤â¤¤²{

ª÷¬O¥¿±`ªº¡A¦]¬°¤½¥q²b­È¦­´N¬O­t¼Æ¤F¡A¸ê¤£©è¶Å¡AªÑªFªº¿ú¦­´N³£¿N

¥ú¤F¡A¤â¤Wªº²{ª÷³£¬O­É¨Óªº¡A©Ò¥H­n¬O¨S¦³¶Ò¸ê¦¨¥\©Î¦¬¨ìÅv§Qª÷¡A°ò

¥»¤W´N¬Oµ¥µÛ¯}²£²Mºâ¡C

3.§Ú´£¤F«Ü¦h¦¸ªÑ¥»¿±µÈªº«ÜÄY­«¡A¯uªº¤§«á¼W¸ê§¹¦¨±¡§Î¤§¤U¡A­ìªÑªFªº

«ùªÑ¤ñ¨Ò¯uªº³Qµ}ÄÀ¤Ó¦h¤F¡A¥H³Ì«á¼W¸ê¨ì50»õªÑ=2»õªÑADS¨Óºâ¡A´Nºâ

³Ì«á³Q20»õ¤¸¦¬ÁÊ¡A´«ºâ¦^¨Ó¤]¤~¤@ªÑADS10¤¸¡A¬Ý¬Ý´î¸ê«e(1ADS=5ªÑ)¤@

°ï¦Ñ·à¤Í¦b1~3¶ô¤§¶¡¡A¦]¬°¬Y¨Ç¤HºÆ¨g¹ª§j¦Ó¥[½X¤£¤Ö¡A´«ºâ´î¸ê«á(1AD

S=25ªÑ)¡Aµ¥©ó¥[½X»ù®æ¦bUSD5~15¤¸¤§¶¡¡A¯uªº20»õ¤¸³Q¨ÖÁÊ¡A¥i¯à³£ÁÙ

¬O½ß¿úªº¡A§ó¦óªpÁÙ¦³§ó¦­´Á¦¨¥»§ó°ªªº·à¤Í¡A´N³o¨¤«×¨Ó¬Ý¡A½Öªºµo¨¥

¤ñ¸ûµ½·N¡A§Ú·Q¦Û¦³¤½µû³â¡A¤Ï¥¿¥[­Ó¶È¨Ñ°Ñ¦Ò¤§Ãþªº¦ý®Ñ´N¥i¥H¤F¹ï§a!?

4.¤½¥qªº¬ãµo¬O§_¦¨¥\³o­Ó§Ú¨S³o»ò±M·~¥i¥H§PÂ_¡A¦ý¥H³Ì¼ÖÆ[ªº±¡§Î¨Ó¬Ý

´Nºâ¤½¥q¥i¥H¬ãµo¦¨¥\¡A¥H¤½¥q²³ø¨Ó¬Ýµû¦ôAD¤j·§¥i®³¤UDupixent¬ù30%

~40%ªº¾P°â¡A¦ýDupixent¬O¥]§t¤F¤@°ï¾AÀ³¯g(COPD¡B­ý³Ýµ¥)¡A°²³]

Eblasakimab¬ÛÃö¾AÀ³¯g¤]³£®³¤U¡A¤]³£®³¤UDupixent¬ù30%~40%ªº¾P°â¡A

¥HDupixent°ª®p¹w¦ô¾P°â150»õ¨Ó¬Ý¡A¦ô­Ó50»õ¦n¤F¡A¦ý¤½¥qÁÙ­n¥Iµ¹CSL

¨½µ{ª÷¸òÅv§Qª÷¡A¦©°£µ¹CSLªº´Ú¶µ¡A¹w¦ô¤j·§´N¬O®³­Ó¾P°âÃB10%~15%¬O

·¥­­¤F¡A¤j·§¦~À禬¥i¥H¹F¨ì5»õ~7.5»õ¡A§é²{¦^¨Ó¤½¥q»ù­È¦h¤Ö´Nµ¹·à¤Í

¦Û¤v§PÂ_¤F(³o¬O°ò©óEblasakimab¦¨¥\¥B®³¤U¦h¼Ë¾AÀ³¯gªº±¡ªp°µ¥Xªº°²

³])¡A¦Ü©óFarudodstat³£ÁÙ¬O¥¼ª¾¼Æ´N¥ý¤£¦Ò¼{¤F.....

¥H¤W¬O§Ú¦Û¤v¤£¬Ý¦nªº­ì¦]³â¡A³æ¯Âı±o¦º©ê¤U¥h¡A¦¨¥\¤F¤]µLªk¤jÁÈ¡A¥¢±Ñ

¤F´N·Ç³Æ¤U¥«¡A¨º´N¤£Ä~Äò°Ñ»P¤F¡A¦ý¥H¥Ø«eªº»ù®æ¨Ó¬Ý¡A·à¤Í­Ì¥X²M¤]®³¤£

¦^¦h¤Ö¤F¡A°ò¥»¤W´N¬O©ñµÛµ¥©_ÂÝ¥X²{¤F....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¼z²´µøª÷10152715  µoªí®É¶¡:2023/12/27 ¤W¤È 10:55:59²Ä 6519 ½g¦^À³
www.google.com/finance/quote/ASLN:NASDAQ?sa=X&ved=2ahUKEwia4Y7bzq6DAxXgrlYBHYUVCwcQ3ecFegQIIhAf
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/26 ¤U¤È 10:23:42²Ä 6518 ½g¦^À³
¦³¤H¤ß¦sµ½©À©¹¤U¹w´úªÑ»ù¡A¤S»¡¤£¥X¥ô¦ó¨ãÅé²z¥Ñ

¬Ý°_¨Ó¬O¦b¦æ¾P®£Äß¡A·Ç³Æ¦^¸É¡A§_«h¬Ý¤£¥X¥ô¦ó²z¥Ñ³o¼Ë°µ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©ú¤Ñ¹L«á10151242  µoªí®É¶¡:2023/12/26 ¤U¤È 06:01:56²Ä 6517 ½g¦^À³
¤w¸g´X¦~¤F¡A³o¨Ç¾÷ºc³Û¥Xªº»ù®æ¦ó®É¹F¼Ð¤F©O¡A¬Û«H³o¨Ç¾÷ºc´N¨¬°÷Åý§A½ß¥»½ß¨ì¦º
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/24 ¤W¤È 12:12:52²Ä 6516 ½g¦^À³
¤£½×¬Ý¦n¬ÝÃa³£¬O­Ó¤Hªº¿W¥ß«ä¦Ò»P§PÂ_¡A³£À³µ¹¤©´L­«¡A§Ú¤]¥i¯à¬Ý¿ù

¼W¥[ªk©wªÑ¥»³o¬Oªk³Wªº°ÝÃD¡A¤£¬O£¸¯ë¤H¥i¥H§Ë²M·¡¡A©Ò¥H

§Ú¥Î¤F½Ķª©¡A¦Ü©ó¤½¥qªº·s»D¸ê°T»P²³ø¡A§Ú»P¤j³¡¥÷ª©¤Í£¸¼Ë³£¬O¥ý¬Ý­^¤åª©ªº¡A

§Ú±`§ó¥¿Google½Ķªº¿ù»~¡A¦³¨Ç¤H¨S¦b¬Ý¥i¯à¤£ª¾¹D§Ú¤w§ï¹L¡A®É¶¡·|ÃÒ©ú£¸¤Á

¦pªG¦p§ë¸ê¾÷ºc¹w¦ô£¸¦~¤ºªÑ»ù16¬ü¤¸¡A¥ý«e½æªº«Ü°ª¿³ªºª©¤Í¥¼¨Ó¯uªº·|«á®¬¡C

³o­Ó¥¼¨Ó¤£·|«Ü¤[¡A¥Ø«e§Ú¤ñ¸û¤£¾á¤ßªÑ»ù°ª§C¡A§Ú¤ñ¸ûÃö¤ß¨ÖÁÊ»ùªº°ª§C¡A§Ú·Q

«Ü¦h¤H·|¸ò§Ú¦³¬Û¦P·Qªk¡A¥Î¦Û¦³¸êª÷§ë¸ê¡A¦b¤£¼vÅT¥Í¬¡±¡ªp¤U¤~¯à¦w¤ß§ë¸ê¡A·íµMÀò§Q»P§_¹B®ð§êºt

¬Û·í¤jªº¤ñ²v¡A¤£¬OÀ´ªº¦h´N·|Àò§Q

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/12/23 ¤U¤È 11:28:55²Ä 6515 ½g¦^À³
1.¼W¥[ªk©wµn°O¸ê¥»ÃB¥»¨Ó´N¬O¤½¥q¬°¤FÂX±iÀç¹B³W¼Ò©ÎÄw¸êªº¹Lµ{¡A¨S¹ê»Úµo¦æ·sªÑ¤£·|¦³¹ê½è¼vÅT¡A¦ý³o¦¸µn°O¸ê¥»ÃB¿±µÈ¨ì5­¿Ãø¹D¤£¬O¦]¬°ªÑ»ù§C·G¦Ó¾É­Pªº¡I¡H¦Ó¥B½T¹ê´N¬O¦³»Ý¨D¤~·|¥Ó½Ð¼W¥[³o»ò¦h¡A¤£µMµn°O¸ê¥»ÃB¨S¨Æ¿±µÈ¨ì5­¿¬O¡I¡H

2.½T©w¼W¸ê·|¥Ñ­ìªÑªF»{ªÑ¤£·|µ}ÄÀ«ùªÑ¤ñ¨Ò¡I¡Hµn°O¸ê¥»ÃB¼W¥[¥u¬O´£°ª¤½¥q¥iµo¦æªÑ¼Æ¤W­­¡A¦ý¦pªG¨«¨p¶Òªº¸Ü¥i¬O¤£·|¦³­ìªÑªF»{ªÑ³á¡Aaslan003¤@´Á¸Ñª¼«áªº¨p¶Ò¡ABVF¸òK2ªº«ùªÑ¤]¬O¨p¶Ò+»{ªÑÅv¡A½Ð°Ý­ìªÑªF¦³«ö«ùªÑ¤ñ¨Ò»{ªÑ¡H²{¦b¤â¤W¦³aslnªº«ùªÑ¤ñ¨Ò¦­³Qµ}ÄÀ¨ìÄê±¼°Õ¡C

3.±q¨º»ò¤[¥H«e¶}©lµe¤j»æ¡A¨S·Q¨ì¤j¥[½X¦b0.7¡A¯u¬O¨I±o¦í®ð¡A¨ØªA¡I

4.½Ð·à¤Í­Ì¥H«áºÉ¶q¥h¬Ý¤½¥qªº­^¤å¤½§i­ì¤å¡A¦³®É­Ô¤Ó¥õ¿à½Ķ³nÅé©Î¬Oª©¤Íªº·N¨£Ãø§K¦³¿ù¡AªÈµ²¦b³æ¦rªº±¹Ãã·Q¹³¤F¤@°ï¡Aµ²ªG¤½¥q¤½§i³£¨S¥J²Ó¬Ý¡A³o¦¸¼W¥[µn°O¸ê¥»³£¥Õ¯È¶Â¦r¼g¤FªÑªF·|¨Mij´N¬O±q²{¦³ªº10»õªÑ¼W¥[¨ì50»õªÑ¡Aµ¥ªÑªF·|³q¹L¡A¨S¦³¥i¯à§é°J³o¥ó¨Æ.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/23 ¤U¤È 10:22:43²Ä 6514 ½g¦^À³
­Ó¤H²q´ú¥i¯à¨ÖÁʪÌ--- ªÑ»ù¶W¹L280¬ü¤¸ªº¤@®a«D¬ü°ê¥Í§Þ¤½¥q ( ¤j®a¥i¥H±q²³ø¤¤¥h²q´ú¥i¯à¨ÖÁʪÌ)

¨ÖÁʽͧP¹ê¤O :

TREK-DX :(´Á«Ý©ú¦~¤¤µo¥¬³o¨Ç´¿¨Ï¥Î¹L dupilumab ªº±wªÌ¤¤¬ã¨seblasakimabªºÀø®Ä¼Æ¾Ú)

TREK-AD : TREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab ¦³¼ç¤O¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅT

Àø®Ä¡A¨Ã¦¨¬° AD ªº»â¥ýÀøªk

FAST-AA : (´Á«Ý©ú¦~¤¤µo¥¬´³¨r¬ã¨sªº¶i¤@¨B¼Æ¾Ú)

¨ä¥L¦³¼ç¤OType 2 driven diseases

COPD : (ºC©Êªý¶ë©ÊªÍ¯f ´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº¶i¤@¨B¼Æ¾Ú )

Astma : ( ®ð³Ý )

CSU ( ëC³Â¯l )

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/23 ¤U¤È 09:36:01²Ä 6513 ½g¦^À³
¸ê°T¨Ó·½ : Understanding the Increase in Authorized Share Capital: A Comprehensive Guide

¼W¥[ªk©wªÑ¥»ªº­ì¦]

1.ÂX±i©M¦¨ªø¾÷·|¡G¤½¥q¿ï¾Ü¼W¥[ªk©wªÑ¥»ªº¥D­n­ì¦]¤§¤@¬O¾AÀ³¥¼¨Óªº¦¨ªø©MÂX±i­pµe¡C³z¹L´£°ª­­ÃB¡A¤½¥q¥i¥H¦b¥¼¨Óµo¦æ§ó¦hªÑ²¼¡A±q¦Ó¦b»Ý­n®ÉÄw¶°§ó¦h¸êª÷¡C³o¤@¦¨ªø´£¨Ñ¤FÆF¬¡©Ê¡A¨Ã½T«O¤½¥q³B©ó¦³§Q¦ì¸m¥H§ì¦í¥X²{ªº¦¨ªø¾÷·|¡C

2.§l¤Þ§ë¸êªÌ©M¸êª÷¡G¼W¥[ªk©wªÑ¥»¨Ó¥i¥H¨Ï¤½¥q¹ï¼ç¦b§ë¸êªÌ©M¶U´Ú¤H§ó¨ã§l¤Þ¤O¡C¸û°ªªºªk©w¸ê¥»·N¨ýµÛ¤½¥q¦³¯à¤Oµo¦æ§ó¦hªÑ²¼¡A³o·N¨ýµÛ§ó¤jªºªÑ¥»°ò¦¡CÂX¤jªº¸ê¥»°ò¦¥i¥HÀ°§U«Ø¥ß§ë¸êªÌªº«H¤ß¡A¨Ã¨Ï¤½¥q§ó®e©ö¬°¦UºØ±M®×©Î¥ø·~Àò±o¸êª÷¡C

3.¦X¨Ö»P¦¬ÁÊ¡G¦b¦X¨Ö©Î¦¬Áʪº±¡ªp¤U¡A¤½¥q³q±`»Ý­n¼W¥[¨äªk©wªÑ¥»¡C§@¬°¥æ©öªº¤@³¡¤À¡A³o¤@¼W¥[¥i¯à¬O«P¶i·sªÑµo¦æ

©Ò¥²»Ýªº¡C³z¹LÄw¶°ªk©w¸ê¥»¡A¤½¥q½T«O¾Ö¦³¶¶§Q¡B¦³®Ä²v¦a¶i¦æ¦¹Ãþ¥æ©ö©Ò»ÝªºÆF¬¡©Ê¡C

4.­û¤u«ùªÑ­pµe¡]ESOP¡^¡G¤½¥q¥i¥H¼W¥[ªk©wªÑ¥»¥H¹ê¬I­û¤u«ùªÑ­pµe¡]ESOP¡^¡CESOP ¦®¦b³z¹L¬°­û¤u´£¨Ñ¥H¹w©w»ù®æÁÊ

¶R¤½¥qªÑ²¼ªº¾÷·|¨Ó¿EÀy­û¤u¡C¼W¥[ªk©wªÑ¥»¨Ï¤½¥q¯à°÷µo¦æ±Mªù¥Î©ó³o¨Ç­p¹ºªºÃB¥~ªÑ¥÷¡A±q¦Ó¿EÀy­û¤u¨Ã¨Ï¥L­Ìªº§Q

¯q»P¤½¥qªº§Q¯q«O«ù¤@­P

¼W¥[±ÂÅvªÑ¥»ªº¹Lµ{¡G

¼W¥[ªk©wªÑ¥»ªº¹Lµ{¦]¥qªkºÞÁÒ°Ï©M¤½¥q³¹µ{ªº¤£¦P¦Ó¦³©Ò¤£¦P¡CµM¦Ó¡A¥¦³q±`¯A¤Î¥H¤U¨BÆJ¡G

1.¸³¨Æ·|§å­ã¡G¤½¥q¸³¨Æ·|³q¹L¨Mij¡A«Øij¼W¥[ªk©wªÑ¥»¡C¸Ó¨MijÀH«á±N´£¥æªÑªF¤j·|§å­ã¡C

2.ªÑªF§å­ã¡GªÑªF¦¬¨ì¦³Ãö¼W¥[ªk©wªÑ¥»ªº«Øijªº³qª¾¡A¨Ã¦³¾÷·|¦bªÑªF¤j·|¤W´N¸Ó¨Mij¶i¦æ§ë²¼¡C¸Ó¨Mij¥²¶·Àò±oªÑªF¥²

­nªº¦h¼Æ§å­ã¤~¯àÄ~Äò¶i¦æ¡C

3.ºÊºÞ¦X³W©Ê¡G¤@¥¹Àò±oªÑªF§å­ã¡A¤½¥q¥²¶·¿í¦u¬ÛÃö¥qªkºÞÁҰϪºªk«ß©MºÊºÞ­n¨D¡C³o¥i¯à¯A¤Î´£¥æ¥²­nªº¤å¥ó¨Ã¦V¾A·í

ªººÊºÞ¾÷ºc¤ä¥I¥²­nªº¶O¥Î¡C

4.­×§ï¤½¥q³¹µ{¡G¬°¤Ï¬M¼W¥[ªºªk©wªÑ¥»¡A¹ï¤½¥q³¹µ{¶i¦æ¬ÛÀ³­×§ï¡C³o¨Ç­×¥¿®×³q±`·|´£¥æµ¹ºÊºÞ¾÷ºc¡C

µ²½×

¼W¥[ªk©wªÑ¥»¬O¤@¶µµ¦²¤©ÊÁ|±¹¡A¨Ï¤½¥q¯à°÷¾AÀ³¤£Â_ÅܤƪºÀô¹Ò¡B´M¨D¦¨ªø¾÷·|¨Ã¼W±j¨ä°]°Èª¬ªp¡C³z¹LÂX¤j¥iµo¦æªÑ²¼¼Æ¶qªº­­¨î¡A¤½¥q¥i¥H¬°¥¼¨ÓªºÂX±i°µ¦n·Ç³Æ¡A§l¤Þ¼ç¦bªº§ë¸êªÌ¡A¨Ã«P¶i¦UºØ¤½¥q¦æ°Ê¡CµM¦Ó¡A¤½¥q¦b¹ï¨äªk©wªÑ¥»¶i¦æ¥ô¦óÅܧ󤧫e¡A¥²¶·¿í´`ªk«ßµ{§Ç¨ÃÀò±oªÑªF§å­ã¡C

±`¨£°ÝÃD (FAQ)

Q1: ¤°»ò¬Oªk©wªÑ¥»¡H

A1¡Gªk©wªÑ¥»¬O«ü¤½¥q¨Ìªk¤¹³\¦VªÑªFµo¦æªºªÑ¥÷ªº³Ì¤j¼Æ¶q¡C¥¦¥Nªí¤½¥q¥i¥Hµo¦æªºªÑ²¼Á`»ù­È¡C

Q2¡G¬°¤°»ò¤½¥q»Ý­n¼W¥[ªk©wªÑ¥»¡H

A2¡G¤½¥q¿ï¾Ü¼W¥[ªk©wªÑ¥»ªº­ì¦]¦³«Ü¦h¡C¥¦¥i¯à¬O¬°¤F¾AÀ³¥¼¨Óªº¦¨ªø©MÂX±i­p¹º¡A§l¤Þ§ë¸êªÌ©M¸êª÷¡A«P¶i¨ÖÁÊ¡A©Î¹ê

¬I­û¤u«ùªÑ­p¹º¡]ESOP¡^¡C

°ÝÃD 3¡G¼W¥[ªk©wªÑ¥»¹ï¤½¥q¦³¦ó¦n³B¡H

A3¡G¼W¥[ªk©wªÑ¥»¬°¤½¥q´£¨Ñ¤FÆF¬¡©Ê©M¥¼¨ÓÄw¶°§ó¦h¸ê¥»ªº¯à¤O¡C¥¦¨Ï¤½¥q¯à°÷§ì¦í¦¨ªø¾÷·|¡A§l¤Þ§ë¸êªÌ¡A«P¶i¤½¥q¦æ

°Ê¡A¨Ã³z¹L­û¤u«ùªÑ­pµe¨ó½Õ­û¤u§Q¯q¡C

Q4¡G¼W¥[ªk©wªÑ¥»ªº¬yµ{¬O«ç¼Ëªº¡H

A4¡G¼W¥[ªk©wªÑ¥»ªº¬yµ{¨Ì¥qªkºÞÁÒ°Ï©M¤½¥q³¹µ{ªº¤£¦P¦Ó¦³©Ò¤£¦P¡C¤@¯ë¥]¬AÀò±o¸³¨Æ·|§å­ã¡B³z¹LªÑªF·|´M¨DªÑªF§å

­ã¡B¿í¦uºÊºÞ­n¨D¡B­×§ï¤½¥q³¹µ{¡C

Q5: ªk©wªÑ¥»¼W¥[«á¥i¥H´î¤Ö¶Ü¡H

A5¡G¬Oªº¡A¥i¥H³z¹LÀò±o¸³¨Æ·|©MªÑªF§å­ãªºÃþ¦ü¬yµ{¨Ó´î¤Öªk©wªÑ¥»¡CµM¦Ó¡A¿í¦uªk«ß­n¨D¨Ã¿í´`´î¤Öªk©wªÑ¥»ªº¥²­nµ{

§Ç«D±`­«­n¡C

°ÝÃD 6¡G¼W¥[ªk©wªÑ¥»¹ï²{¦³ªÑªF¦³¦ó¼vÅT¡H

A6¡G¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ù­È¡CµM¦Ó¡A¦pªGµo¦æ·sªÑ¡A´N·|µ}ÄÀªÑÅv¡C²{¦³ªÑªF¦³Åv¥H¨ä

²{¦³«ùªÑ¤ñ¨ÒÁʶR·sªÑ¡A¥Hºû«ù¨ä«ùªÑ¤ñ¨Ò¡C

Q7¡G¼W¥[ªk©wªÑ¥»»Pµo¦æ·sªÑ¬Û¦P¶Ü¡H

A7¡G¤£¬O ¼W¥[ªk©wªÑ¥»¬O«ü´£°ª¤½¥q¥i¥Hµo¦æªºªÑ²¼¼Æ¶qªº­­¨î¡C¥t¤@¤è­±µo¦æ·sªÑ¯A¤Î¹ê»Ú³Ð«ØªÑ¥÷¨Ã±N¨ä¤À°tµ¹ªÑªF

Q8: ¼W¥[ªk©wªÑ¥»¬O§_¦³¥ô¦óªk«ß­n¨D©Î­­¨î¡H

µª8¡G¬Oªº¡A¤½¥q¦b¼W¥[ªk©wªÑ¥»®É»Ý­n¿í¦u¨äºÞÁÒ½d³ò¤º¯S©wªºªk«ß©MºÊºÞ­n¨D¡C³o¨Ç­n¨D¥i¯à¥]¬A´£¥æ¥²­nªº¤å¥ó¡B¤ä¥I

¶O¥Î¥H¤ÎÀò±oºÊºÞ¾÷ºc©MªÑªFªº§å­ã¡C

Q9¡G¼W¥[ªk©wªÑ¥»¬O§_·|¼vÅT¤½¥qªº°]°È³øªí¡H

A9¡G¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT¤½¥qªº°]°È³øªí¡CµM¦Ó¡A·í¦]¼Wµo¦Óµo¦æ·sªÑ®É¡A¥i¯à·|¼vÅT¸ê²£­t¶ÅªíªºÅv¯q³¡¤À©M¨CªÑ

¬Õ¾l¡]EPS¡^ªº­pºâ¡C

Q10¡Gªk©wªÑ¥»¨Ó¥i¥H¦h¦¸¼W¥[¶Ü¡H

A10: ¬Oªº¡Aªk©wªÑ¥»¨Ó¥i¥H®Ú¾Ú¤½¥q­n¨D¦h¦¸¼W¥[¡CµM¦Ó¨C¦¸¼W¸ê³£»Ý­n¿í¦uªk«ßµ{§Ç¨ÃÀò±oªÑªF©MºÊºÞ¾÷ºcªº¥²­n§å­ã¡C

¸ê°T¨Ó·½ : Understanding the Increase in Authorized Share Capital: A Comprehensive Guide

¥H¤U­Ó¤H¤À¨É:

A ¥»¦¸´£°ªªk©wªÑ¥»ªº½T»P¨ÖÁʦ³Ãö

B ¤½¥q¤½§i´£¨ìµø±¡ªp³q¹L¥H¤UªÑªF¨Mij ( ¥H«eªk©wªÑ¥»10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ )

¡]A¡^10,000,000 ¬ü¤¸¤À¬° 1,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ­±ÃB©Î²¼­±»ù­È 0.01 ¬ü¤¸¡C

(B) 50,000,000 ¬ü¤¸¡A¤À¬° 5,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ­±ÃB©Î²¼­±»ù­È 0.01 ¬ü¤¸¡C

¥H¤W¨â®×³q¹Lªí¨M ( ¤]¦³¥i¯à¾Ü¤¤ )

°ÝÃD 6¡G¼W¥[ªk©wªÑ¥»¹ï²{¦³ªÑªF¦³¦ó¼vÅT¡H

A6¡G¼W¥[ªk©wªÑ¥»¤£·|ª½±µ¼vÅT²{¦³ªÑªFªº«ùªÑ¤ñ¨Ò©ÎªÑ¥÷»ù­È¡CµM¦Ó¡A¦pªGµo¦æ·sªÑ¡A´N·|µ}ÄÀªÑÅv¡C²{¦³ªÑªF¦³Åv¥H¨ä

²{¦³«ùªÑ¤ñ¨ÒÁʶR·sªÑ¡A¥Hºû«ù¨ä«ùªÑ¤ñ¨Ò¡C

C ¬Ý§¹ Understanding the Increase in Authorized Share Capital: A Comprehensive Guide ½Ķª©

¦A¬Ý¤½¥q¥l¶}2024¦~1¤ë24¤éÁ{®ÉªÑªF¤j·|ªº¤½§i·|µo²{ ¦ü´¿¬ÛÃÑ «e«á©IÀ³

D ÁÙ¦n 0.7¥H¤U¦³¦A¤j¥[½X ¦¨¥»¤j­°¤@¥b

E ¥æµ¹¤jªÑªF, ºÊ¹î¤H BVF Tang capital Vivo Capital Citadel ¥h§ë²¼¨M©w(À³¸Ó¤£·|ªí¨M¹ï¦Û¤v¤£§Qªº¨Æ)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/12/23 ¤U¤È 05:56:14²Ä 6512 ½g¦^À³
«ç»ò·|¨S¦³§C»ù¥i¥H¦^¸É©O¡AªÑ»ù¤£´N¤S¯}©³¤F¶Ü......¡A³o¦¸ªk©wµn°OªÑ¼Æ¤@¦¸¼W¥[40»õªÑ¯uªº¬O¤Ó«ÕÀq¤F¡A¥Hasln¤½¥¬ªº2023Q3°]³øÅã¥Ü¡AÁöµMªk©wµn°OªÑ¼Æ¦³10»õªÑ¡A¦ý¹ê»Ú¥uµo¦æ¤j¬ù4.3»õªÑ¡A25ªÑ=1ads¨Óºâ¡A¤j¬ù¬°1720¸UªÑads¡Aµ¥©óÁÙ¦³2280¸UadsªºªÅ¶¡¥i¥H¼W¸ê¡A³o¦¸ª½±µ§âµn°OªÑ¼Æ¼W¥[¨ì50»õªÑ¡A¦pªG¯uªº¥þ³¡µo¦æ¥Nªí·|¦³2»õªÑªºads¡A­Ó¤H¤£­t³d¥ô²q´ú¥i¯à¬°¤F¥¼¨Ó¦X§@¹Ù¦ñ´£¨Ñ¤T´Á¸êª÷¦Ó¼W¸ê¤JªÑ¥ý°µ·Ç³Æ¡A¦ý¥Ñ©óªÑ»ù§C°g¡A©Ò¥H¼W¸êªÑ¼Æ¥u¯à¿±µÈªº¦p¦¹¥¨¤j¡A­ì¥»2280¸Uadsªº®Ú¥»¤£¨¬¥H©Ó±µ¡A½Ö¥sªÑ»ùÄꦨ³o¼Ë¡A©Ò¥H¤~»¡ºÞ²z¶¥¼h¤£ª`­«ªÑ»ù¡A¾É­PÄw¸ê®É»Ý­n¼Wµo¤j¶qªÑ²¼¡A­ì¦³ªÑªF«ùªÑ³Qµ}ÄÀ¨ìÃz¬µ¡A³oºØºÞ²z¶¥¼h®Ú¥»µLÃÄ¥i±Ï¡A§Y¨Ï³Ì«áUSD20»õ¤¸³Q¦¬ÁÊ¡A§éºâads¤@ªÑ10¤¸¡A¬Û«HÁÙ¬O¦³¤j³¡¤À¦Ñ·à¤Í¬O½ß¿úªº¡A²¦³º­n¬O¨S¦³¦b³Ìªñ¥[½XÅu¥­ªº¸Ü¡A¯uªº¦Ñ·à¤Í«ùªÑ¦¨¥»À³¸Ó³£¤£§C¡A¨ººØ¦¨¥»0.5¥i¥H½´X­¿ªº´N¤Ö»¡¤F§a¡A¤£µM²{¦b0.4¤SÁȦh­¿°Õ¡A«ùªÑ¦¨¥»¬O¥i¥H¥Î³Ûªº´N¬O¤F¡I¡H­n¤£­n¬Ý¬Ý±q¥xªÑ´N¶}©l¤@¸ôµe¤j»æªº®É­ÔªÑ»ù¦h¤Ö¡A³o»ò¬Ý¦nªº¸Ü¡AÁ`¤£·|¦­´Á´N¨S«ù¦³¡A²{¦b¤~¤j¶q§C»ù¶R¶i§a¡AÁ`¤§¡A¯uªº¦Ñ·à¤Í­Ì¦h«O­«¡A²{¦b³B¤À¤]¦¬¦^¤£¤F¤°»ò¤F¡A¥u¨D³Ì«áµ²ªG¯à¦^¥»´N¦n¡A¤jÁÈÀ³¸Ó¬O¨S«ü±æ¤F.....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/12/23 ¤U¤È 05:19:29²Ä 6511 ½g¦^À³
¤w¸g¨ì½T»{¥ë¦ñªº³Ì«á¶¥¬q¤F¡C¤£µM¤£¥Î¤j¶O©P±i¥hÂX±iªÑ¥»¡C¹w´ÁªÑªF·|¶}§¹´N·|ª¾¹D¥ë¦ñ¬O½Ö¡C¦Ó¥B¹ê»Ú»{ªÑªÑ»ù©MªÑ¼Æ¤½¥q³£ºâ¦n¤F,¥u¬O¥Ø«e¤£¯à»¡¡C³Ì«á,¥ë¦ñ©Òñªº«´¬ù¤@©w¬O»¡,¤T´ÁÁ{§É¼Æ¾Ú«Ü¦n®É,¦³Àu¥ý½Í§P¨ÖÁÊÅv§Q¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·RµL­­10148552  µoªí®É¶¡:2023/12/23 ¤U¤È 01:26:40²Ä 6510 ½g¦^À³
To ¤p©ú¤j:

0.01¥u¬OªÑ²¼­±ÃB¡A¹ê»Ú»{ªÑ»ù®æ¸òªÑ¼Æ¡A¤½¥q©|¥¼¤½¥¬¡H

µù1¡G¦¹¦¸¼W¥[40»õªÑ¥»¡A±À´ú¬O¥Î¨Ó¼W¸ê¡B3´Á¸ÕÅç¥Î.

µù2¡G2024.1.24³q¹Lij®×«á¡A´N·|¦A¶i¦æ«á­±ªº¼W¸ê»{ªÑ¡A³o®É«á´N·|ª¾¹D¬O½Ö§ë¸ê¡AÀRÀRµ¥«Ý3´Á¹êÅçµ²ªG¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/23 ¤W¤È 11:12:48²Ä 6509 ½g¦^À³
Ãö©ó¥l¶}2024¦~1¤ë24¤éÁ{®ÉªÑªF¤j·|ªº¤½§i

2023¦~12¤ë22¤é¡AASLAN Pharmaceuticals Limited¡]¡u¥»¤½¥q¡v¡^µo¥X±N©ó2024¦~1¤ë24¤é¤W¤È9:00¦b²H°¨¿ü¤j¹D3¸¹¼h¥l¶}Á{®ÉªÑªF¤j·|ªº³qª¾¡]¡u³qª¾¡v¡^ 18 Centennial Tower, Singapore 039190 ¨Ñ¦Ò¼{¨Ãµø±¡ªp³q¹L¥H¤UªÑªF¨Mij¡G

¨Mij¤@¡G

(i) §@¬°¤@¶µ´¶³q¨Mij¡A¼W¥[¤½¥qªºªk©wªÑ¥»¡G

¡]A¡^

¸ê®Æ¨Ó·½¡G10,000,000 ¬ü¤¸¤À¬° 1,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ­±ÃB©Î²¼­±»ù­È 0.01 ¬ü¤¸¡C

(B)

TO¡G50,000,000 ¬ü¤¸¡A¤À¬° 5,000,000,000 ªÑ´¶³qªÑ¡A¨CªÑ­±ÃB©Î²¼­±»ù­È 0.01 ¬ü¤¸¡C

¨Mij2¡G

(i) §@¬°¤@¶µ¯S§O¨Mij¡A¤½¥q²{¦³ªº²Õ´³¹µ{¤jºõ©M³¹µ{²Ó«h¡]§Y²Ä¤Q¤@¦¸­×­q©M­«­zªº¤½¥q²Õ´³¹µ{¤jºõ©M³¹µ{²Ó«h¡^¥þ³¡¥Ñ·sªº²Õ´³¹µ{¤jºõ©M³¹µ{²Ó«h¨ú¥N¡]¥»¤½¥q²Ä¤Q¤G¦¸­×­q¤Î­«­zªº²Õ´³¹µ{¤jºõ¤Î³¹µ{²Ó«h¡C

Ãö©óij®×¤Gªº»¡©ú¡G¹ï¤½¥q³¹µ{¤jºõ¤Î³¹µ{²Ó«hªº­×§ï¶È­­©ó¤½¥q³¹µ{¤jºõ²Ä¤C±ø¸ü©ú¤½¥q¸ê¥»ªº­×§ï¡A¥H¤Ï¬M¤W­zªk©wªÑ¥»ªº¼W¥[¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/23 ¤W¤È 09:53:03²Ä 6508 ½g¦^À³
¦U¦ì¤j¤j

¨È·à±d1¤ë24¤éÁ{®ÉªÑªF·|¡A

¨Mij®×¤@¡A0.01¬ü¤¸¡A¬O¼W¸ê¶Ü

¬Ý¤£¤ÓÀ´

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/19 ¤U¤È 07:33:28²Ä 6507 ½g¦^À³
¸Ø±i¤j

·PÁ§Aªº§ó¥¿»P¸É¥R¡AÅý¤j®a¦Y¤F©w¤ß¤Y¡Aªº½T¦pµL­­¤j©Ò»¡«K©y´N¬O³Ì¤j§Q¦h¡A³o¤äªÑ²¼¶^ªº²ö¦W¨ä§®¡A

«ç»ò¤U¥h«ç»ò¤W¨Ó¡A³Ì«á·|ÁÙ¤©¤½¹D¡A©ö¸g´£¨ì­é·¥¥²´_¤ñ³ë´c¦Hªº±¡ªp¨ì¹F·¥ÂI«á¡A¥²©wÂà¦n¡C

µ¥¨ì§Q¦h¨ÓÁ{¡A¥X²{Á`¶R¶i¡A¨º»ò¦h¤H·mµÛ¦^¸É¡A­n¥Î¤°»ò»ù®æ¤~¯à¶R¨ì¡H ¤H±ó§Ú¨úªº¹D²z£¸ÂI¤]¤£ÃøÅ鮩¡C

«ö·Ó¨º´µ¹F§J³W©w¡A¥ø·~ªÑ»ù³s30¤Ñ§C©ó1¬ü¤¸·|¦¬¨ìĵ§i¡A¥¼¨Ó180¤Ñ¶·³]ªkÅýªÑ»ù¦^¤É¨ì1¬ü¤¸¡A§_«h´N·|­±Á{¤U¥«©R¹B¡C¦ý¹ê»Ú±¡ªp¬O¡A³\¦h¤½¥q¥i¥H¥D±i¦AÀò±oÃB¥~¤@¦¸180¤Ñ¼e­­´Á¡A§Y«K¯uªº³Q­n¨D¤U¥«¤]¥i¥H¤W¶D¡A¦b³o¬q´Á¶¡¨ÌµM¯àºû«ù±¾µP¦a¦ì¡C

¥H¤W¤À¨É¡A¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/12/19 ¤U¤È 05:22:41²Ä 6506 ½g¦^À³
§ó¥¿:

ªÑ»ù§C©ó1¬ü¤¸¡A¸g¹L30¤Ñ«á¡A±N³Qĵ§i©µ«á6­Ó¤ë§ïµ½(§Y113¦~6¤ë«eªÑ»ù­n°ª©ó1¬ü¤¸³sÄò10¤Ñ)¡A

¦Ó113¦~6¤ë©¡º¡(ÁÙ§C©ó1¬ü¤¸)ÁÙ¯à¦A©µ6­Ó¤ë¡A§Y113¦~12¤ë­YªÑ»ù¤´§C©ó1¬ü¤¸¡A¤~·|³Q­n¨D¤U¥«¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·RµL­­10148552  µoªí®É¶¡:2023/12/19 ¤U¤È 01:56:58²Ä 6505 ½g¦^À³
±q7¤ë¤G´Á¸Ñª¼¨´¤µ¡A¥¼¨£¥ô¦óªº§QªÅ¡AªÑ»ù¥Ñ4.X¶^¨ì0.43¤¸¡A¤w¸g¸y±Ù¤Q¤À¤§¤@¡C

¦Ó¶^¦h´N¬O³Ì¦nªº§Q¦h!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/18 ¤U¤È 05:11:30²Ä 6504 ½g¦^À³
§CÀÉ¥X¤j¶q¡Aµ´«DÃa¨Æ¡A

¦p¦³¦^´ú¾ã²z¤£¯}«e§C0.43¡A¦³¾÷·|§Î¦¨²Ä2°¦¸}¡A

¦Aµ¥«Ý®ø®§°t¦X¡A

°µ¤@¬q¹³¼Ëªº¤Ï¼u¡A

¨ì¤F³o®É­Ô¤]¨S¤°»ò¦n¿éªº¤F¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©ú¤Ñ¹L«á10151242  µoªí®É¶¡:2023/12/18 ¤U¤È 02:46:51²Ä 6503 ½g¦^À³
³o­Ó¤pªi¬q³Ì§C¥Ñ0.43º¦¨ì0.66³Ì«á¦¬0.578...¦ý¬O«o¯d¤Fªøªøªº¤W¤Þ½u¥BÃzªñ´Á¤Ñ¶q140¸UªÑ,¦pªG2¤Ñ¤º¨S¦³¬ð¯}³o­Ó0.66»ù¦ì,±N·|¶}©l©¹¤U¨«,¬Æ¦Üª½±µ¯}0.43ªº»ù¦ì©¹0.2«e¶i....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/16 ¤U¤È 10:44:14²Ä 6502 ½g¦^À³
§ó¥¿»P¸É¥R

¥b¤s¸y¤j

1 TREK-AD¤G´Á§¹¦¨«á¥¿ÁÚ¦V¤T´ÁÁ{§É, ¦³¼ç¤O¤S¯àÁÚ¦V¤T´ÁÁ{§É¦ó¨Ó¥¢±Ñ, ªÑ»ù³QÄY­«¿ù±þ»P§C¦ô, ¤w½æ¥X©Î¨S½æ¥X³£¬O

­Ó¤H¿ï¾Ü¨S¦³¹ï©Î¿ù, ®t§O¦b©ó¤w½æ¥X½T©wÁ«·l , ¥¼½æ¥XÁÙ¦³Â½Âà¾÷·|

¨Ì¾Ú¤½¥q12¤ë12¤é ¤½§i¸ê°T eblasakimab ªvÀø¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢ªº TREK-AD 2b ´Á¬ã¨s¨ú±o¦¨¥\«á¡A

¥Ø«e¥¿¦b½T»{¼ç¦b¦X§@¹Ù¦ñ¡C

2 TREK-DX°ò©ó TREK-AD ¬ã¨sµ²ªGªº§ó·s¼Ð·Ç(¥l¶ÒEASI ¦Ü¤Ö18¤À , IGA score 3 ©Î4 )¡A¦b¦³dupilumab¸gÅ窺±wªÌ¤¤¬ã¨seblasakimabÀø®Ä, ³o­ÓÁ{§É¸ÕÅçªvÀø16¶g¡A°lÂÜ8¶g¡AÁ`¦@24¶g( 6­Ó¤ë)¡A¥ý«e¦¬¤Jªº¨ü¸Õ«Ü¦h¤w¹FEASI 18¤À¥H¤W ¡A¬Æ¦Ü¤j©ó21¤À¡A«á­±¦¬®×¥u¬O¦b¸É¨¬²Å¦X¦¬®×¼Ð·Ç(­Ó¤H¹w¦ô2024¦~¤¤¤½§i¨ä¤¤¼Æ¾Ú)

( 2023¦~11¤ë30¤é²³øP42 ¬Ý¥XTREK-DXÄ~Äò¦¬®× TREK-DX: phase2 study in dupilumab-experienced patients on going )

3 63% ªºdupilumab ªvÀø±wªÌ¦b16 ¶g«á¥¼¯à¹F¨ì³z©ú©Î±µªñ³z©úªº¥Ö½§¡]¬ã¨sªÌÁ`Åéµû¦ô[IGA] µû¤À¬°0 ©Î1¡^¡A¨Ã¥B¦b¹F¨ì³oºØ¤ÏÀ³ªº±wªÌ¤¤36¶g«á¤j¬ù¤@¥b¦bÀH«áªºªvÀø«áµLªkºû«ù³oºØ¤ÏÀ³ , ©Ò¥H³o¬O¤@­Ó¬Û·í¤jªº±wªÌ¸sÅé¡A¯Ê¥F¦w¥þ¡Bªø´Áªº´À¥NªvÀø¿ï¾Ü¡C TREK-DX ªÓ­t­«¤j¨Ï©R

4 Farudodstat ªvÀø´³¨rªº FAST-AA ¬ã¨s¤¤¦w¥þ©Ê¼Æ¾Úªº¼f¬dÅã¥Ü¨S¦³¥X²{¨xŦ©Î¨ä¥L¦w¥þ©Ê°ÝÃD¡A¤ä«ùÂX¤j¤J²Õ¼Ð·Ç¥H

¥]¬A¤£¤ÓÄY­«ªº±wªÌ¡C¦]¬°ÂX¤j¦¬®×´Á¤¤¼Æ¾Ú±N¦b2024 ¦~¤¤¤½§G

5 ¨Ì¾Ú¨º´µ¹F§J¥æ©ö©Ò«h³W©w¡A¦pªG¤½¥qªÑ»ù³sÄò30­Ó¥æ©ö¤é (30¤Ñ)§C©ó1 ¬ü¤¸¡A©Î¥¼º¡¨¬¨ä¥L­n¨D®É¡AÃÒ¨é¥æ©ö©Ò´N·|

µo¥Xĵ§i¡A¥²¶·¦b180 ¤Ñ¤º«ì´_ªÑ»ù¡A­Y¥¼¹F¦¨«K·|³Q±j¨î¤U¥«©ÎÂಾ¨ì¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò

(¤j®a¥[ªo 30­Ó¥æ©ö ¤é¤º¦¬½L¤j©ó1¬ü¤¸ ¦M¾÷´N¸Ñ°£ ­«·s­pºâ ( ¬ù12¤ë29¤é¥ª¥k )

6 ·í¤@¤äªÑ²¼¦]¤£²Å¦X­n¨D¦Ó³QºKµP®É¡A¥¦¨Ã¤£·|´N¦¹®ø¥¢¡C¬Û¤Ïªº¥¦¶}©l¦b³õ¥~¥æ©ö (OTC) ¥«³õ¶i¦æ¥æ©ö

ªÑªF¨ÌµM¬O¤½¥qªÑªF, ¾Ö¦³ªÑªFÅv·¸(¥]¬A±ÂÅv¨ÖÁʤ]¦³§A¤@¥÷)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥d¦b¥b¤s¸y10153098  µoªí®É¶¡:2023/12/16 ¤W¤È 12:52:10²Ä 6501 ½g¦^À³
·Q»¡­n­Ë¤F ¤S¬ðµMº¦25% ¦Ñ¦­´N©ñ±ó¥[½X¤F

½Ð°Ý¥¼º¡1¬ü¤¸¦h¤[´N¤S­n­±Á{¤U¥«?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/15 ¤U¤È 11:24:12²Ä 6500 ½g¦^À³
¸É¥R»¡©ú

·Pı¨S¦³§C»ù¥i¥H¦^¸É

Recruitment in TREK-DX, studying eblasakimab in dupilumab-experienced patients, using updated criteria based on findings from TREK-AD, has commenced at US sites, with additional sites in Europe expected to open in the first half of 2024.

Recruitment³o­Ó¦r¬O ¥l¶Ò·s¦¨­û¡A¥l¶Ò·s§L¡A¸É¥Rªº·N«ä¡A¤w¦¬®×ªº²Å¦X¼Ð·Ç¯d¥Î¡A¦A¸É¨¬¤£²Å¦X¼Ð·Ç¡]EASI ¤p©ó18¤À¡^ªº¤H¼Æ¡A¤£¬O

±q·s¦¬®×¡C

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/15 ¤U¤È 08:39:07²Ä 6499 ½g¦^À³
¤p©ú¤j

Trek-dx ­ì¥»2024¦~²Ä¤@©u¤½§iÁ{§É¼Æ¾Ú¡A¦]¬°Trek-ADµo²{¥l¶ÒEASI¤j©ó18¤À¡A¤j©ó21¤À¡A¹ï·Ó²Õ»P¹êÅç²Õ®t¶Z¤~¯à©Ô¤j¡A¤]´N¬O»¡

¹êÅç²ÕÀø®Ä¤£·|§ïÅÜ¡A¦ý¹ï·Ó²Õ·|¦]¯e¯fÄY­««×¼W¥[¦ÓµLªkÅã²{Àø®Ä¡ATREK-DX ªº©Û¶Ò¤u§@¤Q¤G¤ëªì¤w¦b¬ü°ê±Ò°Ê¡A(°ò©ó TREK-AD ¬ã¨sµ²ªGªº§ó·s¼Ð·Ç¡A¦b¦³dupilumab¸gÅ窺±wªÌ¤¤¬ã¨seblasakimabÀø®Ä¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹w­p±N©ó 2024 ¦~¤W¥b¦~±Ò°Ê)¡A³o­ÓÁ{§É¸ÕÅçªvÀø16¶g¡A°lÂÜ8¶g¡AÁ`¦@24¶g¡A­Ó¤H»{¬°¬O§ó·s¦¬®×¼Ð·Ç¡A¥ý«e¦¬¤Jªº¨ü¸Õ«Ü¦h¤w¹FEASI 18¤À¥H¤W¡A¬Æ¦Ü¤j©ó21¤À¡A«á­±¦¬®×¥u¬O¦b¸É¨¬²Å¦X¦¬®×¼Ð·Ç¡A±ß´X­Ó¤ë¤½§i¼Æ¾Ú¨Ã¤£­«­n¡A­«­nªº¬OÀø®Ä­n¦n¨ÖÁÊ»ù½X¤~·|°ª¡A¥t¥~­ì¥»¦b¬ü°ê¦¬®×¡A³o¦¸ÂX¤j¨ì¼Ú¬w¡AÂX¤j¼Ú¬w¥«³õªº¥ø¹Ï¤ß±j¯P¡AThe study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.

(¹w¦ô2024¦~²Ä¤G©u¤½§iÁ{§É¼Æ¾Ú¡A AA 2024¦~²Ä¤@©u¤½§i¡^

³Ìªñ¤½§i°T®§ª`·N³o¨â­Ó­^¤å³æ¦r (±À´ú¦X§@¹Ù¦ñ¦b°µ³Ì«á½T»{¡A³Ì«á¿ï¾Ü)

1 process is underway to identify potential partners ¡] Identify¬O½T»{ªº·N«ä¡A¥¿¦b½T»{¦³¼ç¤O¹Ù¦ñ ¡^

2 Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications. Selection¿ï¾Üªº·N«ä¡A ¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡A±Neblasakimab¦b²§¦ì©Ê¥Ö½§ª¢»P¨ä¥L¾AÀ³¯g±À©¹²Ä¤T´ÁÁ{§É¸ÕÅç

3¦pªGÁÙ¦b§ä¦X§@¹Ù¦ñ·|¥Î find , seekµ¥­^¤å¦r

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/14 ¤W¤È 12:24:08²Ä 6498 ½g¦^À³
²§¦ì©Ê¥Ö½§ª¢AD ¨r´³AA¡AºC©Êªý¶ë©ÊªÍ¯fCOPD, ¹L±Ó®ð³Ý¡A³o¥|­Ó¾AÀ³¯g³£¬O¤jÃÄ¡AºÝ¬Ý¨ÖÁʪ̥X»ù¡A·Pı¥Ø«e³B¦b¦h¤èºW±Û½Í§P¤¤¡A

·íµM­n¥ý§â·íªì±ÂÅv¹L¨Ó­nµ¹CSLªº¨½µ{ª÷»P¾P°âÅv§Qª÷¥ýCover±¼¡A¤½¥q­n²bÁȦh¤Ö¡A­Ó¤Hµû¦ô¦³3~10»õ¬ü¤¸»ù­È,¤£·|¦³¤Ñ©R¤j²q´úªº¤Ñ»ù¨ÖÁÊ¡A¤£­n§Ñ¤F¤½¥q°õ¦æªø±Mªø¬O¨ÖÁÊ¡C

¥H¤W¨â«h¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/13 ¤U¤È 11:49:29²Ä 6497 ½g¦^À³
Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications.

¥ÎSelection ³o­Ó¦r¬O¿ï¾Üªº·N«ä¡A¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡A±Neblasakimab¦b²§¦ì©Ê¥Ö½§ª¢»P¨ä¥L¾AÀ³¯g±À©¹²Ä¤T´ÁÁ{§É¸ÕÅç¡A

¸É¥R»¡©ú¡G¤w§¹¦¨¤G´Á¡A¨ä¥L¾AÀ³¯g¦pCOPD,¥i¥Hª½±µ¶i¤J¤T´ÁÁ{§É¡Aªí¥Ü¤w¦³¦h®a¥Í§Þ¤½¥q¦b½Í§P¤¤¡A¤½¥q­n±q¤¤¿ï¥X±ø¥ó³Ì¦nªº¨ÖÁʪ̡A

³Ì­«­nªº¬O¨ÖÁÊ»ù®æ¡A»P¥Ø«eªÑ»ùµLÃö¡A³Q¨ÖÁʤ½¥q·íµM­n¤U¥«¡A¤U¥«¤££¸©w¬OÃa¨Æ¡A¥i¯à¬O¦n¨Æ¡C

²×©ó·Q³q¨º¨Ç§ë¸ê¾÷ºc¬°¦ó¨S¦b©È¡A³Ì­«­nªº¬O¨CªÑ¨ÖÁÊ»ù®æ¡A¤£¬O¥Ø«eªÑ»ù¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/13 ¤U¤È 06:40:35²Ä 6496 ½g¦^À³
¦U¦ì¤j¤j

¨Ì¥H«eºD¨Ò¤Î¤½¥q¸Û«H¡A

¨È·à±d¥¼¨Ó¨Ã¤£¼ÖÆ[¡A

Trek-dx¨ì²{¦b¦~©³¤F¡AÁÙ¦b§ó§ï±µ®×¼Ð·Ç¡A³s¼Ú¦{±µ®×­n¨ì©ú¦~¤W¥b¦~¤~¶}©l¡A´Nºâ±µ®×¶¶§Q¨ì¸ÕÅ秹¦¨¡A¤w±µªñ©ú¦~¦~©³¡A¸ò¤§«e»¡©ú¦~¤W¥b¦~¸Ñª¼¡A®Ú¥»¤£¤@¼Ë¡A³o¶BÄF¶°¹Î¨S±Ï¤F¡A

²{¦bªÑ»ù¶È0.47¤¸¡A©ú¦~¦~¤¤´N¤U¥«¤F¡AÁÙ¦³¥¼¨Ó¶Ü¡A

³s¼Ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/12/13 ¤W¤È 11:26:32²Ä 6495 ½g¦^À³
´«¥y¸Ü»¡¡G

´N¬O¤w¸g¦³§ä¨ì¦X§@¹Ù¦ñ¡A¨Ãñ¦³·N¦V®Ñ¡C¦ý®a¼Æ©Îª÷ÃB¤£²z·Q¡A©Ò¥H­n¦h§ä´X®a¡A

¦]¬°Ã±¦³·N¦V®Ñ¡AK2 HealthVentures LLC¤~¦P·N±NÁÙ´Ú´Á­­®i©µ¦Ü«á¦~¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©t¨àÃÄ10140658  µoªí®É¶¡:2023/12/13 ¤W¤È 10:39:39²Ä 6494 ½g¦^À³
§Y¨Ï¤½¥q¦b¦~²×»¡©ú¥Ø«e¸ÕÅ窺´Áµ{¡A»ù®æÁÙ¬O¨S¦³°_¦â¡A¥NªíÁÙ¬O¨S¤H·Q»{¦P¥¦¡F³o¼Ë¬Ý¨Ó«ùªÑ°ªªº·à¤Í­Ì¡A¹w­p3¤ë¤S­n¦A¥I¬Û·íª÷ÃBªº«OºÞ¶O¡A¤j®aÁÙ¬O­n«ù¬Õ«O®õ! «ö³Ì·sªº»¡©ú¨Ó¬Ý¡A©ú¦~¤W¥b¦~¶È¦³003ªº2A¼Æ¾Ú¥i¨Ñ°Ñ¦Ò¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/12 ¤U¤È 09:53:51²Ä 6493 ½g¦^À³
ASLAN Pharmaceuticals¨ÖÁÊ»ù®æ°ª§C¬Ý²£«~¼Æ¶q»P¼ç¤O( 1- 4 ÂIÅýASLAN Pharmaceuticals¨ÖÁÊ»ù®æ´£°ª¬O¦X²zªº)

1 FAST-AA ¬ã¨s¦w¥þ¸ê®Æ¨S¦³µo²{·s¥X²{ªº¨xŦ©Î¨ä¥L¦w¥þ°ÝÃD (JAK §í¨î¾¯ ³Ì¤j¦w¥þ©Ê¬O¨x·l¶Ë)

FAST-AA ¬ã¨sÅã¥Ü¦w¥þ¥i¥H¬°±wªÌ´£¨Ñ¦³»ù­ÈªºªvÀø¿ï¾Ü ( ¨S¦³µo²{¨x·l¶Ë) ( ¦w¥þ©Ê+ ¦³®Ä©Ê)

2 ®Ú¾ÚTREK-AD ¬ã¨sªºµ²ªG¡ATREK-DX ¯Ç¤J¼Ð·Ç¤w¶i¦æ­×§ï¡A¥H¯Ç¤JEASI µû¤À¦Ü¤Ö¬°18 ªº±wªÌ¡A¨Ã¥B¿W¥ßµû¼f­û¹ï°ò½u

EASI µû¤Àªº½T»{¤w±o¨ì¹ê¬I (TREK-DX ¦b¥l¶ÒEASI µû¤À¦Ü¤Ö¬°18¤Àªº±wªÌ«á¼Æ¾Ú¹w´Á·|«Ü«GÄR­È±o´Á«Ý )

3 ¥¿¦b¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¡A±Neblasakimab±À¶i AD ©M¨ä¥L¾AÀ³¯gªº²Ä¤T´ÁÁ{§É¸ÕÅç

( ¤w¸gµo²{¦¬®×¼Ð·Ç°ò½uÀã¯l­±¿n©MÄY­«µ{«×«ü¼Æ EASIµû¤À¦Ü¤Ö 21¤À Åý¤T´Á¦¨¥\²v¤j´T´£¤É )

4 ¸êª÷À£¤O¤j´T´î»´

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿ûÅK¨k¤l10144826  µoªí®É¶¡:2023/12/12 ¤U¤È 08:22:13²Ä 6492 ½g¦^À³
¼ÐÃÑ

©Ò¦³§Y®É¥«³õ·s»D

ASLAN Pharmaceuticals ´£¨Ñ¨ä Eblasakimab ©M Farudodstat ±M®×ªº¦~²×§ó·s

20 ¤ÀÄÁ«e¤U¤È8:00 [GMT+8]

³z¹L

Àô²y³q°TªÀ

ªü´µ¯S±¶§Q±d¯«¸gºôµ¸

¤À¨É

Ä~eblasakimab ªvÀø¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢ªº TREK-AD 2b ´Á¬ã¨s¨ú±o¦¨¥\«á¡A¥Ø«e¥¿¦b´M§ä¼ç¦b¦X§@¹Ù¦ñ¡C

TREK-DX ªº©Û¶Ò¤u§@¤w¦b¬ü°ê¯¸ÂI¶}©l¡A¸Ó¯¸ÂI¨Ï¥Î°ò©ó TREK-AD ¬ã¨sµ²ªGªº§ó·s¼Ð·Ç¡A¦b¦³dupilumab¸gÅ窺±wªÌ¤¤¬ã¨seblasakimab¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹w­p±N©ó 2024 ¦~¤W¥b¦~¶}©ñ¡C

¹ïFarudodstatªvÀø´³¨rªº FAST-AA ¬ã¨s¤¤¥X²{ªºª¼ªk¦w¥þ©Ê¼Æ¾Úªº¼f¬dÅã¥Ü¨S¦³¥X²{¨xŦ©Î¨ä¥L¦w¥þ©Ê°ÝÃD¡A¤ä«ùÂX¤j¤J²Õ¼Ð·Ç¥H¥]¬A¤£¤ÓÄY­«ªº±wªÌ¡C¥Ø«e¹w­p¤¤´Á¼Æ¾Ú±N¦b 2024 ¦~¤¤´Á¤½§G¡C

Âà¤Æ¤u§@ÃÒ©ú¤Feblasakimab¦b COPD ¤¤ªº¼ç¤O¡AÀY¹ïÀY¼Æ¾Úªí©ú¥i¯àÀu©ódupilumab¡A¤ä«ùeblasakimab¸Ñ¨M¼sªxªº AD ¦X¨Ö¯gªº¼ç¤O¡C

¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 12 ¤ë 12 ¤é¡]Àô²y³q°TªÀ¡^- ASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ´£¨Ñ·~°È§ó·s¥H¤Î»P¨äµ{¦¡eblasakimab©Mfarudodstat¬ÛÃöªº§ó·s¡C

°õ¦æªø Carl Firth ³Õ¤hªí¥Ü¡G¡u2023 ¦~¡AASLAN ¦b¦h­Ó¤è­±¨ú±o¤F­«¤j¶i®i¡X¡X¦b²Ä¤G¶¥¬q´ú¸Õ¤¤±À¶i§Ú­Ìªº¨â­Ó¥D¾É¶µ¥Øeblasakimab©Mfarudodstat¡A¨Ã«Ø¥ß·~°È¶}µo¦X§@¥H¶i¤@¨B¶}µo©M§Q¥Îeblasakimab ¡¨ ¡Aªü´µÄõ»sÃÄ¡C¡uTREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab¦³¼ç¤O¦b¤£¼vÅTÀø®Äªº±¡ªp¤U¬°²§¦ì©Ê¥Ö½§ª¢AD ´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¨Ã¦¨¬°AD ªº»â¥ýÀøªk¡C¦¹¥~¡A±qÀY¨ì§Àªº¼Æ¾ÚÅý§Ú­Ì²`¨ü¹ª»R¡C- ÀY½Ķ¬ã¨sªí©ú¡A»Pdupilumab¬Û¤ñ¡A eblasakimab°w¹ïIL-13¨üÅ骺¿W¯S§@¥Î¾÷¨î¤Þ°_¤F¤£¦Pªº¤ÏÀ³©M²Ó­M¦]¤l¯S¼x¡C³o¬°eblasakimabªº®t²§¤ÆÁ{§É¯S¼x´£¨Ñ¤F°ò¦¡A¨Ãªí©ú¥¦¥i¯à¹ï±wªÌ¦³®Ä¡C¨º¨Ç¹ïdupilumab¡X¡X§Ú­Ì¥¿¦b TREK-DX ¸ÕÅ礤´ú¸Õ³o¤@ÂI¡C¥O¤H¿³¾Äªº¬O¡A¦b¨Ï¥Î¤HÃþ COPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅ礤¡A§Ú­ÌÆ[¹î¨ìeblasakimab¤ñdupilumab¨ã¦³§ó±jªº®ÄªG¡A¨Ã¥B§Ú­Ì´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº§ó¦h¼Æ¾Ú¡C

Firth ³Õ¤hÄ~Äò»¡¹D¡G¡§2024 ¦~¡A§Ú­Ì±NÄ~Äò±À¶ifarudodstat§@¬°´³¨r (AA) ªº·s«¬ªvÀø¤èªk¡C ¡¨ ¡u»P¨ä¥LDHODH §í¨î¾¯¤£¦P¡A¦b¼f¬dFAST-AA ¬ã¨sªºª¼ªk¦w¥þ¸ê®Æ®É¡A§Ú­Ì¨S¦³¬Ý¨ì·s¥X²{ªº¨xŦ©Î¨ä¥L¦w¥þ°ÝÃD¡C§Ú­Ì¬Û«H¡A¾Ö¦³¤@ºØ¦³®ÄªºÃĪ«¡A¥B¤£¦s¦bJAK §í¨î¾¯ªº¦w¥þ³d¥ô¡A¥i¥H´£¨Ñ¦³»ù­ÈªºÃĪ«¡C¦b¦¹°ò¦¤W¡A§Ú­ÌÂX¤j¤F¤J²Õ¼Ð·Ç¡A±N¤£¤ÓÄY­«ªºAA ±wªÌ¯Ç¤J¨ä¤¤¡A§Ú­Ì»{¬°³o¨Ç±wªÌ¤]¥i¯à¨ü¯q¡A¦ý¥i¯à¤£²Å¦X¥Ø«e§å­ãªº¨t²ÎªvÀø©Î¨ä¥L¥¿¦b¶i¦æªº¸ÕÅ窺¸ê®æ¡C³Ì«á¡A§@¬°§Ú­Ì§V¤Oªº¤@³¡¤À¬°¤F´î¤Ö 2024 ¦~ªº²{ª÷®ø¯Ó¡A§Ú­Ì³Ìªñ­×§ï¤F»P K2 HealthVentures ªº¶U´Ú¨óij±ø´Ú¡A¥H¤j´T´î¤Ö¥¼¨Ó 12 ­Ó¤ëªº¨ì´Á¥I´ÚÁ`ÃB¡C¡¨

¨Ì¥¬©Ô¦N³æ§Ü§ó·s

ASLAN is conducting clinical trials of its lead program, eblasakimab, in adult, moderate-to-severe AD patients. In July, ASLAN announced positive topline results from a Phase 2 TREK-AD study that demonstrated eblasakimab¡¦s potential as the first biologic in moderate-to-severe AD to demonstrate a competitive efficacy profile with once-monthly dosing from initiation. In October, new data was presented from an analysis of patients with severe disease (baseline Eczema Area and Severity Index [EASI] score at least 21), showing a marked widening in placebo-adjusted efficacy. ASLAN has engaged Seth J. Orlow, MD PhD, of the specialist firm, Pharus, with deep and extensive industry relationships in dermatology, to advise on global partnership discussions for eblasakimab.

ASLAN is also evaluating eblasakimab in the Phase 2 TREK-DX study in dupilumab-experienced, moderate-to-severe AD patients. 63% of dupilumab-treated patients fail to achieve clear or nearly clear skin (Investigator¡¦s Global Assessment [IGA] score of 0 or 1) after 16 weeks1, and around half of those patients that do achieve this response do not maintain it after the subsequent 36 weeks2, so this is a sizable patient population that lacks safe, long-term alternative treatment options. Based on findings from the TREK-AD study, which highlighted the changing patient population in the US, the TREK-DX inclusion criteria have been modified to enroll patients with an EASI score of at least 18 and independent reviewer confirmation of baseline EASI scores has been implemented. US sites are now recruiting according to the updated criteria and additional sites in Europe are expected to open in the first half of 2024. ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.

For the first time, ASLAN demonstrated the potential utility of eblasakimab in an indication beyond AD. Data generated in a human translational model of COPD demonstrated that eblasakimab was effective in reducing IL-4 and IL-13 driven airway hyperresponsiveness. Unlike drugs targeting the IL-13 cytokine, eblasakimab blocks signaling of both IL-4 and IL-13 through the type 2 receptor, which may provide for utility in a broader range of indications, including those not solely driven by IL-13. New, promising data of head-to-head comparison with dupilumab in this translational model will be presented at an upcoming scientific meeting.

Farudodstat update

Farudodstat, a highly selective dihydroorotate dehydrogenase (DHODH) inhibitor, is being investigated for the treatment of AA in the FAST-AA Phase 2 trial. Blinded safety data emerging from the study has shown no liver or other major safety concerns to date in patients enrolled supporting farudodstat¡¦s improved safety profile compared to the first-generation of approved DHODH inhibitors. Farudodstat could, therefore, provide an important treatment option for patients with less severe disease looking for a safe systemic therapy. ASLAN has received approval from the study¡¦s Institutional Review Board to expand the enrollment criteria to include patients with 30% or greater hair loss, a milder patient population who currently lack approved systemic treatment options, and is implementing the change to the protocol. JAK inhibitors, which carry several boxed warnings, were recently approved only to treat patients with severe AA. Due to the recent increased availability of approved therapies in severe AA and the expansion of the trial to include moderate AA patients, ASLAN expects topline interim data from the study to be available in mid-2024.

Corporate updates

ASLAN amended the terms of its loan agreement with K2 HealthVentures. In order to substantially reduce the total payments due to K2 HealthVentures over the next 12 months and extend the date from which the Company is required to make monthly repayments to January 2025, ASLAN made a prepayment of $12.0 million which has been applied to the outstanding principal under the loan agreement. $13.0 million of principal now remains outstanding under the loan agreement. The prepayment allows the Company to reduce total cash burn through 2024.

2024 expected milestones

Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications.

Topline readout from the TREK-DX study of eblasakimab.

Topline interim data readout from FAST-AA study of farudodstat in AA in mid-2024.

Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

Upcoming conference attendance

ASLAN¡¦s management team will be participating in the Dermatology Summit in San Francisco on January 7, 2024, at the Hyatt Regency, and the LifeSci Corporate Access Event at the Beacon Grand Hotel, San Francisco, from January 8-10, 2024.

Thaci et al (2019) J Dermatol Sci 94(2):266-275

Worm et al (2020) JAMA Derm 156(2):131-143

About eblasakimab

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. Eblasakimab¡¦s unique mechanism of action enables specific blockade of the Type 2 receptor and has the potential to improve upon current biologics used to treat allergic disease. By blocking the Type 2 receptor, eblasakimab prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) ¡V the key drivers of inflammation in AD. Positive results from the Phase 2b TREK-AD study in moderate-to-severe AD support eblasakimab¡¦s potential to deliver a monthly dosing regimen from initiation in AD without compromising on efficacy and with an encouraging safety profile demonstrated to date, with preparations for Phase 3 underway. ASLAN is also investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.

About farudodstat

Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor that suppresses immune cell proliferation and IFN-£^ secretion by blocking de novo production of pyrimidines required for DNA replication. Compared to first-generation DHODH inhibitors, farudodstat has been shown to be approximately 30 times more potent in its inhibition of DHODH and T cell activity and has demonstrated a well-tolerated safety profile. ASLAN has generated data showing that farudodstat can potentially protect against the loss of immune privilege in hair follicles, supporting its potential as a first-in-class treatment option for alopecia areata (AA). A Phase 2a proof-of-concept trial in AA is currently underway with an interim readout expected in mid-2024.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in mid-2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the Website or follow ASLAN on LinkedIn.

Forward-looking statements

This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the Company). These forward-looking statements may include, but are not limited to statements regarding the Company¡¦s business strategy and clinical development plans; the Company¡¦s plans to develop and commercialize eblasakimab and farudodstat; the safety and efficacy of eblasakimab and farudodstat; the Company¡¦s plans and expected timing with respect to manufacturing activities, clinical trials, clinical trial enrolment and clinical trial results for eblasakimab and farudodstat; the potential of eblasakimab as a first-in-class treatment for atopic dermatitis and of farudodstat as a first-in-class treatment for alopecia areata; the potential benefits, capabilities and results of the Company¡¦s collaboration efforts; and the Company¡¦s cash runway. The Company¡¦s estimates, projections and other forward-looking statements are based on management¡¦s current assumptions and expectations of future events and trends, which affect or may affect the Company¡¦s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; the fact that results of earlier studies and trials may not be predictive of future trial results; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic, the ongoing conflict between Ukraine and Russia and bank failures on the Company¡¦s business and the global economy; general market conditions; changes in the competitive landscape; and the Company¡¦s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company¡¦s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company¡¦s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 24, 2023. All statements other than statements of historical fact are forward-looking statements. The words believe, may, might, could, will, aim, estimate, continue, anticipate, intend, expect, plan, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

Media and IR contacts

ASLAN Media and IR contacts

Emma Thompson

Spurwing Communications

Tel: +65 6206 7350

Email: ASLAN@spurwingcomms.com Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: arr@lifesciadvisors.com

¥D­n¼Ð»x

·j¯Á¡A¨Ò¦p AAPL ©Î¦¬¯q

Show advanced search

Markets

Latest News

Analyst Ratings

Earnings Call Transcripts

SPACs & IPOs

FDA Approvals

Show more

Sector News

Healthcare

Technology

¬¡¤O

¤u·~

®ø¶OªÌ¨¾¿m

®i¥Ü§ó¦h

³Ì·s¨Ó¦Û

¬ü°ê¥þ°ê¼s¼½¤½¥q°]¸gÀW¹D

¸ô³zªÀ

´^³ÕªÀ

¬ü³qªÀ

µØº¸µó¤é³ø

®i¥Ü§ó¦h

¬ü°ê¬F©²

¬ü°êÃÒ¨é¥æ©ö©e­û·|³Æ®×

Á{§É¸ÕÅç

±M§Q¥Ó½Ð»P®Ö­ã

FDA - ÃÄ«~®Ö­ã

FDA - ·s»D½Z

®i¥Ü§ó¦h

API¡B¶}µo¤H­û

API¤å¥ó

API©w»ù

Discord ·s»D¾÷¾¹¤H

±b¤á

µn¤J

«Ø¥ß§K¶O±b¤á

±ø´Ú

|

Áô¨p

­·ÀI´¦ÅS¡Gª÷¿Ä¤u¨ã©M/©Î¥[±K³f¹ô¥æ©ö¯A¤Î°ª­·ÀI¡A¥]¬A·l¥¢³¡¤À©Î¥þ³¡§ë¸êª÷ÃBªº­·ÀI¡A¥i¯à¤£¾A¥Î©ó©Ò¦³§ë¸êªÌ¡C¥[±K³f¹ôªº»ù®æªi°Ê·¥¤j¡A¥i¯à·|¨ü¨ìª÷¿Ä¡BºÊºÞ©Î¬Fªv¨Æ¥óµ¥¥~¦b¦]​​¯Àªº¼vÅT¡C«OÃÒª÷¥æ©ö¼W¥[¤Fª÷¿Ä­·ÀI¡C¦b¨M©w¥æ©öª÷¿Ä¤u¨ã©Î¥[±K³f¹ô¤§«e¡A±zÀ³¸Ó¥R¤À¤F¸Ñ»Pª÷¿Ä¥«³õ¥æ©ö¬ÛÃöªº­·ÀI©M¦¨¥»¡A¥J²Ó¦Ò¼{±zªº§ë¸ê¥Ø¼Ð¡B¸gÅç¤ô¥­©M­·ÀI°¾¦n¡A¨Ã¦b»Ý­n®É´M¨D±M·~«Øij¡C§Ú­ÌÂÔ´£¿ô±z¡A¥»ºô¯¸©Ò¥]§tªº¼Æ¾Ú¤£¤@©w¬O§Y®Éªº¡A¤]¤£¤@©w¬O·Ç½Tªº¡Cºô¯¸¤Wªº¼Æ¾Ú©M»ù®æ¤£¤@©w¥Ñ¥ô¦ó¥«³õ©Î¥æ©ö©Ò´£¨Ñ¡A¦ý¥i¯à¥Ñ°µ¥«°Ó´£¨Ñ¡A¦]¦¹»ù®æ¥i¯à¤£·Ç½T¡A¨Ã¥B¥i¯à»P¥ô¦ó¯S©w¥«³õªº¹ê»Ú»ù®æ¦³©Ò¤£¦P¡A³o·N¨ýµÛ»ù®æ¬O«ü¥Ü©Êªº¡A¨Ã¤£¥Nªí»ù®æ¡C¾A¦X¥æ©ö¥Øªº¡C¹ï©ó¦]±zªº¥æ©ö©Î±z¹ï¥»ºô¯¸©Ò§t¸ê°Tªº¨Ì¿à¦Ó³y¦¨ªº¥ô¦ó·l¥¢©Î·l®`¡A§Ú­Ì©M¥»ºô¯¸©Ò§t¸ê®Æªº¥ô¦ó´£¨ÑªÌ§¡¤£©Ó¾á¥ô¦ó³d¥ô¡C¥¼¸g§Ú­Ì©M/©Î¸ê®Æ´£¨ÑªÌ©ú½T¨Æ¥ý®Ñ­±³\¥i¡A¸T¤î¨Ï¥Î¡BÀx¦s¡B½Æ»s¡B®i¥Ü¡B­×§ï¡B¶Ç¿é©Î´²§G¥»ºô¯¸©Ò¥]§tªº¸ê®Æ¡C©Ò¦³´¼¼z°]²£Åv§¡¥Ñ´£¨Ñ¥»ºô¯¸©Ò§t¸ê®Æªº´£¨ÑªÌ©M/©Î¥æ©ö©Ò«O¯d¡C®Ú¾Ú±z»P¼s§i©Î¼s§i°Óªº¤¬°Ê¡A§Ú­Ì¥i¯à·|±qºô¯¸¤W¥X²{ªº¼s§i°Ó¨º¸ÌÀò±o¸ÉÀv¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/12/12 ¤U¤È 12:30:55²Ä 6491 ½g¦^À³
2023¦~12¤ë9¤é¨È·à±d¤½§i

»P K2 HealthVentures LLC ñ­qªº¶U´Ú¨óij­×¥¿

2021¦~7¤ë12¤é¡A®Ú¾Ú¶}°Ò羣®qªk«ß²Õ«ØªºÁŧK¤½¥qªü´µÄõ»sÃĦ³­­¤½¥q¡]¥H¤U²ºÙ ¡§¤½¥q¡¨¡^©M¯S©ÔµØ¦{ªº¤@®a¤½¥q¨È´µÄõ»sÃÄ¡]¬ü°ê¡^¦³­­¤½¥q¡]¡§¨È´µÄõ¬ü°ê¡¨¡^§@¬°­É´Ú¤H»P¨È´µÄõ»sÃĨp¤H¤½¥qñ­q¤F¶U´Ú¡B¾á«O©M¾á«O¨óij¡]¡§¶U´Ú¨óij¡¨¡^¡CLtd.¡A¤@®a®Ú¾Ú·s¥[©Y¦@©M°êªk«ß¦¨¥ßªº¨p¤HªÑ¥÷¦³­­¤½¥q¡]¡§·s¥[©YASLAN¡¨¡A»P¤½¥q©MASLAN USA¤@°_¡A¦U¬° ¡§¶U´Ú¤è¡¨¡A¦XºÙ ¡§¶U´Ú¤è¡¨¡^¡A§@¬°¾á«O¤H¡A¶U´Ú¤H¡A¨ä·í¨Æ¤è¡AK2 HealthVentures LLC§@¬°¦æ¬F¥N²z¤H¡A§@¬°©è©ã¥N²z¤HªºAnkura Trust Company, LLC¡A¸g¸Ó­×¥¿®×ªº¬Y¨Ç²Ä¤@­×¥¿®×­×­q¶U´Ú¡B¾á«O©M¾á«O¨óijªº¤é´Á¬°2023¦~6¤ë30¤é¡C¡m¶U´Ú¨óij¡n³W©w³Ì¦h¤À¥|§å´£¨Ñ°ª¹F4,500¸U¬ü¤¸ªº©w´Á¶U´Ú¡A¨ä¤¤¥]¬A¦b¥æ©öµ²§ô®Éª`¸êªºªì©l2,000¸U¬ü¤¸©w´Á¶U´Ú¡C¨´¤µ¬°¤î¡A¸Ó¤½¥qÁ`¦@­É¤J¤F2,500¸U¬ü¤¸¡A¤À§O¬O²Ä¤@©M²Ä¤G§å©w´Á¶U´Ú¡C

2023¦~12¤ë6¤é¡A¤½¥qñ­q¤F¶U´Ú¨óijªº­×¥¿®×¡]¡§²Ä¤G­×¥¿®×¡¨¡^¡A®Ú¾Ú¸Ó­×¥¿®×¡A¶U´Ú¤H¦P·N©µªø¡m¶U´Ú¨óij¡n³W©wªº´Á­­¡A¦b¸Ó´Á­­¤º¡A¤½¥qµL»ÝÀvÁÙ¥¼ÀvÁÙªº¥»ª÷¡]¦b¦¹´Á¶¡¡A§Q®§¥I´Ú±NÄ~Äò®Ú¾Ú¶U´Ú¨óijªº±ø´Ú¨ì´Á©M¤ä¥I¡^¡C²{¦b¡A¤½¥q³Q­n¨D«ö¤ë¤ä¥I¥»ª÷ªº²Ä¤@­Ó¤é´Á¬O2025¦~1¤ë1¤é¡C

¦¹¥~¡A®Ú¾Ú²Ä¤G­×¥¿®×¡A¡]i¡^¤½¥q¦VºÞ²z¥N²z¤H¤ä¥I¤F1,200¸U¬ü¤¸¡A³oµ§´Ú¶µ¤w¾A¥Î©ó¶U´Ú¨óij¤Uªº¥¼Àv¥»ª÷¡]¡§¹w¥I´Ú¡¨¡^¡F¡]ii¡^¶U´Ú¤H©MºÞ²z¥N²z¤H§K°£¤F¶U´Ú¨óij¤¤­ì¥»­n¨Dªº2.0¢Hªº¹wÁÙ´Ú¶O¡C¹w¥I´Ú¥Í®Ä«á¡A®Ú¾Ú¶U´Ú¨óij¡A1,300¸U¬ü¤¸ªº¥»ª÷¤´¥¼ÀvÁÙ¡C

Ãö©ó²Ä¤G­×¥¿®×¡A¶U´Ú¤H¤wÀò±o¶U´Ú¤è¾Ö¦³ªº¬Y¨Çª¾ÃѲ£Åvªº¯d¸mÅv¡A¦ýºD¨Ò°£¥~¡C

²Ä¤G­×¥¿®×ªº°Æ¥»§@¬°ªþ¿ý4.1ªþ©ó¦¹¡A¨Ã¥H¤Þ¥Î¤è¦¡¯Ç¤J¦¹³B¡C¤W­z¹ï²Ä¤G¥óªº´y­z¨Ã¤£§¹¾ã¡A¦Ó¬O°Ñ·Ó¦¹ÃþÃÒª«¶i¦æ¤F¥þ­±­­©w¡C

*************************************************************************************************

ÅÞ¿è«ä¦Ò(¥H¤U¦C3ÂI¬°«e´£)¡G

1.¨È·à±d112¦~12¤ë9¤é¤½§i»PK2 HealthVentures LLCñ­q¶U´Ú«´¬ùªºÁٴڤ驵ªø¦Ü2025(114)¦~1¤ë1¤é¡C

2.¨È·à±d²Ä¤T©u°]³ø¬ÒÅS²{ª÷¥u°÷¥Î¨ì113¦~¤U¥b¦~¡C

3.112¦~12¤ë20¤éªÑ»ù§C©ó1¤¸©¡º¡30¤Ñ¡A±NÂಾ¦Ü¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò(¬°´Á180¤Ñ§Y113¦~6¤ë16¤é¤î)¡C

--------------------------------------ÅÞ¿è«ä¦Ò¦p¤U---------------------------------------------------

¤@¯ë¶U´Ú»È¦æ¬Ý°]³ø¡A²{ª÷¬y¥u°÷¥Î¨ì113¦~©³¡A¦­´N«B¤Ñ¦¬³Ê¤F¡A

¦Ó¥B¨È·à±d±N³Q²¾¦Ü¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò(¬°´Á180¤Ñ)¡A§Y113¦~6¤ë16¤é«e§ä¤£¨ì°]·½±N³Q¤U¥«¡C

¤W­z¸ê°TK2 HealthVentures LLC³£ª¾¹D¡A«ç¥i¯àÁÙ¦P·N®i©µ¦Ü114¦~1¤ë1¤é¡C

¦^ÅU¤µ¦~6¤ë22¤éªº¤é¥»±ÂÅv®É¶¡(¤£¥i¯à¥u°Q½×¤@¬P´Á(7¤Ñ)¡A6¤ë22¤é´N¹ï¥~¤½§i)¡A

¹w¦ô3~6­Ó¤ëªº°Q½×¬O¥²­nªº¡A

¹w¦ô112¤ë12¤ë¤w¸g¦b±µ¬¢¬ÛÃö±ÂÅv©Î¨ÖÁÊÃÄ°Ó¡A©ú¦~²Ä2©uªº¬Y¤Ñ±N¹ï¥~¤½§i(¦p¦P6¤ë22¤é¤½§i¤é¥»±ÂÅv)

¦]¬°¤w¸g¦b¸òÃÄ°Ó°Q½×±ÂÅv©Î¨ÖÁʨƩy¡A¾á¥ôºÊ¹î¤Hªº§ë¸ê¤½¥qª¾¹D¨È·à±d¤½¥q¤º³¡ª¬ªp¡Aª¾¹D°]·½¨S°ÝÃD¡A©Ò

¥H¤~´±¦P·NÁÙ´Ú´Á­­®i©µ¡C

(²{ª÷¤£°÷(§tÁ{§É¤T´Á)¡BªÑ»ù§C©ó¬üª÷1¤¸³Q¤U¥«µ¥°ÝÃD±N¤£·|µo¥Í)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/11 ¤U¤È 10:49:31²Ä 6490 ½g¦^À³
°¶¤jªº¦L«×¸Ö¤H®õ¤àº¸¬°¬ü¦n¥@¬Éªº³Ð§@µL¼Æ¨Î¥y¦W¨¥¡AÅý¤H¼È®É§Ñ«o¤F¹Ð¥@ªº¯ÉÂZ¡A¦p²M²D­µ¯ë¡C

~¤£­nþÓ«æ¡A³Ì¦nªºÁ`·|¦b³Ì¤£¸g·Nªº®É­Ô¥X²{¡C

¡ã¶È¶È¯¸¦b¨º¨à±æµÛ¤j®ü¡A§A®Ú¥»¨Sªk¾î´ç¥¦¡C

~¥Í¦p®Lªá¤§µºÄê¡A¦º¦p¬î¸­¤§ÀR¬ü¡C

~·í§A¿ù¹L¤Ó¶§¦Ó¬y²\¡A§A¤]±N¿ù¹L¸s¬P¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/5 ¤U¤È 10:05:29²Ä 6489 ½g¦^À³
¤p©ú¤j

¦³¤H¬ÝªÅ¦³¤H¬Ý¦h¥»À³µ¹¤©´L­«¡A§Ú¦b©³³¡²z©Ê¬Ý¦n¡A¤ÀªRªº¤º®e¾¨¶q¨Ï¥Î¤½¶}¼Æ¾Ú¡A

¥t¥~§Ú¤À¨É­·®æ»P¤Ñ©R¤j§¹¥þ¤£¦P¡A§A·Q¤Ó¦h¤F¡A§Ú·Pı§A¤w¦^¸É¡A¯¬ºÖ§A¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/5 ¤U¤È 09:26:54²Ä 6488 ½g¦^À³
¥xÁÞ¤j

Á¿¥y¶}§¹¯ºªº¸Ü¡A§A§O¤¶·N¡A

§Ú¦³ÂIÃhºÃ§A¬O¤Ñ©R¤jªº¤À¨­¡A

«¢«¢¡A·PÁ§Aªº¤ÀªR

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/5 ¤U¤È 08:40:57²Ä 6487 ½g¦^À³
¤p©ú¤j

@ ¤p¤½¥q³£¬O±q¥¢±Ñ¤¤§l°_¸gÅç³vº¥²æ­L´«°©Åܦ¨¤j¤½¥q ( Áx¹DÀù©ñ±ó¬ãµoºâ¬O¥¢±Ñ 003Âà´«¾AÀ³¯g (¨r´³)¨S¦³¥¢±Ñ

Eblasakimab 2B ¯à¶i¤J¤T´ÁÁ{§Éªí¥Ü¦³¦¨¥\¼ç¤O, 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|µ¹¤©¤fÀY³ø§i§ó¥YÅã¨ä¿W¯S©Ê»P

®t²§¤Æ ( ¨C¤ë¤@°w )

@ 7¤ë6¤é¼Æ¾Ú­Ó¤H»{¬°¬O´Á¤¤¤ÀªR, 2023 ¦~ 10 ¤ë 13 ¤é¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº±ß¶¡³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú ( §¹¾ã¼Æ¾Ú ) ²Ä¥|©u±N¤½§i¥Íª«¼Ð°O

Eblasakimab reduced airway constriction and enhanced dilation

in ex vivo model of COPD (2b ´Á¬ã¨s§¹¾ã¼Æ¾Ú½Ð°Ñ¦Ò2023¦~11¤ë³Ì·s²³ø )

@ ¦pªGEblasakimab ¦bITT»P¸ûÄY­«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯µû¤À¤j¤j­°§C

( «ümean change frm baseline IGA 0/1 EASI-75 EASI-90 ) ³oÃÒ©úEblasakimab¦³ÅãµÛÀø®Ä,

¦pªGEblasakimab ¦b¸ûÄY­«ªº±wªÌ¤¤ªí²{¥X¦â¡A¦w¼¢¾¯¤]ªí²{¦P¼Ë¥X¦â¡A³oÃÒ©úEblasakimab Àø®Ä¤£¦p¹w´Á,

¨Æ«á¤ÀªRÃÒ©ú Eblasakimab ¦bITT»P ¸ûÄY­«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯¦b¸ûÄY­«ªº±wªÌµû¤À«o¤j¤j­°§C

ITT mean change frm baseline ¹ï·Ó²Õ Q2W -51.1 %

Patients with EASI >18 ¹ï·Ó²Õ Q2W -42.3 %

Patients with EASI >21 ¹ï·Ó²Õ Q2W -38 %

µo²{¹ï·Ó²Õ¦U²ÕÀø®ÄÅܰʫܤj

ITT mean change frm baseline ¹êÅç²Õ 600mg Q4W -73 %

Patients with EASI >18 ¹êÅç²Õ 600mg Q4W -75 %

Patients with EASI >21 ¹êÅç²Õ 600mg Q4W -74.5%

Eblasakimab ¦bITT»P ¸ûÄY­«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯¦b¸ûÄY­«ªº±wªÌµû¤À«o¤j¤j­°§C

¨ä¥LIGA 0/1 EASI-75 EASI-90 ¤]¦³¦P¼Ë±¡ªp (°Ñ¦Ò2023¦~¤Q¤ë²³ø )

@ ¥H¤U¬O2023¦~ 11¤ë²³ø»¡©ú¬°¦ó­n°µ¨Æ«á¤ÀªR

• TREK-AD ¬O¤@¶µ¦b 9 ­Ó°ê®a¶i¦æªº¥þ²y¾¯¶q½d³ò¬ã¨s¡A´ú¸Õ eblasakimab¬ù300¦W¤¤«×¦Ü­««×AD±wªÌ ¬ã¨sµ²ªG¬O¥¿­±

ªº¡A¨Ã®i¥Ü¤F¨C¤ëµ¹ÃĪº¼ç¤O¬ã¨s¦b 3 ­ÓÃöÁ侯¶q¤¤¹F¨ì¤F ITT ±Ú¸sªº¥D­n²×ÂI©MÃöÁ䦸­n²×ÂI

600mg Q4W ²Õ¦b¼Æ­È¤W¬Oªí²{³Ì¦nªº²Õ§O¡]EASI ¤À¼Æ­°§C 73%¡Ap=0.001¡^

Eblasakimab °_®Ä§Ö (Page 23 2¶g¹FÅãµÛ®t²§)¡A­@¨ü©Ê¨}¦n¡Aµ²½¤ª¢©Mª`®g³¡¦ìµo¥Í²v§C

• ¨Æ«á¤ÀªRÃÒ©ú¦w¼¢¾¯½Õ¾ã¤À¼Æ¦³¥i¯à¶i¤@¨BÂX¤j¨ä¥L´X¶µ³Ìªñªº¬ã¨s¤@­P¡A¦w¼¢¾¯¤ÏÀ³°ª©ó¤Q¦~«e¶i¦æªºdupilumab ¬ã¨s

¦b¬ü°ê¡A°ª¤ñ¨Òªº»´«×±wªÌ«P¦¨¤F¸û°ªªº¦w¼¢¾¯¤ÏÀ³¡]¶W¹L¤T¤À¤§¤@ªº±wªÌ¬ü°ê±wªÌªº EASI µû¤À§C©ó 18¡^

Eblasakimab ¦bITT»P¸ûÄY­«ªº±wªÌ¤¤ªí²{¦P¼Ë¥X¦â¡A¦ý¦w¼¢¾¯¦b¸ûÄY­«ªº±wªÌµû¤À«o¤j¤j­°§C

@ 1 Top shareholders include BVF, Tang Capital, Vivo Capital, Citadel

( ¨Ì¾Ú10¤ë 11¤ë¤½¥q²³ø³o¥|®a§ë¸ê¾÷ºc¾á¥ôSurveyor ºÊ¹î¤H)

ºÊ¹î¤H¦³Åv½Õ¬d¤½¥q·~°È¤Î°]°Èª¬ªp¡A¤½¥q¬ÛÃö³¡ªùÀ³°t¦X´£¨Ñ¬d®Ö©Ò»Ý¤§Ã¯¥U¤å¥ó¥H«O»ÙªÑªFÅv¯q

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/5 ¤W¤È 01:44:26²Ä 6486 ½g¦^À³
°O±o¡A

³o®a¤½¥q¦¨¥ß¦Ü¤µ¡A

¨S¦³¦¨¥\¹L¤@¦¸¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/5 ¤W¤È 01:36:48²Ä 6485 ½g¦^À³
¥xÁÞ¤j

³o´X¤Ñ¦¨¥æ¶q¥[Á`¡A

¤£¨ì1M¡A

´Nºâ¦³¤ß¤H¥þ¦Y¡A

ÁÙ¤£¨ì5%¡A

¤£¨¬¼vÅT¥þ§½¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/5 ¤W¤È 01:26:44²Ä 6484 ½g¦^À³
¥xÁÞ¤j

§Ú¨S¦³¨º»ò¼ÖÆ[¡A¬Ý¸Ó¤½¥q¤½¥¬¼Æ¾Ú«áÁÙ·|­×§ïªº§@ªk¡A´N¥Nªí¥L¬O«H¥Î¯}²£ªº¤½¥q¡Aceo¤]¬O¦L«×ªü¤T«á¥N¡A

®g½b«á¤~µe¹v¡A½Ö«H¡A

§Ú»{¬°¤§«e«Ü¦h¸ÕÅç¼Æ¾Ú¡A¤@©w¦³¥L­Ì¥ô·N¤W¤U¨ä¤â¡A­J¶Ã­×¥¿ªº±¡ªp¡A

³y¦¨²{¦b¤½¥q»¡¤°»ò¡A³£¨S¤H¬Û«H¥L­Ìªº°­¸Ü¡A¥«³õ¤]²@¤£¶R±b¡A

¶^¨ì¥«­È¤ñ²{ª÷ÁÙ¤Öªº±¡§Î¡A

§Ú»{¬°©ú¦~²Ä¤@©uDX¸ÕÅç¡A¬O¤£·|¦¨¥\ªº¡A¤½¥q·|¦A½s¤@¨Ç²z¥Ñ°­¸Ü¡A»¡­n°µ²Ä3´Á¡A¦A¨Ó·d­Ó´î¸ê¼W¸ê§âÀ¸¡AÄF¤@¨Ç¸êª÷¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/5 ¤W¤È 12:49:40²Ä 6483 ½g¦^À³
³o´X¤Ñ§CÂI©³³¡¥X¶q¡A³o¬O½Ö¶Rªº? µª®×«Ü²M·¡·íµM昰¦³¤ß¤H¦b¶R

¶q¥ý»ù¦æ¡A¤£­n¥u¬Ý»ù¦Ó¤£¬Ý¶q

»ù®æ¥i¥HÄF¤H¡B¦ý¦¨¥æ¶q¤£·|ÄF¤H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/12/4 ¤U¤È 11:50:22²Ä 6482 ½g¦^À³
¤p©ú¤j

1«¢«¢¡I§Ú²qµ¥¤Ñ©R¤j¶R¦n¶Rº¡´N·|¥X¨Ó¡H

«Øijª©¤Í¦³½æ¥X«á¦³»ù®t¥i¦Ò¼{¦^¸É¡A¨S¦^¸É½T©wÁ«·l¡A¦³¦^¸É·|¤ñ¨S¦^¸É¥¼¨Ó³Óºâ¤j

¦pªG¥¼¨Ó¤½¥q³Q¨ÖÁÊ¡A¦b¨ÖÁÊÁ`ª÷ÃB©T©w±¡ªp¤U¡A»P¥Ø«eªÑ»ù°ª§CµLÃö¡A»PMarket cap¦³Ãö

Market Cap ¶V°ª¡A¨ÖÁÊ»ù¶V§C¡AMarket Cap ¶V§C¡A¨ÖÁÊ»ù¶V°ª¡A²{¦bMarket cap§C¨ì¬ù900¸U¬ü¤¸¡A»·§C©ó¤½¥q²Ä¤T©u²{ª÷4080¸U¬ü¤¸ªº©_¯S²{¶H¡A«O¦u¨Ó¬Ý¥u­n¦³Lebrikizumab¨ÖÁÊÁ`ª÷ÃB参¦Ò»ù11»õ¬ü¤¸ªº£¸¥b¡A¨CªÑ¨ÖÁÊ»ù·|Åý¤pªÑªF»P§ë¸ê¾÷ºc¬Û·íº¡·N¡C

2 ¤Ñ©R¤j2023¦~6¤ë23¤é¤À¨É»¡¥@¬É«e¤­¤jÃļt·|«æµÛ§äASLN ½Í¨ÖÁÊ¡A³o¬O50»õ¬ü¤¸¦y®p¾P°â¤jÃÄ¡C

27.7»õ±ÂÅvª÷¤Q20%¤À¼í⋯Áô§t¦y®p¾P°â¬ù55»õ¬ü¤¸¡C

3 Lebrikizumab¨ÖÁÊ参¦Ò»ù11»õ¬ü¤¸

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©ú¤Ñ¹L«á10151242  µoªí®É¶¡:2023/12/4 ¤U¤È 11:29:32²Ä 6481 ½g¦^À³
¥»·Q¤£µo¨¥¤F~¦ý¬OªÑ»ù¥O¤HÅå³Y¨ì·Qµo¤@¤U¼o¤å....¶ZÂ÷¤W¦¸µo¤å¨ì¤µ¤Ñ¤~µuµu60¤Ñ , ´N¥Ñ1.62¶^¨ì0.51 ,

¦pªG·í®É¤£´î¸ê²{¦bªº»ù®æ´N­è¦n0.1,·Q·í®É´î¸ê«e2.4¥þ³¡¥X²æªºµ¦²¤¬O¹ïªº , ¤@¨Ó¤@¦^¸ê²£®t²§24­¿ !

¦pªG·í®É§ë¸ê120¸U²{¦b»ù­È5¸U

¦pªG·í®É§ë¸ê240¸U²{¦b»ù­È10¸U

¦pªG·í®É§ë¸ê480¸U²{¦b»ù­È20¸U

¦pªG·í®É§ë¸ê720¸U²{¦b»ù­È30¸U

¦pªG·í®É§ë¸ê960¸U²{¦b»ù­È40¸U

®¥³ß«Ó°¶¤j1.4»ù¦ì§Y®É¥X²æ !!

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2023/10/5 ¤U¤È 11:29:35²Ä 6435 ½g¦^À³

¶ZÂ÷¤W¦¸¸Ñª¼¥¢±Ñ«á...¤S¹L¤T­Ó¤ë~

2023/7/5ªÑ»ù3.8¶ô¦ý¨ì¤µ¤Ñ¥u³Ñ¤U1.62¤F,¦A¹L¤T­Ó¤ëÀ³¸Ó´N·|¯}1¶ô,¦pªG­n¨ÖÁʦ­´N³Q¨ÖÁʤF,½Ð¤j®a¤£­n¥Õ¤é¹Ú¤F!

2021¦~§Ú´N¬Ý³z³o¤äªÑ²¼¤F!¥u·|¼W¸êÄF¿ú..ªÑ»ù¶^¨ì1¤¸¦A´î¸ê,­«­nªºÁ{§É«o¨S±Ë¦nµ²ªG!¤§«á´N·|¹³Âû³J¤ô»åªÑ0.1ªº»ù®æ ! ¤£«H¶Ü? 2024¦~¨Ó¬Ý

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2023/7/6 ¤U¤È 10:41:26²Ä 6353 ½g¦^À³

±Nªñ¤@¦~¨S¨Óµo¨¥¤F~¤µ¤Ñ¤S¬O¸Ñª¼¥¢±Ñ...¾ú¸g¤F´î¸ê¤À©îÁקK¤U¥«,ªÑ¼Æª½±µ°£¤W6,ÁöµMÁקK¤U¥«©R¹B...¦ý¼Æ¾ÚÁÙ¬O¤£ª§®ð,´N§ÚªºÆ[¹îªÑ»ù¦b¥¼¨Ó¥b¦~ÁÙ·|«ùÄò±´§C¨ì1¬ü¤¸¤§¤U~¤d¸U¤£­n¤£¬Û«H...©^ÄU¤j®a¤£­n¦Aª±³o¤@¤ä¤F!!§ß¤£°_ªºªü¤æ

¤£¬Û«Hªº¥h¬Ý§Ú¥H¤Uªºµo¨¥§a !

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/5/27 ¤U¤È 03:08:40²Ä 5352 ½g¦^À³

¥Ø«e¤w¸g¤U±´0.4¤§¤U¤F,´«ºâ¦¨¥xªÑ»ù®æ¤j¬ù2.4¶ô¥ª¥k,ªñ´Á¤º¨S¦³­«¤j§Q¦h®ø®§ªº¸Ü,ªÑ»ù´N·|¬O¦b©¹¤U¾_Àú,¤£¹L©¹¤U¦h¤Ö¤w¸g¤£­«­n¤F!

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/3/2 ¤U¤È 11:16:14²Ä 5145 ½g¦^À³

¤§«e¥»¤Hªº¯d¨¥³£¤w¸g¤@¤@ÅçÃÒ.......ªÑ»ù¤w¸g©¹0.8¾aªñ ! ±µ¤U¨Ó·|ºCºC¤U±´¨ì0.4¥ª¥k ! ³ÌºGªº¬O¦pªG30¤Ñ¤ºªÑ»ù³£¯¸¤£¤W1¶ô¿ú~ÁÙ­n­±Á{¤U¥«­·ÀI ~ ¤£¹L¬üªÑ«Ü¬y¦æ¤À©îªÑ²¼´î¤Ö§AªºªÑ¥÷µM«á¼W¥[ªÑ²¼­±­È¨ÓÁקKªÑ²¼¤U¥«...§Æ±æ¨È·à±d¤£­n¨«¨ì³o¤@¨B

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/1/19 ¤W¤È 09:59:39²Ä 5061 ½g¦^À³

¶ZÂ÷¤W¦¸¯d¨¥(2021/12/28)¹L¤F¤j¬ù20¤Ñ~¨ì¤F¤µ¤Ñ¥Ø«e¤w¸g¶^¸¨1¶ô¤§¤U...

(2021/9/29)¸Ñª¼¤j¶^¤§®ÉÁÙ¦³2.5¶ô,¥B·í®É¥»¤H¤w¸gÂ_¨¥¤§«áÁÙ·|«ùÄò¤j¶^...

¬Ýªk¨Ì¤£ÅܱNÄ~Äò©¹0.8¾aªñ~¦A¨Ó´N¬O©¹0.5»ù¦ì¾aÃl....

¤d¸U¤£­n¬Û«H±Ë»ò³o·sÃĤñ±Ë»òÁÙ­n¦nªº°­¸Ü ? §Aª¾¹D¥«­±¤W¾AÀ³©Ê¥Ö½§ª¢·sÃĦ³¦h¤Ö¶Ü ? ª¾¹D¤F§A´N¤£·|Ä~Äò§ë¸êASLN¤F....

³¯¤j§Aªºµo¨¥¨S¦³°ÝÃD~¤£»Ý­n³Q¤H«Â¯Ù~~¤]¤£·|¦³ªk«ß³d¥ô !

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58²Ä 5008 ½g¦^À³

¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk....

¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~

¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !!

ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³

¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ..

¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£­n¤£¬Û«H ?

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³

¥H¤U§ó¥¿¬°004

¤j®aÁÙ°O±o¶Ü¡H

¨È·à±d³£¬O¤@³eªº§@­·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨Ó­Ó004¡K

¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|í¹L¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H

·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³

­Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ,

¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü?

³q±`¼Æ¾ÚÀu³£¬Oº¦¤@­¿!¤£·|À£§CÅý§A¦Y³fªº©Ô!

¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~

¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³

¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1­¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W,

¦pªG¯uªº¦p³o­ÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O­«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ?

¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³

¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³

¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X­¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£­n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)!

°ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,­I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³o­Óª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê­¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ!

¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£­n¨I¾K¦b¹Ú¸Ì­n¶}©l¾Ç·|­±¹ï²{¹ê !

¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ !

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/12/4 ¤U¤È 09:40:37²Ä 6480 ½g¦^À³
«Ó¤j

µL©Ò¿×¤F¡A´N·í¹J¨ì¤F¶BÄF¶°³QÄF¤F¡A

¤£¹L³s¤Ñ©R¤j³£¤£¨£¤F¡A

¦³ÂI©_©Ç¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2023/12/4 ¤U¤È 09:11:54²Ä 6479 ½g¦^À³
¦Û±q½æ¥X¨È·à±d«á´N¨S¦bª`·N

­è­è¬ðµMÂI¨ì·à¤lªÑ»ù¯u¬OÅå§b¤F

©~µM¥u³Ñ0.6

(·íªì1.4©ñ±ó½æ¥ú¯u¬O½æ¹ï)

¤j®a«O­«ªü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/29 ¤U¤È 10:25:49²Ä 6478 ½g¦^À³
¤p©ú¤j

«ùªÑÃøºâ ª¾¹D«ùªÑµ²ºc¤ñ¸û­«­n

«ùªÑµ²ºc

0.08% % of shares held by all insiders

39.13% % of shares held by institutions

39.16% % of float held by institutions

17 Number of institutions holding shares

Top institutional holders

Holder Shares / Date reported /% out /Value

Tang Capital Management, LLC 1,901,552 29 Sept 2023 25.03% 1,293,055

BVF Inc. 1,049,999 29 Sept 2023 13.82% 713,999

Velan Capital Investment Management LP 625,000 29 Sept 2023 8.23% 425,000

Vivo Capital, LLC 568,182 29 Sept 2023 7.48% 386,363

Parkman Healthcare Partners LLC 372,741 29 Sept 2023 4.91% 253,463

Temasek Holdings (Private) Limited 335,615 29 Sept 2023 4.42% 228,218

Sio Capital Management, LLC 254,150 29 Sept 2023 3.34% 172,822

Citadel Advisors Llc 172,478 29 Sept 2023 2.27% 117,285

Schonfeld Strategic Advisors Llc 91,500 29 Sept 2023 1.20% 62,220

Millennium Management Llc 80,456 29 Sept 2023 1.06% 54,710

¥H¤U³o¤T®aÄå°£¥H25¤~¬O¯u¥¿ªÑ¼Æ

K2 HealthVentures Equity Trust LLC 26,466,126/25 13G 2023/03/20

BIOTECHNOLOGY VALUE FUND L P 42,440,000/25 13G 2023-03-06

TANG CAPITAL PARTNERS LP 26,824,625/25 13G/A 2023-02-14

¬°ªü´µÄõ»sÃĦ³­­¤½¥q´£¨Ñ 12 ­Ó¤ë»ù®æ¹w´úªº 3 ¦ì¤ÀªR®vªº¤¤¦ì¼Æ¥Ø¼Ð¬° 15.00¡A³Ì°ª¦ô­p¬° 17.00¡A³Ì§C¦ô­p¬° 15.00¡C ¹w¦ô¤¤¦ì¼Æ¸û¤W¦¸»ù®æ 0.69 ¬ü¤¸ ¦³ 2,073.91%¤Wº¦¼ç¤O

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦³¿ù½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/29 ¤W¤È 01:26:03²Ä 6477 ½g¦^À³
¥xÁÞ¤j

§A¦CÁ|ªº¨º¨Ç¤j©@«ùªÑÁ`­p

¤w¶W¹L¥Ø«e¤½¥q²{¦³ªÑ²¼Á`¼Æ¡A

16,350,000ªÑ¡A

¥i¯à¦³¨Ç¬O´î¸ê«e«ùªÑ¡A

»Ý°£¥H5¡A

§Ú¬d¤£¨ì¥¿½T¸ê®Æ¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/28 ¤U¤È 10:37:50²Ä 6476 ½g¦^À³
³o´X®a«ù¦³ASLAN Pharmaceuticals ºâ¬O¤j©@¤¤ªº¤j©@

Tang Capital Management, LLC 1,901,552 13F 2023 /09/29

BVF Inc. 1,049,999 13F 2023 /09/29

K2 HealthVentures Equity Trust LLC 26,466,126 13G 2023/03/20

BIOTECHNOLOGY VALUE FUND L P 42,440,000 13G 2023-03-06

TANG CAPITAL PARTNERS LP 26,824,625 13G/A 2023-02-14

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/11/28 ¤W¤È 10:11:29²Ä 6475 ½g¦^À³
©ú(113)¦~¤W¥b¦~¨½µ{¸O¦p¤U:

2¤ë15¤é¦U°òª÷¤½¥q¤½¥¬112¦~Q4«ùªÑ©ú²Ó

3¤ëTREK-DX¡BAA¸Ñª¼

4¤ë¤½§i113¦~Q1°]³ø(²{ª÷¥i¤äÀ³¨ì113¦~8¤ë)

4¤ë»P¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)¥l¶}Á{§É¤T´Á«e·|ijEnd-of-Phase 2 (EOP2) meeting

5¤ë°Ñ¥[¤é¥»²Ä2©¡°ê»Ú¥Ö½§¯f¬ã¨s¾Ç·|(ISID)(TREK-DX¡BAA¸Ñª¼¼Æ¾ÚÀ³¸Ó¨Óªº¤Î°e¥X)

5¤ë15¤é¦U°òª÷¤½¥q¤½¥¬113¦~Q1«ùªÑ©ú²Ó

6¤ë©³«e¤½¥q·|¶i¦æ¨p¶Ò¡B±ÂÅv¡B³Q¨ÖÁʩΤU¥«

½Ð¦U¦ì¤j¤j¸É¥R©Î«ü¥¿.ÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/11/28 ¤W¤È 08:30:13²Ä 6474 ½g¦^À³
whalewisdom.com/stock/asln

¸Óºô¯¸´£¨Ñ2021¦~Q3¦Ü¤µ(2023¦~Q3)¦U°òª÷¹ï¨È·à±d¼W´îªÑ¼Æ¼Æ¾Ú

¦Ó¥B²{¦b¬Ý¨ìªº2021¦~Q3¦Ü2023¦~Q3ªº«ùªÑ¼Æ¡A³£¬O¤w¸g´î¸ê(¤µ¦~2¤ë´î¸ê)§¹ªº¼Æ¾Ú

¦U¦ì¥i¥H±q2021¦~Q3¶}©l¬d¨C©uTang Capital Management, LLCªº¶i¥X¶q

Tang Capital Management, LLC¬O±q2021¦~Q3¶}©l¶R¶i¨È·à±d

¦U¦ì¥i¥H¬d¨ìTang Capital Management¤½¥q­t³d¤H¦P®É¥H

TANG CAPITAL PARTNERS LP

©M

TANG CAPITAL MANAGEMENT LLC

³o¨â®a°òª÷¤½¥q¤j¶q¶R¶i¨È·à±d

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/27 ¤U¤È 11:15:41²Ä 6473 ½g¦^À³
¤p©ú¤j

¬Ý°_¨ÓTang Capital Management, LLC«ùªÑ¦û¤ñ¦³»~¡A¦³¤H¥i¥H´£¨Ñ§ë¸ê¾÷ºc¯u¹êªº«ùªÑ»P¦û¤ñ¡HÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/27 ¤U¤È 10:43:13²Ä 6472 ½g¦^À³
Tang Capital Management, LLC 1,901,552 29 Sept 2023 25.03% (13F)

§Ú»{¬°¸ê®Æ¦³»~¡A 1,901,552/16,350,000=11.63% «D 25.03%

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/27 ¤U¤È 10:21:19²Ä 6471 ½g¦^À³
¸Ø±i¤j

whalewisdom.com/stock/asln

VIVO CAPITAL, LLC ½æ¤F 2,272,726ªÑ ¯d 568,182 ªÑ (¥i¯à¬O¬Ý¨ì·s¼Æ¾Ú¤£½æ¤F ¦p¤Ï¦V¶R¦^ ¤£ª¾¹D·|«ç¼Ë?)

«ùªÑ¨º»ò¦h§ë¸ê¾÷ºc¤@ÂI¤]¨S¦b©È ¤Ï¦Ó¬O¤pªÑªF©È¨ì¤£­p¦¨¥»±þ¥X

7¤ë6¤é¶^¨ì²{¦b§â003 004 ªº»ù­È¥þ³¡¶^¥ú¥úªº«D¦X²z¶W¶^ , «ç»ò¤U¥h «ç»ò¤W¨Ó ! ´²¤á¥Ã»·¬O³Ì¤j¿é®a

«e¤Q¤j Holder Åܰʤ£¤j

«e¤Q¤j Holder / Shares / ¦û¤ñ

Tang Capital Management, LLC 1,901,552 29 Sept 2023 25.03% (13F)

BVF Inc. 1,049,999 29 Sept 2023 13.82% (13F)

Velan Capital Investment Management LP 625,000 29 Sept 2023 8.23% (13F)

Vivo Capital, LLC 568,182 29 Sept 2023 7.48% (13F)

Parkman Healthcare Partners LLC 372,741 29 Sept 2023 4.91% (13F)

Temasek Holdings (Private) Limited 335,615 29 Sept 2023 4.42% (13F)

Sio Capital Management, LLC 254,150 29 Sept 2023 3.34% (13F)

Citadel Advisors Llc 172,478 29 Sept 2023 2.27% (13F)

Schonfeld Strategic Advisors Llc 91,500 29 Sept 2023 1.20% (13F)

Millennium Management Llc 80,456 29 Sept 2023 1.06 (13F)

¥t¥~ÁÙ¦³13G/A §ë¸ê¾÷ºc ( ¬Ý¤£À´«ùªÑ¦û¤ñ«ç»òºâ? ) ( «ùªÑ¨º»ò¦h ¤@ÂI¤]¨S¦b©È Åܰʤ£¤j )

Shares / ¦û¤ñ

K2 HealthVentures Equity Trust LLC 26,466,126 6.20 13G 2023/03/20

BIOTECHNOLOGY VALUE FUND L P 42,440,000 9.99 13G 2023-03-06

TANG CAPITAL PARTNERS LP 26,824,625 7.80 13G/A 2023-02-14

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/25 ¤W¤È 01:44:16²Ä 6470 ½g¦^À³
¤½¥q³£§Ö¦º¤F¡A

µe¤j»æ¦ó¥Î¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/11/24 ¤U¤È 04:46:29²Ä 6469 ½g¦^À³
1.²§¦ì©Ê¥Ö½§ª¢¯f±w¥þ²y2»õ¤H¡A¥Ø«e¥u¦³¦Ê¤À¤§8 ¯f±w¨Ï¥ÎDupilumab¡A¨Ï¥ÎDupilumabªº¯f±w¤¤¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä¡A¬OÄY­«¥¼³Qº¡¨¬ªº¯e¯f¡C

2.eblasakimab ©M dupilumab ¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¥Ö½§¬¡Àˤ¤ªºÀY¹ïÀY¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î¡C

2.¨Ï¥Î¤w«Ø¥ßªº¤HÃþªÍ¤Á¤ù COPD ¼Ò«¬¡A·s¼Æ¾ÚÃÒ©ú eblasakimab ¨ã¦³´î¤Ö®ð¹D¦¬ÁY©M¼W±jÂX±iªº¼ç¤O¡C

Å޿軡©ú«Ø¥ß¦b¤W­z3ÂI«e´£½T©w¤U¡C

1.ÀY¹ïÀY¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î¡C§Yeblasakimab·|·m¨«­ì¥ÎdupilumabªvÀøªº¯f±w¡Cµ¹ÃÄÀW²v¥Ñ¨â¶g¤@¦¸§ï¦¨¤@­Ó¤ëµ¹ÃĤ@¦¸¡C

2.¨Ï¥ÎDupilumabªº¯f±w¤¤¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä¡C§Y»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|¤£¥u¦³¤@ºØ¡A¦ý¤w¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä¡A©Ò¥H¹w¦ô¤£·|¦³¤Ó¦hºØ»¤µo¸ô®|(¹w¦ô¦³¤TºØ¤£¦Pªº»¤µo¸ô®|ºâ®t¤£¦h)¡CDupilumab§í¨î¤F¨ä¤¤¤@ºØ»¤µo¸ô®|¡C

3. TREK-DX¬O­n§ä¥ÎDupilumabªvÀø¨S®Äªº¯f±w¡A§Y§ä«e­±¥t¥~¨âºØ»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|ªº¯f±w¡A³o¬O¤@ºØ¬D¾Ô(TREK-DX©ú¦~²Ä¤@©u¸Ñª¼¥¢±Ñ¤]¨SÃö«Y¡A¦]¬°¨È·à±dÁ{§É¤T´Á¥i¥H§äAD·UÄY­«ªº¯f±w¨Ó¸ÕÅç)¡C

4.¤G´ÁÁ{§É¸ÕÅçÅã¥Ü¡AAD·UÄY­«ªº¯f±w¡A¨Ï¥ÎeblasakimabªºÀø®Ä·U¦n¡C(AD·UÄY­«ªº¯f±w¡A»¤µo¦]¤l¬O¤£¬O¨«¨ä¥L»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|?¤£ª¾¹D)¨È·à±dÀ³¸Ó¦bTREK-DX¸ÕÅ礤·|¼W¦¬¥ÎDupilumabªvÀø¨S®Ä¦ý¯f±¡ÄY­«ªº¯f±w¡C

5.ÀY¹ïÀY¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î¡C(¦pªG»¤µo¦]¤l¨«IL-13R »P IL-4R¬O¨â±ø¤£¤@¼Ëªº»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|¡A¨º¨È·à±d¦¨¥\¤F¡A¦]eblasakimab¥i¥H¦P®É§í¨î³o¨âºØ¤£¤@¼Ëªº»¤µo²§¦ì©Ê¥Ö½§ª¢¾÷¨îªº¸ô®|)¡C

6. COPD¥ÎeblasakimabªvÀø¡Cµ¹ÃÄÀW²v¦³·Q¹³ªÅ¶¡¡C

¦³½Ð¦U¦ì¤j¤j«ü¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/21 ¤U¤È 10:54:01²Ä 6468 ½g¦^À³
¸Ó¿ô¤F§a¡A

³Ð¾ú¥v·s§C0.92¡A«Ü§Ö´N¤U¥«¡A

3´Á¸ÕÅç¡A¸g¶O©O¡A½Ö´±§ë¸ê¡A

³Ìªñ¤@ª½©ñ§Q¦h®ø®§¡A

¨ä¤¤¥²¦³¶B

³s¦hÀY¤Ñ©R¤j¤]¥¢Áp¤F¡A

³o¤½¥q¨S±Ï¡AÄF¤F«Ü¦h¦~¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/11/16 ¤U¤È 04:56:51²Ä 6467 ½g¦^À³
§ë¸ê¨È·à±dªº¹ï¨R°òª÷¤Î¸ê²£ºÞ²z¤½¥q¡A«ùªÑ©ú²Ó(²Ä¤T©u)¦p¤Uºô¯¸:

whalewisdom.com/stock/asln

7¤ë6¤é¤j½æªÑ²¼¬O

ºû¨U¸ê¥»¦³­­³d¥ô¤½¥q

½æ¥X2,272,726ªÑ

(³Ñ568,182ªÑ)

¦Ó

ºû¨U¸ê¥»¦³­­³d¥ô¤½¥q

¦b¤µ¦~²Ä¤@©u

´N¬O¶R¶i2,272,726ªÑ

(¶R½æªÑ¼Æ¤@¼Ë)

(²Ä¤@©u¤À¶¥¬q¶R¶i,¦A7¤ë6¤é¤@¦¸½æ¥X,¤~¯àÀ~¥X¤@°ï´²¤á)

(¬Ý¤£¦n´N¥þ½æ§a,¬°¦óÁÙ¯d568,182ªÑ)

¥t¥~

­ð¤½¥q¦b²Ä¤T©u¦A¶R¶i773,484ªÑ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/14 ¤U¤È 07:07:41²Ä 6466 ½g¦^À³
¨Ì¨È·à±dªº«e¬ì°O¿ý¡A

§Ú»{¬°¨S¦³¾÷·|·ÓTempest

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2023/11/14 ¤W¤È 06:31:04²Ä 6465 ½g¦^À³
Tempest Therapeutics¾ÌÔ£1¤Ñ±q18¼h¦aº»¤É¨ì¤Ñ°ó¡H

2023.10.11-¬üªÑ¤SÅå²{¤@©]ötº¦ªñ40­¿¤j¤ûªÑ

www.fx168news.com/article/326113

±q24¤p®É«eªº¨CªÑ30¬ü¤Àªº»ù®æ¤Wº¦¨ì¤F¥Ø«eªº6.40¬ü¤¸¡Cº¦´T¶W¹L2,000¢H¡A³Ì°ª飙¨ì39.7­¿.....

--------------------------------------------------------------------------------------------

¨È·à¹w­p©ó2024 ¦~²Ä¤@©u¤½§GTREK-DX¸ÕÅ窺¥D­n¼Æ¾Ú(Eblasakimab¦b¥ý«e±µ¨ü Dupilumab ªvÀøªº¨k©Ê©Î¤k©Ê¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤¤ªº¬ã¨s)

¸U¤@¼Æ¾Ú¥¿­±¡A«ö¥Ø«eªÑ»ù1¤é¤S¸Ó½º¦´X­¿?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/14 ¤W¤È 12:22:44²Ä 6464 ½g¦^À³
³o¦ìµoªíºtÁ¿ªÌ¬O¤½¥qÂàĶ¬ì¾Ç³¡¥D¥ô¡A¨Ó¦Û¥[¦{¡AªA°È¹LLebrikizumab ¬ãµo¤½¥qDermira»PLily

«á¨ÓLebrikizumab ³QLily¥H11»õ¬ü¤¸¨ÖÁÊ¡A¦]¬°Lily·Ç³Æ¨ÖÁʦ³¼ç¤OªºAD¶}µo¤¤ÃĪ«¡A·Ç³Æ»PDupilumab ¥¿­±¤j¹ï¨M¡C

¹³Aslan Pharmaceuticals ³oºØÁ`¥«­È¬ù1800¸U¬ü¤¸¤S¦³Ävª§¼ç¤O¡A¥i¥H¶i¤J¤T´ÁÁ{§É¡AªÑ»ù·|¶^ªº²z¥Ñ³Ì¤j¥i¯à¬OªÎ¤ô¤£¸¨¥~¤H¥Ð¡A¥xÆWªÑªFÄw½X³QÀ~¥X«á(½æÀ£¨Ó¦Û¥xÆWªÑªFªº¥i¯à©Ê³Ì¤j)¡A¸¨¤J¤jªÑªF¤â¤¤«á´N¬OªÑ»ù¤ÏÂ઺¶}©l¡AªÑ¼Æ¤Ö¡AÁ`¥«­È¤p¡A¥¼¨Ó¼W­È­¿¼Æ¦p§ë¸ê¾÷ºc¹w¦ô¬Û·í¥iÆ[¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/13 ¤U¤È 11:38:46²Ä 6463 ½g¦^À³
¦p©ú¤Ñ¤j©Ò¨¥¡A¤µ¤Ñ¥¿¦¡¶^¯}¤@¤¸¡A

¨C¤Ñ¯}©³¡AÂ÷¤U¥«´N§Ö¤F¡A

³o¤½¥q³s¸ÕÅç«á³ø§i³£¯à­×¥¿¡A

Moa¦³®Ä¥i¯à¤]¬O­Ó§¾¡A¥i¯à³y°²ªº

³o¤½¥q¥»¨Ó´NµL¸Û«H¡A

³Ìªñ¦h¦¸½Ð±M®a°­¸Ü³s½g¡A¥«³õ¤]¤£¶R³æ¡A

¨Ì¦¹»ù¦ìÁÙ°ø¨¥­n°µ¤T´Á¸ÕÅç¡A¯u¬O¤Ñ¯u¦n¯º¡A¿ú¨º­Ó¥Õè¥I¡A

¤@ÄF¦AÄF¡A±q¥xÆWÄF­Ë¬ü°ê¡A

¯u½M¤F²´¡A²{¥u¯àÅ¥¤Ñ©R»{¿é

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ß§»10147985  µoªí®É¶¡:2023/11/11 ¤U¤È 07:31:00²Ä 6462 ½g¦^À³
¸Ø±i¤j¡ã½Ð°Ý¤@¤U¦³µL½Ķ¡A¬O¦b»¡©ú¤°»ò­«ÂI¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/11/11 ¤U¤È 06:19:41²Ä 6461 ½g¦^À³
m.youtube.com/watch?v=HvJGBLvuYmo
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/11/11 ¤U¤È 06:11:16²Ä 6460 ½g¦^À³
Dr. Ferda Cevikbas, Aslan Therapeutics - YouTube

m.youtube.com/watch?v=HvJGBLvuYmo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/11/8 ¤U¤È 02:26:28²Ä 6459 ½g¦^À³
¤K¤ë©³¤w¥X²Maslan«ùªÑ¡A¦³©¯³B¤À»ù®æÁÙ¦b2¤¸¥H¤W¡A±q¥xÆW¨ì¬ü°ê¡A¤@¸ô¶R¶i¡A³B¤À«e¥Ø«eADR«ùªÑ¦¨¥»¬ù¬°USD12.5~13¤¸¥ª¥k(´«ºâ¦^·íªì¥xªÑ¤j·§¬O¤@ªÑTWD14~15¤¸¥ª¥k)¡A³o¤@µ§§ë¸ê¤]ºâ¬O¥H-85%¦¬³õ¡A§Ú¬Û«H§Úªº«ùªÑ¦¨¥»¦b¦Ñ·à¤Í¸ÌÀ³¸Óºâ¬O¬Û¹ï§Cªº¤F¡A¸Ü¤£¦h»¡¤F¡A¤j·§¤]¬O³Ì«á¤@½g¤F¡A¥Ø«e³o¼Ë¬Ý¤U¨Ó¤j·§¥u¦³©ú¤Ñ¹L«á¤j¤j»¡ªº¸û¬°·Ç½T¡A¨ä¥Lµe¤j»æªº´Nºâ¤F¡A11¤ë»ù®æ¤]¹Gªñ1¤¸¤U¥««O½Ã¾Ô¡A¸ò©ú¤Ñ¹L«á¤j¤j¹w¦ôªº¤@¼Ë³o´N¤£¦h»¡¤F¡A¥Ø«e²{ª÷°÷ºÙ¨ì2024¤U¥b¦~¡A¦ý2024¤W¥b¦~¦³¤°»ò©O?¥u¦³ASLAN003ªº´Á¤¤¼Æ¾Ú¡AASLAN004ªº¤G½u¦]¬°­×§ï¸ÕÅ窺½t¬G¡A¤w¸g¤£ª¾¹D¦ó®É·|§¹¦¨¤F¡A¥u¯d¤U©ú¦~·|¶}©l¶i¦æ¤T´Á¤Î¤é¥»¤@´Á¡A¦ý¤é¥»¤@´Á»¡¹ê¦bªº¦³¨S¦³°µ±o¤£¼vÅT¤j§½¤F¡A¤½¥q¨S¿ú°µ¤T´Á¡A¦ý¥H¥Ø«e¨Ó»¡¡A¨ì¤F©ú¦~¤U¥b¦~¡AASLAN004¤]¨S¤°»ò·s¶i«×¤F¡A­n§ä¤jÃļt¦X§@¤T´Á¡A¯uªº¦³³o»ò®e©ö?¥H¥Ø«e¥«­È¨Ó»¡¡AUSD5»õ¤¸¬O25­¿¡AUSD10»õ¤¸¬O50­¿¨S¿ù³â¡A¦ý¥HASLANªÑ»ù¤@ª½¦b¯}©³¨Ó»¡¬O¦³½Öªº¥D¤O³¡¦ì«ù¦³¦¨¥»USD1.2¤¸ªº³â¡A¨º°®¯Üµ¥¨ìªÑ»ù0.5¤¸¦A¨Ó»¡¤£´NÅܦ¨50­¿¡B100­¿§ó§l¤Þ¤H?¥H¥Ø«eªÑ¥»¨Óºâ(«áÄò¨S¦³¼W¸ê¿±µÈªº¸Ü)¡A¥«­È1»õ¤¸¤j·§¬OADR1ªÑ6¤¸(´«ºâ¦^¥xªÑ¤j¬ù1ªÑ7~8¤¸)¡A¦Ñ·à¤Í¥i¥Hµû¦ô¤@¤U¡A«ù¦³³o»ò¦h¦~¡AÁÙ­n«_µÛ¤U¥«ªº­·ÀI¡A³ø¹S²v­n§ì¦h¤Ö?¦¬ÁÊ»ù®æ°_½X­n¹F¨ì¦h¤Ö¤~¯à±µ¨ü?§Ú¦Û¤vµû¦ô«á¬Oı±oºâ¤F¡AÄêªd§ß¤£¤WÀð¡A®É¶¡¸ò¿ú³£µ¹¤F¡A¥u¥æ¥X³oºØ¦¨ÁZªº¸Ü¡A§Ú¤£»{¬°¥¼¨Ó·|¦³©Ò§ïµ½¡AÁ`¤§¦Ñ·à¤Í­Ì«O­«.......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/6 ¤U¤È 11:11:15²Ä 6458 ½g¦^À³
·s»D½Z¤¤¦³´£¨ìÀY¹ïÀYÁ{§É¸ÕÅç Head-to-Head trial ¡]¥D­n¬O»Pdupilumab¶i¦æ¤ñ¸û¡^

³oºØÁ{§É¸ÕÅç·s¤è¦¡昰­n»P¤w¤W¥«ÂÂÃĶi¦æÃĪ«Àø®Ä»P¦w¥þ©Ê¶i¦æ§óª½±µ¤ñ¸û¡A¥Øªº¦b©ó¥[§ÖÁ{§É¸ÕÅç»PÃĪ«¼f¬d®Éµ{

¥i参¦Ò¡G

·sÃÄÂÂÃĽ֤ñ¸û¦n¡HÀY¹ïÀYÁ{§É¸ÕÅç PK ¸Ñ±K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/11/6 ¤U¤È 10:21:08²Ä 6457 ½g¦^À³
¥þ¤å½Ð°Ñ¦Ò¤½¥q·s»D½Z

ASLAN PHARMACEUTICALS PRESENTS NEW DATA ON EBLASAKIMAB IN ATOPIC DERMATITIS AND COPD TRANSLATIONAL MODELS AT THE 7th DERMATOLOGY DRUG DEVELOPMENT SUMMIT

ªü´µÄõ»sÃĤ½¥q¦b²Ä¤C©¡¥Ö½§¯fÃĪ«¶}µo°ª®p·|¤W®i¥Ü Eblasakimab ¦b²§¦ì©Ê¥Ö½§ª¢©MºC©Êªý¶ë©ÊªÍ¯fÂà¤Æ¼Ò«¬¤¤ªº·s¼Æ¾Ú ªü´µÄõ»sÃĪѥ÷¦³­­¤½¥q 2023 ¦~ 11 ¤ë 3 ¤é¬P´Á¤­±ß¤W 7:00

eblasakimab©Mdupilumab¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¥Ö½§¬¡Àˤ¤ªºÀY¹ïÀY¬ã¨sÃÒ¹ê¤Feblasakimab¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î

¨Ï¥Î¤w«Ø¥ßªº¤HÃþªÍ¤Á¤ù COPD ¼Ò«¬¡A·s¼Æ¾ÚÃÒ©úeblasakimab¨ã¦³´î¤Ö®ð¹D¦¬ÁY©M¼W±jÂX±iªº¼ç¤O

µ²ªG­º¦¸ÃÒ©úeblasakimab¦b AD ¥H¥~ªº¨ä¥L¾AÀ³¯gªº¼ç¦b¥Î³~

¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~11 ¤ë3 ¤é¡]Àô²y³q°TªÀ¡^- ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¨Ó§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬±À¥X·s²£«~¼Æ¾Ú©ó2023 ¦~10 ¤ë31 ¤é¦Ü11 ¤ë2 ¤é¦b°¨ÂĽѶë¦{ªi¤h¹yÁ|¦æªº¥Ö½§¯fÃĪ«¶}µo°ª®p·|(DDDS) ¤W¤½§G¡C³o¨Ç¼Æ¾Ú¶°´£¨Ñ¤F±j¤ÆÃÒ¾Ú¡AÃÒ©úeblasakimab ¦b²§¦ì©Ê¥Ö½§ª¢(AD) ¤¤ªº®t²§¤Æ§@¥Î¾÷¨î¡A¥H¤Î­º¦¸®i¥Ü¤F¨ä¦b·s¾AÀ³¯g¡X¡XºC©Êªý¶ë©ÊªÍ³¡¯e¯f (COPD) ¤¤ªºÀ³¥Î¡A¸Ó¯e¯f¥i¥Ñ 2 «¬µoª¢ÅX°Ê¡C

¦b AD ±wªÌªº¥Ö½§¬ï¨ë¬¡Àˤ¤¶i¦æªºeblasakimab ©Mdupilumab¤§¶¡ªºÀY¹ïÀY¬ã¨sÅã¥Ü¡A§½³¡¥Ö½§²Õ´¤Àªcªºµoª¢²Ó­M¦]¤lªºªí¹F¦s¦b®t²§¡A eblasakimabªvÀø§ó¦³®Ä¦a­°§CTh2 ²Ó­M¦]¤lIL-13¡BIL-4©MIL-13 ªºªí¹F¡C»PªvÀødupilumab ¡C³o¨Çªì¨Bµ²ªGÅçÃÒ¤F¥ý«eµo¥¬ªº¨Ó¦Û AD ±wªÌ¥~©P¦å³æ®Ö²Ó­Mªº¼Æ¾Ú1 ¡A³o¨Ç¼Æ¾Ú¨Ó¦ÛASLAN »PShawn Kwatra ³Õ¤h¡]¬ù¿«ÀN´¶ª÷´µ¤j¾ÇÂå¾Ç°|¡^©MMadan Kwatra ³Õ¤h¡]§ù§J¤j¾Ç¡^ªº¬ã¨s¦X§@¡C³o¨Ç¼Æ¾Ú¦@¦PÃÒ©ú¤Feblasakimab»Pdupilumab¬Û¤ñªº®t²§¤Æ§@¥Î¡A¨Ã±j½Õ¤Feblasakimab¹v¦V IL-13R ªº¼ç¦bÀu¶Õ¡A³o¥i¯à¾É­P§ó¦³®Ä¦aªýÂ_ 2 «¬°T¸¹¶Ç¾É¡A¦P®É¤£¼vÅT 1 «¬¨üÅé¡C

ASLAN ¤]§Q¥Î¤w«Ø¥ßªº¤HÃþ¨ÑÅéºë±K¤Á³ÎªÍ¤Á¤ùÂ÷Åé¼Ò«¬¡A´£¨Ñ¤F¬ã¨seblasakimab¦b COPD ¤¤§@¥Îªº·s¼Æ¾Ú2¡C¸Ó¼Ò«¬¨Ï¥Î IL-4 ©M IL-13¡]°Ñ»P COPD ¯e¯f¯f²z¾ÇªºÃöÁä Th2 ²Ó­M¦]¤l¡^´ú¸Õ¤FªÍ²Õ´¤¤ªº®ð¹D°ª¤ÏÀ³©Ê (AHR) 3¡CEblasakimab¥i³z¹L´î¤Ö®ð¹D¦¬ÁY¡AÅãµÛ­°§C IL-4 ©M IL-13 »¤¾Éªº AHR¡C¦¹¥~¡AIL-4 ©M IL-13 ¨Ï®ð¹D¹ï¾L¥ÒÁxÆPªº¤ÏÀ³¶i¤@¨B¦¬ÁYÅܱo±Ó·P¡A¦ý³oºØ±Ó¤Æ³QeblasakimabªvÀøªýÂ_¡C¬°¤FÀˬd¹ï®ð¹DÂX±iªº¼vÅT¡A¨Ï¥ÎºÖ²ö¯Sù»¤¾É¤ä®ðºÞÂX±i¡CIL-4 ©M IL-13 ¹w³B²z¦bªvÀø«á 5 ¤ÀÄÁ¤ºÅãµÛ­°§C¤FºÖ²ö¯Sù¤Þ°_ªºÂX±i¡A¦ý³o¨Ç®ÄÀ³³Qeblasakimab¦³®Ä°fÂà¡A«ì´_¤F®ð¹Dªº¥¿±`¤ÏÀ³¡C¦]¦¹¡Aeblasakimab¦¨¥\ªýÂ_¤FªÍ²Õ´¤¤IL-4/IL-13»¤¾ÉªºAHR¡A«ì´_¤F®ð¹D¦¬ÁY©MÂX±iªº¥¿±`¤ÏÀ³¡A³o¦bCOPD¤¤¨ã¦³Á{§É·N¸q¡CEblasakimab³z¹L 2 «¬¨üÅéªýÂ_ IL-4 ©M IL-13¡A»P¶È°w¹ï IL-13 ²Ó­M¦]¤lªºÃĪ«¬Û¤ñ¡A¥¦¦³¥i¯à¦b§ó¼sªxªº¾AÀ³¯g¤¤§ó¦³®Ä¡C

¡uºC©Êªý¶ë©ÊªÍ¯f¬O¥þ²y²Ä¤T¤j±`¨£¦º¤`­ì¦]4¡A¨Ã¥B¬O¤@ºØ²§½è©Ê¯e¯f¡A«Ü¤j¤@³¡¤À±wªÌ¨ü¨ì 2 «¬ÅX°Ê¯f²zªº¼vÅT¡A¦Ó³o¨Ç±wªÌªº°w¹ï©ÊªvÀø¿ï¾Ü½d³ò¦³­­¡C§Ú­Ì¦bÂà¤Æ¼Ò«¬¤¤´£¨Ñªº¼Æ¾Ú¹ï©ó±´¯Áeblasakimab¦b AD ¥H¥~ªº¨ä¥L¾AÀ³¯g¤¤ªº¼ç¤O¦ÜÃö­«­n¡A§Ú­Ì¬Û«Heblasakimab¨ã¦³¥¨¤jªº¼ç¤O¡A¥i¥H¬° COPD ´£¨Ñ¦³®Ä¥B®t²§¤ÆªºªvÀø¿ï¾Ü¡A¸Ó¥«³õ¹w­p±N¨ì2032¦~±N¹F¨ì 300 »õ¬ü¤¸¡A¡vASLAN »sÃĤ½¥q°õ¦æªø Carl Firth ³Õ¤h»¡¡C¡§ÁöµMeblasakimab¤w¸g¦b AD ¤¤®i¥Ü¤F¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¥B¤£¼vÅTÀø®Ä¡A¦ý¦b¥Ñ 2 «¬ª¢¯gªº±`¨£¼ç¦b¥Íª«¾ÇÅX°Êªº¨ä¥L¯e¯f¤¤¡AÁÙ¦³¥¨¤jªº¥¼¶}µo¼ç¤O¡C¡¨

ASLAN Pharmaceuticals Âà¤Æ¬ì¾Ç¥DºÞ Ferda Cevikbas ³Õ¤hªí¥Ü¡G¡§§Ú­Ì´£¨ÑªºÂà¤Æ¼Æ¾Ú´£¨Ñ¤Feblasakimab¿W¯S§@¥Î¾÷¨îªºÃÒ¾Ú¡A¨Ã±j½Õ¤F¨ä»P°w¹ï IL-4R ªºÃĪ«ªº°Ï§O¡C¡¨ ¡§§Ú­Ì«Ü°ª¿³¨üÁܦb¥»¦¸¦æ·~·|ij¤W®i¥Ü³o¨ÇÂà¤Æ¼Ò«¬¡A¨Ã®i¥Üeblasakimab¦b¸Ñ¨M AD ©M COPD ¤¤ 2 «¬ÅX°Êª¢¯gªº¼ç¤O¡C¡¨

¹ï³o¨âºØÂà¤Æ¼Ò«¬ªº¬ã¨s¥¿¦b¶i¦æ¤¤¡AALSAN ­p¹º´£¥æ¥þ­±ªº¼Æ¾Ú¶°¥H¦b§Y±NÁ|¦æªº¬ì¾Ç·|ij¤Wµo¥¬¡CÃĪ«¶}µo°ª®p·|ªºÂ²³ø¥i³z¹L ASLAN ºô¯¸¦s¨ú¡C

Ãö©óeblasakimab

Eblasakimab¬O¤@ºØ¼ç¦bªº¤@¬y³æ®è§ÜÅé¡A°w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé¨È°ò¡A³o¬OÅX°Ê¦hºØ¹L±Ó©Êµoª¢¯e¯fªºÃöÁä³~®|¡CEblasakimab¿W¯Sªº§@¥Î¾÷¨î¯à°÷¯S²§©ÊªýÂ_ 2 «¬¨üÅé¡A¨Ã¦³¥i¯à§ïµ½¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C³z¹LªýÂ_ 2 «¬¨üÅé¡Aeblasakimab¥iªý¤î¥Õ²Ó­M¤¶¯À4 (IL-4) ©M¥Õ²Ó­M¤¶¯À13 (IL-13) ªº«H¸¹¶Ç¾É¡A¦Ó¥Õ²Ó­M¤¶¯À4 (IL-4) ©M¥Õ²Ó­M¤¶¯À13 ( IL-13) ¬OAD µoª¢ªºÃöÁäÅX°Ê¦]¤l¡C¤¤«×¦Ü­««× AD ªº 2b ´Á TREK-AD ¬ã¨sªº¿n·¥µ²ªG¤ä«ùeblasakimab±qAD ªvÀø¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×ªº¼ç¤O¡A¦Ó¤£¼vÅTÀø®Ä¡A¨Ã¥B¨´¤µ¬°¤îÃÒ©ú¤F¥O¤H¹ª»Rªº¦w¥þ©Ê¡A¬°2 ´ÁÁ{§É¸ÕÅç°µ¦n¤F·Ç³Æ3 ¶i¦æ¤¤¡CASLAN ¤]¦b 2 ´Á¸ÕÅç TREK-DX ¤¤¬ã¨seblasakimab¦b¸g¾ú¹Ldupilumab ªº¤¤«×¦Ü­««× AD ±wªÌªºÀ³¥Î¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/4 ¤W¤È 12:46:58²Ä 6456 ½g¦^À³
ªü´µÄõ»sÃĤ½¥q¦b²Ä¤C©¡¥Ö½§¯fÃĪ«¶}µo°ª®p·|¤W

®i¥Ü Eblasakimab ¦b²§¦ì©Ê¥Ö½§ª¢©MºC©Êªý¶ë©ÊªÍ¯fÂà¤Æ¼Ò«¬¤¤ªº·s¼Æ¾Ú

eblasakimab ©M dupilumab ¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¥Ö½§¬¡Àˤ¤

¬ã¨sÃÒ¹ê¤F eblasakimab ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ§@¥Î

¨Ï¥Î¤w«Ø¥ßªº¤HÃþªÍ¤Á¤ù COPD ¼Ò«¬¡A·s¼Æ¾ÚÃÒ©ú eblasakimab ¨ã¦³´î¤Ö®ð¹D¦¬ÁY©M¼W±jÂX±iªº¼ç¤O

µ²ªG­º¦¸ÃÒ©ú eblasakimab ¦b AD ¥H¥~ªº¨ä¥L¾AÀ³¯gªº¼ç¦b¥Î³~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/11/2 ¤U¤È 10:58:37²Ä 6455 ½g¦^À³

§Æ±æ Piper Sandler¤ÎH.C. Wainwright³o2®a¤½¥q¯à¬Ý¹ï¤@¦¸¡A

Piper Sandler ­«¥Ó¹ï Aslan Pharmaceuticals (ASLN) ªº¶R¤Jµû¯Å

¡A

¶ø´µ¥Å¦w¦N¬¥ 2023¦~10¤ë30¤é ¤U¤È 6:56

|¦b¤µ¤Ñµo¥¬ªº¤@¥÷³ø§i¤¤¡APiper Sandler ªº Edward Tenthoff

­«¥Óªü´µÄõ»sÃĤ½¥q¡]ASLN ¡V ¬ã¨s¡^ªº¶R¶iµû¯Å

³ø§i¡^¡A¥Ø¼Ð»ù¬° 15.00 ¬ü¤¸¡C ¤½¥qªÑ²¼¤w¦¬½L

¤W¶g¤­»ù®æ¬° 1.07 ¬ü¤¸¡C

¥Ø«e¡A¤ÀªR®v¹ï¨È·à±d»sÃĪº¦@ÃѬO±j¯Pªº

¶R¤J¥­§¡¥Ø¼Ð»ù¬° 15.67 ¬ü¤¸¡A

¦b¤µ¤Ñµo¥¬ªº¤@¥÷³ø§i¤¤¡A

H.C. Wainwright·Å¿à¯SÁÙ­«¥Ó¹ï¸ÓªÑªº¶R¤Jµû¯Å¡A¥Ø¼Ð»ù¬° 17.00 ¬ü¤¸¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/31 ¤U¤È 09:25:35²Ä 6454 ½g¦^À³
©t¨àÃĤj

§A»¡ªº¨S¿ù --- ¬Ý¨ì«Ü¦h¦Ñ·à¤Í­Ì³£µ´±æ¤F! Åý¤Hı±oÃø¨ü ¡K¡K.

­Ó¤H»{¬° «Ü¦h§ë¸ê¤H·|»{¬°ªÑ»ù¤U¶^»PÀø®Ä¤£¦n²£¥ÍÁp·Q, ¨Æ¹ê¤W¬O³o¼Ë¶Ü? ¥i¯à¹ï¤]¥i¯à¿ù, ¥¢±æ©Ê±þ½LÅýªÑ»ùÄY­«¶W¶^

¤G´Áµ²§ô¥i¥H°µ¦¸±Ú¸s¤ÀªR¥H§ä¥X¤T´Á³Ì¨ÎÀø®Äµ¦²¤ , ¤T´Á´Áµ²§ô´N¤£¥i¥H¦A°µ¦¸±Ú¸s¤ÀªR

¤Ñ©R¤j7¤ë6¤é¶K¤å´£¨ì¨Ì¤µ±ß³ø§i,¥­§¡EASI­°´T«e6¶g¤ô·Ç¬O¦p¹w´Á,¦ý7~16¶g¶]¤£°Ê¡K.

¨Æ¹ê¤W¤£¬O¦p¦¹, «Øij¤Ñ©R¤j¬ÝIQVIA Biotech & ASLAN Pharmaceuticals KOL Panel Discussion (21¤À15¬í--24¤À15¬í¹Ïªí) ( §â¹Ïªí¥Î¤â¾÷©ç¤UºCºC¬Ý )

¥H¤U¬O¼Æ¾Ú¬O¨Ì¾Ú 2023 ¦~ 10 ¤ë 13 ¤éªü´µÄõ»sÃĤ½¥q¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú»P2023 ¦~ 10 ¤ë 24 ¤éªü´µÄõ»sÃĤµ¤Ñ±N¦@¦P¥D¿ì KOL ¤p²Õ°Q½×¡A°Q½×²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç©MªvÀø®æ§½ªºÅܤÆ

¦¬®×¤ÀªR ( IQVIA Biotech & ASLAN Pharmaceuticals KOL Panel Discussion)

ITT EASI 16- 66 ¦@289¤H(100%) EASI score mean 27.9 IGA3/4 58.8%/41.2%

EASI 18- 66¦¬®×231¤H (80%) EASI score mean 30.7 IGA3/4 51.5%/48.5%

EASI 21- 66¦¬®×181¤H (63%) EASI score mean 33.8 IGA3/4 40.3%/59.7%

( EASI¤j©óµ¥©ó21 IGA/4 ´N¬O¦¬­««×¯f±w ¥H¤U¼Æ¾Úµo²{ ¯f±w¶VÄY­«Àø®Ä¶VÅãµÛ

IGA3/4 40.3%/59.7% IGA 4¯f±w¤ñIGA3ÄY­« (dupilumab¤T´ÁIGA3/4 51%/49%)

dupilumab¤T´ÁIGA4 ¦û49% eblasakimab ¤GB IGA4 ¦û59.7%

¤S¬O¥|¶g¤@°w ³o¬O§Ú¬Ý¥X¼ç¤Oªº­ì¦], eblasakimab ¥¼¨ÓAD ¥«³õ¥þ²yª§¹ÜÁÉ

(¿z¿ï1 ²Å¦X¥Íª«¼Ð°O¯f±w 2 EASI score ¤j©óµ¥©ó 21¤À 600mg ¥|¶g¤@°w

«O¦u¤@ÂI600mg ¨â¶g¤@°w«Øij¦C¤JÁ{§É³]­p 240»õ¬ü¤¸ªºAD ¥«³õ¤£­n¦³·Q­n¿W¦û¥«³õªº©ÀÀY , ¯dÂI¥«³õµ¹§OªºÃÄ )

(dupilumab¤T´Á¬O³]­p300mg¤@¶g¤@°w »P ¨â¶g¤@°w)

A 600mgQ4w ¤£°µ¦¸±Ú¸s¤ÀªR¦b²Ä4¶g´N¹F¨ìÅãµÛ®t²§¤@ª½¨ì²Ä10¶g»P¹ï·Ó²Õ¹F¨ì³Ì¤j®t¶Z , ²Ä11¶g¤~¨«¥­Ä~Äò©¹¤Uª½¨ì16¶g

B 600mgQ4w ¦¸±Ú¸s¤ÀªREASI¤j©óµ¥©ó18 ¦b²Ä2¶g´N¹F¨ìÅãµÛ®t²§¤@ª½¨ì²Ä16©P(»P¹ï·Ó²Õ¶V©Ô¶V»· , 300mg Q2w 400mg Q2w ¤]¤@¼Ë¦b²Ä2¶g´N¹F¨ìÅãµÛ®t²§¤@ª½¨ì²Ä16©P»P¹ï·Ó²Õ¶V©Ô¶V»·

400mg Q4w ªí²{¸û®t²Õ Áö¦³¹F¨ìÅãµÛ®t²§ ¦b²Ä6¶g¥H«á´N¨«¥­

C ITT EASI 16- 66 ¦@289¤H(100%) EASI score mean 27.9 IGA3/4 58.8%/41.2%

600mg Q4W ( 59¤H) -73.0% /--51.1%) p=0.001

400mg Q4W ( 59¤H) -61.9% /--51.1%) p=0.1054 ( ªí²{¤í¨Î²Õ )

400mg Q2W( 56¤H) -65.8% /--51.1%) p=0.029

300mg Q2W( 58¤H) -69.8 % /--51.1%) p=0.005

¦w¼¢¾¯²ÕQ2W( 57¤H) --51.1%

D EASI 18- 66¦¬®×231¤H (80%) EASI score mean 30.7 IGA3/4 51.5%/48.5%

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°18 ªº±wªÌ ( 231¤H) ¨È²Õªº¤ÀªR¤¤¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G

600mg Q4W ( 47¤H) -75% /-42.3 %¡]p<0.0001¡^

400mg Q4W ( 49¤H) -60.4% /-42.3 %¡]p<0.0098¡^

400mg Q2W( 46¤H) -73.5%/ -42.3 %¡]p<0.0001¡^

300mg Q2W( 44¤H) -71.8%/-42.3 %¡]p< 0.0001¡^

¦w¼¢¾¯²ÕQ2W( 45¤H) -42.3 %

E EASI 21- 66¦¬®×181¤H(63%) EASI score mean 33.8 IGA3/4 40.3%/59.7%

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ( 181¤H ) ªº±wªÌ¨È²Õªº¤ÀªR¤¤¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G

600mg Q4W( 31¤H) -74.5% /38.0%¡]p<0.0001¡^¡A

400mg Q4W ( 39¤H) -60.2% /-38 %¡]p<0.0068¡^( ªí²{¤í¨Î²Õ )

400mg Q2W( 41¤H) -72.7%/38.0%¡]p<0.0001¡^¡A

300mg Q2W( 32¤H) -69.8%/38.0%¡]p<0.0001¡^¡A

¦w¼¢¾¯²ÕQ2W( 38¤H) -38 %

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õ¤ÀªR¤¤¡A¹F¨ìEASI-75 ªº±wªÌ¦Ê¤À¤ñ¬°¡G¹êÅç²Õ/¦w¼¢¾¯²Õ

600mg Q4W ( 31¤H)53.6%/12.9% (p=0.009)¡A

400mg Q4W ( 39¤H)36.1%/12.9%¡]p=0.0328¡^( ªí²{¤í¨Î²Õ )

400mg Q2W ( 41¤H)49.7% / 12.9% (p=0.0014)¡A

300mg Q2W( 32¤H) 52.1%/12.9% ( p=0.001)

¦w¼¢¾¯²ÕQ2W( 38¤H) 12.9%

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌÀò±oÅçÃÒªº²§¦ì©Ê¥Ö½§ª¢¬ã¨sªÌ¾ãÅéµû¦ô(vIGA-AD) µû¤À¬°0/1 ªº±wªÌ¦Ê¤À¤ñ¦p¤U¡G¹êÅç²Õ /¦w¼¢¾¯²Õ

600mg Q4W( 31¤H) 29.8% /6.8% (p=0.0172)¡A

400mg Q4W ( 39¤H) 9.6%/6.8% ( ªí²{¤í¨Î²Õ )

400mg Q2W( 41¤H) 37.6% /6.8%(p=0.0030) ¡A

300mg Q2W ( 32¤H)27.1%/6.8%¡]p=0.0297¡^¡A

¦w¼¢¾¯²ÕQ2W( 38¤H) 6.8 %

¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/10/31 ¤U¤È 04:50:18²Ä 6453 ½g¦^À³
ªü´µÄõ§Y¨È·à±d¡A½Ķ³nÅéÃö«Y¡A·Pı¨È·à±d¿¤¦b¦b¥´¼s§i¦p¤UĶ¤å

How ASLAN Pharmaceuticals Limited is Revolutionizing the Pharma Industry

ªü´µÄõ»sÃĦ³­­¤½¥q¦p¦ó¹ý©³§ïÅÜ»sÃÄ·~

ªü´µÄõ»sÃĦ³­­¤½¥q¤w¦¨¬°»sÃÄ·~ªº¹CÀ¸³W«h§ïÅܪ̡A¹ý©³§ïÅܤFÃĪ«ªº¶}µo¤è¦¡¡A¬°¥þ²y±wªÌ±a¨Ó¤F§Æ±æ¡C ¾ÌÂǨä³Ð·s¤èªk©M­P¤O©ó¸Ñ¨M¥¼º¡¨¬ªºÂåÀø»Ý¨D¡A¨È·à±d»sÃĦ³­­¤½¥q¹ï»sÃÄ·~²£¥Í¤F­«¤j¼vÅT¡C

¨È·à±d»sÃĦ³­­¤½¥q¹ý©³§ïÅܲ£·~ªºÃöÁä¤è¦¡¤§¤@¬O±Mª`©óºë·ÇÂåÀø¡C ³z¹L§Q¥Î¦yºÝ§Þ³N©M¥ý¶iªº¤ÀªR¡A¸Ó¤½¥q¯à°÷ÃѧO³Ì¦³¥i¯à±q¨äªvÀø¤¤¨ü¯qªº¯S©w±wªÌ¸sÅé¡C ³oºØ¦³°w¹ï©Êªº¤èªk¤£¶È¼W¥[¤FÁ{§É¸ÕÅ窺¦¨¥\¾÷·|¡AÁÙ½T«O±wªÌ¦b¥¿½Tªº®É¶¡±µ¨ü¥¿½TªºªvÀø¡C

°£¤Fºë·ÇÂåÀø¤§¥~¡Aªü´µÄõ»sÃĦ³­­¤½¥q¤]¾Ö©ê¨ó§@ªº¤O¶q¡C ¤½¥q¿n·¥´M¨D»P¾Ç³N¾÷ºc¡B¬ã¨s²Õ´©M¨ä¥L»sÃĤ½¥qªº¦X§@Ãö«Y¡A¥H¥[³t·sÀøªkªº¶}µo¡C ³z¹L¶×¶°¸ê·½©M±M·~ª¾ÃÑ¡A¨È·à±d»sÃĦ³­­¤½¥q¯à°÷§ó¦³®Ä¦aÀ³¹ï½ÆÂøªºÂåÀø¬D¾Ô¡C

¦¹¥~¡Aªü´µÄõ»sÃĦ³­­¤½¥q¦b¸~½F¾Ç»â°ì¨ú±o¤F­«¤j¶i®i¡C ¸Ó¤½¥qªº³Ð·s²£«~½u¥]¬A¤@¨t¦C°w¹ï¦UºØÀù¯gªº¼Ð¹vÀøªk¡A¥]¬A­GÀù¡B¨ÅÀù©M¤j¸zÀù¡C ³o¨ÇÀøªk¦bÁ{§É¸ÕÅ礤Åã¥Ü¥X¦³§Æ±æªºµ²ªG¡A¬°¥ý«eªvÀø¿ï¾Ü¦³­­ªº±wªÌ±a¨Ó¤F·sªº§Æ±æ¡C

ªü´µÄõ»sÃĦ³­­¤½¥q­P¤O©ó¥H±wªÌ¬°¤¤¤ß¡A³o¬O¨ä°Ï§O©ó¶Ç²Î»sÃĤ½¥qªº¥t¤@­Ó¤è­±¡C ¸Ó¤½¥q¿n·¥»P±wªÌÅv¯q¹ÎÅé¦X§@¡A¨Ã±N±wªÌªºÆ[ÂI¯Ç¤J¨äÃĪ«¶}µo¹Lµ{¡C ³oºØ¤èªk½T«O±q¬ã¨sªº¦­´Á¶¥¬q¨ì·sÀøªkªº³Ì²×§å­ã¡A³£¦Ò¼{±wªÌªº»Ý¨D©M°¾¦n¡C

¦¹¥~¡Aªü´µÄõ»sÃĦ³­­¤½¥q¦b¥þ²y¾Ö¦³±j¤jªº¼vÅT¤O¡A¦b¨È¬w¡B¼Ú¬w©M¬ü°ê¶}®i·~°È¡C ³oºØ¥þ²y¼vÅT¤O¨Ï¸Ó¤½¥q¯à°÷¶i¤J¤£¦Pªº¥«³õ¨ÃÀò±o¼sªxªº¸ê·½¡C ³z¹LÂX¤j·~°È½d³ò¡Aªü´µÄõ»sÃĦ³­­¤½¥q¯à°÷±N¨ä³Ð·sÀøªk±aµ¹¥@¬É¦U¦aªº±wªÌ¡AµL½×¥L­Ì¨­¦b¦ó³B¡C

ªü´µÄõ»sÃĦ³­­¤½¥q¹ï»sÃÄ·~ªº¼vÅT¤£®e¤pòó¡C ¸Ó¤½¥qªºÃĪ«¶}µo³Ð·s¤èªk¡B¹ïºë·ÇÂåÀøªºÃöª`¡B¹ï¨ó§@ªº­«µø¥H¤Î¹ï¥H±wªÌ¬°¤¤¤ßªº©Ó¿Õ³£¬°¨ä¦¨¥\°µ¥X¤F°^Äm¡C ³z¹L¬D¾Ô¶Ç²Î³W½d©M¾Ö©ê·s§Þ³N¡A¨È·à±d»sÃĦ³­­¤½¥q¥¿¦b¬°§ó¦³®Ä²v¡B§ó¦³®Äªº»sÃÄ·~¾Q¥­¹D¸ô¡C

Á`¤§¡Aªü´µÄõ»sÃĦ³­­¤½¥q¥¿¦b³z¹L¨ä³Ð·s¤èªk¡B¨ó§@«äºû©M¥H±wªÌ¬°¤¤¤ßªºµJÂI¡A¹ý©³§ïÅÜ»sÃÄ·~¡C ¾ÌÂǺë·ÇÂåÀø¤èªk¡A¸Ó¤½¥q¯à°÷¶}µo¥X¼Ð¹vÀøªk¡A¬°±wªÌ±a¨Ó·sªº§Æ±æ¡C ³z¹L¿n·¥´M¨D¦X§@¹Ù¦ñÃö«Y¨Ã»P±wªÌÅv¯q¹ÎÅé¦X§@¡A¨È·à±d»sÃĦ³­­¤½¥q¥¿¦b¥[³t·sÀøªkªº¶}µo¡C ¨ä¥þ²y¼vÅT¤O¶i¤@¨B¨Ï¸Ó¤½¥q¯à°÷±µÄ²¨ì¥@¬É¦U¦aªº±wªÌ¡C ªü´µÄõ»sÃĦ³­­¤½¥q¹ï»sÃÄ·~ªº¼vÅT¬O¤£¥i§_»{ªº¡A¨ä¹ï³Ð·s©M±wªÌÅ@²zªº©Ó¿Õ¬°¾ã­Ó¦æ·~¾ð¥ß¤F·s¼Ð·Ç¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿ûÅK¨k¤l10144826  µoªí®É¶¡:2023/10/31 ¤U¤È 04:40:29²Ä 6452 ½g¦^À³
¥[¤W§Ú­Ì¹ï±wªÌ©MÂå⽣ªº½Õ¬dµ²ªG¡A⽀«ù§Ú­Ì¹ïeblasakimab ªº 3 ´Á¬ã¨s­p¹º¡A§Ú­Ì¹w­p±N©ó 2024 ¦~»P¥þ²y°Ó·~¦X§@¹Ù¦ñ⼀°_±Ò°Ê¸Ó¬ã¨s¡A¡v Firth ³Õ⼠¸É¥R¹D¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©t¨àÃÄ10140658  µoªí®É¶¡:2023/10/31 ¤W¤È 11:50:10²Ä 6451 ½g¦^À³
¬Ý¨ì«Ü¦h¦Ñ·à¤Í­Ì³£µ´±æ¤F! Åý¤Hı±oÃø¨ü¡F¹ï©ó¥Ø«eªºª¬ªp¡Aı±o¥u¦³¤½§G¤G½u´Á¤¤¼Æ¾Ú¡AÅý¤j²³¤F¸Ñ¦bªA¥Î¹L§ù¥²ª¢ªº­I´º­È¤U¡A004ÁÙ¦³ªvÀø®ÄªG¡A³o¼Ë004³oÁûÃĤ~¦³¾÷·|­«·s³Q»{¦P¡A¤£µMÀ³¸ÓÁÙ¬O¹³©ú¤Ñ¤j¤À¨Éªº¤@¼Ë¡A´Â¦V¯}1¶ôªº¸ô«e¶i¦Ó¤w¡C

¤j®a¬Ã­«¦Û¤vªº¤f³U°Ú!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/30 ¤U¤È 11:43:21²Ä 6450 ½g¦^À³
¤p©ú¤j

1 ¨º´µ¹F§J¥æ©ö©Ò«h³W©w¡A¦pªG¤½¥qªÑ»ù³sÄò30 ¤Ñ§C©ó1 ¬ü¤¸¡A©Î¥¼º¡¨¬¨ä¥L­n¨D®É¡AÃÒ¨é¥æ©ö©Ò´N·|µo¥Xĵ§i¡A¥²¶·¦b180 ¤Ñ¤º«ì´_ªÑ»ù¡A­Y¥¼¹F¦¨«K·|³Q±j¨î¤U¥«©ÎÂಾ¨ì¤W¥«¼Ð·Ç¸û§Cªº¥æ©ö©Ò (³Q¨ÖÁʪº¾÷²v»·¤j©ó¤U¥«¾÷²v)

2©ú¦~²Ä¤@©u¼Æ¾Ú¥þ³¡¥X¨Ó¬O¨ÖÁʦn®É¾÷ , ¤T´ÁÁ{§Éªº¿ú¬O¨ÖÁʤ½¥q¥Xªº , ¤£¥Î¾á¤ß¤T´ÁÁ{§É¸g¶O , ¦]¬°®Ú¾Ú­×­q¦X¬ù±ø´Ú¡A¨È·à±d-KY±N©óASLAN004¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥ICSL­ºµ§´Ú¶µ3,000¸U¬üª÷¡CCSL±N¥i¦¬¨ú³Ì°ª¹F9,500¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F6.55»õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨ú­Ó¦ì¼Æ¤¤¦ì¼Æ¦Ü10%¤§Åv§Qª÷ (¬ù¦Ê¤À¤§7.5) ½Ð°Ý¤j®a¤S­n¦b¼Ú¬ü¨È±Ò°Ê¤T´ÁÁ{§É ¤S­n¥ýµ¹3,000¸U¬üª÷, ¿ú±q¦ó¦Ó¨Ó ? (³Q¨ÖÁʪº¾÷²v»·¤j©ó¤U¥«¾÷²v)

3 ©ú¦~²Ä¤@©u¼Æ¾Ú«G²´, ¤é¥»¦³±Ò°Ê¤@´ÁÁ{§É , eblasakimab¼Ú¬ü¨È¦³±Ò°Ê¤T´ÁÁ{§É ¬O¥¿­±«ü¼Ð

4 Piper Sandler Companies¬O¤@®a¬ü°ê¸ó°ê§ë¸ê»È¦æ©Mª÷¿ÄªA°È¤½¥q¡A±Mª`©ó¨ÖÁÊ¡B°]°È­«²Õ¡B¤½¶}µo¦æ¡B¤½¦@ª÷¿Ä¡B¾÷ºc¸g¬ö¡B§ë¸êºÞ²z©MÃÒ¨é¬ã¨s¡C¸Ó¤½¥q³z¹L¨ä¥D­n¤l¤½¥q Piper Sandler & Co¡A­±¦V¥ø·~¡B¾÷ºc§ë¸êªÌ©M¤½¦@¹êÅé¡C

­û¤uªñ2000¤H ¤µ¤Ñ­«¥Ó¹ïªü´µÄõ¤½¥q¶R¤Jµûµ¥ ¥Ø¼Ð»ù15¬ü¤¸, »P H.C. Wainwright & Co. ¤K¤ë¤¤­«¥Ó¹ïªü´µÄõ¤½¥q¶R¤Jµûµ¥ ¥Ø¼Ð»ù15¬ü¤¸-17¬ü¤¸ «Ü±µªñ

5 Æ[¹î­«ÂI: ¤µ¦~ 11 ¤ë 2 ¤éÁ|¦æªº²Ä¤C©¡µoª¢©Ê¥Ö½§¯f¥Ö½§¯fÃĪ«¶}µo¦~«×°ª®p·|¤W¡A¤¶²Ð¤F eblasakimab ¦bºC©Êªý

¶ë©ÊªÍ¯f (COPD) ¤HÃþÂà¤Æ¼Ò«¬¤¤ªºªì¨Bµ²ªG¡C

• Farudodstat ªº FAST-AA ¬ã¨sªº¥D­n¤¤´Á¼Æ¾Ú¹w­p±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡C

TREK-Dx study 2024 ¦~²Ä¤@©u«×¤½§G¼Æ¾Ú ( 75¤H ¨Ï¥Îdupilumab ¤¤Â_¯f±w §ï¥Îeblasakimab )

• ¹w­p ASLAN ªº¦X§@¹Ù¦ñ Zenyaku Kogyo Co. ±N¦b¤é¥»±Ò°Ê eblasakimab ªº 1 ´Á¸ÕÅç¡C

2024 ¦~¤W¥b¦~ASLAN ¥¿¦b¹ï TREK-AD ¬ã¨s¶i¦æ«ùÄò¤ÀªR¡A¨Ã­p¹º´£¥æ¥Íª«¼Ð°O¼Æ¾Ú©M±wªÌ³ø§iªºµ²ªG¡A¥H«K¦b¥¼¨Óªº

¬ì¾Ç¤j·|¤Wµoªí¡C

¹w­p±N»P¬ü°ê­¹«~ÃĪ«ºÞ²z§½Á|¦æ²Ä 2 ¶¥¬qµ²§ô·|ij¡AÀH«á eblasakimab ªº²Ä 3 ¶¥¬qÁ{§É­pµe¹w­p±N©ó2024¦~±Ò°Ê¡C

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/10/28 ¤W¤È 12:14:39²Ä 6449 ½g¦^À³
¥xÁÞ¤j

§Ú§Æ±æ§A¬O¹ïªº¡A

¥u¤£¹L±q¥xÆW¿é¨ì¬ü°ê¡A§Ú¤w¤£©ê§Æ±æ¡A

¤½¥q¤@¦A±j½Õ·|¦b©ú¦~°µ3´Á¡A°ÝÃD¬O¥H¦¹ªÑ»ù¦p¦ó¦A¶Ò´Ú¼W¸ê¡A

¦Ó¥BªÑ»ù¯}1¬ü¤¸¤S¦³¤U¥«¦M¾÷¡A

¸g¶O±q¦ó¦Ó¨Ó¡AÁÙ¨Sºâ­n¥ICSLªº±ÂÅvª÷¡A

¥xÁÞ¤j¤Ñ©R¤j§A­Ìªº¬Ýªk©O

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/27 ¤U¤È 11:55:09²Ä 6448 ½g¦^À³
¸É¥R»¡©ú

¤p²Õ°Q½×·|¤¤ eblasakimab 2b TREK-AD study ¹Ï¤ù´£¨ì ¦b²Ä¥|¶g®É¹êÅç²Õ»P¹ï·Ó²Õ¦±½u´N©Ô¶}¹F¨ìÅãµÛ®t²§¡A¤ÀªREASI>18¤À ¹êÅç²Õ»P¹ï·Ó²Õ¦b²Ä¤G¶g¦±½u´N©Ô¶}¹F¨ìÅãµÛ®t²§¡A§e²{¶VÄY­«¯f±wÀø®Ä¶V¦nªºÁͶաA³o¬O­«¤jµo²{

±q¹Ï¤ùµo²{¥»¦¸¹êÅç±q EASI±q16¤À¦¬¨ì66¤À¡A«D±`ÄY­«¯f±wEASI 50¤À¥H¤W¬ù¦³¦Ê¤À¤§10 .

·Pı¦³¤H¦bÀ£§CªÑ»ù¦¬Äw½X¡A¥Ø«eÁ`¥«­È¬ù2000¸U¬ü¤¸(ªÑ»ùxªÑ¼Æ)¡A´«ºâªÑ¼Æ¬ù16666000ªÑ¡A¤jªÑªF¬ù´x±±6¦¨¡A¥|¦¨´²¤á¡AÄw½X³Q¦¬±o®t¤£¦h¤F

¤­»õ¬ü¤¸³Q¨ÖÁÊ¡A·|¦³25­¿º¦´T¡A¤Q»õ¬ü¤¸³Q¨ÖÁÊ¡A·|¦³50­¿º¦´T¡A·Q¤£³q´²¤á½æ¥úªÑ²¼¡A¤½¥q¦A¤½§G¦n¼Æ¾Ú昰¤£¬O­n¾ã¸JºÝ¨«¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/27 ¤U¤È 10:41:04²Ä 6447 ½g¦^À³
¤p©ú¤j: ¦³»ù®t«Øij»°§Ö¶R¦^

¤G´ÁÁ{§É: ¥i¥H¥ý®g½b«á¦A½Õ¾ã¨¤«× ­×¥¿¶Õ¶Õ ( ¤G´ÁÁ{§É¥D­n¬O±´¯Á¦w¥þ©Ê»P¦³®Ä¾¯¶q¡A±´¯Áµ¹ÃÄÀW²v»P¦p¦ó§ó¦³®Ä¿z¿ï¨ü¸Õ¡A ±´¯Á¦p¦ó¼W¥[¤T´ÁÁ{§É¦¨¥\¾÷²v)

¤T´ÁÁ{§É: ½Õ¾ã¦n¨¤«× ­×¥¿¦n¶Õ¶Õ®g¥X«á´N¨S¦³­×¥¿¾÷·|¤F (¤@½¨âÀü²´)

¨È·à±d»sÃÄ2023 ¦~ 10 ¤ë 24 ¤é¤W¤È 11:00¡]¬ü°êªF³¡®É¶¡) ±N¦@¦P¥D¿ìÃö©ó²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç©MªvÀø®æ§½Åܤƪº KOL ¤p²Õ°Q½× ASLAN ºÞ²z¼h±N®i¥Ü TREK-AD ¬ã¨sªº·s¼Æ¾Ú¥H¤Î¨Ó¦Û±wªÌ©M³B¤èªÌ½Õ¬dªº AD ªvÀø«e´ºªº·s¥«³õ¬ã¨s¼Æ¾Ú

TREK-AD ¬ã¨s:¥l¶Ò¯f±wEASI score ¤j©óµ¥©ó21¤À¦@181¤H

EASI score ¥­§¡¤À¼Æ 33.8¤À ¬ü°ê¯f±w45¤H EASI score ¥­§¡¤À¼Æ 34.3¤À

(dupilumab¤T´Á EASI score ¥­§¡¤À¼Æ31.8-33¤À) ( ¯e­·ª¾«l¯óªO¿ºÃÑ©¾¦Ú)( ¥l¶Ò¯f±w¶VÄY­«Àø®Ä¶V¦n)

IGA score : eblasakimab 2b IGA 3 (¤¤«×) (73 ¤H 40.3%) IGA 4 (­««×) ( 108 ¤H 59.7% )

(dupilumab¤T´Á IGA score IGA 3 (¤¤«×) ( 51%- 52 % ) IGA 4(­««×) ( 48% -49% )

(¯e­·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY­«Àø®Ä¶V¦n )

Mean change from baseline :

ITT 289¤H eblasakimab 2b 600mg Q4w -73 / - 51.1

EASI score ¤j©óµ¥©ó18¤À 600mg Q4w -75 / - 42.3

EASI score ¤j©óµ¥©ó21¤À 600mg Q4w -74.5 / - 38 (¯e­·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY­«Àø®Ä¶V¦n)

EASI 75 : eblasakimab 2b ITT 289¤H 600mg Q4w 52% /24.4%

EASI score ¤j©óµ¥©ó18¤À EASI 75 600mg Q4w 55.6% /15.4% (dupilumab¤T´Á 300mg Q2w 50.3%/15.2%

(¯e­·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY­«Àø®Ä¶V¦n)

IGA 0/1 eblasakimab 2b ITT 289¤H 600mg Q4w 31.2% /15.1 %

EASI score ¤j©óµ¥©ó18¤À 600mg Q4w 30.6% / 8 % dupilumab¤T´Á 300mg Q2w 34.7 % / 10.2%

(¯e­·ª¾«l¯óªO¿ºÃÑ©¾¦Ú) ( ¥l¶Ò¯f±w¶VÄY­«Àø®Ä¶V¦n)

¥»¦¸¥l¶Ò ITT 289¤H 100% EASI score ¤j©óµ¥©ó18¤À ¦û80% EASI score ¤j©óµ¥©ó21¤À ¦û63% ¤p©ó21¤À ¦û37%

»P·|±M®a¥«³õ¹w¦ô : eblasakimab 1L 17% ( AD 40.8 »õ¬ü¤¸) 2L 26% ( ¹L±Ó ®ð³Ý COPD 62.4 »õ¬ü¤¸ )

¥»¦¸KLO ¤p²Õ°Q½× TREK-AD ¬ã¨sªº·s¼Æ¾Ú¥H¤Î¨Ó¦Û±wªÌ©M³B¤èªÌ½Õ¬dªº AD ªvÀø«e´ºªº·s¥«³õ¬ã¨s¼Æ¾ÚÀò±o°Ñ»y·|¬Ì±M®a

¦nµû»PÀò±o³\¦hÄ_¶Q«Øij ( ¥»¦¸KLO ¤p²Õ°Q½× ¦³¶W¹L¤@¥b¯f±wÄ@·N´«ÃÄ )

( ²§¦ì©Ê¥Ö½§ª¢¯f±w¥þ²y2»õ¤H( ¬ü°ê4140¸U¤H ¼Ú·ù3070¸U¤H ¤¤°ê 3560¸U¤H¤é¥»500¸U¤H) ¥Ø«e¥u¦³¦Ê¤À¤§8 ¯f±w¨Ï¥ÎDupilumab , ¨Ï¥ÎDupilumabªº¯f±w¤¤¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä,¬OÄY­«¥¼³Qº¡¨¬ªº¯e¯f

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/10/26 ¤W¤È 09:50:03²Ä 6446 ½g¦^À³
¥«³õ¤ÏÀ³¥Ã»·¬O¹ïªº

¨ì²{¦b¤S¦A­×§ïDX¦¬®×¼Ð·Ç¡A

¥i¨£¤½¥q¦³¦hÄê¡A¥¢±Ñ¦h¦¸ÁÙ·d¤£²Mª¬ªp¡A

¨ì²{¦b¤´¦b®g½b«á¦Aµe¹v¡A

¥«³õ¤£¶R³æ¨S±Ï¤F¡A

±q¥xÆW¶BÄF¨ì¬ü°ê

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/24 ¤U¤È 09:26:10²Ä 6445 ½g¦^À³

¤G´ÁÁ{§É¸ÕÅçPhase 2

昰¥H¤p³W¼Ò¤§¯f¤H¨ü¸ÕªÌ¬°¹ï¶H¡A©Ò»Ý¤H¼Æ¬ù¼Æ¤Q¦Ü¼Æ¦Ê¤H¡A¥Ø¼Ð¬Oµû¦ô¤£¦P¾¯¶q¹ï¯f¤HªºÃĮĻP¦w¥þ©Ê¡A§@¬°²Ä¤T´ÁÁ{§É¸ÕÅ羯¶q¤§¨Ì¾Ú¡A¥Õ¸Ü»¡

´N¬O±´¯Á¦w¥þ©Ê»P¦³®Ä¾¯¶q¡A±´¯Áµ¹ÃÄÀW²v»P¦p¦ó§ó¦³®Ä¿z¿ï¨ü¸Õ¡A±´¯Á¦p¦ó¼W¥[¤T´ÁÁ{§É¦¨¥\¾÷²v ¡Aeblasakimab 2b ´ÁTREK-AD study ¥u昰±µÄò£¸´ÁÁ{§É¦A±´¯Á¦w¥þ©Ê»PÀø®Ä¡A¨S¦³©Ò¿×ªº¦¨¥\©Î¥¢±Ñ¡A§ë¸ê¤H§â¤G´ÁÁ{§É¬Ýªº¤Ó¦n©Î¤£¦n¬O«D²z©Êªº¸ÑŪ¡AªÑ»ù¤w³QÄY­«±þ¹LÀY¡A

¤½¥qµû¦ô¦³¶}µo¼ç¤O´N·|Ä~Äò©¹¤T´Á¨«¡A

³Ì­«­nªº¬O§ë¸ê¤H­nª`·NÆ[¹î¤½¥q°Ê¦V¡C

EASI ÄY­«©Ê¤À§O¦p¤U¡G

0 = ²M´·

0¡P1-1¡P0 = ´X¥G²M´·

1¡P1-7¡P0 = »´«×

7¡P1-21¡P0 = ¤¤«×

21¡P1-50¡P0 = ÄY­«50¡P1-72¡P0 = «D±`ÄY­«

¥»¦¸¦¸±Ú¸s¤ÀªREASI¤À¼Æ21¤À¥H¤W¡]­««×¡^¥i¥HÀò±o·¥¨ÎÀø®Ä¡A²q´ú¤T´ÁÁ{§É¤£·|¥l¶Ò¤Ó¦h¤¤«×¯f±w¡A¥H­««×¯f±wEASI¤À¼Æ

21¤À¥H¤W¬°¥D­n¹ï¶H¡A

¹êÅç²Õ»P¹ï·Ó²Õ®t¶Z¤~·|©Ô¤j, ¤~·|Àò±o·¥¨ÎÀø®Ä¡C

¤½¥q­«­n°T®§

2023 ¦~ 10 ¤ë 18 ¤é

¨È·à±d»sÃıN¦@¦P¥D¿ìÃö©ó²§¦ì©Ê¥Ö½§ª¢Á{§É¸ÕÅç©MªvÀø®æ§½Åܤƪº KOL ¤p²Õ°Q½×

ASLAN ºÞ²z¼h±N®i¥Ü TREK-AD ¬ã¨sªº·s¼Æ¾Ú¥H¤Î¨Ó¦Û±wªÌ©M³B¤èªÌ½Õ¬dªº AD ªvÀø«e´ºªº·s¥«³õ¬ã¨s¼Æ¾Ú

¦b¦¹µù¥U§Y¥i°Ñ¥[ 2023 ¦~ 10 ¤ë 24 ¤é¤W¤È 11:00¡]¬ü°êªF³¡®É¶¡¡^Á|¦æªººô¸ô¬ã°Q·|

¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 10 ¤ë 18 ¤é ¡V ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬±N¦@¦P¥D¿ì»P»â¥ýªºÁ{§É¬ã¨s²Õ´ (CRO) ¶i¦æ¤p²Õ°Q½×¡A¡§²§¦ì©Ê¥Ö½§ª¢ªºÅܤƭ±»ª¡GDupilumab ±À¥X«á¤C¦~¤¤Á{§É¸ÕÅç©MªvÀø®æ§½µo¥Í¤F«ç¼ËªºÅܤơ¨¡A¨ä¤¤ÃöÁä·N¨£»â³S(KOL) Jonathan Silverberg ±N¥X®uMD¡BPhD¡BMPH¡]³ìªvµØ²±¹y¤j¾ÇÂå¾Ç»P°·±d¬ì¾Ç¾Ç°|¡^©M April W. Armstrong¡AMD¡BMPH¡]¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ°·±d¤¤¤ß¡^¡C

³o¶µºô¸ô¬ã°Q·|¬¡°Ê±N¥]¬A ASLAN ©M CRO ªººtÁ¿¡AÀH«á»P¨â¦ì KOL ¶i¦æ¤p²Õ°Q½×¡A°Q½×²§¦ì©Ê¥Ö½§ª¢ (AD) Á{§É¸ÕÅç©MªvÀø®æ§½ªºÅܤơB³o¨ÇÅܤƹïÁ{§É¼Æ¾Ú©M·sÀøªkªº¼vÅT¡A¥H¤ÎÀu¤ÆAD ¸ÕÅ窺¼ç¦b¸Ñ¨M¤è®×¡C

ASLAN ºÞ²z¼h±N°Q½×eblasakimab 2b ´Á TREK-AD ¬ã¨sªº¼Æ¾Ú¡A¨Ã±N¤¶²Ð°w¹ï AD ±wªÌ©M³B¤èÂå¥Í¹ï·í«e©M¥¼¨ÓªvÀøªº¬Ýªkªº½Õ¬dªº·s¥«³õ¬ã¨s¡C

½Ð¦b¦¹³Bµù¥U¡A°Ñ¥[ 2023 ¦~ 10 ¤ë 24 ¤é¬P´Á¤G¤W¤È 11:00 ¦Ü¤¤¤È 12:00¡]¬ü°êªF³¡®É¶¡¡^ªººô ¸ô¼s¼½¡A©ÎÆ[¬Ý¬¡°Ê­«¼½

¤°»ò¬OÃöÁä·N¨£»â³S¡H

½Ð·j´M

Key Opinion Leader (KOL)

What is a key opinion leader?

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/10/24 ¤U¤È 04:42:53²Ä 6444 ½g¦^À³
¤Ñ©R¤j¤Î¦U¦ì¤j¤j

³o¤½¥q¥¼¨ÓÁÙ¦³§Æ±æ¶Ü¡A

±q7¤ë6¤é°_¦Ü¤µ¤w³s¶^§Ö4­Ó¤ë¡A¤£ª¾¨ä­ì¦]¡A¼Æ¾ÚÁö¤£¨Î¡A¦ý¤£¦Ü¿éCntb¡A²{¦b¤S¦^1¤¸¡A¬Ý¨Ó¤£¼ÖÆ[¤F¡A

·Pı¤½¥q¤w¨S±Ï¤F¡A·|¦A¦¸¤U¥«¡A

¨È·à±d°ª¼hÁȨ찪Á~¡A¤£¦b¥G§ë¸êªÌ¡A·íªì¦b¥x¤W¥«¤~´X¦~¡A´N¥ô·NºM¥X¥xÆW¡A´NÀ³¸Óı®©¡A³o¬O¤@®aµL¸Û«H¤½¥q¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/15 ¤W¤È 09:31:35²Ä 6443 ½g¦^À³

­«ÃĸɥR

1 ¤½¥q¹w©w¥»©u±N»P¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)¥l¶}Á{§É¤T´Á«e·|ijEnd-of-Phase 2 (EOP2) meeting

2 EOP2 meeting®Ú¾ÚEblasakimab²§¦ì©Ê¥Ö½§ª¢ªºÁ{§É«e, ¤@´Á , 2B TREK-AD Á{§É¸ÕÅçµ²ªG¡A°w¹ïÁ{§É¤T´Á»P¥Ó½ÐÃÄÃÒ(NDA)«eªº³W¹º¡A¥]§tÃĪ«¤Æ¾Ç»s³y»PºÞ¨î(CMC)¡B¤T´ÁÁ{§É¸ÕÅç(pivotal trial)³]­p( ¾¯¶q ¥ÎÃÄÀW²v ¦¬®×¤H¼Æ ²Õ§O ¦¬®×±ø¥ó ¥D­n»P¦¸­nÀø®Ä«ü¼Ð)¡AÁ{§É¸ÕÅç¦w¥þ©Ê»P¬ü°êFDA¶i¦æ¥R¤À°Q½×¡C¬ü°êFDA¦b·|ij¤¤¤]·|´£¨Ñªº«Øij

3§ë¸ê¤H·|¥ô»{¬°FDA®Ö­ãÃÄÃÒ¬O¬ÝÃĪ«Àø®Ä­n¤ñ²{¦³ÃĪ«¦n, ³o¬O¤@ºØ°g«ä

4 ¬ü°êFDA¨Ì¾Ú 2 (¨Æ¥ý¬ù©w¦nªº³]­p±ø¥ó¬O§_¹F¼Ð¨Ó®Ö­ãÃÄÃÒ)(¥D­n¬O¦w¥þ©Ê ¦³®Ä©Ê

ÃĪ«¤Æ¾Ç»s³y»PºÞ¨î(CMC) )

5 tralokinumab Àø®Ä¦³¤ñ Dubilumab ±j¶Ü? ¬°¤°»ò¬ü°êFDA ®Ö­ã tralokinumab ÃÄÃÒ ( ¦]¬°¨Æ¥ý»P¬ü°êFDA¬ù©w¦nªº¤T´ÁÁ{§É¹êÅç³]­p±ø¥ó¹F¼Ð) ( «D¥u¬ÝÃĪ«¶¡ªºÄvª§)

6²§¦ì©Ê¥Ö½§ª¢¯f±w¥þ²y2»õ¤H( ¬ü°ê4140¸U¤H ¼Ú·ù3070¸U¤H ¤¤°ê 3560¸U¤H

¤é¥»500¸U¤H) ¥Ø«e¥u¦³¦Ê¤À¤§8 ¯f±w¨Ï¥ÎDupilumab , ¨Ï¥ÎDupilumabªº¯f±w¥u¦³¦Ê¤À¤§30-40 ì±o²z·QÀø®Ä,¬OÄY­«¥¼³Qº¡¨¬ªº¯e¯f, ¹w´Á¬ü°êFDA¥¼¨Ó·|®Ö­ã§ó¦h¥Íª«»s¾¯³æ®è§ÜÅéÃĪ«) , FDA §Æ±æ¦w¥þ¦³®ÄÃĪ«¶V¦h¶V¦n, ³Ì¦n°ª¶Q¤£¶Q ¥H«O»Ù¯f±wÅv§Q

7 AD¥«³õ¨ì2029¦~¹w¦ô240»õ¬ü¤¸, ¤£¥²¥þ®³ ,¥u­n®³¤U²Å¦X¥Íª«¼Ð°O»P¤£¾A¦X¨Ï¥Îdupilumabªº¯f±w, ¥«³õ´N°÷Åå¤H¤F ) ¥Ø«e¥u¦³dupilumab »PTralokinumab ¨âºØ¥Íª«»s¾¯³æ®è§ÜÅéÃĪ«,Tralokinumab¼Æ¾ÚÁö®t ((FDA 2021¦~12¤ë ®Ö­ãtralokinumab ÃÄÃҥثe·Ç³Æ¶}½æ¤¤)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/14 ¤W¤È 10:49:18²Ä 6442 ½g¦^À³
¨S¦³¤H·|ÃhºÃeblasakimab ¦³®³FDA ÃÄÃÒ¼ç¤O (¤£¥Î¦¸±Ú¸s¤ÀªR ) ²z©Ê¬Ý«Ý¤GB Á{§É §Q¥Î°²´Á¦n¦n¬Ý 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³Ì·s³ø§i¤¤

ªü´µÄõ»sÃĤ½¥q¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³Ì·s³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú

TREK-AD ¬ã¨s«á´Á¤fÀY³ø§i´Á¶¡´£¨Ñªº¼Æ¾Úªí©ú¡Aeblasakimab§@¬°²Ä¤@­ÓªvÀø¤¤­««×²§¦ì©Ê¥Ö½§ª¢ªº¥Íª«»s¾¯¨ã¦³¼ç¤O¡A±q¶}©l®É¨C¤ë¤@¦¸µ¹ÃĪº®ÄªG¨ã¦³Ävª§©Ê

•¨Ó¦Û¹ï±w¦³ÄY­«¯e¯fªº±wªÌ¡]°ò½uEASI µû¤À¦Ü¤Ö21¡^¡]¦ûITT ±wªÌªº63%¡^ªº¨Æ«á¤ÀªRªº·s¼Æ¾ÚÅã¥Ü¡A¨C¤ëªA¥Î600 mg ¨Ì¥¬©Ô§Æº¿¡A«ùÄò16 ¶g¡A¾É­PEASI µû¤À­°§C74.5% ¡]»P¦w¼¢¾¯²Õ¬° 38.0%¡Ap<0.0001¡^¡AEASI-75 ¬° 53.6%¡]¦w¼¢¾¯²Õ¬° 12.9%¡Ap=0.0009¡^¡AÅã¥Ü¦w¼¢¾¯½Õ¾ãÀø®ÄÅãµÛÂX¤j

¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 10 ¤ë 13 ¤é¡]Àô²y³q°TªÀ¡^¡X ASLAN Pharmaceuticals Pte Ltd¡]NASDAQ¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A­P¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡C«Å§G¦b²Ä 32¦b¦¨¤H¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤ªºeblasakimab¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·| (EADV) ¤j·| ©¡¡C

Eric L. Simpson Âå¾Ç³Õ¤h¡B«X°Ç©£°·±d»P¬ì¾Ç¤j¾ÇÂå¾Ç¥Ö½§¬ì Frances J. Storrs ±Ð±Â©M TREK-AD ¬ã¨sªº­º®u¬ã¨s­û¤¶²Ð¤F¸Ó¬ã¨sªº¥D­nµ²ªG¡A¸Ó¬ã¨s¥ý«e©ó 7 ¤ë«Å¥¬¡C

1»P¦w¼¢¾¯¬Û¤ñ¡A Eblasakimab¦b²Ä16 ¶g®É¹F¨ì¤F¥D­n²×ÂI¡A§YÀã¯l­±¿n©MÄY­«©Ê«ü¼Æ(EASI) µû¤À¬Û¹ï©ó°ò½uªºÅܤƦʤÀ¤ñ¡A¦b¤T­Óµ¹ÃIJդ¤¨ã¦³²Î­pÅãµÛ©Ê¡G¨C¥|©P¤@¦¸600mg ¾¯¶q¡]¨C¥|©P600mg¡^¡A³o¦b¼Æ­È¤W¬O³Ì¦nªº°õ¦æÁu¡A¨C¨â¶g¤@¦¸ 400mg ¾¯¶q¡]400mg Q2W¡^©M¨C¨â¶g¤@¦¸ 300mg ¾¯¶q¡]300mg Q2W¡^¡C

2¨Ï¥Î³o¨Ç¾¯¶qªºeblasakimabªvÀøªº±wªÌ¦bªvÀøªº³Ìªì´X¶g¤º¨³³t°_®Ä¡A¨ì²Ä¥|¶g®É EASI µû¤À¦³²Î­p¾Ç¤WªºÅãµÛ§ïµ½¡C

3Eblasakimab¦b©Ò¦³¾¯¶q¤ô¥­¤U³q±`­@¨ü©Ê¨}¦n¡Aµ²½¤ª¢©Mª`®g³¡¦ì¤ÏÀ³ªºµo¥Í²v¸û§C¡CEADV ¤j·|¤W¤]µoªí¤F°ò©ó¹ïÄY­« AD ±wªÌªº¨Æ«á¤ÀªRªº·s¼Æ¾Ú¡]°ò½u EASI µû¤À¦Ü¤Ö¬° 21¡A¦û·N¹ÏªvÀø (ITT) ¤H¸sªº 63%¡^¡C¦¹¨È²Õªº¤¤¦ì°ò½u EASI µû¤À¬° 31.1¡]¦b¬ü°êµn°Oªº±wªÌ¬° 31.0¡^¡A

4¦Ó ITT ±Ú¸sªº¤¤¦ì¼Æ¬° 24.0¡]¦b¬ü°êµn°Oªº±wªÌ¬° 19.2¡^¡C¨È²Õ¤ÀªRµ²ªGªí©ú¡A eblasakimabªvÀøªºÀø®Ä»P ITT ±Ú¸s¬Û·í¡A¦ý¦w¼¢¾¯¤ÏÀ³ÅãµÛ­°§C¡C

5 §Ú­Ì«Ü°ª¿³¦b EADV ¤j·|¤W®i¥Ü TREK-AD ¬ã¨sªº¥D­n¼Æ¾Ú©M·sªºªþ¥[¤ÀªR¡C§Ú­Ìªº¬ã¨sµ²ªG¤ä«ù¤Feblasakimab§@¬°²§¦ì©Ê¥Ö½§ª¢ (AD) ªº·s«¬ªvÀø¤èªkªº¼ç¤O¡A±q¶}©l®É¨C¤ëµ¹ÃĤ@¦¸¡A¥B¤£¼vÅTÀø®Ä¡A

6 ASLAN »sÃĤ½¥q­º®uÂåÀø©x Alex Kaoukhov ³Õ¤h»¡¡C¡u¹ï AD ±wªÌ¨È²Õªº¨Æ«á¤ÀªRµ²ªG±j½Õ¤F¤F¸Ñ AD Á{§É¸ÕÅ礤±wªÌ¸sÅéÅܤƪº­«­n©Ê¡C

7ÁöµM»PÁ`Åé¸ÕÅç¤H¸s¬Û¤ñ¡Aeblasakimab¦b±wªÌ­«¯g¤¤ªºªí²{¦P¼Ë¥X¦â¡A¦ý±w¦³¸û»´¯e¯fªº±wªÌ¼Æ¶q¼W¦h¥i¥HÅãµÛ´£°ª¦w¼¢¾¯¤ÏÀ³¡C¡¨

( 6, 7 »¡©ú¨È²Õ¤ÀªR­ì¦]) (¸û»´¯e¯fªº±wªÌ¼Æ¶q¼W¦h¥i¥HÅãµÛ´£°ª¦w¼¢¾¯¤ÏÀ³ ) (¤T´Á·|¦¬­«¯g±wªÌ)

8 TREK-AD ¬ã¨sªº¿n·¥µ²ªG¬°eblasakimab§@¬°ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº·sÀøªkªº¼ç¤O´£¨Ñ¤F¥O¤H«HªAªº®×¨Ò¡A¥¦¥i¥H³z¹L´£¨Ñ¤è«K¡B¦³®Ä©M¦w¥þªºªvÀø¿ï¾Ü¨Ó´£°ª±wªÌªºÅ@²z¼Ð·Ç¡A¡v

Eric»¡L. Simpson¡AÂå¾Ç³Õ¤h¡A«X°Ç©£°·±d»P¬ì¾Ç¤j¾ÇÂå¾Ç¥Ö½§¬ì Frances J­ì¦]. Storrs ±Ð±Â¡ATREK-AD ¬ã¨s­º®u¬ã¨s­û¡C

²Ä 32©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|ºtÁ¿¸Ô±¡¡G¿ð¨ì¤fÀY³ø§i

TREK-AD ªºµ²ªG¡G¤@¶µ°w¹ï¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢¦¨¦~±wªÌªº eblasakimab ÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó 2b ´Á¬ã¨s¡]ºK­n ID 6703¡^

AD ¬O¤@ºØ±`¨£¡BºC©Ê¡B¦h¦]¤l¥Ö½§¯f¡A¨ä¥D­n§K¬Ì¯S¼x¬O»²§U T ²Ó­M 2¡C²Ó­M¿E¯À¥Õ²Ó­M¤¶¯À (IL) 4 ©M IL-13 ³Q»{¬°¬O AD ªºÃöÁäÅX°Ê¦]¯À¡C¨âªÌ³£³z¹L¦@¨Éªº 2 «¬¨üÅé¡]¤@ºØ¥Ñ IL-4R£\ ©M IL-13R£\1 ²Õ¦¨ªº²§¤G»EÅé¡^µo¥X°T¸¹¡CEblasakimab¬O¤@ºØ¼ç¦bªº¤@¬y³æ®è§ÜÅé¡A°w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé¨È°ò¡A³o¬OÅX°Ê¦hºØ¹L±Ó©Êµoª¢¯e¯fªºÃöÁä³~®|¡C

9 TREK-AD¡]¤@¶µeblasakimabªvÀø¤¤­««× AD ¦¨¤H±wªÌªº 2b ´Á¬ã¨s¡^ªº¿n·¥¼Æ¾Úªí©ú¡Aeblasakimab¦³¼ç¤O±q¤@¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅTÀø®Ä¡C

ITT ±Ú¸s¤¤ªº 289 ¦W±wªÌ³QÀH¾÷¤À°t¦Ü¨C¤ë¤@¦¸ 400mg¡]400mg Q4W¡^©Î 600mg¡]600mg Q4W¡^ªºeblasakimab ²Õ¡A©Î¨C¨â¶g¤@¦¸300mg¡]300mg Q2W¡^©Î400mg¡]400mg Q2W¡^ªº²Õ§O¡A©Î¦w¼¢¾¯Q2W ²Õ¡A«ùÄò16 ¶g¡A¦b¨â¦¸©Î¤T¦¸­t²ü¾¯¶q«á¡C

10 ¹ï°ò½u EASI µû¤À¦Ü¤Ö¬° 21¡]ÄY­«¯e¯f¡^ªº±wªÌ¶i¦æ¤F¨È¸s¨Æ«á¤ÀªR¡C

¦b ITT ±Ú¸s¤¤¡A»P¦w¼¢¾¯¬Û¤ñ¡A²Ä 16 ¶g®Éeblasakimab¾¯¶q600mg Q4W¡B400mg Q2W ©M300mg Q2W ªºEASI µû¤À§ïµ½ÅãµÛ¸û¤j¡]-73.0% [p=0.001]¡B-65.8% [p=0.029 ] ©M-69.8 % [P=0.005] vs -51.1%¡^¡C

11 ¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õªº¤ÀªR¤¤¡A»PITT ¤H¸s¬Û¤ñ¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G

600mg Q4W -74.5% /38.0%¡]p<0.0001¡^¡A

400mg Q2W -72.7%/38.0%¡]p<0.0001¡^¡A

300mg Q2W -69.8%/38.0%¡]p=0.0001¡^¡A

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õ¤ÀªR¤¤¡A¹F¨ìEASI-75 ªº±wªÌ¦Ê¤À¤ñ¬°¡G¹êÅç²Õ/¦w¼¢¾¯²Õ

600mg Q4W 53.6%/12.9% (p=0.0009)¡A

400mg Q2W 49.7% / 12.9% (p=0.0014)¡A

300mg Q2W 52.1%/12.9% ( p=0.001)

400mg Q4W 36.1%/12.9% ¡]p=0.0328¡^

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌÀò±oÅçÃÒªº²§¦ì©Ê¥Ö½§ª¢¬ã¨sªÌ¾ãÅéµû¦ô(vIGA-AD) µû¤À¬°0/1 ªº±wªÌ¦Ê¤À¤ñ¦p¤U¡G¹êÅç²Õ /¦w¼¢¾¯²Õ

600mg Q4W 29.8% /6.8% (p=0.0172)¡A

400mg Q2W 37.6% /6.8%(p=0.0030) ¡A

300mg Q2W 27.1%/6.8%¡]p=0.0297¡^¡A

400mg Q4W ²Õ¬° 9.6%/6.8%

12¾ãÅé¦Ó¨¥¡A¥D°ÊªvÀø²Õªº°±ÃIJv¬Û·í¡A¦Ó¦w¼¢¾¯²Õªº°±ÃIJv¸û°ª¡CEblasakimab ªº­@¨ü©Ê¨}¦n¡F»P¦w¼¢¾¯¬Û¤ñ¡A eblasakimabªºµ²½¤ª¢©Mª`®g³¡¦ì¤ÏÀ³µy°ª¡]¤À§O¬° 5.6% ©M 4.7%¡^¡A¦w¼¢¾¯§¡¬° 1.8%¡C

°£¤F³Ì·sªººt¥Ü¤§¥~¡AÁÙ¦bEADV ¤j·|¤W®i¥Ü¤FÃö©óeblasakimab©MFarudodstatªº¤T±i¹q¤l®ü³ø¡C±z¥i¥H¦bASLAN ºô¯¸ªº¥Xª©ª«³¡¤À½u¤W¬d¬Ý¹q¤l®ü³øªº°Æ¥»¡C

¥H¤W¤À¨É ¨Ì¾Úªü´µÄõ»sÃĤ½¥q¦b²Ä 32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·|¤j·|¤Wªº³Ì·s³ø§i¤¤®i¥Ü¤F Eblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº 2b ´Á¬ã¨sªº·s¼Æ¾Ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/13 ¤U¤È 11:26:46²Ä 6441 ½g¦^À³
¤G´ÁÁ{§É¦b±´¯Á ( ¾¯¶q µ¹ÃÄÀW²v ¥l¶Ò¼Ð·Ç ¦w¥þ©Ê ) ¨Æ«e¤ÀªR»P¨Æ«á¤ÀªR³£¦P¼Ë­«­n ( ¬°¤T´ÁÁ{§É°µ·Ç³Æ )

Eblasakimab¥uÆ[¹î16¶g §ó¨S¦³¨Ï¥ÎÃþ©T¾J, ¦b¨C²Õ¤H¼Æ¤£¦hªº±¡ªp¤U¦³³o¼Ë¼Æ¾ÚÀ³¸Óµ¹¤©¹ªÀy (¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç¤j·|·Ç¤©¤fÀY³ø§i´N¬O³Ì¤jªÖ©w)

ASLAN PHARMACEUTICALS ¦b²Ä32 ©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç¤j·|±ß´Á¤fÀY³ø§i¤¤®i¥Ü¤FEblasakimab ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº2B ´Á¬ã¨sªº·s¼Æ¾Ú- TREK-AD ¬ã¨sªº±ß´Á¤fÀY³ø§i´Á¶¡´£¨Ñªº¼Æ¾ÚÃÒ©ú¤Feblasakimab §@¬°²Ä¤@­Ó¥Íª«»s¾¯ªº¼ç¤O¦b¤¤«×¦Ü­««×²§¦ì©Ê¥Ö½§ª¢¤¤¡A±q¶}©l®É¨C¤ë¤@¦¸µ¹ÃĪº®ÄªG¨ã¦³Ävª§©Ê- ¨Ó¦Û¹ï±w¦³ÄY­«¯e¯fªº±wªÌ¡]°ò½uEASI µû¤À¦Ü¤Ö21¡^¡]¦ûITT±wªÌªº63%¡^ªº¨Æ«á¤ÀªRªº·s¼Æ¾Ú¡AÅã¥Ü¨C¤ëªA¥Î600 mg eblasakimab «ùÄò16 ¶g¡A¾É­PEASI µû¤À­°§C74.5%¡]¦w¼¢¾¯²Õ¬°38.0%¡Ap<0.0001¡^¡AEASI-75 ­°§C53.6%¡]¦w¼¢¾¯²Õ¬°12.9%¡Ap=0.0009¡^

­«­n¼Æ¾Ú¦p¤U

¦b¹ï°ò½uEASI µû¤À¦Ü¤Ö¬°21 ªº±wªÌ¨È²Õªº¤ÀªR¤¤¡A»PITT ¤H¸s¬Û¤ñ¡Aeblasakimab ªvÀø²Õ»P¦w¼¢¾¯²Õ¤§¶¡²Ä16 ¶g®ÉEASI ¦Ê¤À¤ñÅܤƬ۹ï©ó°ò½uªº®t²§§ó¤j¡G

600mg Q4W -74.5% /38.0%¡]p<0.0001¡^¡A

400mg Q2W -72.7%/38.0%¡]p<0.0001¡^¡A

300mg Q2W -69.8%/38.0%¡]p=0.0001¡^¡A

¦b¨È²Õ¤ÀªR¤¤¡A¹F¨ìEASI-75 ªº±wªÌ¦Ê¤À¤ñ¬°¡G¹êÅç²Õ/¦w¼¢¾¯²Õ

600mg Q4W 53.6%/12.9% (p=0.0009)¡A

400mg Q2W 49.7% / 12.9% (p=0.0014)¡A

300mg Q2W 52.1%/12.9% ( p=0.001)

400mg Q4W 36.1%/12.9% ¡]p=0.0328¡^

Àò±o¸gÅçÃÒªº²§¦ì©Ê¥Ö½§ª¢¬ã¨sªÌ¾ãÅéµû¦ô(vIGA-AD) µû¤À¬°0/1 ªº±wªÌ¦Ê¤À¤ñ¦p¤U¡G¹êÅç²Õ /¦w¼¢¾¯²Õ

600mg Q4W 29.8% /6.8% (p=0.0172)¡A

400mg Q2W 37.6% /6.8%(p=0.0030) ¡A

300mg Q2W 27.1%/6.8%¡]p=0.0297¡^¡A

400mg Q4W ²Õ¬° 9.6%/6.8%

¾ãÅé¦Ó¨¥¡A¥D°ÊªvÀø²Õªº°±ÃIJv¬Û·í¡A¦Ó¦w¼¢¾¯²Õªº°±ÃIJv¸û°ª¡C Eblasakimab ªº­@¨ü©Ê¨}¦n¡F »P¦w¼¢¾¯¬Û¤ñ¡Aeblasakimab ªºµ²½¤ª¢©Mª`®g³¡¦ì¤ÏÀ³µy°ª¡]¤À§O¬° 5.6% ©M 4.7%¡^¡A¦w¼¢¾¯§¡¬° 1.8%¡C°£¤F³Ì·sªººt¥Ü¤§¥~¡AÁÙ¦b EADV ¤j·|¤W®i¥Ü¤F¤T±iÃö©ó eblasakimab ©M Farudodstat ªº¹q¤l®ü³ø¡C ¹q¤l®ü³øªº°Æ¥»¥i¦b ASLAN ºô¯¸ªº¥Xª©ª«³¡¤À½u¤W¬d¬Ý¡C(eblasakimabµ²½¤ª¢¤ñ²v¤ñDupilumab §C¬Û·í¦h)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/10/13 ¤U¤È 10:34:54²Ä 6440 ½g¦^À³
¶BÄF¶°¹Î¤½¥q

²{¦b¤½¥q»¡¤°»ò³£¨S¤H«H¤F

¦b¼Ú¬wµoªíªº¼Æ¾Ú¡A¸Ì­±´N¦³¦Û¬Û¥Ù¬Þ¤£¦X²zªº¦a¤è¡A

®g½b«á¦Aµe¹v¡A

Ãø©Ç¥«³õ¤´¤£¶R³æ¡A

³o®a¤½¥q¤wµL¸Û«H¥i¨¥¡A

«Ó°¶¤jÂ_§À¨D¥Í¤~¬O¹ïªº¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/11 ¤U¤È 08:51:07²Ä 6439 ½g¦^À³
¥Ø«e§e²{Eblasakimab»Pdupilumab Ävª§ºA¶Õ

1¬ü°êFDA 2023¦~10¤ë2¤é§_¨MLebrikizumabÃÄÃҥӽР(»s³y¤è­±¥X°ÝÃD)

Eblasakimab ¤Ö¤F¤@­ÓÄvª§¹ï¤â, 2b ´Á¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡A¥]¬A±wªÌ³ø§iªºµ²ªG©M¥Íª«¼Ð°O¼Æ¾Ú¡A¹w­p±N©ó 2023 ¦~²Ä¥|©u«×´£¨Ñ (¥Íª«¼Ð°O¼Æ¾Ú±À´ú°µ¬°¤T´ÁÁ{§É¥l¶Ò¨ü¸Õ°Ñ¦Ò¼Ð·Ç, AD¥«³õªñ240»õ¬ü¤¸,¤£¥²¥þ®³ ,¥u­n®³¤U²Å¦X¥Íª«¼Ð°O»P¤£¾A¦X¨Ï¥Îdupilumabªº¯f±w, ¥«³õ´N°÷Åå¤H¤F ) ¥Ø«e§e²{Eblasakimab»Pdupilumab Ävª§ºA¶Õ

Tralokinumab ¼Æ¾ÚÁö®t (FDA 2021¦~12¤ë ®Ö­ãtralokinumab ÃÄÃÒ)

2 ¤GB Á{§É¬O¦b§ä³Ì¨Î¾¯¶q Eblasakimab§ä¨ì600mg4¶g¤@°w , dupilumab§ä¨ì300mg2¶g¤@°w , lebrikizumab §ä¨ì250mg2¶g¤@°w

·í¦~dupilumab ¤T´ÁÁ{§É¨Ï¥Î¾¯¶q¬°300mg ¤@¬P´Á¤@°w »P 300mg ¤G¬P´Á¤@°w («á¨ÓÃĪ«¤W¥« ¨Ï¥Î300mg¤G¬P´Á¤@°w)

Eblasakimab¤Gb´ÁÁ{§ÉÃĪ«¦w¥þ©Ê¦n «Øij¤½¥q¤T´ÁÁ{§É¨Ï¥Î600mg¤G¬P´Á¤@°w»P¥|¬P´Á¤@°w ( ¨C¤ë¤@°w) ¥H¥Íª«¼Ð°O¼Æ°µ¬°¤T´ÁÁ{§É¥l¶Ò¨ü¸Õªº°Ñ¦Ò¼Ð·Ç, ÅýÀø®Ä¤j´T´£¤É °t¦X°ª¦w¥þ©Ê»PÀu¨}»s³y( ¤w©e°UThermo Fisher Scientific ¶}©l»s³y3´ÁÁ{§É¥ÎÃÄ »P¥¼¨Ó°Ó·~¤Æ¤§ÃĪ«»s³y)¥H¤À­¹2029¦~¥þ²y240»õ¬ü¤¸AD ¥«³õ (Eblasakimab³W¹º¹L±Ó®ð³Ý ,ëC·ò¯lCSU »P COPD )

Àø®Ä«ü¼Ð ¤@ (4¶g1°w)

A IGA 0/1

Eblasakimab 2b 600mg (n=59) Q4W 31.2%/ 15.1% p=0.0502 ( 4¶g1°w) 2.01­¿

(59¤HP­È¦³¹F¼Ð) (80¤HP­È·|§ó§C)

B EASI-75%

eblasakimab 2b 600mg (n=59) Q4W 52.%/ 24.4% p value 0.0040 ( 4¶g1°w) 2.13­¿

C EASI-90%

Eblasakimab 2b 600mg (n=59) Q4W 27.6%/ 7.9% p value 0.0080( 4¶g1°w) 3.49­¿

Àø®Ä«ü¼Ð ¤G (2¶g1°w)

A IGA 0/1

eblasakimab 2b 400mg (n=56) Q2W 32.6 %/15.1% P value 0.0380 ( 2¶g1°w)

eblasakimab 2b 300mg (n=58) Q2W 33.1%/15.1% P value 0.0327 ( 2¶g1°w)

dupilumab 2b 300mg (n=64) /(n=61)Q2W 30 %/ 2 % P value 0.001 ( 2¶g1°w)

dupilumab phase 3 Solo1 300mg (n=224) /(n=224 )Q2W 37.4%/ 10 .2%

P value 0.001 ( 2¶g1°w)

dupilumab phase 3 Solo2 300mg (n=233) /(n=236 )Q2W 36%/ 8%

P value 0.001 ( 2¶g1°w)

tralokinumab ECZTRA 1 15.8% /7.1 % P=0.002 (300mg 2¶g1°w16¶g) ( 601¤H/ 197¤H)

tralokinumab ECZTRA 2 22.2 % /10.9 % P< 0.001 (300mg 2¶g1°w16¶g) ( 591¤H/ 201¤H) (FDA 2021¦~12¤ë ®Ö­ãtralokinumab ÃÄÃÒ)

B EASI-75%

eblasakimab 2b 400mg Q2W (n=56) 43.6/24.4% P value 0.0360 ( 2¶g1°w)

eblasakimab 2b 300mg (n=58) Q2W 51.2/24.4% P value 0.0050 ( 2¶g1°w)

dupilumab 2b 300mg (n=64) / (n=61 ) Q2W 53.1%/11.5% p value 0.001 ( 2¶g1°w)

dupilumab phase 3 solo1 300mg (n=224) /(n=224 )Q2W 50.3%/ 15.2 %

P value 0.001 ( 2¶g1°w)

dupilumab phase 3 solo2 300mg (n=233) /(n=236 )Q2W 44%/ 12%

P value 0.001 ( 2¶g1°w)

tralokinumab ECZTRA1 25% /12.7% P < 0•001 (300mg 2¶g1°w16¶g) ( 601¤H/ 197¤H)

tralokinumab ECZTRA2 33.2% / 11.4% P < 0•001 (300mg 2¶g1°w16¶g) ( 591¤H/ 201¤H) (FDA 2021¦~12¤ë ®Ö­ãtralokinumab ÃÄÃÒ)

C EASI-90%

eblasakimab 2b 400mg (n=56) Q2W 25.3%/7.9% p value 0.0177 ( 2¶g1°w)

eblasakimab 2b 300mg (n=58) Q2W 30.8%/7.9% p value 0.0028( 2¶g1°w)

dupilumab 2b 300mg( n=64)/ n=61) 29.7 %/3.3 % p value 0.001 ( 2¶g1°w)

dupilumab phase 3 solo1 300mg (n=224) /(n=224 )Q2W 32.8%/ 7.4 %

P value 0.001 ( 2¶g1°w)

dupilumab phase 3 solo2 300mg (n=233) /(n=236 )Q2W 30%/ 7%

P value 0.001 ( 2¶g1°w)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G«Ó°¶10144972  µoªí®É¶¡:2023/10/7 ¤W¤È 07:49:45²Ä 6438 ½g¦^À³
§Ú¬Q±ß¤w¸g¥Î1.4¤¸¥ª¥k½æ¥ú³oÄêªÑ

²{¦b¤ß±¡¶W¯ÅµÎ©Z¡A¥H«á¦A¤]¤£¥Î¬Ý³oÄêªF¦è

¤j®a¬Ã­«¡A§Æ±æ³oÄêªF¦è¤£·|¦A¶^¯}1¤¸

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/10/6 ¤U¤È 10:12:20²Ä 6437 ½g¦^À³
ªÑ»ùªº½T¥O¤H¥¢±æ, ¥­¤ß¦Ó½×³o¥u¬O¤@­Ó¤G´ÁÁ{§É, ¥Í§Þ¤½¥q¦b¤G´ÁÁ{§É¥u¦³±´¯Á»Pµû¦ô¡A¦³µo®i¼ç¤O¦AÄ~Äò©¹¤T´ÁÁ{§É¨«¡AFDA¥¼¨Ó¥u¬Ý¨â­Ó¤T´ÁÁ{§É¼Æ¾Ú , §ë¸ê¤H¤ÏÀ³¹LÀY¤F, ²z©Ê¬Ý«Ý¤G´ÁÁ{§É , ¤Ó°õµÛ»P¤Ó§¹¬ü¥D¸q¤Ï¦Ó¤£¦n

²Ä¥|©u­«­n¨Æ¶µ¦p¤U

1¤U¬P´Á10¤ë11¤é¨ì13¤é¬ì¾Ç¤j·|¤W¶i¦æºt¥Ü ( 3­Ó¤fÀY³ø§i 1­Ó®ü³ø®i¥Ü °÷¥÷¶q¬ã¨s¤~·|­ã¤©¤fÀY³ø³ø)

2 2b ´Á¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡A¥]¬A±wªÌ³ø§iªºµ²ªG©M¥Íª«¼Ð°O¼Æ¾Ú¡A¹w­p±N©ó 2023 ¦~²Ä¥|©u«×´£¨Ñ (¥Íª«¼Ð°O¼Æ¾Ú±À´ú°µ¬°¤T´ÁÁ{§É¥l¶Ò¨ü¸Õ°Ñ¦Ò¼Ð·Ç, AD¥«³õªñ240»õ¬ü¤¸,¤£¥²¥þ®³ ,¥u­n®³¤U²Å¦X¥Íª«¼Ð°O»P¤£¾A¦X¨Ï¥Îdupilumabªº¯f±w, ¥«³õ´N°÷Åå¤H¤F )

3 ¦w¥þ©Ê: ¾ãÅé¦Ó¨¥¡A¥D°ÊªvÀø²Õªº°±ÃIJv¬Û·í¡A¦Ó¦w¼¢¾¯²Õªº°±ÃIJv¸û°ª¡C ¨S¦³µo²{·sªº¦w¥þ°T®§¡A¥B¿n·¥ªvÀø²Õ©M¦w¼¢¾¯²Õ¤§¶¡ªº¤£¨}¨Æ¥ó (AE) ÀW²v¬Û·í¡C ©Ò¦³¿n·¥ªvÀø²Õ¤¤³Ì±`¨£ªºAE ¬O»ó«|ª¢¡]¦w¼¢¾¯²Õ¬°13.4%¡A¦w¼¢¾¯²Õ¬°8.8%¡^¡B²§¦ì©Ê¥Ö½§ª¢¡]¦w¼¢¾¯²Õ¬°8.6%¡A¦w¼¢¾¯²Õ¬°7.0%¡^¡BÀYµh¡]¦w¼¢¾¯²Õ¬°6.9%¡A¦w¼¢¾¯²Õ¬°7.0%¡^¤Î¤W©I§l¹D¹D·P¬V¡]¦w¼¢¾¯²Õ¬° 6.5%¡A¦w¼¢¾¯²Õ¬° 5.3%¡^¡C µ²½¤ª¢¡]¦w¼¢¾¯¬°5.2%¡A¦w¼¢¾¯¬°1.8%¡^¡Bª`®g³¡¦ì¤ÏÀ³¡]¦w¼¢¾¯¬°4.7%¡A¦w¼¢¾¯¬°1.8%¡^©M¯p¯l·P¬V¡]¦w¼¢¾¯¬°3.0%¡A¦w¼¢¾¯¬°3.5%¡^ªºµo¥Í²v¸û§C ( µ²½¤ª¢µo¥Í²v¬ù¥u¦³dupilumab ¥|¤À¤§¤@ )

3 »P¬ü°ê­¹«~©MÃĪ«ºÞ²z§½Á|¦æ²Ä¤G¶¥¬qµ²§ô·|ij¡A¨Ã¹w­p©ó 2024 ¦~±Ò°Ê eblasakimab ªº²Ä¤T¶¥¬qÁ{§É¶}µo­p¹º

4 TREK-DX¡]EblasaKimab ¦b Dupilumab ¤¤ªº¸ÕÅç¡^eblasakimab ¦b¦³dupilumab ªvÀø¸gÅ窺±wªÌ¤¤¶i¦æªº¬ã¨s¡A¹w­p©ó2024 ¦~²Ä¤@©u¤½§G¸Ó¬ã¨sªº¥D­n¼Æ¾Ú

5Aslan 003¨r´³ ¤G´Á ¹w­p©ó2024 ¦~²Ä¤@©u¤½§G¸Ó¬ã¨sªº¥D­n¼Æ¾Ú

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/10/5 ¤U¤È 11:38:06²Ä 6436 ½g¦^À³

¬°®É¤w±ß¡A

¤j´dµL¨¥¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©ú¤Ñ¹L«á10151242  µoªí®É¶¡:2023/10/5 ¤U¤È 11:29:35²Ä 6435 ½g¦^À³
¶ZÂ÷¤W¦¸¸Ñª¼¥¢±Ñ«á...¤S¹L¤T­Ó¤ë~

2023/7/5ªÑ»ù3.8¶ô¦ý¨ì¤µ¤Ñ¥u³Ñ¤U1.62¤F,¦A¹L¤T­Ó¤ëÀ³¸Ó´N·|¯}1¶ô,¦pªG­n¨ÖÁʦ­´N³Q¨ÖÁʤF,½Ð¤j®a¤£­n¥Õ¤é¹Ú¤F!

2021¦~§Ú´N¬Ý³z³o¤äªÑ²¼¤F!¥u·|¼W¸êÄF¿ú..ªÑ»ù¶^¨ì1¤¸¦A´î¸ê,­«­nªºÁ{§É«o¨S±Ë¦nµ²ªG!¤§«á´N·|¹³Âû³J¤ô»åªÑ0.1ªº»ù®æ ! ¤£«H¶Ü? 2024¦~¨Ó¬Ý

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2023/7/6 ¤U¤È 10:41:26²Ä 6353 ½g¦^À³

±Nªñ¤@¦~¨S¨Óµo¨¥¤F~¤µ¤Ñ¤S¬O¸Ñª¼¥¢±Ñ...¾ú¸g¤F´î¸ê¤À©îÁקK¤U¥«,ªÑ¼Æª½±µ°£¤W6,ÁöµMÁקK¤U¥«©R¹B...¦ý¼Æ¾ÚÁÙ¬O¤£ª§®ð,´N§ÚªºÆ[¹îªÑ»ù¦b¥¼¨Ó¥b¦~ÁÙ·|«ùÄò±´§C¨ì1¬ü¤¸¤§¤U~¤d¸U¤£­n¤£¬Û«H...©^ÄU¤j®a¤£­n¦Aª±³o¤@¤ä¤F!!§ß¤£°_ªºªü¤æ

¤£¬Û«Hªº¥h¬Ý§Ú¥H¤Uªºµo¨¥§a !

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/5/27 ¤U¤È 03:08:40²Ä 5352 ½g¦^À³

¥Ø«e¤w¸g¤U±´0.4¤§¤U¤F,´«ºâ¦¨¥xªÑ»ù®æ¤j¬ù2.4¶ô¥ª¥k,ªñ´Á¤º¨S¦³­«¤j§Q¦h®ø®§ªº¸Ü,ªÑ»ù´N·|¬O¦b©¹¤U¾_Àú,¤£¹L©¹¤U¦h¤Ö¤w¸g¤£­«­n¤F!

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/3/2 ¤U¤È 11:16:14²Ä 5145 ½g¦^À³

¤§«e¥»¤Hªº¯d¨¥³£¤w¸g¤@¤@ÅçÃÒ.......ªÑ»ù¤w¸g©¹0.8¾aªñ ! ±µ¤U¨Ó·|ºCºC¤U±´¨ì0.4¥ª¥k ! ³ÌºGªº¬O¦pªG30¤Ñ¤ºªÑ»ù³£¯¸¤£¤W1¶ô¿ú~ÁÙ­n­±Á{¤U¥«­·ÀI ~ ¤£¹L¬üªÑ«Ü¬y¦æ¤À©îªÑ²¼´î¤Ö§AªºªÑ¥÷µM«á¼W¥[ªÑ²¼­±­È¨ÓÁקKªÑ²¼¤U¥«...§Æ±æ¨È·à±d¤£­n¨«¨ì³o¤@¨B

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/1/19 ¤W¤È 09:59:39²Ä 5061 ½g¦^À³

¶ZÂ÷¤W¦¸¯d¨¥(2021/12/28)¹L¤F¤j¬ù20¤Ñ~¨ì¤F¤µ¤Ñ¥Ø«e¤w¸g¶^¸¨1¶ô¤§¤U...

(2021/9/29)¸Ñª¼¤j¶^¤§®ÉÁÙ¦³2.5¶ô,¥B·í®É¥»¤H¤w¸gÂ_¨¥¤§«áÁÙ·|«ùÄò¤j¶^...

¬Ýªk¨Ì¤£ÅܱNÄ~Äò©¹0.8¾aªñ~¦A¨Ó´N¬O©¹0.5»ù¦ì¾aÃl....

¤d¸U¤£­n¬Û«H±Ë»ò³o·sÃĤñ±Ë»òÁÙ­n¦nªº°­¸Ü ? §Aª¾¹D¥«­±¤W¾AÀ³©Ê¥Ö½§ª¢·sÃĦ³¦h¤Ö¶Ü ? ª¾¹D¤F§A´N¤£·|Ä~Äò§ë¸êASLN¤F....

³¯¤j§Aªºµo¨¥¨S¦³°ÝÃD~¤£»Ý­n³Q¤H«Â¯Ù~~¤]¤£·|¦³ªk«ß³d¥ô !

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58²Ä 5008 ½g¦^À³

¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk....

¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~

¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !!

ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³

¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ..

¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£­n¤£¬Û«H ?

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³

¥H¤U§ó¥¿¬°004

¤j®aÁÙ°O±o¶Ü¡H

¨È·à±d³£¬O¤@³eªº§@­·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨Ó­Ó004¡K

¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|í¹L¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H

·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³

­Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ,

¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü?

³q±`¼Æ¾ÚÀu³£¬Oº¦¤@­¿!¤£·|À£§CÅý§A¦Y³fªº©Ô!

¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~

¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³

¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1­¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W,

¦pªG¯uªº¦p³o­ÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O­«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ?

¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³

¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ

·|­û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³

¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X­¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£­n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)!

°ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,­I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³o­Óª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê­¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ!

¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£­n¨I¾K¦b¹Ú¸Ì­n¶}©l¾Ç·|­±¹ï²{¹ê !

¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ !

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/9/9 ¤U¤È 05:46:55²Ä 6434 ½g¦^À³
®Ú¾Ú¸Ó¤½¥q¦V¬ü°êÃÒ¨é¥æ©ö©e­û·| (SEC) ´£¥æªº³Ì·s 13F ¤å¥ó¡ASio Capital Management LLC ¦b²Ä¤@©u«×±N¨ä«ù¦³ªºASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN ¡V§K¶O³ø§i¡^ªÑ²¼«d´î¤F80.0 %¡C¸Ó°òª÷¦b´Á¤º¥X°â1,016,608ªÑ«á¡A«ù¦³¸Ó¤½¥qªÑ²¼254,150ªÑ¡CºI¦Ü³Ìªñ¤@­Ó©u«×¥½¡ASio Capital Management LLC ¾Ö¦³ ASLAN Pharmaceuticals ¬ù 1.82% ªºªÑ¥÷¡A»ù­È 732,000 ¬ü¤¸¡C

¨ä¥L¤@¨Ç¤j«¬§ë¸êªÌ¤]¶R½æ¤F ASLN ªºªÑ²¼¡CVirtu Financial LLC ¦b²Ä¥|©u«×±N¨ä«ù¦³ªº ASLAN Pharmaceuticals ªÑ¥÷¼W«ù¤F 389.6%¡CVirtu Financial LLC ¦b¤W­Ó©u«×ÃB¥~ÁʶR¤F 70,109 ªÑ«á¡A¥Ø«e¾Ö¦³¸Ó¤½¥q 88,106 ªÑ¡A»ù­È 32,000 ¬ü¤¸¡CRenaissance Technologies LLC ¦b²Ä¤@©u«×¦¬ÁʤF ASLAN Pharmaceuticals »ù­È 64,000 ¬ü¤¸ªº·s¾¦ì¡CªáºX¶°¹Î¦b²Ä¥|©u«×¦¬ÁʤF ASLAN Pharmaceuticals »ù­È 104,000 ¬ü¤¸ªº·s¾¦ì¡C¬ü°ê»È¦æ DE ¦b²Ä¤@©u«×¼W«ù¤F ASLAN Pharmaceuticals ªºªÑ¥÷ 34.4%¡C¬ü°ê»È¦æ (Bank of America Corp DE) ¦b¤W­Ó©u«×ÃB¥~ÁʶR¤F 66,544 ªÑ«á¡A¥Ø«e¾Ö¦³¸Ó¤½¥q 259,722 ªÑ¡A»ù­È 233,000 ¬ü¤¸¡C³Ì«á¡AMillennium Management LLC ¦b²Ä¥|©u«×±N¨ä«ù¦³ªº ASLAN Pharmaceuticals ªÑ¥÷¼W¥[¤F 4.1%¡CMillennium Management LLC ¦b¤W­Ó©u«×ÃB¥~ÁʶR¤F 64,784 ªÑ«á¡A¥Ø«e¾Ö¦³ 1,654,153 ªÑ¸Ó¤½¥qªÑ²¼¡A»ù­È 595,000 ¬ü¤¸¡C¥Ø«e42.23%ªºªÑ¥÷¥Ñ¾÷ºc§ë¸êªÌ«ù¦³¡C

´X¦ì¬ã¨s¤ÀªR®v¤wµo¥¬¦³Ãö ASLN ªÑ²¼ªº³ø§i¡CHC Wainwright ¦b 8 ¤ë 14 ¤é¬P´Á¤@ªº¤@¥÷³ø§i¤¤­«¥Ó¤F ASLAN Pharmaceuticals ªÑ²¼ªº¡§¶R¤J¡¨µû¯Å¡A¨Ã±N¥Ø¼Ð»ù³]©w¬° 17.00 ¬ü¤¸¡CRoth Mkm ¦b 8 ¤ë 14 ¤é¬P´Á¤@ªº¤@¥÷³ø§i¤¤­«¥Ó¤F ASLAN Pharmaceuticals ªÑ²¼ªº¡§¶R¤J¡¨µû¯Å¡A¨Ã³]©w¤F 15.00 ¬ü¤¸ªº»ù®æ¥Ø¼Ð¡C

Àò¨ú§Ú­Ì¹ï ASLN ªº³Ì·s¤ÀªR

¨È·à±d»sÃĪѲ¼ªí²{

ASLN ªÑ²¼¶g¤­¶}½L»ù¬° 2.08 ¬ü¤¸¡C¸Ó¤½¥qªº 50 ¤Ñ²¾°Ê¥­§¡½u¬° 2.41 ¬ü¤¸¡A200 ¤Ñ²¾°Ê¥­§¡½u¬° 3.29 ¬ü¤¸¡C¸Ó¤½¥qªº³t°Ê¤ñ²v¬°2.26¡A¬y°Ê¤ñ²v¬°2.26¡A¶Å°ÈªÑ¥»¤ñ²v¬°3.84¡C¸Ó¤½¥q¥«­È¬°3401¸U¬ü¤¸¡A¥«¬Õ²v¬°-0.64¡A¨©¶ð­È¬°1.76¡CASLAN Pharmaceuticals Limited ªº 12 ­Ó¤ë§CÂI¬° 1.70 ¬ü¤¸¡A12 ­Ó¤ë°ªÂI¬° 4.69 ¬ü¤¸¡C

ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN ¡VÀò¨ú§K¶O³ø§i¡^³Ìªñ©ó 8 ¤ë 11 ¤é¬P´Á¤­¤½§G¤F©u«×¦¬¯qµ²ªG¡C¸Ó¤½¥q³ø§i¥»©u«×¨CªÑ¦¬¯q¡]0.11 ¬ü¤¸¡^¡A¤ñ¤ÀªR®v´¶¹M¹w´Áªº¡]0.80 ¬ü¤¸¡^°ª¥X 0.69 ¬ü¤¸¡C¸Ó¤½¥q¥»©u«×À禬¬° 1200 ¸U¬ü¤¸¡CªÑ²¼¬ã¨s¤ÀªR®v¹w´ú ASLAN Pharmaceuticals Limited ¤µ¦~ªº¨CªÑ¦¬¯q±N¬°-3.01¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/26 ¤U¤È 09:49:34²Ä 6433 ½g¦^À³
§ó¥¿»P¸É¥R

¤p¾ð¤j§ó¥¿¬°¤p©ú¤j

¨â¦ì¤j¤j¹ï¤½¥qªÑ»ù§C°gªí¥ÜÃö¤Á¡A¬Û«H«Ü¦h¤H¤]·|¦³¦P¼Ëªº½èºÃ¡A¥H¤U¤»ÂI­È±o²`«ä¡C

1¸³ºÊ¨Æ«ùªÑ¡A«e¤Q¤jªÑªF«ùªÑ³Ì·s±¡ªp¡A²¦³º¥L­Ì«ùªÑ¤ñ§Ú­Ì¤jªº¦h

2ªÑ»ù§C°g昰§_ªí¥ÜÃĪ«¥¼¨Ó¨S¦³¼ç¤O¡H

3²§¦ì©Ê¥Öª¢¨ä¥LÃÄÃÒ®Ö­ã昰§_Àø®Ä£¸©w­nĹ¹LDupilumab¡H¦pªG昰³o¼Ë¡A¥H«á´N¤£·|¦³¨ä¥LÃĪ«³Q®Ö­ã¡A¦pªG昰³o¼Ë¡A¦UºØ¯e¯f¥u¦³£¸ºØÃĪ«¡AFDA¤~¤£·|·F³oºØ

·l®`¯f±wÅv¤Oªº昰¡C

ÃĪ«¯S¦â¤ñÀø®Ä¶W¶V­«­n¡A¦w¥þ©Ê¤ñÀø®Ä­«­n¡A¤è«K©Ê¤ñ¤£¤è«K©Ê­«­n¡AÃĪ«»ù®æ¾A¤¤¤ñÃÄ»ù©ù¶Q­«­n¡C

4 TREK-AD 2b ´Á¬ã¨sªº¿n·¥Á{§É¼Æ¾Ú±N eblasakimab ©w¦ì¬°ªvÀø²§¦ì©Ê¥Ö½§ª¢©M¨ä¥L¹L±Ó©Ê¯e¯fªº¼ç¦b»â¥ýÀøªk¡A³o­Ó¤£¬O¦b±j¯Pªí¹F©Ý®i¨ä¥L¾AÀ³¯gªº¥ø¹Ï¤ß¡H

5 Eblasakimab 昰²Ä¤@­Ó®i¥Ü¤F¨C¤ë¤@¦¸µ¹Ãļç¤O¡A°£¤F¤´¦b¶i¦æªº¶i¤@¨B¤ÀªR¤§¥~¡A¥D­nªº±wªÌ¼Æ¾Ú©MÂå¥Í½Õ¬dªºµ²ªG¤ä«ù§Ú­Ì¶i¦æ¤@¶µÃöÁ䪺 3 ´Á¬ã¨s­p¹º¡A³o¥y¸Ü昰¤£¬O¦b»¡©ú¼Æ¾Ú昰Åܰʪº¡A­n§ë½Z°ê»Ú¥Ö½§¯f­«­n´Á¥Z¼Æ¾Ú·|¥Î³Ì¦nªºÁÙ¬O·|¥Î³Ì®tªº¡H

6 Eblasakimab¡A§Ú­Ì¹w­p©ó 2024 ¦~»P¥þ²y°Ó·~¦X§@¹Ù¦ñ¤@°_±Ò°Ê¤T´ÁÁ{§É¸ÕÅç,³o¥y¸Ü¦b·t¥Ü¤°»ò¡H¨S¦³½Í¦n±ø¥ó¦p¦ó£¸°_±Ò°Ê¡H

Waiting,waiting

patient,patient

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/25 ¤U¤È 10:17:45²Ä 6432 ½g¦^À³
¤p¾ð¤jªGµM¦³¬Ý¸ê°T¡A9¤ë¤½¥¬2b¥¿¦¡³ø§i¡A»¡¤£©w¤S¨Ó­Ó¤j½­×¡A±q¨½µ{¸O¨Ó¬ÝÀ³¸Ó¬O²Ä¥|©u·|¦³Â½­×¡C

¹w­p§Y±N¨ì¨Óªº¨½µ{¸O

• TREK-AD ´£¨Ñªº¦³Ãö¥Íª«¼Ð»x©M¯f±w¨ä¥LªþÄݼƾڳø§i±N¦b2023¦~²Ä¥|©uªº¬ì¾Ç¤j·|¤W´£¥æ¥Xª©¡A­Ó¤H¬ã§P¯f±wªº¥Íª«¼Ð»x»P¨ä¥LªþÄݼƾڥi¥H§óºë·Ç¤ÀªRÀø®Ä¥H°µ¬°©ú¦~¤T´ÁÁ{§É¥l¶Ò¯f±wªº¶Àª÷¼Ð·Ç¡Aªº½T·|¨Ó­Ó¤j½­×¡C

• ¨Ï¥Î¹L dupilumab ªº±wªÌ¤¤¶i¦æ eblasakimab ªº TREK-DX ¸ÕÅ窺¥D­n¼Æ¾Ú¹w¦ô¦b2024 ¦~²Ä¤@©u«×µo§G¡C

• Farudodstat ªº FAST-AA ´³¨r¬ã¨sªº´Á¤¤¼Æ¾Ú¹w­p±N©ó 2024 ¦~²Ä¤@©uµo¥¬¡C

• Zenyaku¹w­p±N©ó2024¦~¤W¥b¦~¦b¤é¥»±Ò°Êeblasakimabªº¤@´Á¸ÕÅç

¸É¥R

ÃĪ«ªº¾AÀ³¯gµLªkĹªÌ¥þ®³¡Aeblasakimab¦³¥Íª«¼Ð»x»P¨ä¥LªþÄݼƾڥi¥H§óºë·Ç¤ÀªR¾A¦X±Ú¸s¡A¤S¦³¨Ï¥ÎdupilumabÀø®Ä¤í¨Îªº¯f±w±Ú¸s¡A¨ä¾A¥Î¯f±w¤ñ²vÂX¤j¤£¤Ö¡C¾AÀ³¯g¶V¦h¡A¾AÀ³¯gªº¥«³õ¶V¤j¥¼¨Ó±ÂÅv©Î¨ÖÁʪº»ù½X¶V°ª¡C

°£¤FAD,eblasakimab¦b¹L±Ó®ð³Ý¡A¦ÛÅé§K¬Ì¯e¯f¤è­±¥¼¨Ó¤]·|¶i¦æÁ{§É¬ã¨s

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/8/25 ¤W¤È 11:01:10²Ä 6431 ½g¦^À³

¨Ì¤½¥q¥H«eªº¸Û«H

¥L»¡ªº¥ô¦ó¸Ü§Ú³£¤£¤Ó¬Û«H¤F¡A

²{¦b³s¤½¥¬ªºªº­«­n¼Æ¾Ú¡AÁ٨ƫá§ó¥¿¡A

¥i¨£¤½¥q¤§¯à¤O¤Î¿ì¨Æ¤§¯ó²v¡A

¥L­Ì¦Û¤v¤@ª½»¡ªºÃĦ³¦h¦n¡A¤@¤ë¤@¾¯

²{ªp¥«³õ´N¤£¶R³æ¡AªÑ»ùµL¶q½L¶^¡A

³o®a¤½¥q¤£¦ýÃÄ·d¤£¦n¡A

¥«³õ¹ï¨ä¸Û«H¤]¥´°Ý¸¹¡A

9¤ë¤½¥¬2b¥¿¦¡³ø§i¡A

»¡¤£©w¤S¨Ó­Ó¤j½­×¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/24 ¤U¤È 01:22:43²Ä 6430 ½g¦^À³
eblasakimab昰¤£¬Oª÷µP±o¥D¤£¬Oª©­±¤W¥ô¦ó¤H»¡¤Fºâ¡A¦Ó¬O¥Ñ¥Ö½§¯f»â°ì±M®a»¡¤Fºâ¡A¨S¦³¬Ý¨ì¼Æ¾Ú«e§Ú«Ü«O¦u¡A¬Ý¨ì¼Æ¾Ú«á§Ú¤£±o¤£¼ÖÆ[¡Aª§°õµL¯q¡A®É¶¡¬O³Ì¦nªºÃÒ©ú¡A½Ð­@¤ßµ¥«Ý¡A¥t¥~­n¤ñÀø®Ä¥ý¬Ý昰¨â¶g¤@°wÁÙ¬O¥|¶g£¸°w,¦w¥þ©Ê¦p¦ó,¨Ï¥Î¤è«K©Ê,»ù®æ¦p¦ó,¥ÎDupilumab¨â¶g¤@°w»Peblasakimab¥|¶g£¸°w¨Ó¤ñ¤]¤£­Û¤£Ãþ¡A«Øij¤½¥q¥Î600mg¥|¶g£¸°w

°µ¬°¤T´ÁÁ{§É¸ÕÅ羯¡A¿n·¥¶i¨ú¡A¦pªG­n«O¦u¦]À³¤]¥i¦A¥[¤J300mg¨â¶g¤@°w¡A

¥Î¨âºØ¾¯¶q¡A¨ì®É¬Ý¬Ý¼Æ¾Ú¦p¦ó¦A¨M©wªvÀø¾¯¶q»PÀW²v¡C

eblasakimab¦³ª÷µP±o¥D¼ç¤Oªº½×­z¨Ì¾Ú¦p¤U

This is the first time we¡¦ve seen a once-a-month treatment option deliver competitive efficacy data, which would be

a game-changer for patients with AD,¡¨ said Eric L. Simpson, M.D., Frances J. Storrs Professor of Medical

Dermatology at the Oregon Health and Science University and Lead Investigator in the TREK-AD study. ¡§We

haven¡¦t seen much in the way of advancement since the launch of dupilumab, and there remains a huge unmet

burden of disease experienced by patients. These results support eblasakimab¡¦s potential to be a leading therapy for the treatment of AD, if approved

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/8/24 ¤W¤È 10:13:01²Ä 6429 ½g¦^À³
¤£ºÞ¬O¼Æ¾Ú½Õ¾ã«e©Î«á¡A¥H¹êÅç²Õ/¹ï·Ó²Õ­¿¼Æ¤ñ¨Ó¬Ýebl³£¬O²¤»¹©óleb¸òdup¡A©Ò¥H¤~¥HEASI-90¼Æ¾Úªºµ´¹ï­È»¡ebl¬Oª÷µPªº¤£¬O?½Õ¾ã«á¤£ºÞ¥H¹êÅç²Õ/¹ï·Ó²Õ­¿¼Æ©Î¬OEASI-90¼Æ¾Ú¨Ó¬ÝÁÙ¬Oª÷µP¶Ü?¹êÅç²Õ/¹ï·Ó²Õ­¿¼Æ¤ñ©Ô¤j¡Bp­È­°§C·íµM¦³§U©ó¹êÅç¹LÃö³o¬O¤£ª§ªº¨Æ¹ê¡A¦ý¤]¥Nªí¤FeblªºÃĮĻ¹©óleb¤Îdup¥i¯à©Ê¤£§C¡A¦p¦¹¤@¨Óªº½T¤]¥u³Ñ¥|¶g¤@°wªºÀu¶Õ¡A¹ï¤ñ1b¸ÕÅçµ²ªG¤Î¹êÅç³]­p­«ÂI³£¬O©ñ¦b¤G¶g¤@°w¡A¤£´N¬O«ü±æÃĮįà¶W¶Vdup?²{¦b­«¤ß©ñ¦b¬°¥|¶g¤@°w¤£´N¬O¤G¶g¤@°wÃĮĨä£Àu©ódupªºµ²ªG?¦p¦¹¤@¨ÓÃĪ«¨úÃÒ«á¡A«áÄò­t³d¥«³õ¦æ¾P­«­n©Ê¤£¨¥¦Ó³ë¡A¥«³õ¹ï©óÀø®ÄÀu©ódupªº´Á«Ý¸¨ªÅ¡A¾É­PªÑ»ù±Y¶^¤]¬O¨Æ¹ê¡AÃø¤£¦¨³o¨Ç³£¬O¤Ûı?¤Ñ©R¤j¹ïaslanªº¨ÖÁÊ»ù¤]³£«O¦uªº¤@¸ô¤U­×¡A¤£¤]¬O¦Ò¶q¨ìaslanªºªñªp¦Ó°µ¥Xªº¹w´ú?³Ì«á§Y¨Ï±ÂÅv©Î³Q¨ÖÁÊ¡AÃø¹D±ÂÅv©Î³Q¨ÖÁÊ»ù­È¤@ÂI³£¨S¦³­°§C?§Ú¤]Ãiªº»¡¤F¡A¤Ï¥¿»¡¨Ç¤£¦nÅ¥ªº´N¬O¿ï¾Ü©Êª¾Ä±Ðù¡A¨ì©³½Ö¤~¬O¿ï¾Ü©Êª¾Ä±¡A§Ú´N¸òµÛ©ú¤Ñ¹L«á¤j¤jªº¸}¨B¨ÓÀ˵ø³Ì«áµ²ªG´N¦n¤F......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/23 ¤U¤È 08:28:29²Ä 6428 ½g¦^À³
·PÁªoºj¤j¤À¨Éªº¥¿­±¸ê°T¡A³o­Ó¤Gb´Á¹êÅçÁÙ¦bÆ[¹î¶i¦æ¤¤¡A±qclinical trial ¸ê°T6¤ë30¤é昰primary completion,¹w¦ô¤E¤ë30¤é¤~昰study completion¡A©¡®É¤~¦³§ó§¹¾ã¸ê®Æ§e²{¥H«K¦b²Ä¥|©u¦b°ê»Ú­«­n´Á¥Zµoªí¬ã¨sµ²ªG¡C¼Æ¾Ú§ó·s­n¬Ý昰§_¹êÅç²Õ»P¹ï·Ó²Õ³£§ó·s¡A¨â²Õ­¿¼Æ¤ñ昰§_¼W¥[¡Ap­È昰§_§ó¤p

¥Ø«eÆ[¹î¨ì¹êÅç²Õ»P¹ï·Ó­¿¼Æ¤ñ¼W¥[¡Ap­È§ó¤p¡A³o¤£昰¦n®ø®§¤°»ò¤~¬O¦n®ø®§¡H

¿ï¾Ü©Êª¾Ä±¥»昰¤H©Ê¡A¦b³o­Ó¸ê°T²V²cªº®É¥N«O¦³«ÈÆ[²z©Êªº½T¬Û·í¤£®e©ö¡C

EASI-75

­ì¥ý¤½§i¼Æ¾Ú

¹êÅç²Õ62.7% ¹ï·Ó²Õ30.7% p=0.0041

¹êÅç²Õ¡þ¹ï·Ó²Õ­¿¼Æ¤ñ2.042

³Ì·s§ó·s¼Æ¾Ú

¹êÅç²Õ52% ¹ï·Ó²Õ24.4% p=0.0040

¹êÅç²Õ¡þ¹ï·Ó²Õ­¿¼Æ2.131

EASI-90

­ì¥ý¤½§i¼Æ¾Ú

¹êÅç²Õ34.1% ¹ï·Ó²Õ10.1% p=0.0088

¹êÅç²Õ/¹ï·Ó²Õ­¿¼Æ3.376

³Ì·s§ó·s¼Æ¾Ú

¹êÅç²Õ27.6% ¹ï·Ó²Õ7.9% p=0.0080

¹êÅç²Õ/¹ï·Ó²Õ­¿¼Æ3.493

EASI-75¡AEASI-90 600mg, ¨C¤ë£¸°w¡A±q§ó·s¼Æ¾Ú¨Ó¬Ý¡A¹êÅç²Õ/¹ï·Ó²Õ­¿¼Æ

¼W¥[¡AP­È­°§C¡A§ó¥YÅã¨äÄvª§¼ç¤O¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/8/23 ¤U¤È 03:00:02²Ä 6427 ½g¦^À³
¥xÁÞ¤j¤jªº²§¦ì©Ê¥Ö½§ª¢¥Íª«»s¾¯¬ãµo¦Ê¦Ìª§¹ÜÁÉ¡Aª÷¡B»È¡B»ÉµPblablaªº¡Aµ²ªGaslan½Õ¾ã¤F2bªº³Ì²×¸ÕÅçµ²ªG¡AEASI-90¸òEASI-75ªº¼Æ¾Ú³£¤U­×¤F¡A¬Ý¨Ó¬O¤°»òµP³£®³¤£¨ì¤F©O¡A¥u³Ñ4¶g¤@°w¥i¥H®³¨Ó»¡¼L¤FXD¡A¬ÛÃö¸ê°T¥i¬Ýaslanªºsec¤å¥ó¡A©xºô¤WªºÂ²³ø¸ê®Æ¤]¤w§ó·s..........

·|­û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/7/19 ¤U¤È 10:58:10²Ä 6395 ½g¦^À³

²§¦ì©Ê¥Ö½§ª¢¥Íª«»s¾¯¬ãµo¦Ê¦Ìª§¹ÜÁÉ

1 ²§¦ì©Ê¥Ö½§ª¢¥Íª«»s¾¯¬ãµo¦p¦P¦Ê¦ÌÁÉ ¨ú«e¤T¦W ª÷µP »ÈµP »ÉµP ( EASI-90 EASI-75 vIGA-AD 0 /1 )

2 ¤@¯ë¦Ê¦ÌÁɨú«e¤T¦W Æ[²³¥Ø¥ú³£·|§ëª`¦b ª÷µP »ÈµP »ÉµP±o¥D, ³o¦¸TREK-AD ¤G´Á¬ã¨s§ë¸ê¤H¥Ø¥ú¤Ï¦Ó§ëª`¦b²Ä¥|¦W

( ¹ï·Ó²Õ)¤W, §Ñ¤FTREK-AD ¥|¶g¤@°w¤~¬O EASI-90ªºª÷µPÁɱo¥D, ³o¬OÃø«×³Ì°ªªº¤ñÁÉ, ¹êÅç²Õ»P¹ï·Ó²Õ®t¶Z´N©úÅã©Ô¥X¨Ó (ÃÒ©úÃĪ«ªº¦³®Ä©Ê) ( ¨â¶g¤@°w¤]¬O¤@ ¼Ë±j)

3¤£­n§Ñ¤F Eblasakimab ¬O¥|¶g¤@°w»P dupilumab¨â¶g¤@°w¤ñ¸û¤@ÂI¤]¤£®t , ¦P¼ËªºEASI-75%»ÈµPÁÉ »P IGA 0/1»ÉµPÁÉ ¦b¤H¼Æ¤£¦h»PÃĪ«¬~²æ¤£¨¬±¡ªp¤U ©ÎªÌ¦³¨Ç©â¨ì¹ï·Ó²Õªº¨ü¸Õ¤]¥i¯à¥Ö½§Äo¬ÝÂå¥Í¥ÎÃÄ,¦b³o¨Ç¼vÅTÅܼƤ§¤UEblasakimab ¼Æ¾Ú¤@ÂI¤]¤£®t ( dupilumab ¦]¨C²Õ¤H¼Æ¹F224-233¤H P value < 0.0001 )

4 TREK-AD ¬ã¨s¤¤¨C¥|©P¤@¦¸ªº600mg eblasakimab¹F¨ì ¤F¨ã¦³²Î­p¾Ç·N¸qªº¥D­n²×ÂI¡A62.7% ªº±wªÌ¹F¨ì EASI-75¡A34.1% ¹F¨ì EASI-90¡A31.2% ¹F¨ì vIGA-AD 0 ©Î 1 ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/17 ¤U¤È 10:44:43²Ä 6426 ½g¦^À³
ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

£¸¤½¥q¤K¤ë¤Q¤@¤é¤½§i³o½g¸ê°T»P¤C¤ë¤»¤é¤½§i¤Gb¼Æ¾Ú¡A®É¶¡®t¬ù£¸­Ó¤ë¤S¤­¤Ñ¡A±À´ú³o­Ó¤ë»P¦X§@¹Ù¦ñ¦³±K¤Á°Q½×¡A¤K¤ë¤Q¤@¤é³o½g¸ê°T­È±o¥J²Ó¾\Ū¡A¥¼¨Ó­«­n®Éµ{»P¤T´ÁÁ{§Éªº¥¼¨Ó³W¹º¡Aµª®×¥þ¦b¸Ì­±¡C

¤G Dupilumab ¦b¥xÆW£¸­Ó¤ë¶O¥Î¬ù50000¤¸¡A¨â¶g¤@°w¤@¦~¬ù60¸U¡A¬ü°ê§ó¶Q¡AEblasakimab ¥|¶g£¸°w¡A°Æ§@¥Î§C¡A¶O¥Î´î¥b¡A¨äÀu¶Õ·|§l¤Þ¯f±wÂà´«ÃĪ«¡C

¤T Topline data ½Ð¤£­n¦A½¦¨³»½u¼Æ¾Ú¡A¥¿½T½Ķ昰¸ÕÅç¼Æ¾Ú¡AGoogle ½Ķ¿ù»~¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¾ð10152786  µoªí®É¶¡:2023/8/14 ¤W¤È 08:57:13²Ä 6425 ½g¦^À³
R¤j@

Q:µL®Ä«á¤~¨Ì§Ç¨Ï¥Îtralokinumab©Îeblasakimab?

A:³o¥yÀ³¸Ó¬OÂصü!¬ãµo¤¤ÁÙ¥¼¤W¥«ªºeblasakimab¤@¯ë¨S¤°¤Hª¾¹D§a?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2023/8/14 ¤W¤È 06:56:45²Ä 6424 ½g¦^À³
3.2013¦~¡A¬ü°ê®Ö­ãGileadÃļtC«¬¨xª¢·sÃÄSovaldi¤W¥«¡A2014¦~³Ð¤U104»õ¬üª÷À禬¡C

2018¦~¡AC¨x·sÃÄ¥«³õÅQ¥D´«¤H§¤. AbbVie¦bC¨x·sÃĪºÀ禬¤w¶W¶VGilead

ibmi.taiwan-healthcare.org/zh/news_detail.php?REFDOCTYPID=&REFDOCID=0pmtqystg6exacto

~100%ªv¡²vªºC¨x¯«ÃĦѤjÅܦѤG¡ADupilumabªºIGA0/1(¥u¬Oªñ40%±wªÌ¯à°÷´X¥G§¹¥þÂ\²æ¯f¨_§xÂZªºµ{«×)¯à¤[§¤ÅQ¥D¦ì?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2023/8/12 ¤W¤È 09:32:50²Ä 6423 ½g¦^À³
1.Trogarzo·R´þÃĬO³Ì¥½½u¤¤ªº³Ì¥½¥ÎÃÄ(«e«á½uÃĪ«¬O§ÜÃĩʦҶq)¡A¦bAD¥ÎÃĤW¡A¦³­n¨D±wªÌ±o¥ý¥ÎDupilumab¡AµL

®Ä«á¤~¨Ì§Ç¨Ï¥Îtralokinumab©Îeblasakimab?

2.DupilumabªºÀ³µª²v¤£¬OC¨x¯«Ãįë~100%ªv¡²v¡A¬I¥´«áµL®ÄªÌ¤@¤j°ï¡C ®ð³ÝÃÄXolair¦b¬ü°ê¤W¥«¤£¤[¡A§Ú¤@­ÓªB¤Í¯S¦a­¸

¥h¬ü°ê¦Û¶O¬I¥´¡AµLÀø®Ä!!!

(Xolair-Á`IgE≥30IU/mL»PMepolizumab¶Ý»Ä©Ê¥Õ¦å²y≥300/uL¡A2ÃĪ«¦s¦³¥Íª«¼Ð»x®t²§¤Æ¡A±wªÌ±Ú¸s¤£¦P)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¾ð10152786  µoªí®É¶¡:2023/8/11 ¤U¤È 10:44:58²Ä 6422 ½g¦^À³
¨ÖÁʪºÃļt¦b¨º¡H©Î³\¬Oµêºc¡H

°²³]¦³³Q¨ÖÁʨº±ø¥ó¦p¦ó¡H¥i¯à¤£¨Î©Ò¥H¬G§Ë¥Èµê¡H

³oµo¥Í¦b¦Ñ·à³£¤£·N¥~¡A±q¥xÆW¨ì¬ü°êÄF§½ªº¥\¤O¤é¯q¶i¨B¡I

¥u¦³ªÑ»ù¤U¶^³Ìµ¹¤O¡I

¥~¥[¦Û¾É¦Ûºtªº¥äµ£¥[®àÀYªº¬~¸£¡H©Î³\¸Ó²M¿ô¤F¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/11 ¤U¤È 10:20:26²Ä 6421 ½g¦^À³
2023 ¦~ 8 ¤ë 11 ¤é

ªü´µÄõ»sÃÄ (ASLAN Pharmaceuticals) ¤½§G 2023 ¦~²Ä¤G©u«×°]°È·~ÁZ¨Ã´£¨Ñ¤½¥q³Ì·s°ÊºA

TREK-AD ©ó 7 ¤ë³ø§i¤F¿n·¥ªº¸ÕÅç¼Æ¾Ú( Positive topline data)¡A³o¬O¤@¶µeblasakimabªº 2b ´Á¬ã¨s¡A¦b¤T­Ó¾¯¶q²Õ¤¤§¡¹F¨ì¤F¥D­n²×ÂI¡A¨ã¦³²Î­p¾Ç·N¸q¡C³o¨Ç¼Æ¾Úªí©ú¡A eblasakimab¬O¤@ºØ¼ç¦bªº¤@¬y§ÜÅé¡A¬O ²Ä¤@­ÓªvÀø¤¤­««×¯SÀ³©Ê¥Öª¢ªº¥Íª«»s¾¯¡A±q¶}©l¨C¤ë¤@¦¸µ¹ÃÄ´NÅã¥Ü¥X¨ã¦³Ävª§©ÊªºÀø®Ä¯S¼x ¼Æ¾Ú¤ä«ùeblasakimab©ó 2024 ¦~¶i¤J 3 ´ÁÁ{§É¶}µo­p¹º TREK-DX¡]¦bDupilumab¸g¾ú¹L AD ±wªÌ¤¤¶i¦æ EblasaKimab ¸ÕÅç¡^ªºÅª¼ÆÅã¥Üeblasakimabªº 2 ´Á¬ã¨s©M FAST-AA¡]FArudodstat ´³¨r¬ã¨s¡^farudodstatªº 2a ´Á¬ã¨s¡A¹w­p±N©ó 2024 ¦~²Ä¤@©u«×µo¥¬

ºI¦Ü2023 ¦~ 6 ¤ë 30 ¤é¡A¤½¥q«O«ù°·±dªº¸gÀ窬ªp¡A¾Ö¦³ 4090 ¸U¬ü¤¸ªº²{ª÷©M²{ª÷µ¥»ùª«¡F7 ¤ë¥÷¦¬¨ì 1,200 ¸U¬ü¤¸ªº¹w¥I¾Ô²¤³\¥i¥I´Ú¡A¹w­p²{ª÷¶]¹D±N©µªø¦Ü 2024 ¦~¤U¥b¦~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/11 ¤U¤È 10:11:42²Ä 6420 ½g¦^À³
¤½¥q¤w»¡©ú2024·|±Ò°Ê¤T´ÁÁ{§É¡A¤T´ÁÁ{§É§Ú¥H«e»¡¹L«Ü¦h¦¸¤£·|¬O¥Ñ¤p¤½¥q¦Û¤v°µ¡A·íµM¬O¥Ñ¦X§@¹Ù¦ñ¥X¿ú¨Ó°µ¡A¬JµM¥Ñ¦X§@¹Ù¦ñ¨Ó°µ¡A±À½×¤U¥h´N¬O·|¦³±ÂÅv©Î¨ÖÁÊ¡A¦h£¸ÂI­@¤ß¡A¦h£¸¥÷²z´¼¡A¦h£¸ÂI±À²z¡A¤£¥²¹L¥÷¬Ý¤Ó¦n©Î¬Ý¤ÓÃa¡A¤]¤£­n°õµÛIGA 0/1¹êÅç²Õ»P¹ï·Ó²Õ¤ñ£¸©w­n¤T­¿¤~¯à®³ÃÄÃÒ¡Atralokinumab ¤G­¿´N®³¨ì¬ü°êFDA®Ö­ãÃÄÃÒ¡A°õµÛ»P®£·W昰³Ì

¤jªº­·ÀI¡Atralokinumab¶}½æ»Ý­n·Ç³Æ

´Á¡A¥]¬A¦æ¾P¤H­û¥l¶Ò»P°V½m¡A¨ì2027

ADÃĪ«¥þ²y¦~Àç·~ÃB¹w¦ô170»õ¬ü¤¸¨ì200»õ¬ü¤¸¡A±N¥Ñ5~6ÁûÃĪ«¤À­¹¤jÃÄ¥«³õ¡A¥t¥~¬JµM¥Ñ¦X§@¹Ù¦ñ¥X¿ú¨Ó°µ´N¨S¦³¤½¥q¸êª÷¤£¨¬ªº°ÝÃD¡A¥u¦³¸êª÷¤À¶¥¬q¶i±b»P¥¼¨Ó¤Q¦h¦~¾P°âÅv§Qª÷·½·½¤£µ´¡C

ª`·N¤µ¦~²Ä¥|©u¤G´Á§¹¾ã¼Æ¾Ú»P°ê»Ú´Á¥Zµoªí¡A©ú¦~TREK -DX¤G´Á¬ã¨s»PFArudodstat ¯Z¨r¬ã¨s¤Ga¼Æ¾Úµoªí¡C

¥H¤W¤À¨É ¶È¨Ñ参¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/8/11 ¤U¤È 10:08:41²Ä 6419 ½g¦^À³
»P¬ü°ê­¹«~ÃÄ«~ºÊ·þºÞ²z§½·|­±¤ÎÀH«áªº·|ij

¨Ì¤Ú¨F°ò³æ§Üªº3´ÁÁ{§É¶µ¥Ø¹w­p±Nû£°Ê

µo¥Í¦b 2024 ¦~¡C

(¤T´Á§@¨ì¤@¥b,³Q¨Öªº¾÷·|¤j)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸Ø±i10133098  µoªí®É¶¡:2023/8/11 ¤U¤È 09:05:40²Ä 6418 ½g¦^À³
......§Ú­Ì¹ï¨Ì¥¬©Ô¨F°ò³æ§ÜªºÃöÁä3´Á¬ã¨sªº­p¹º¡A§Ú­Ì¹w­p±N¦b2024¦~»P¥þ²y°Ó·~¦X§@¥ë¦ñ¤@°_û£°Ê³o¶µ¬ã¨s¡C......

(°]³ø¥X¨Ó¤F¡C¬O©MÀq§J¤@°_¬ã¨s??)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/8/11 ¤U¤È 04:02:17²Ä 6417 ½g¦^À³
Adbry(tralokinumab)2022¦~¤~¶}©l¾P°â¡A·|¤£·|¯uªº¦³12»õ¬ü¤¸ªº»ù­È¡A±o¬Ý±µ¤U¨Ó¹ê»Ú¾P°âÃB¡ALebrikizumabÁÙ¨S®³¨ìÃÄÃÒ¡Aªº½TAdbry(tralokinumab)ÃĮĤ£¬ð¥X¤]¥iÀò±oÃÄÃҨäW¥«¡A©Ò¥HEblasakimab¤T´Á¹LÃö¾÷²v¤j¡A§Ú¨Ã¤£§_»{¡A·íµM¤T´Á«áÄò¦p¦ó³]­p¥æµ¹±M®a§Ú¤]¨S·N¨£¡A¦ý§Y¨Ï®³ªº¨ìÃÄÃÒ¡A¨C­ÓÃĪ«ªº¾P°âª¬ªp¤]¬O¦UÃļtªº¬D¾Ô¤§¤@¡A©Ò¥H¤~·|½èºÃ§Y¨Ï¥i¥H¤W¥«¡A¦ý¥«¥e²v¯à®³¨ì¦h¤Ö?±q¨Ó¨SªÈµ²¦b¬O§_¥i¥H¨úÃÒ¤W¡A²¦³º¹³¤¤¸Î·R´þ·sÃĹL¤F¡A¦ý¾P°â¤@ª½©Ô¤£°_¨Ó¤]¬OªPµM¡A¦bÃĮĨS¯S§O¬ð¥X¡A¥«¦û²v¯à¦p­ì¥»¹w´Áªº°ª?¥t¥~¤G´Á¸ÕÅç¡A¤j®a§O§Ñ¤F¡A¤½¥q¤@ª½¹w³]400mgQ2W·|¨ú±o³Ì¦nÀø®Ä¡A¬Æ¦ÜÁÙ¸òCMOÃļt¦X§@¶}µo400mgªº¿@ÁYª©¥»¡A¬Æ¦ÜDupilumab¤G½uªvÀø¤]¬O400mgQW³]­p¡Aµ²ªG²{¦bµ²ªG¥X¨Ó¬O600mgQ4W¼ç¤O³Ì¤j¡A¨º¬O¤£¬O¥Nªí¤½¥q¹ïEblasakimab´x´¤«×¨S·Q¹³¤¤°ª!?¨º²{¦b»¡¤½¥q°ª¼h¬Ý¨ì600mgQ4W¼ç¤O¦h¤j¦h¿³¾Ä¯à°÷¨ú«H¦h¤Ö¤H¡A³Ì­«­nªº¬O¤½¥q²{ª÷³¡¦ì¤w¸g¤£¦h¤F¡A§Y¨Ï¦³¦b½Í±ÂÅv©Î¨ÖÁʩζҸê¡A¦pªGªñ´ÁµLªk¦³¤@­Óµ²ªG¡AÀH²{ª÷³¡¦ì«ùÄò¤U­°¡A½Í§P¤O¤]·|¤U­°¡A³s®É¶¡¤]¤£¯¸¦b¤½¥q³oÃä¡A­Yªñ´ÁµLªk¨ú±o¤@­Ó¦³¹ê½è¶i®iªºµ²ªG¡A´N¬OºC©Ê¦º¤`¡AÃø¤£¦¨³o¨Ç­t­±¦]¯À³£¥i¥HµLµø?¥u­n¤@¥yÃĪ«¦³¼ç¤O´N¥i¥H©¿µø¤@¤Á!?¦Ó³o¼ç¤O§Ú¬Ý¥«³õ¨Ã¤£±µ¨üªü¡A¦Ó¥BSEC¤å¥ó¦Ü¤µ¤]³£¨S¦³·sªº¤jªÑªF(«ùªÑ¶W¹L5%)ªº¥Ó³ø¸ê®Æ¡A»¡§ë¸ê¾÷ºc¦Y³fÁÙ¨S¦Y°÷¡A¬Ý°_¨Ó¤]¨S¤H­n¦Y°Ú.........
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/8 ¤U¤È 09:36:57²Ä 6416 ½g¦^À³
Eblasakimab tralokinumab PK ¤@¤U

¬ü°êFDA 2021¦~12¤ë®Ö­ã¤¦³Á¸ó°êªº»sÃĤ½¥qLEO Pharma ¶}µoªº IL-13§í¨î¾¯Adbry (tralokinumab)¤W¥«¡AAdbry³Ìªì¬O¥Ñªü´µ§Q±d¡]AstraZeneca¡^¤½¥q¶}µo¡ALEO Pharma¦b2016¦~»Pªü´µ§Q±d¹F¦¨¨óij¡AÀò±oAdbryªº¥þ²y¶}µoÅv¯q

»ù­È¤W¬Ý12»õ¬ü¤¸

Tralokinumab ³oºØ¤Ñ©R¤j³£¬Ý¤£°_ªº¼Æ¾Ú ¬ü°êFDA¤]®Ö­ã¤W¥« , ¨CºØ¯e¯f»Ý­n«Ü¦h¤£¦PÃÄ, ¤j®a¬Ý¬Ý¨ÅÀùªÍÀù¦³¦h¤ÖÃĪ«¤W¥«, ¤£»Ý­n¦Û¤vÀ~¦Û¤v ¥u­n²£«~¦w¥þ¦³¯S¦â¤£¥Î¾á¤ßEblasakimab¤W¤£¤F¥«

( ¨S¬Ý¨ì¼Æ¾Ú­n«O¦u ¬Ý¨ì¼Æ¾Ú¤Ï¦Ó­n¼ÖÆ[)

¨Ò¦p¥Ûªo¤½¥q¬£¥|²Õ¤H­û¥h±´°É¥Ûªo ¨ä¤¤¤@²Õ«õ¨ì«~½è«Ü´Îªºªo¤« ( ¤@²Õ¨S«õ¨ì ¤G²Õ®t±j¤H·N)

½Ð°Ý¤j®a¥Ûªo±´°É¦³¨S¦³¦¨¥\ ? ¤G´ÁÁ{§É´N¬O±´°É ±´¯Á ( ¥¼¨Ó¤T´ÁÁ{§É¥D­n ¦¸­nÀø®Ä«ü¼Ð¥Ñ±M®aÅU°Ý¥h¨M©w

½ü¤£¨ì§A¾á¤ß!

tralokinumab ¤T´Á¼Æ¾Ú

¥D­nÀø®Ä«ü¼Ð IGA 0/1 ( 300mg ¨â¶g¤@°w 16¶g )

tralokinumab ECZTRA 1 IGA 0/1 15.8% /7.1 % P=0.002 (300mg2¶g1°w16¶g) ( 601¤H/ 197¤H)

tralokinumab ECZTRA 2 IGA 0/1 22.2 % /10.9 % P< 0.001 (300mg 2¶g1°w16¶g) ( 591¤H/ 201¤H)

Eblasakimab 2b 600mg (n=59) Q4W 31.2%/ 15.1% p=0.0502 ( 4¶g1°w16¶g)

eblasakimab 2b 400mg (n=56) Q2W 32.6 %/15.1% P value 0.0380 ( 2¶g1°w16¶g)

eblasakimab 2b 300mg (n=58) Q2W 33.1%/15.1% P value 0.0327 ( 2¶g1°w16¶g)

¥D­nÀø®Ä«ü¼Ð EASI-75

tralokinumab ECZTRA 1 EASI-75 25% /12.7% P < 0¡P001 (300mg 2¶g1°w16¶g) ( 601¤H/ 197¤H)

tralokinumab ECZTRA 2 EASI-75 33.2% / 11.4% P < 0¡P001 (300mg 2¶g1°w16¶g) ( 591¤H/ 201¤H)

eblasakimab 2b 600mg (n=59) Q4W 62.7%/ 30.7% p value 0.0041 ( 4¶g1°w16¶g)

eblasakimab 2b 400mg Q2W (n=56) 54.5 /30.7% P value 0.0322 ( 2¶g1°w16¶g)

eblasakimab 2b 300mg (n=58) Q2W 60.7/30.7% P value 0.0064 ( 2¶g1°w16¶g)

¦¸­nÀø®Ä«ü¼Ð EASI-90 µ¥

tralokinumab ECZTRA 1 EASI-90 14.5%/4.1% P < 0¡P001 ( 300mg2¶g1°w16¶g) ( 601¤H/ 197¤H)

tralokinumab ECZTRA 2 EASI-90 18.3%/5.5% P < 0¡P001 ( 300mg2¶g1°w16¶g) ( 591¤H/ 201¤H)

Eblasakimab 2b 600mg (n=59) Q4W 34.1%/ 10.1% p value 0.0088 ( 4¶g1°w16¶g)

eblasakimab 2b 400mg (n=56) Q2W 32.6 %/10.1% p value 0.0194 ( 2¶g1°w16¶g)

eblasakimab 2b 300mg (n=58) Q2W 37.7%/10.1% p value 0.0033 ( 2¶g1°w16¶g)

¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¯¤p©ú10152293  µoªí®É¶¡:2023/8/8 ¤U¤È 12:21:20²Ä 6415 ½g¦^À³
³o¶BÄF¤½¥q.

¥¿¦b­e©µ´Ý³Ý¡A

ºCºC¦º¤`¤¤¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/8/4 ¤U¤È 03:31:28²Ä 6414 ½g¦^À³
¤d¸U§O¦A»¡¼ç¤O¤Q¨¬¤ª¤ª¡A¦pªG¥«³õ¤W¨S¤H»{¦P¡A¦ó¨Ó¸êª÷Äò°µ¤T´Á?¥«³õ¼ç¤O¯uªº¦p¦¹¥¨¤j¡A¥«­È¤£·|¦p¦¹§C¡A¥u¦³¦Û¤v»{¬°¼ç¤O¤Q¨¬¦Ó¤£¥h±´°Q¤£³Q¥«³õ»{¦Pªº­ì¦]¡A§Ú»{¬°¤£¬O²³¤H¬Ò¾K§Ú¿W¿ô¡A¤]¤£¬O¤°»ò¥ýª¾¥ýı¡AÃø¤£¦¨¥«³õ¤£µ¹¿ú¡A¦U¦ì¥ýª¾­Ì­n±Ç¿úÅýASLAN¥h°µ¤T´Á?¤£¬O¨Sµ¹®É¶¡¸ò¸êª÷ÅýASLANµo´§¡A¦Ó¬O¼Æ¦~¹L¥h¡A®É¶¡µ¹¤F¡A¸êª÷¤]¶Ò¤F¤£¤Ö¡A¦ý¦Ü¤µ³s­Ó¥i¥HÅܲ{ªº¦³»ù­È¸ê²£³£µ¹¤£¥X¨Ó¡A¶}¼QASLAN¤£µL¹D²z§a¡AÃø¤£¦¨ÁÙ­n»¡ASLAN¦n´Î´Î?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/8/4 ¤U¤È 03:04:55²Ä 6413 ½g¦^À³
¹ï©óEblasakimab¤T´Á¹êÅçµ²ªG¡A§Ú¤]ı±o¼Ë¥»¼Æ©Ô¤jÀ³¸Ó¦¨¥\¾÷²v«Ü°ª¡A¥i¬O¦bÃĮĨèS¦³¤ñDupilumab¤ÎLebrikizumab¦³©úÅ㪺Àu¶Õªº±¡ªp¤U¡AÁöµM¦³4¶g¤@°wªºÀu¶Õ¡A¦ý¸gFDA®Ö­ã¤@½u¼Ð·ÇÀøªk²¦³ºÁÙ¬ODupilumab¡A­ì¥»±H±æ¦bÃĪ«Àø®Ä¤W¯à°÷¶W¶VDupilumab¡A¥Ø«e¬Ý°_¨Ó¬O¨S¿ìªk¤F¡A¥u¯à¨Ì¿à4¶g¤@°wªº¤è«K©Ê¨Ó¼W¥[ªvÀø¤H¼Æ¡A¦p¦¹¯à°÷·m¤U¦h¤ÖAD¥«³õ¥«¥e²v?§Úı±o³o¬O¤G´Á¸Ñª¼µ²ªG¥XÄl«á±Y½Lªº¥D¦]¡A¨Ã«DÃĪ«µL®Ä¡A¦Ó¬O¦bÃĮĨS¦³¯S§O¬ð¥Xªº±¡ªp¤U­n·m¥eDupilumab¥«³õ¡A¯à·m¨ì¦h¤Ö?AD¥«³õ¬O«Ü¤j¡A¦ý­Y¤j¦h¼Æ±wªÌ¤´¨Ï¥ÎDupilumab¡A§Y¨Ï®³¨ìÃĵý¡A¥«³õ¤W»ù­È¤´¤£·|°ª¡A¬Ý¬ÝTralokinumab¸òLebrikizumab³Q¨ÖÁÊ»ù®æ¬Ò¤£ºâ°ª¡A§ó¦óªp¬OÃĮĮt¤£¦hªºEblasakimab¡AºI¦Ü¤T¤ë©³±b¤W²{ª÷ÁÙ¦³USD57.5M¡A¥[¤W¤é¥»±ÂÅvUSD12M¤]¤~69.5M¡A¨Ì·Ó¤@©u­n¿N±NªñUSD20M¨Ó¬Ý¡A±b¤W²{ª÷»¡¤£©wºÙ¨ì2024Q1µ²ªG¥X¨Ó³£«Ü«j±j¡A§ó¹N½×­n¤T´ÁÁÙ­n¤ä¥I°ªÃB±ÂÅvª÷¡A³o±¡ªp¤j·§¸òCNTB¦³87%¹³§a¡A©Ò¥H¥«­È¶^¨ì³ÑUSD4000¸U¤£¨ì¡A¸òCNTB¥«­ÈUSD5000¸U¨ä¹ê®t¤£¤F¦h¤Ö¤F......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªL®õ10030886  µoªí®É¶¡:2023/8/4 ¤W¤È 10:59:25²Ä 6412 ½g¦^À³
¥@¨Æ¦p´Ñ§½§½·s

ªÑ»ù¦ü®öªiªi©_

¤H«È­¾

Åý«¥­ÌÄ~Äò¬Ý¤U¥h§a¡I¡I¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/3 ¤U¤È 11:27:05²Ä 6411 ½g¦^À³
Eblasakimab¦³¨S¦³¼ç¤O½Ð¾\Ū³o½g¤å³¹

Aslan hopes fewer side effects can catapult atopic dermatitis med over Dupixent after mixed readout

¦A»¡£¸¦¸°ò¥»Æ[©À

1 ¤G´ÁÁ{§É¦b±´¯ÁÀø®Ä¡A¦w¥þ©Ê¡Aµ¹ÃÄÀW²v»P¾¯¶q¡A¤G´ÁÁ{§É¥u¦b±´¯Á ¨S¦³©Ò¿×ªº¦¨¥\»P¥¢±Ñ¡AFDA¥u¬Ý¨â­Ó¤T´ÁÁ{§É¡C

2 P­È¤p©ó0.05 ¬O¦b»¡³o­Ó¹êÅç¦pªG¦A­«°µ100¦¸¹êÅç ¤p©ó¤­¦¸ªº¾÷²v·|¥X¿ù

¤£¬O¦b»¡Àø®Ä¡AEblasakimab¥|²Õ¸ÕÅ礤¡AÁöµM¤H¼Æ¤£¦h¡A¦³¤T²Õ¦bIGA 0/1

EASI-75 EASI-90 ³£¹F²Î­pÅãµÛ®t²§

¯S§O¬OEASI-90³o£¸Àø®Ä«ü¼Ð¡C

3 ¦b EASI-90 ªº¤T­Ó²Õ¤¤¡Aeblasakimab ªºªí²{Àu©ó Dupixent ªº¾ú¥v¸ÕÅç¡A³o¨Ç²Õ¦b¥D­n²×ÂI¤W¨ú±o¤F¦¨¥\¡C®Ú¾Ú Aslan ªº¤Û¿O¤ùºt¥Ü¡A¨C¨â¶g´£¨Ñ 300 ²@§J¾¯¶q¡AªA¥ÎÁÉ¿Õµá©M¦A¥Í¤¸­«½SÃĪ«ªº±wªÌ¦b 2b ´Á¬ã¨s¤¤¡A¦³ 29.7% ªº±wªÌ¹F¨ì¤F EASI-90 ¤À¼Æ¡A¦Ó 32.8% ¦b 3 ´Á¬ã¨s¤¤¹F¨ì¤F³o¤@¥Ø¼Ð,³Ì­«­nªº昰eblasakimab¥|¶g£¸°w¨ú±o«e©Ò¥¼¦³ªº¾ú¥v¼Æ¾Ú¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªoºj·Æ±¼10153108  µoªí®É¶¡:2023/8/2 ¤U¤È 12:54:57²Ä 6410 ½g¦^À³
³Q°ª»ù¦¬ÁʬO¤jÃļtı±o¦³¼ç¤O¡A¬Ý¬Ýaslan²{¦b¦³½Öı±o¥L¦³¼ç¤O!?³o¸Ì·Pı¨C¦¸¦³§Oªº¤½¥q³Q°ª»ù¦¬ÁÊ´N·|¿³¾Ä¤@ªi¡A§Oªº¤½¥q³Q°ª»ù¦¬Áʤ£¥Nªíaslan¤]¦³³o­Ó¼ç¤O¡A§Ú¤]¨Ó«ø¥Ø¥H«Ý¬Ý¬Ý·|¤£·|¤U¥«¦n¤F¡A·Pı³Ó²vÁÙ¤ñ¸û°ª......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2023/8/1 ¤U¤È 10:49:57²Ä 6409 ½g¦^À³
¦Ê°·¡]Biogen¡^³Ì«á¥H¨CªÑ 172.5 ¬ü¡A¨ÖÁÊÁ`ª÷ÃB 73 »õ¬ü¤¸¦¬ÁÊ Reata Pharmaceuticals ¡A¸Ó¨u¨£¯e¯fÃĪ«¹w¦ô¨ì2029¦~¦~¾P°âÃB¹F13»õ¬ü¤¸¡A

³o»P²§¦ì©Ê¥Ö½§ª¢¥«³õ¬Û¤ñ¤p¦h¤F¡AEblasakimab¼ç¤O¤Q¨¬¡AASLAN Pharmaceuticals ³Q¨ÖÁʪº»ù®æ·|¤£·|¶^¯}¤j®aªº²´Ãè¡H«ø¥Ø¥H«Ý¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
12345678910¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

F-¨È·à±d

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!